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INTRODUCTION 
Chapter 1. 
General introduction and aim of the thesis 
1.1 Classification of vasodilating drugs 
Vasodilating drugs can be classified on basis of the mechanism of action 
but also on the ultimate vasodilator profile, i.e. venodilation, arteriodilation 
or a combination of both. In the following sections a brief overview has 
been presented of the classification of vasodilating drugs according to these 
two criteria. 
1.1.1 Mechanism of action 
Vasodilation can be induced basically by three different mechanisms of 
action: Interference with the neural or humoral (the renin-angiotensin-
aldosterone system) control of vasomotor tone and an action on the vascular 
wall. 
Neural mechanism 
The cardiovascular control centers of the medulla oblongata receive their 
input from higher brain centers and from the afferent nerve endings of 
mechanoreceptors (Fig. 1 ). From these medullary centers signals are mediated 
to the heart via both sympathetic and parasympathetic nerve fibers and to 
the vasculature via predominantly sympathetic nerve fibers. Drugs may 
interact with the neural regulation of vasomotor tone at different levels. For 
example, veratrum alkaloids decrease the sympathetic activity by an increase 
in sensitivity of the baroreceptors. Examples of drugs affecting the higher 
brain centers are the sedatives, hypnotics, tranquilizers, rauwolfia alkaloids 
and a-methyldopa. The latter, as well as the a2-adrenoceptor agonist 
clonidine, also directly affects the medullary centers. On the level of the 
ganglia, ganglion-blockers like hexamethonium impair neural transmission. At 
the adrenergic nerve endings interference with noradrenaline synthesis 
(a-methyldopa), storage (rauwolfia alkaloids), or release into the synaptic cleft 
(guanethidine, bretylium) can reduce the noradrenaline-mediated vasomotor 
tone. Finally, interference with neural control can be accomplished by 
blockade of post-junctional eXt- (present on veins and arterioles) and 
Fig. 1 
Afferent fibers of 
baroreceptors 
Arterioles 
® 
Veins 
Interference with the neural regulation of vasomotor tone by drugs at 
different levels of the nervous system. 1 = Veratrum alkaloids; 2 = 
sedatives, hypnotics, tranquillizers and a-methyldopa; 3 = a-methyldopa and 
clonidine; 4 = ganglion-blocking drugs; 5 = a-methyldopa; 6 = rauwolfia 
alkaloids; 7 = adrenergic blocking drugs; 8 = at-adrenoceptor blockers; 9 = 
a2-adrenoceptor blocker. Presynaptic receptors have been omitted from this 
figure. For a description see text. 
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az- {present principally on arterioles) adrenoceptors with prazosin {a1), 
yohimbine (az) and phentolamine {a1 and az). The role of pre-junctional 
receptors will not be discussed here; for a review on this subject see Langer 
and Armstrong (1986). 
Renin -angiotensin -aldosterone system 
In addition to the neural control, vasomotor tone can be influenced 
humorally via the renin-angiotensin-aldosterone system {for an extensive 
review see Dzau and Pratt, 1986). Several factors including an increase in 
sympathetic nerve activity, a reduction in renal perfusion pressure and the 
anti-diuretic hormone concentration, a decreased sodium and/or chloride load 
and other changes in plasma electrolyte concentrations (K+ , Mg2+ ) enhance 
the release of the proteolytic enzyme renin (for a review see Derkx, 1987) 
from the juxtaglomerular cells in the afferent arterioles of the kidneys 
(Fig. 2). By cleaving the leucyl-leucine bond, renin converts angiotensinogen 
into angiotensin-! which in turn is converted into angiotensin-11 via the 
angiotensin converting enzyme. Angiotensin-11 exerts a number of 
pharmacological actions, such as an aldosterone-mediated sodium retention, 
arteria- and venoconstriction and .cardiostimulation. Drugs may interfere with 
the actions of the renin-angiotensin-aldosterone system by ~-adrenoceptor 
blockade at the level of the juxtaglomerular cells or by inhibition of renin or 
the angiotensin converting enzyme. Furthermore, the action of angiotensin-11 
can be blocked by the angiotensin-II antagonists and the angiotensin-11-
induced increase in the aldosterone activity can be offset by aldosterone 
inhibitors like spironolactone (Fig. 2). 
Vascular cellular mechanism 
Vasodilating drugs which induce vasodilation at the level of the vascular 
wall are often considered to be "true vasodilators". Some of the events 
involved in the vascular contraction and possible sites of interference with 
contractile processes by vasodilating drugs have been schematically depicted 
in Fig. 3; for details, one may refer to review reports {Bolton, 1979; Cauvin 
et al., 1983; Van Zwieten, 1984). The free calcium concentration in the 
cytosol can be increased by a calcium release from intracellular stores and 
transmembrane influx through receptor- and potential operated channels. The 
increase in the free calcium concentration in the cytosol leads via 
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Interference with the humoral regulation of vasomotor tone by drugs at 
different levels of the renin-angiotension-aldosterone system. 
1 = 13-adrenoceptor blockers; 2 = renin inhibitors; 3 = angiotensin converting 
enzyme inhibitors; 4 = angiotensin-II antagonists; 5 = aldosterone antagonists. 
For a description see text. 
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calcium-calmodulin binding to kinase activation and, finally, to actin-myosin 
activation resulting in smooth muscle contraction. Interference with the 
influx of extracellular calcium can be induced by blockade of the receptors 
regulating the receptor operated channels (az-adrenoceptor and probably the 
angiotensin-II receptor and 5-hydroxytryptaminez receptor), by 
hyperpolarization which inhibits influx through the potential operated 
channels or by blocking the potential- and probably also receptor operated 
channels with .calcium-channel blockers. Calcium-channel blockers do not 
seem to antagonize the a1-adrenoceptor-mediated vasoconstriction since these 
receptors induce a release of calcium from intracellular stores rather than 
mediate an influx of calcium through calcium-channels (Van Zwieten and 
Timmermans, 1983). Drugs that increase the intracellular cAMP- or cGMP 
content cause relaxation probably due to inhibition of kinase activity (cAMP 
and cGMP), a reduction in the free calcium concentration (cAMP) or 
inhibition of calcium influx (cGMP). An increase in these two second 
messengers can be accomplished by 13z-adrenoceptor stimulation (cAMP), an 
inhibition of cAMP breakdown by phosphodiesterase-inhibitors, an 
enhancement of the cyclase-activity either "directly", for example by nitrates, 
or via the release of endothelium derived compounds such as the endothelium 
derived relaxing factor(s) or prostacyclin. Vasodilation can thus also be 
induced via the endothelium by the "endothelium-dependent" vasodilators of 
which acetylcholine, ATP, ADP, substance P, bradykinin, arachidonic acid and 
the phospholipase Az inhibitor quinacrine are representatives. These 
substances need, in contrast to the "endothelium-independent" vasodilators, 
like the calcium-channel blockers and nitrates, an intact endothelium for their 
vasodilator actions and a lack thereof may lead to vasoconstriction rather 
than vasodilation (see Furchgott, 1983). The (or one of the) endothelium 
derived relaxing factor(s) has recently been claimed to be nitric oxide 
(Moncada et al, 1987). 
1.1.2 Vasodilator profile: arterial, venous and mixed vasodilation. 
Vasodilator drugs often act preferentially on the arterial or venous 
vasculature (Table 1), but the mechanism underlying this preference is not 
always fully understood. Phentolamine, which blocks both the a1-and 
az-adrenoceptors, dilates the arterioles more so than the veins (Miller et al., 
19 7 6), whereas the 0:1-blocker prazosin dilates the venous and arterial 
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Fig. 3 
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Schematic representation of some of the pathways 1 involved in the contraction 
of a vascular smooth muscle cell and possible sites of interefence with 
vasoconstriction by vasodilating substances. ROC = receptor operated 
channels; POC = potential operated channel; AC = adenylate cyclase; GC = 
guanylate cyclase; EDRF = endothelium derived relaxing factor; a1 = 
a1- adrenoceptor; 15z = 15z-adrenoceptor; Pz = purinergicz-receptor. Az = 
adenosinez-receptor. For a description see text. 
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vasculature to a similar extent (see Scriabine and Taylor, 1986). It can be 
speculated that these differences are due to the distribution of a-adrenergic 
receptors. While both post-synaptic a1 and az-adrenoceptors have been 
clearly shown in 'in-vivo' studies to be present in arterioles, the 
a1-adrenoceptor seems to be the dominant receptor in the venous capacitance 
vessels in several species (see Langer and Hicks, 1984). The calcium-channel 
blockers act predominantly on the arterial side which might be due to the 
distribution of az-adrenoceptors as suggested above. The az-adrenoceptor-
mediated vasoconstriction has namely been associated with an influx of 
extracellular calcium and been demonstrated to be susceptible to 
calcium-channel blockade (Van Zwieten and Timmermans, 1983). However, a 
great variety exists between different tissues and species with respect to 
a-adrenoceptor distribution and the susceptibility of the a-adrenoceptors to 
calcium-channel blockers (Timmermans and van Meel, 1983; Cauvin et al., 
1983; Vanhoutte, 1985). This indicates that no firm conclusions can be drawn 
when trying to explain the profile of the above mentioned drugs. 
Hydralazine, minoxidil and to a lesser extent, angiotensin converting enzyme 
inhibitors also have a preference for arterial vessels. Nitrates, like 
nitroglycerine and isosorbide-dinitrate, act predominantly on the venous 
vasculature whereas nitroprusside and, as mentioned above, prazosin act 
equally on both the arterial and venous vessels. 
Table 1. Classification of vasodilating drugs based on their preference for 
arterial, venous or both types of blood vessels. 
Arterial 
Hydralazine 
Minoxidil 
Calcium-channel blockers 
Angiotensin converting 
enzyme inhibitors 
Phentolamine 
Venous 
Nitroglycerin 
Isosorbide-dinitrate 
Arterial + Venous 
Prazosin 
Nitroprusside 
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Fig. 4 
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Schematic representation of the changes in systemic hemodynamic variables 
and in tissue blood flow and some of the consequences of counterregulatory 
mechanisms invoked during treatment with vasodilating drugs. TPR = total 
peripheral resistance; CO = cardiac output; BP = blood pressure. The 
interrupted (with a minus sign) and uninterrupted lines indicate, 
respectively, the reduction and facilitation of the variable involved. 
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1.2 Hemodynamic consequences of arterial and venous vasodilation 
The systemic and regional hemodynamic profiles of vasodilators have been 
recently reviewed (Saxena and Bolt, 1986). Briefly, arterial vasodilation 
results in a decrease in total peripheral vascular resistance and consequently 
in a decrease in arterial blood pressure, whereas venous vasodilation leads to 
an increase in venous capacitance and, therefore, a reduction in ventricular 
filling pressure, stroke volume and cardiac output (Fig. 4). Thus vasodilation 
on either side results in a drop in arterial blood pressure. In an attempt to 
maintain arterial blood pressure, several counterregulatory mechanisms (neural 
as well as humoral) become operative; these counterregulatory responses may 
modify the direct vasodilator actions of vasodilating drugs on organs and 
tissues (Fig. 4). 
The effects of counterregulation are unique for the left ventricle since 
this part of the heart compromises its own blood supply during part of the 
cardiac cycle. Only 15% of the coronary blood flow, nourishing almost 
exclusively the subepicardium, occurs during systole because of the 
extravascular compression and wall tension developed during this part of the 
cardiac cycle (see Berne and Rubio, 1979). The remaining 85% of coronary 
flow occurs during diastole and supplies the subendocardial and, to a lesser 
extent, subepicardial layers. In the subendocardial layers, which depend thus 
entirely on diastole for their perfusion, vasodilator reserve is exhausted at a 
higher perfusion pressure (70 mmHg in dogs) than in the subepicardial layers 
(40 mmHg; Winbury and Howe, 1979). In the physiological state, like during 
exercise, vasodilator reserve in the subendocardial layers is sufficient to meet 
the increased oxygen-demand of the myocardium. The increase in heart rate, 
which causes a reduction in duration of diastole, does not exhaust vasodilator 
reserve because even during heavy exercise arterial blood pressure is 
maintained or elevated. On the other hand, the reduction in blood pressure 
(by peripheral vasodilation) and the baroreceptor reflex-mediated tachycardia 
(especially during acute administration of vasodilators) decrease both the 
perfusion pressure of the subendocardial layers and the perfusion time 
(Fig. 5). As a result the increase in subendocardial blood flow is. less than 
the increase in subepicardial flow. This holds true especially for arterial 
vasodilation since with venodilation preload, and thus intramyocardial pressure 
in the subendocardial layers, is reduced which favorably influences the 
perfusion pressure of the subendocardial layers. For myocardium supplied by 
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Fig. 5 
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Vasodilation and its consequences for the perfusion of the different 
myocardial layers. V = vasodilator; The interrupted lines (with a minus sign) 
and interrupted lines indicate, respectively, the reduction and facilitation of 
the variable involved. For a description see text. 
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non -diseased coronary arteries the reduction in the subendocardial-
subepicardial blood flow ratio induced by the vasodilating drugs has no 
clinical implications as subendocardial blood flow is still commensurate with 
the needs of the subendocardial layers. However, when a coronary artery is 
obstructed and vasodilator reserve is already reduced, the combination of a 
decrease in arterial blood pressure and a reflex-tachycardia may have 
deleterious effects on the perfusion of especially the subendocardial layers 
(see section 1.3 coronary artery disease). 
1.3 Therapeutic use of vasodllatlng drugs 
Hypertension 
The use of vasodilators in hypertension is a rational approach since these 
drugs antagonize the major hemodynamic disturbance in most forms of 
hypertension namely the increase in total peripheral resistance. To prevent 
counterregulatory mechanisms from abolishing the beneficial actions of 
vasodilators, a combination therapy with 13-adrenoceptor antagonists and/or 
diuretic agents is often needed in the clinical situation. Furthermore, during 
chronic treatment 13-adrenoceptor antagonists have an additive hypotensive 
action which may allow reduction of the doses of the drugs used. 
Coronary artery disease 
Nitrates, which have a more marked action on the venous side, have been 
used for decades in the treatment of angina pectoris due to different causes. 
The beneficial actions of nitrates is primarily ascribed to the reduction of 
cardiac preload and, to some extent, afterload (Williams et al., 1965; Burggraff 
and Parker, 1974) which decrease ventricular dimension and wall tension and 
therefore lower myocardial oxygen demand. The decrease in wall tension also 
increases the effective diastolic perfusion pressure of the subendocardial 
layers. Another more recently appreciated factor contributing to the anti-
ischemic actions of nitrates is that these drugs dilate the large epicardial 
vessels and thereby reduce the severity of the coronary artery stenosis 
(Brown et al., 1981). 
In the last decade calcium-channel blockers have been under investigation 
in the treatment of coronary artery disease. Although their efficacy has been 
proven in coronary artery spasm, the usefulness of calcium-channel blockers 
in stable angina pectoris remains a matter of debate as in the clinical setting 
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arterial vasodilators not always favorably influence the myocardial oxygen 
balance. By reducing the afterload the arterial vasodilators often cause an 
increase in heart rate, a major determinant of myocardial oxygen-demand. 
The increase in heart rate also reduces the duration of the diastolic perfusion 
time. This, together with the reduction in perfusion pressure by the 
hypotensive action of these drugs may be harmful for, in particular, flow to 
the subendocardial layers. An increase in blood flow can still occur via 
dilatiop at the ,site of the coronary artery stenosis {which is not always 
possible), via dilation of coronary collaterals (which may not always be 
present) or via dilation in the terminal arteriolar bed (which is generally 
believed to be maximal during myocardial ischemia). But vasodilators have 
also been reported to induce "coronary steal" either from subendocardium to 
subepicardium distal to a fixed corQnary artery stenosis (Gross and Warltier, 
1981; Weintraub et al., 1981; Gewirtz et al., 1984) or from ischemic 
myocardium distal to a completely occluded coronary artery to normally 
perfused myocardium (Gross and Warltier, 1981). These observations have led 
to the concept that in ischemic myocardium arterial vasodilators reduce the 
distal coronary perfusion pressure , by vasodilation irt non-ischemic 
myocardium, 
myocardium. 
thereby "stealing" blood from perfusion pressure dependent 
Recently, however, several studies have suggested that 
vasodilation is not maximal in ischemic myocardium in which case vasodilator 
therapy may still be useful (Gorman et al., 1984; Heusch and Deussen, 1984; 
Aversano and Becker, 1985; Canty and Klocke, 1985; Pantely et al., 1985). 
Furthermore, combination therapy with ~-adrenoceptor antagonists has proven 
superior to monotherapy with 1 either class of drugs. This has revived 
interest in vasodilators as a therapeutic in (stable) angina pectoris. 
Congestive Heart Failure 
A role for vasodilators in heart failure (a situation in which the heart is 
unable to pump blood at a rate commensurate with the metabolic needs of 
body tissues), seems at first less obvious than in the case of hypertension 
since the primary cause for heart failure is often the myocardium. However, 
the peripheral vasculature responds to cardiac pump failure with constriction 
of the arterioles and veins causing a further deteriorating of myocardial 
performance. The aim of vasodilator therapy is therefore to reduce pre- and 
afterload of the heart, thereby normalizing the ventricular dimension and 
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pump function (Cohn and Franciosa, 1977; Chatterjee and Parmley, 1977). 
Furthermore, in the failing circulation the arteriolar constriction is 
particularly pronounced in the renal, splanchnic, dermal and muscular regions 
(see Drexler et al., 1985, 1986a) and vasodilators should therefore preferably 
dilate these vascular beds in order to normalize perfusion thereof. 
Migraine 
The pathogenesis of migraine and related headaches remains controversial. 
Several hypotheses, like the neuronal, vascular, or ischemia hypothesis (Blau, 
1987), have not been able to completely explain the clinical signs of 
migrainous headaches. The reason for these different theories regarding the 
pathophysiology of migraine may be that migraine, like hypertension, is a 
syndrome where the underlying causative factors may vary in different 
patients. 
The introduction of vasodilators (calcium-channel blockers) in the 
treatment of migraine is based on two separate reasonings. The first 
involves the hypothesis by which advocates initial, mainly intracranial, 
vasoconstriction during the prodromal phase, followed by extracranial 
vasodilation causing the head pain (Wolff, 1963). Although this concept of a 
pure vascular basis of migraine headache may be an oversimplification (Olesen 
et al., 1981; Bruyn, 1984), a number of studies have found a reduced cerebral 
blood flow during the initial phase of migraine (O'Brien, 1971; Skinhoj, 1973; 
Simard and Paulson, 1973; Norris et al., 1975; Henry et al., 1978; Sakai and 
Meyer, 1978). Yamamoto and Meyer (1980) considered that calcium-channel 
blockers would prevent the initial cerebral vasospasm and, therefore, also 
mitigate the subsequent painful vasodilation during the headache phase. 
Indeed, some studies indicate that nimodipine (Gelmers, 1983; Meyer and 
Hardenberg, 1983) and nifedipine (Kahan et al., 1983), may be of value in 
migraine prophylaxis. The second reasoning, based on which another calcium-
channel blocker flunarizine was introduced assumes that migraine is due to a 
focal cerebral ischaemia (Amery, 1982). The resulting accumulation of calcium 
and the consequent cell damage and migraine headache would then be 
suppressed by calcium-channel blockers. 
Another observation which appears to be of interest is the high potency 
of nimodipine in antagonizing rabbit basilar artery contractions induced by 
5-hydroxytryptamine (Towart, 1981); the latter is released (and then depleted) 
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from blood platelets during migraine headaches (Lance, 1982). 
5-Hydroxytryptamine and several antimigraine drugs (Johnson and Saxena, 
1978; Saxena and Verdouw, 1982; Saxena et al.,l983; Saxena, 1987) are 
extremely effective in constricting cranial extracerebral arteriovenous 
anastomoses, which may open up during the headache phase of migraine 
(Heyck, 1969; Saxena, 1978}. The relationship between 5-hydroxytryptamine, 
arteriovenous shunting and calcium-channel blockers is, however, not known. 
·gl ~ N02 CHs~o-q C·O-CH 
o I o s 
CH3 ~ CHs 
H 
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Fig. 6 
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~OCH3 
V"ocH3 
(:(»_:::· Nl-0-~ 
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CH2-CH2 - N (CH3)2 
Diltiazem 
Chemical structure of the three 'first generation' calcium-channel blockers 
verapamil, nifedipine and diltiazem. Note the great differences in structure. 
1.4 Drugs used in this thesis 
Calcium-channel blockers 
In the early sixties German scientists (Lindner, 1960; Haas and Hartfelder, 
1962} observed that prenylamine and verapamil exerted, besides coronary 
vasodilator actions, negative inotropic effects on isolated cat and rabbit 
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myocardium. At first these drugs were believed to be 13-adrenoceptor 
blocking agents as they opposed the catecholamine-induced effects on the 
heart (Melville and Benfey, 1965; Haas and Busch, 1967). However, 
Fleckenstein et al. (1967) reported that the effects of prenylamine and 
TABLE 2 RELATIVE EFFECTS OF CALCIUM ANTAGONISTS IN EXPERIMENTAL 
PREPARATIONS COMPARED WITH THERAPEUTIC LEVELS IN MAN* 
Verapamil Nifedipine Diltiazem 
Therapeutic level in man 
ng/ml 80-400 25-100 50-300 
molecular weight 455 346 415 
molar weight 2-8 X 10·7 M 0.5-2 X 1 o-7 M 1-7 X 10·7 M 
protein binding about 90% about 95% about 85% 
molar value, corrected for protein 2-8 X 10·8 M 0.3-1 X 10·8 M 1-5 X 10·8 M 
binding 
Isolated coronary artery contraction 10·7 M 10·8 M 10·7 M 
50% inhibition 
Myocardial depression sx10-aM 5X1Q·7 M 10·4 M 
40% depression of contractile force 
Fast sodium current depression 10·4 M no effect 10·4 M 
Slowing of heart rate by 20% 1o-a M 10·5 M 10·8 M 
Relative effect on AV node vs 6.5:1 1:1 20:1 
contractile force 
* From Singh and Opie (1984) 
verapamil were the result of inhibition of the influx of calcium into the 
I'll:yocardial cells. Consequently, these agents were called calcium-antagonists 
and they were ascribed two main properties: 1) suppression of the slow 
calcium current in ventricular muscle and 2) the reversal of such suppression 
by an increase in external calcium concentration (Fleckenstein, 1968, 1977). 
Later, other properties were discovered such as the protection against 
isoprenaline-induced myocardial calcium overload and inhibition of 
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calcium-induced tension development in vascular smooth muscle. With the 
gradual elucidation of their main mechanism of action these agents are now 
more generally called calcium-entry blockers or calcium-channel blockers. 
During the last decade the "first generation" calcium-channel blockers 
verapamil, nifedipine and diltiazem, which are structurally unrelated to each 
other (Fig. 6), have become widely used in cardiovascular disorders. With 
the differences in chemical structure also the affinity for the myocardium and 
the vasculature varies widely (Table 1). In recent years the so called "second 
generation" agents, analogues of the first generation drugs, have been 
developed in an attempt to obtain substances with greater specificity for 
either cardiac (sinus-node, A V -node, myocytes) or vascular (specific vascular 
bed) tissues. In this respect especially the dihydropyridine-derivatives 
Nifedipine 
Nimodipine Nisoldipine 
Fig. 7 
Chemical structure of the dihydropyridine calcium-channel blockers 
nifedipine, nisoldipine and nimodipine. 
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(nifedipine, nisoldipine, nimodipine; Fig. 7) have grown in number. Compared 
to the parent compound nifedipine, some of these agents have been claimed to 
have a greater selectivity for vascular tissue over cardiac tissue (Kazda et al., 
1980) or for cerebral or coronary arterial beds over other regional beds 
(1'akenaka et al., 1976; Kazda et al., 1980, 1982). 
Current indications for the clinical use of calcium-channel blockers vary 
from stable angina pectoris (Scheidt, 1982), angina at rest and coronary 
vasospasm (Schroeder, 1982), hypertension, hypertrophic cardiomyopathy and 
myocardial infarction (Toggart and Zelis, 1982) and cardiac arrhythmias (Singh 
et al., 1982) to prophylaxis of migraine (Gelmers, 1983) and cerebral ischemia 
due to post-hemorrhagic cerebral vasospasm (Allen et al., 1983). 
Xanthine 
0 CH3 
H3C ~x· N N~ O~N I N 
I 
CH3 
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N 
~~0-CH3 
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Fig. 8 
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I 
CH3 
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UD·CG 212 Cl 
Chemical structure of xanthine, the methylxanthines caffeine and theophylline 
and the pyridazinone-derivatives pimobendan and its 0-demethylmetabolite 
UD-CG 212 Cl. *All substances contain the "active" part of the molecule 
which is thought to be responsible for the phosphodiesterase-inhibiting actions 
of these drugs. 
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Pyridazinone-derivatives 
This class of drugs, to which pimobendan and its 0-demethylmetabolite 
UD-CG 212 Cl (2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-
pyridazinyl)benzimidazole HCl) belong (Fig. 8), exert vasodilator actions on 
the arterial as well as on the venous side (Diederen et al., 1982). Besides 
vasodilator effects the pyridazinone-derivatives possess cardiostimulatory 
actions (Diederen et al., 1982; Van Meel, 1985). The mechanism through 
which the pyridazinone-derivatives exert their actions was at first thought to 
be via phosphodiesterase-inhibition (see Honerjager et al., 1984; Berger et al., 
1985); they share with the phosphodiesterase inhibiting (methyl) xanthines the 
so called "active site" of the molecule which is thought to be responsible for 
phosphodiesterase-inhibition (Fig. 8). However, in addition, the cardiotonic 
actions may also be due to an increased sensitivity of myocardial contractile 
proteins to calcium (Ruegg et al., 1984; Van Meel et al., 1986) or a 
prolongation of the action potential, allowing more calcium to enter the 
myocyte (Honerjager et al., 1984). 
The cardiovascular profile, i.e. vasodilation of venous and arterial beds 
and positive inotropic actions, appears to be particularly favorable for the 
therapy of congestive heart failure (Cohn and Franciosa, 1978). Indeed, 
pimobendan has recently been reported to improve cardiac pump function and 
normalize preload in patients with congestive heart failure at rest (Brand and 
Hagemeyer, 1987) and during exercise (Hagemeyer and Brand, 1987). 
NITROGLYCERIN NICORANDIL 
Fig. 9 
Chemical structure of the classical nitrate nitroglycerin and the nitrate-like 
substance nicorandil. 
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Nicorandil 
Nicorandil (SG-75, N-(2-hydroxyethyl) nicotinamide nitrate; Fig. 9) is a 
new anti-anginal drug with coronary vasodilator properties (Uchida et al., 
1978). In vitro studies have shown that besides the nitrate-like action, an 
increase in intracellular cGMP (Fig. 3), nicorandil also enhances the 
conductance of potassium-channels thereby hyperpolarizing the cell membrane 
(Taira, 1987). As a result nicorandil, in addition to the classical nitrate 
venodilatory action, has a potent effect on the arterial smooth muscle 
vasculature and dilates epicardial conductance as well as intramyocardial 
resistance vessels (Taira, 1987; Suryapranata et al., 1988). At clinical 
dose-range the drug possesses negligible negative inotropic actions (Belz et 
al., 1984). 
The profile of venous and arterial dilation, together with the reported 
anti -ischemic actions (Uchida, 1978; Thorman et al., 1982, 1983) suggest that 
nicorandil might be useful in the treatment of heart failure, coronary artery 
disease and hypertension. 
1.6 Aim of the thesis 
In this thesis the cardiovascular pharmacological actions of a number of 
vasodilating drugs have been studied and compared in pigs. Firstly, we 
compared the vasodilator profile of the dihydropyridine-derivatives 
nisoldipine, nimodipine and nifedipine and also studied the claimed preference 
of nisoldipine for the coronary circulation (Kazda et al., 1980; Serruys et al., 
1985; Drexler et al., 1986b) and of nimodipine for the cerebral circulation 
(Kazda et al., 1982) (chapters 2-5). Secondly, since the perfusion of organs 
and tissues may be compromised in several pathological disorders for which 
vasodilating drugs might be employed (ischemic heart disease, heart failure, 
hypertension), we compared the vasodilator profiles of the dihydropyridine-
derivatives nisoldipine and nimodipine with those of pimobendan, UD-CG 212 
CL and nicorandil after intravenous administration in anesthetized pigs 
(chapters 6-9). Thirdly, in view of the potentially useful combination of 
vasodilators and 13-adrenoceptor antagonists to reduce h;,rpotension -induced 
baroreceptor reflex-mediated tachycardia, we compared the systemic 
hemodynamic actions of the different vasodilating drugs in conscious pigs in 
the absence or presence of 13-adrenoceptor blockade (chapters 9-11). Finally, 
the long-held view that vasodilation in ischemic myocardium is maximal (see 
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Berne and Rubio, 1979) and, therefore, vasodilators may induce coronary 
"steal" (Weintraub et al., 1981; Gross and Warltier, 1981; Gewirtz et al., 1984), 
may not hold true. Recently, vasodilator therapy has been shown to induce 
an improvement of perfusion and function of ischemic myocardial areas by 
recruiting vasodilator reserve (Gorman. et al., 1984; Heusch and Deussen, 1984; 
Aversano and Becker, 1985; Canty and Klocke, 1985; Pantely et al., 1985). In 
view of these new findings, lending support to the possible usefulness of 
vasodilator drugs in myocardial ischemia, we investigated the effects of 
nisoldipine on perfusion of myocardium distal to a fixed concentric coronary 
artery stenosis in conscious pigs (chapter 12). In. addition, the possible 
anti-ischemic action of this drug was studied during myocardial ischemia-
induced in animals subjected to treadmill-exercise (chapter 13). 
References 
Allen, G.S., Ahn, H.S., Preziosi, T.J., Battye, R., Boone, S.C., Boone, S.C., 
Chou, S.N. Kelly, D.L., Weir, B.K., Crabbe, R.A., Lavik, P.J., 
Rosenbloom, S.B., Dorsey, F.C., Insram, C.R., Mellits, D.D., Bertsch, L.A., 
Bo~svert, D.P., Hundley, M.B., Johnson, R.K., Strom, J.A. and Transou, C.R. 
Cerebral arterial spasm - a controlled trial of nimodipine in patients with 
subarachnoid hemorrhage. N. Engl. J. Med .. 308 (11), 619-624, 1983. 
Amery, W.H. Brain hypoxia: the turning-point in the genesis of the migraine 
attack? Cephalalgia 2, 83-109, 1982. 
Aversano, T. and Becker, L.C. l'ersistence of coronary vasodilator reserve 
despite functionally significant flow reduction. Am. J. Physiol. 248, 
H403-H411, 1985. 
Belz, G.G., Mathews, J., Heinrich, J. and Wagner, G. Controlled comparison of 
the pharmacodynamic effects of nicorandil (SG-75) and isosorbide dinitrate 
in man. Eur. J. Clin. Pharmacol. 26, 681-685, 1984. 
Berger, C., Meyer, W., Scholz, H. and Starbatty, J. Effects of the 
benzimidazole deri va ti ves pimobendan and 2- ( 4- Hydroxyphenyl)-
5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl) benzimidazole HCl on 
phosphodiesterase activity and force of contraction in guinea-pig hearts. 
Arzneim. Forsch. I Drug Res. 35(1I), 1668-1673, 1985. 
Berne, R.M. and Rubio, R. Coronary circulation. In: Handbook of physiology, 
Section 2: The Cardiovascular System, Vol. I: The heart, Eds: Berne, R.M., 
Sperelakis, N., Geiger, S.R., Waverly Press, Inc., Baltimore, 1979, pp. 
873-952. 
Blau, J.N. (Ed.). Migraine: Clinical, Therapeutic, Conceptual and Research 
Aspects, Chapman and Hall, London, 1987. 
Bolton, T.B. Mechanisms of action of transmitters and other substances on 
smooth muscle. Physiol. Rev. 3, 606-718, 1979. 
Brand, H.J. and Hagemeijer, F. Hemodynamic effects of pimobendan given 
orally to patients with severe heart failure. Eur. Heart J. 
8 (Abstr. Suppl. 2), 276, 1987. 
31 
Brown, B.G., Bolson, E., Peterson, R.B., Pierce, C.D. and Dodge, H.T. The 
mechanism of nitroglycerin action: stenosis vasodilatation as a major 
component of the drug response. Circulation 64, 1098-1097, 1981. 
Bruyn, G.W. The pathomechanism of migraine as a basis for pharmacotherapy: 
a clinician's epilogue. In: The pharmacological basis of migraine therapy. 
Eds: Amery, W.K., Van Nueten, J.M. and Wauquier, A. Pitman, London, 
1984, pp. 267-278. 
Burggraf!, G.W. and Parker, J.O. Left ventricular volume changes after amyl 
nitrate and nitroglycerin in man, as measured by ultrasound. Circulation 
49, 136-143, 1974. 
Canty, J.M. and Klocke, F.J. Reduced regional myocardial perfusion in the 
presence of pharmacologic vasodilator reserve. Circulation 71 (2), 
370-377. 1985. 
Cauvin, C., Loutzenhiser, R. and Van Breemen, C. Mechanisms of calcium 
antagonist-induced vasodilation. Ann. Rev. Pharmacol. To xi col. 23, 
373-396, 1983. 
Chatterjee, K. and Parmley, W.W. The role of vasodilator therapy in heart 
failure. Prog. Cardiovasc. Dis. 19, 301-325, 1977. 
Cohn, J.N. and Franciosa, J.A. Vasodilator therapy of cardiac failure. N. Engl. 
J. Med. 297, 27-31, 254-258, 1977. 
Cohn, J.N. and Franciosa, J.A. Selection of vasodilator inotropic or combined 
therapy for the management of heart failure. Am. J. Med. 65, 181, 1978. 
Derkx, F.H.M. Human prorenin. Ph.D. thesis, Erasmus University 
Rotterdam, Rotterdam, the Netherlands, 1987. 
Diederen, W., Dammgen, J. and Kadatz, R. Cardiovascular profile of UD-CG 
115, a new orally and long acting cardiotonic compound, not related to 
13-mimetics or cardiac glycosides. Naunyn -Schmiedeberg's Arch.· Pharmac. 
321, R36, 141, 1982. 
Drexler, H., Depenbusch, J.W., Truog, A.G., Zelis, R. and Flaim, S.F. Effects 
of diltiazem on cardiac function and regional blood flow at rest and during 
exercise in a conscious rat preparation of chronic heart failure (myocardial 
infarction). Circulation 71, 1262-1270, 1985. 
Drexler, H., Toggart, E.J., Glick, M.R., Heald, J., Flaim, S.F. and ZeUs, R. 
Regional vascular adjustments during recovery from myocardial infarction 
in rats. J. Am. Coll. Cardiol. 8, 134-142, 1986a. 
Drexler, H., Truog, A.G., Zelis, R. and Flaim, S.F. Regional vascular and 
hemodynamic effects of orally administered nisoldipine in conscious rats. J. 
Cardiovasc. Pharmacol. 8, 151-155, 1986b. 
Dzau, V.J. and Pratt, R.E. Renin-angiotensin system: Biology, physiology, and 
pharmacology. In: The Heart and Cardiovascular System, Eds: Fozzard, H.A. 
Haber E., Jennings R.B., Katz A.M., Morgan H.E., Raven Press, New York, 
1986, pp. 1631-1662. I 
Fleckenstein, A., Kammermeier,· H., Doring, H. and Freund, H.J. Zum 
Wirkungs-mechanismus neuartiger Koronardilatatoren mit gleichzeitig 
Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril. Z. 
Kreislaufforsch. 56, 716-744, 839-853, 1967. 
Fleckenstein, A. Experimental heart failure due to disturbances in 
high-energy phosphate metabolism. In: Proceedings of the Fifth European 
Congress of Cardiology, Athens, 1968, pp. 255-269. 
Fleckenstein, A. Specific pharmacology of calcium in myocardium, cardiac 
pacemakers and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 
17, 149-166, 1977. 
32 
Furchgott, R.F. The role of endothelium in the responses of vascular smooth 
muscle to drugs. Ann. Rev. Pharmacol. Toxicol. 24, 175-197, 1984. 
Gelmers, H.J. Nimodipine, a new calcium antagonist, in the prophylactic 
treatment of migraine. Headache 23, 106-109, 1983. 
Gewirtz, H., Gross, S.L., Williams, D.O. and Most, A.S. Contrasting effects of 
nifedipine and adenosine on regional myocardial flow distribution and 
metabolism distal to a severe coronary arterial stenosis: observations in 
sedated, closed-chest, domestic swine. Circulation 5, 1048-1057, 1984. 
Gorman, M.W., Wangler, R.D., Dewit, D.F. and Sparks, H.V. jr. Progressive 
vasomotor changes in ischaemic myocardium. Acta Med. Scand. 
694 (Suppl), 38-44, 1984. 
Gross, G.J. and Warltier, D.C. Coronary steal in four models of single or 
multivessel obstruction in dogs. Am. J. Cardiol. 48, 84-92, 1981. 
Haas, H., and Busch, E. Vergleichende Untersuchungen der wirkung von 
a-isopropyl-a(n -methyl-N- homoveratryl)-T-aminopropyl)-3,4-dimethoxy-
phenylacetonitril, seiner Derivate sowie einiger andere Coronardilatatoren 
und ~-receptor-affiner Substanzen. Arzneim. Forsch. I Drug Res. 
17, 257-271, 1967. 
Haas, H. and Hartfelder, G. a-isopropyl-a-(n-methylhomoveratryl)-
T- aminopropyl)- 3, 4- dimethoxy-phenylacetonilril, eine Substanz mit 
coronargefaberweiternden Eigenschaften. Arzneim. Forsch. I Drug Res. 12, 
549-558, 1962. 
Hagemeyer, F. and Brand, H.J. Bicycle ergometry in heart failure: decreasing 
stroke volume with increasing pulmonary wedge pressure. Improvement 
after oral pimobendan. Eur. Heart J. 8 (Abstr. Suppl. 2), 352, 1987. 
Henry, P.Y., Vernheit, J., Orgogozo, J.M., Caille, J.M. Cerebral bloodflow in 
migraine and cluster headache. Res. Clin. Stud. Headache 6, 81-88, 1978. 
Heyck, H. Pathogenesis of migraine. Res. Clin. Stud. Headache 2, 1-28, 1969. 
Reusch, G. and Deussen, A. Nifedipine prevents sympathetic vasoconstriction 
distal to severe coronary stenoses. J. Cardiovasc. Pharmacol. 6, 378, 1984. 
Honerjager, P., Heiss, A., Schafer-Korting, M., Schonsteiner, G. and 
Reiter, M. UD-CG 115 a cardiotonic pyridazinone which elevates cyclic 
AMP and prolongs the action potential in guinea-pig papillary muscle. 
Naunyn-Schmiedeberg's Arch. Pharmac. 325, 259-269, 1984. 
Johnson, B.M. and Saxena, P.R. The effect of ergotamine on tissue blood 
flow and the arteriovenous shunting of radioactive microspheres in the 
head. Br. J. Pharmacol. 63, 541-549, 1978. 
Kahan, A, Weber, S., Amor, B., Guerin, F. and Degeorges, M. Nifedipine in the 
treatment of migraine in patients with Raynaud's phenomenon. N. Engl. J. 
Med. 308, 1102-1103, 1983. 
Kazda, s., Garthoff, B., Meyer, H., Schlossmann, K., Stoepel, K., Towart, R., 
Vater, W. and Wehinger, E. Pharmacology of a new calcium antagonistic 
compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophyenyl)-
3,5-pyridinedicarboxylate (Nisoldipine, Bay K 5552). Arzneim. Forsch. 
I Drug Res. 30, 2144-2162, 1980. 
Kazda, S., Garthoff, B., Krause, H.P. and Schlossmann, K. Cerebrovascular 
effects of the calcium antagonistic dihydropyridine derivative nimodipine in 
animal experiments. Arzneim. Forsch. I Drug Res. 32, 331-337, 1982. 
Lance, J.W. Mechanism and Management of Migraine, 4th edn., Butterworths, 
London, 1982. 
33 
Langer, S.Z. and Hicks, P.E. Alpha-Adrenoceptor Subtypes in Blood Vessels: 
Physiology and Pharmacology. J. Cardiovasc. Pharmacol. 6, S547-S558, 
1984. 
Langer, S.Z. and Armstrong, J.M. Prejunctional receptors and the 
cardiovascular system: pharmacological and therapeutic relevance. In: 
Cardiovascular Pharmacology, Ed: Antonaccio, M., Raven Press, New York, 
1984, pp. 197-213. 
Lindner, E. Phenyl-propyl-diphenyl-propylamin, eine neue Substanz mit 
coronargefaber-weiternder Wirkung. Arzneim. Forsch. I Drug Res. 
10, 569-573, 1960. 
Melville, K.I. and Benfey, B.C. Coronary vasodilatory and cardiac adrenergic 
blocking effects of iproveratril. Can. J. Physiol. Pharmacol. 43, 339-342, 
1965. 
Meyer, J.S. and Hardenberg, J. Clinical effectiveness of calcium entry blockers 
in prophylactic treatment of migraine and cluster headaches. Headache 23, 
266-277. 1983. 
Meyer, J.S., Hata, T., Imai, A. Evidence supporting a vascular pathogenesis of 
migraine and cluster headache. In: Migraine - clinical, therapeutical, 
conceptual and research aspects, Ed: Blau, J.N., Chapman and Hall, London, 
1987, pp. 265-302. 
Miller, R.R., Vismara, L.A., Williams, D.O., Amsterdam, E.A. and Mason, D.T. 
Pharmacological mechanisms for left ventricular unloading in clinical 
congestive heart failure: differential effects of nitroprusside, phentolamine, 
and nitroglycerin on cardiac function and peripheral circulation. Circ. Res. 
39, 127-133, 1976. 
Moncada, s., Herman, A.G. and Vanhoutte, P. Endothelium-derived relaxing 
factor is identified as nitric oxide. Trends in Pharmacological Sciences, 
8, 365-368, 1987. 
Norris, J.W., Hachinsky, V.C., Cooper, P.W. Changes in cerebral bloodflow 
during a migraine attack. Br. Med. J. 3, 676-684, 1975. 
O'Brien, M.D. Cerebral blood changes in migraine. Headache 10, 139-143, 
1971. 
Olesen, J., Tfelt-Hansen, P., Henriksen, L. and Larsen, B. The common 
migraine attack may not be initiated by cerebral ischaemia. Lancet ii, 
438-440, 1981. 
Pantely, G.A., Bristow, J.D., Swenson, L.J, Ladley, H.D., Johnson, W.B. and 
Anselone, e.G. Incomplete coronary vasodilation during myocardial 
ischemia in swine. Am. J. Physiol. 249, H638-H647, 1985. 
Ruegg, J.C., Pfitzer, G., Eubler, D. and Zeugner, C. Effect on contractility of 
skinned fibres from mammalian heart and smooth muscle by a new 
benzimidazole deri va ti ve, 4, 5- dihydro- 6- [ 2- (4-methoxyphenyl)-
1 H- benzimidazol-5-yl) -5-methytl-3(2H) -pyridazinone. Arzneim. Forsch. I 
Drug Res. 34(1I), 1736-1738, 1984. 
Sakai, F and Meyer, J.S. Regional cerebral hemodynamics during migraine and 
cluster headaches measured by the 133Xe inhalation method. Headache 18, 
122-132, 1978. 
Saxena, P.R. Arteriovenous shunting and migraine. Res. Clin. Stud. Headache 
6, 89-112, 1978. 
Saxena, P.R. Arteriovenous anastomoses and veins in migraine research. In: 
Migraine - Clinical, Therapeutical, Conceptual and Research Aspects, Ed: 
Blau J.N., Chapman and Hall, London, 1987. 
34 
Saxena, P.R. and De Vlaam-Schluter, G.M. Role of some biogenic substances in 
migraine and relevant mechanism in antimigraine action of ergotamine-
studies in an experimental model for migraine. Headache 13, 142-163, 
1982. 
Saxena, P.R. and Verdouw, P.D. Redistribution by 5-hydroxytryptamine of 
carotid arterial blood at the expense of arteriovenous anastomotic blood 
flow. J. Physiol. 332, 501-520, 1982. 
Saxena, P.R. and Bolt, G.R. Haemodynamic profiles of vasodilators in 
experimental hypertension. Tips 7, 501-506, 1986. 
Saxena, P.R., Koedam, N.A., Heiligers, J., and Hof, R.P. Ergotamine-induced 
constriction of cranial arteriovenous anastomoses in dogs pretreated with 
phentolamine and pizotifen. Cephalalgia 3, 71-78, 1983. 
Scheidt, S.S. The Role of the Calcium Blockers in the Treatment of Chronic 
Stable Angina. In: Calcium Blockers. Mechanisms of Action and Clinical 
Applications, Eds: Flaim, S.F. and Zelis, R., Urban and Schwarzenberg 
Baltimore-Munich, 1982, pp. 231-244. 
Schroeder, J.S. Treatment of Coronary Artery Spasm with Calcium Blockers -
Variant Angina and Unstable Angina. In: Calcium Blockers. Mechanisms of 
Action and Clinical Applications, Eds: Flaim, S.F. and Zelis, R., Urban and 
Schwarzenberg Baltimore-Munich, 1982, pp. 219-230. 
Scriabine, A. and Taylor, D.G. Antihypertensive drugs. In: Cardiovascular 
Pharmacology, Ed: Antonaccio, M., Raven Press, New York, 1984, 
pp. 257-294. 
Serruys, P.W., Suryapranata, H., Planellas, J., Wijns, W., Vanhaleweyk, G.L.J., 
Soward, A., Jaski, B.E. and Hugenholtz, P.G. Acute effects of intravenous 
nisoldipine on left ventricular function and coronary hemodynamics. Am. J. 
Cardiol. 56, 140-146, 1985. 
Simard, D., Paulson, O.B. Cerebral vasomotor paralysis during migraine attack. 
Arch. Neurol. 29, 207-209, 1973. 
Singh, B.N., Koonlawee, N. and Feld, G. Calcium Blockers in the Treatment 
of Cardiac Arrhythmias. In: Calcium Blockers, Mechanisms of Action and 
Clinical Applications. Eds: Flaim, S.F. and Zelis, R. Urban and 
Schwarzenb,erg, Baltimore-Munich, 1982, pp. 245-264. 
Singh, B.N. and Opie, L.H. Drugs for the Heart. III Calcium Antagonists. 
Grune and Stratton, Orlando, 1984, pp. 39-64. 
Skinhoj, E. Hemodynamic studies within the brain during migraine. Arch. 
Neurol. 29, 95-98, 1973. 
Suryapranata, H., Serruys, P.W., De Feyter, P.J., Verdouw, P.D. and 
Hugenholtz, P.G. Coronary vasodilatory action following a single dose of 
nicorandil. Am. J. Cardiol. 1988 (in press). 
Taira, N. Similarity and dissimilarity in the mode and mechanism of action 
between nicorandil and classical nitrates: An overview. J. Cardiovasc. 
Pharmacal. 10 (Suppl. 8), S1-S9, 1987. 
Takenaka, T., Usuda, S., Nomura, T., Maeno, H. and Sado, T. Vasodilator 
profile of a new 1,4-dihydropyridine derivative YC-93. Arzneim. Forsch. I 
Drug Res. 26, 2172-2178, 1976. 
Thormann, J ., Schlepper, M., Kramer, W. and Gottwik, M. Effectiveness of 
nicorandil (SG-75), a new long-acting drug with nitroproperties, in patients 
with coronary artery disease: improvement in left ventricular function and 
regional wall motion without pacing-induced angina. Z. Kardiol. 71, 
747-753, 1982. 
35 
Thormann, J., Schlepper, M., Kramer, W., Gottwik, M. and Kindler, M. 
Effectiveness of nicorandil (SG-75), a new long-acting drug with 
nitroglycerin effects, in patients with coronary artery disease: improved 
left ventricular function and regional wall motion and abolition of 
pacing-induced angina. J. Cardiovasc. Pharmacal. 5, 371-377, 1983. 
Timmermans, P.B.M.W.M. and Van Meel, J.C.A. Differential inhibition of 
a1-adrenoceptor mediated pressor effects by calcium entry blockers in 
pithed normotensive rats. Naunyn-Schmiedeberg's Arch. Pharmacal. 322 
(Suppl), R71, 1983. 
Toggart Jr., J.T. and Zelis, R. The Role of Calcium Blockers in the Treatment 
of Other Cardiovascular Disorders. In: Calcium Blockers. Mechanisms of 
Action and Clinical Applications, Eds: Flaim, S.F. and Zelis, R., Urban and 
Schwarzenberg, Baltimore-Munich, 1982, pp. 265-283. 
Towart, R. The selective inhibition of serotonin-induced contractions of 
rabbit cerebral smooth muscle by calcium-antagonistic dihydropyridines. 
Circ. Res. 48, 650-657, 1981. 
Uchida, Y. Antianginal action of 2-nicotinamidoethyl nitrate (SG-75). Saishin 
Igaku 33, 1629-1635, 1978. 
Vanhoutte, P.M. Calcium-entry blockers, vascular smooth muscle and systemic 
hypertension. Am. J. Cardiol. 55, 1 7B-23B, 1985. 
Van Meel, J .C.A. Cardiovascular effects of the positive inotropic agents 
pimobendan and sulmazole in vivo. Arzneim. Forsch. I Drug ~Res. 35, 
284-288, 1985. 
Van Meel, J.C.A., Gerstenberg, W., Boss, H. and Mrwa, U. Effects of some 
cardiotonics on calcium sensitivity of skinned myocardial fibres. Br. J. 
Pharmacal. 87 (Suppl), 102P, 1986. 
Van Zwieten, P.A. Handboo·k of Hypertension: Pharmacology of 
Antihypertensive Drugs. Ed: Van Zwieten, P.A. Elsevier Science Publishers 
BV, Amsterdam, 1984, vol. 3, pp. 1-6. 
Van Zwieten, P.A. and Timmermans, P.B.M.W.M. Review. Cardiovascular 
az-receptors. J. Mol. Cell. Cardiol. 15, 717-733, 1983. 
Weintraub, W.S., Hattori, S., Agarwal, J., Bodenheimer, M.M., Banka, V.S. and 
Helfant, R.H. Variable effect of nifedipine on myocardial blood flow at 
three grades of coronary occlusion in the dog. Circ. Res. 48, 937-942, 
1981. 
Williams, J.F. jr, Glick, G. and Braunwald, E. Studies on cardiac dimensions 
in intact unanesthetized man. V. Effects of nitroglycerin. Circulation 32, 
767-771, 1965. 
Winbury, M.M. and Howe, B.B. Stenosis: Regional myocardial ischemia and 
reserve. In: Ischemic Myocardium and Antianginal Drugs. Eds: 
Winbury, M.M. and Abiko, Y. Raven Press, New York, 1979, pp. 55-76. 
Wolff, H.G. Headache and other head pain. Second edition. Oxford University 
Press, New York, 1963. 
Yamamoto, M. and Meyer, J .s. Hemicrania! disorder of vasomotor 
adrenoceptors in migraine and cluster headache. Headache 20, 321-335, 
1980. 

37 
V ASODILATORY PROFILE OF DIHYDROPYRIDINE-DERIVATIVES 

CHAPTER 2 
THE EFFECTS OF NISOLDIPINE (BAY K 5552) ON 
CARDIOVASCULAR PERFORMANCE AND REGIONAL BLOOD FLOW 
IN PENTOBARBITAL-ANAESTHETIZED PIGS 
WITH OR WITHOUT 13-ADRENOCEPTOR BLOCKADE 
39 
D.J. Duncker, J.M. Hartog, P.G. Hugenholtz, P.R. Saxenat and P.D. Verdouw. 
Laboratory for Experimental Cardiology (Thoraxcenter) 
and 1Department of Pharmacology, 
Erasmus University Rotterdam, Rotterdam, The Netherlands. 
Br. J. Pharmacal. 88, 9-18, 1986. 

Br. J. Pharmac. (1986), 88, 9-18 
The effects of nisoldipine (Bay K 5552) on 
cardiovascular performance and regional blood flow in 
pentobarbital - anaesthetized pigs with or without 
J:J-adrenoceptor blockade 
D.J. Duncker, J.M. Hartog, P.G. Hugenholtz, P.R. Saxena* & P.D. Verdouw1 
Laboratory for Experimental Cardiology (Thoraxcenter) and Department of Pharmacology*, Erasmus 
University Rotterdam, Rotterdam, The Netherlands 
1 The effects of the 1,4-dihydropyridine derivative nisoldipine, infused intravenously (i.v.) at 3 
different rates (0.25, 0.5 and 1.0 j.lg kg- 1 min - 1), were studied in anaesthetized pigs on cardiovascular 
performance with or without jl-adrenoceptor blockade produced by propranolol. 
2 Nisoldipine caused dose-dependent decreases in arterial blood pressure (30% ), systemic vascular 
resistance (30%) and left ventricular filling pressure ( 15% ), but raised heart rate (25%) and LV dP f dt 
max (20% ). Cardiac output was not significantly affected. 
3 Transmural myocardial blood flow and vascular conductances increased dose-dependently after 
nisoldipine. The elevation in blood flow to the left ventricle favoured epicardial layers. Endocardial 
blood flow showed small increases as the changes in conductance of the endocardial layer more than 
compensated for the loss in perfusion pressure. The endo-epi blood flow ratio decreased from 
1.16 ± 0.05 to 0.70 ± 0.01. Myocardial Orconsumption was unaltered as the decrease in arterial-
c:;oronary venous Orcontent difference (30%) was balanced by the increase in transmural blood flow. 
4 Nisoldipine increased blood flow to skeletal muscle (500%), stomach (50%) and adrenals (25%), 
but decreased that to the liver (50%), spleen (25%) and kidneys (25% ). No changes were noticed in the 
small intestine, skin and brain. In spite of differential effects on blood flow, vascular conductance in all 
organs and tissues, with the exception of the liver, increased. 
5 After jl-adrenoceptor blockade the responses of mean arterial blood pressure, cardiac output and 
systemic vascular resistance to nisoldipine remained virtually unchanged, but the elevations in heart 
rate and LV dP(dt max were abolished, as was the decrease in left ventricular filling pressure. 
6 A higher dose of nisoldipine was required after jl-adrenoceptor blockade to elicit significant 
vasodilatation in the epi- and endocardial layers. However, the reduction in endo-epi blood flow ratio 
by nisoldipine was not affected by propranolol. Myocardial Orconsumption tended to decrease as the 
diminution in the arterial-coronary venous 0 2-content difference (30%) slightly exceeded the increase 
of left ventricular blood flow (30% ). 
7 Except for the brain and liver, effects of nisoldipine on regional vascular conductances were 
attenuated after jl-adrenoceptor blockade. 
Introduction 
41 
jl-Adrenoceptor antagonists and calcium channel 
blockers are widely used in the treatment of hyperten-
sion and ischaemic heart disease. Since these drugs act 
through different mechanisms, their combined use 
might be attractive. Some of the I ,4 dihydropyridines 
(nisoldipine, felodipine), a subgroup of the calcium 
channel blocking agents, exert a strong vasodilator 
effect at concentrations that only slightly affect 
myocardial contractile behaviour. jl-Adrenoceptor 
1 Author for Correspondence. 
antagonists usually lower cardiac output and thereby 
decrease perfusion of most organs and tissues (van 
Boom & Saxena, 1983). Since significant lowering of 
blood pressure can be expected with nisoldipine, 
combined use of these drugs could be detrimental for 
some of these organs particularly when their perfusion 
depends on perfusion pressure. The effects of nisol-
dipine on the distribution of cardiac output have been 
studied during rest and exercise by Drexler et a/. 
(1985), but regional blood flow data on nisoldipine 
after jl-adrenoceptor blockade have not been docu-
_© The Macmillan Press Ltd 191\6 
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men ted. Furthermore, only limited experimental data 
are available on the effects of the combination of 11-
adrenoceptor antagonists and calcium channel block-
ers (Wolffenbuttel & Verdouw, 1983; Warltier et al., 
1984a). We therefore evaluated the cardiovascular 
effects, in particular the distribution of cardiac output, 
of varying doses of nisoldipine with and without 11-
adrenoceptor blockade in the domestic swine. 
Methods 
General 
After an overnight fast Yorkshire pigs (20-30kg) 
were anaesthetized with 120 mg azaperone i.m. and 
150mg metomidate i.v. (both compounds: Janssen 
Pharmaceutica, Beerse, Belgium), intubated and ven-
tilated with a mixture of 0 2 and N20 (1 :2)." Res-
piratory rate and tidal volume were adjusted in order 
to keep arterial blood gases within normal limits. A 
double lumen 8 French (F) catheter was placed in the 
-superior caval vein for administration of sodium 
pentobarbitone (20 mg kg- 1 h -•), and pancuronium 
bromide (4mg), while two 7F catheters were posi-
tioned in the inferior caval vein, for infusions of 
Haemaccel (to replace blood loss), propranolol and 
nisoldipine. Left ventricular and aortic pressures were 
obtained with SF Millar micro-tipped catheters. 
Ascending aortic blood flow was measured by placing 
an electromagnetic flow probe around the vessel after 
thoracotomy. Cardiac output was derived by adding _ 
myocardial blood flow (measured with radioactive 
microspheres; see below) to ascending aorta blood 
flow. Oxygen (00 saturation and haemoglobin were 
determined in blood samples withdrawn from the 
abdominal aorta and the great cardiac vein. Myocar-
dial 0 2-conslimption was calculated by multiplying 
the difference between the aortic 0 2 content and that 
of the great cardiac vein, by myocardial blood flow. A 
stabilization period of at least 30 min was allowed 
before baseline data were collected. 
Regional blood flow 
Distribution of cardiac output was determined by the 
radioactive microsphere method (for details, see Sax-
ena & Verdouw, 1985). Microspheres of 15 ± lp.m 
(mean± s.d.) diameter, labelled with 5 different 
isotopes e03Ru; 113Sn; ~c; 95Nb and 141Ce), were 
injected in random order via a cannula inserted into 
the left atrial appendage. To calibrate flow 
measurements, an arterial reference blood sample was 
withdrawn (10 ml min -I) starting 10 s before and 
continuing until 1 min after completion of each 
microsphere injection. At the end of each experiment 
the animal was killed and various organs and tissues 
(see later) were dissected out, weighed, and placed in 
plastic vials for counting radioactivity. Data were 
processed by use of a set of computer progammes 
described elsewhere (Saxena et al., 1980). 
Experimental protocol 
Fifteen animals received three continuous lOmin 
infusions of nisoldipine (0.25, 0.5 and 1.0 1-1g kg- 1 
min- 1), seven without and eight after 11-adrenoceptor 
blockade with propranolol (0.5mgkg- 1 ±0.5mg 
kg- 1 h -•). Microspheres were injected and haemodyn-
amic data obtained at baseline and at the end of each 
infusion rate. An additional batch of microspheres 
was injected 15 min after administration of propran-
olol in the animals that received the 11-adrenoceptor 
antagonist. The adequacy of the dose of propranolol 
to provide fl-adrenoceptor blockade and the stability 
of the preparation have been described in an' earlier 
communication (Wolffenbuttel & Verdouw, 1983). 
Statistical analysis 
Statistical analysis was performed by use of a two-way 
analysis of variance followed by the Duncan new 
multiple range test (Steel & Torrie, 1980). P values less 
than 0.05 were considered to be statistically sig-
nificant. 
Drugs 
Apart from the anaesthetics, the only drugs used were 
propranolol hydrochloride (ICI-Farma, Rotterdam, 
The Netherlands) and nisoldipine (Bay K 5552, Bayer 
AG, Wuppertal, West-Germany), dissolved in a mix-
ture of polyethylene glycol 400, glycerol and water. 
The nisoldipine solution (0.1 mgml- 1) was diluted 
with 0.9% wfv NaCl immediately before use. The 
effects of the solvent on haemodynamics were negligi-
ble (unpublished data" from this laboratory). 
Results 
Baseline values of the two groups of animals and the 
effects of propranolol are presented in Tables 1 and 2. 
Systemic haemodynamics 
Nisoldipine caused dose-dependent increases in heart 
rate (up to 25%), while mean arterial blood pressure 
decreased dose-dependently up to 30% (Figure 1). The 
decline in blood pressure was mainly due to 
vasodilatation in peripheral vascular beds since car-
diac output was virtually unchanged. Myocardial 
contractility (assessed as LV dP/dt max), was not 
compromised by this calcium channel blocker. Left 
NISOLDIPINE AND II-BLOCKADE 
Table 1 Baseline values of cardiovascular parameters for tbe animals !bat received nisoldipine witbout (group I, 
n = 7) and after j!-adrenoceptor blockade (group 2, n = 8) 
Group I Group 2 
Before After 
propranolol propranolol 
Systemic circulation 
Heart rate (beats min - 1) 92±4 96±3 84± 3• 
Mean arterial blood pressure (mm Hg) 84± 3 81 ±2 77±2 
LV dp/dtmax (mmHgs- 1) 2450± 250 2330 ± 270 1660 ± 170• 
Cardiac output 0 min- 1) 2.8 ±0.2 3.1 ± 0.3 2.6 ± 0.2• 
LV end-diastolic pressure (mm Hg) 10.1 ± 0.9 12.1 ± 0.8 11.4 ± 1.0 
Systemic vascular resistance (mmHgl- 1 min) 31 ±4 27± 2 32± 3• 
Coronary circulation 
LV transmural blood flow (mlmin- 1 g- 1) 1.41 ± 0.18 1.45 ± 0.10 1.15 ± 0.12° 
Endo-epi blood flow ratio 1.16 ± 0.05 1.10 ± 0.03 1.09 ± 0.04 
Arterial-coronary venous oxygen content difference 3.4 ± 0.2 3.7 ± 0.3 3.4±0.2 
(mmoW 1) 
Myocardial 0 2 consumption (llmol min -I g- 1) 4.6 ± 0.3 5.4± 0.5 3.8 ± 0.4• 
LV dP/dt max= maximal rate of rise ofleft ventricular pressure; LV= left ventricular. Endo-epi blood flow ratio = 
ratio of tbe endocardial and epicardial blood flows. Data are presented as mean ± s.e.mean; • P < 0.05 vs before 
propranolol. 
Table 2 Baseline values of organ blood flows and vascular conductances for tbe animals which received nisoldipine 
witbout (group I, n = 7) and after j!-adrenoceptor blockade (group 2, n = 8) 
43 
Flow (mlmin- 1100g- 1) Conductance (I0- 2 mlmin~ 1 mm Hg- 1 100g- 1) 
Group I Group 2 Group I Group 2 
Before After Before After 
propranolol propranolol propranolol propranolol 
LA 115 ± 31 123±9 108±4 140± 42 153 ± 12 139 ± 19 
LVT 141 ± 18 145 ± 10 115 ± 12° 172± 28 178 ±II 147 ± 13° 
LV-endo 149± 15 150± II 117 ± 12• 180± 23 185 ±II 150 ± 13° 
LV-epi 132 ± 20 137 ± 10 IIO ± 12• 161 ± 29 168 ±II 141 ± 14 
RA 133 ± 32 155 ± 22 146 ± 26 163 ±44 191 ±26 185 ± 31 
RV 110 ± 21 120 ±II 106± 14 134± 29 148 ± 13 135 ± 16 
Liver 46± 7 54± 10 43 ± 10• 56±9 65± 12 55± 12 
Spleen 131 ± 17 96± 12 73 ± 9° 131 ± 17 118± 14 94± 10• 
Stomach 15.2 ± 1.6 21 ± 3 17.4 ± 2.5 18±2 26±4 23±3 
Small intest. 30±4 32±6 27 ± 4° 36± 5 40± 8 35 ± 5 
Kidneys 277±47 304± 28 265 ± 24 339 ± 66 375 ± 34 341 ± 29 
Adrenals 214± 39 237±49 188 ± 39• 260± 54 293 ± 60 238 ±47 
Skel. muscle 4.6± 0.9 4.0± 0.4 3.0 ± 0.5 5.6 ± 1.1 4.9± 0.5 3.8 ± 0.6 
Skin 0.65 ± 0.13 1.10 ± 0.39 0.68 ± 0.13 0.82 ± 0.20 1.41 ± 0.52 0.88 ± 0.18 
Brain 29± 5 26± 2 24±2 35±7 32±2 30±2 
LA=left atrium; LVT=Ieft ventricular transmural; LV-endo=left ventricular endocardium; LV-epi=left ventricular 
epicardium; RA=right atrium; RV=right ventricle; small intest.=small intestine; Skel. muscle=skeletal muscle. 
Data are presented as mean ± s.e.mean; • P < 0.05 vs before propranolol. 
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Figure 1 Effects of continuous 10 min infusions of nisoldipine without ( 0) or after (e) ~-adrenoceptor blockade with 
propranolol on heart rate (HR), mean arterial blood pressure (MAP), myocardial contractility (LV dPjdt max), 
cardiac output (CO), left ventricular end-diastolic pressure (L VEDP) and systemic vascular resistance (SVR). Data are 
expressed as percentage of baseline values (pre-propranolol values in the ~-blocked animals). •p<0.05 vs pre-
nisoldipine values. 
ventricular end-diastolic pressure (L VEDP) declined 
by 15% after the highest dose. 
After propranolol the effects of nisoldipine on 
systemic haemodynarnics were only slightly modified. 
Instead of an increase, we now observed either no 
changes (first 2 doses) or slight decreases (highest 
dose) in heart rate and LV dPfdtmax during increas-
ing nisoldipine infusion rates. These decreases, 
however, were not statistically different from those 
observed at the same time period in animals that 
received propranolol only; compare data reported 
earlier by Wolffenbuttel & Verdouw (1983). Mean 
arterial blood pressure and cardiac output responses 
to nisoldipine were similar to those without p-adren-
oceptor blockade, while L VEDP did not change. 
Coronary haemodynamics and myocardial Or 
consumption 
Nisoldipine caused a considerable elevation of left 
ventricular blood flow (up to 55% at the end of the 
highest infusion rate, Figure 2). The microsphere data 
revealed that the epicardial layers especially benefited 
from the increase in flow and, as a result, the endo-epi 
blood flow ratio decreased dose-dependently by up to 
40%. The combined effects of the changes in the 
determinants of myocardial 0 2-demand resulted in 
unaltered Orconsumption as the decrease in arterial-
coronary venous 0 2-content difference was balanced 
by the increase in blood flow. 
The nisoldipine-induced increases in blood flow 
45 
NISOLDIPINE AND II-BLOCKADE 
160 
LV-flow --1 ~a-cv) 0 2-content 
120 I 11 : ~ !~j * i 120 I 80 ~i~* 
o-2 / *! 
80 
·-i-· 
endo/epi M0 2-cons 6 
100 i~* 100 0~6_...-/)3--
• 
*"i ~ *~~ t !--. 60 60 
------!-! 
1.:f~1]~ 
Nisoldipine (j.Lg kg-1 min-') Nisoldipine (j.Lg kg-1 min-1) 
Figure 2 Effects of continuous 10 min infusions of nisoldipine without (0) or after (e) jl-adrenoceptor on left 
ventricular (LV) blood flow, myocardial Orconsumption (M02-cons), the ratio of blood flows in the endo- and 
epicardium (endofepi) and the arterial-coronary venous ~-content difference ((a-cv) 0 2-content). Data are expressed 
as percentage of baseline values (pre-propranolol values in the Jl-blocked animals). • P < 0.05 vs pre-nisoldipine values. 
were considerably less after j!-adrenoceptor blockade 
(up to 30% after the highest dose). Inspection of 
Figure 2 reveals that, after propranolol, a higher 
infusion rate of nisoldipine was required ·to enhance 
transmural myocardial blood flow. Although trans-
mural flow was reduced by propranolol, the latter had 
no effect on the nisoldipine-induced decrements in 
endo-epi blood flow ratio. The arterial-coronary ven-
ous 0 2-difference again decreased, causing slight 
accentuation on nisoldipine-induced decreases in 
myocardial 0 2-consumption. After j!-adrenoceptor 
blockade, nisoldipine caused lesser increments in 
transmural conductance (flow/pressure), more so in 
the right ventricle than in the left ventricle (Figure 3). 
Right and left atria showed responses similar to those 
of the ventricles. Although the endo-epi blood flow 
ratio decreased, endocardial blood flow was main-
tained under both experimental conditions and was 
even augmented after the second dose of nisoldipine in 
untreated animals (Figure 4). Vascular conductances 
in the endo- and epicardial layers of the left ventricle 
increased during nisoldipine infusions, but the respon-
ses weakened in the j!-blocked animals. 
Cardiac output distribution 
Nisoldipine infusions did not exert a uniform effect on 
the various regional vascular beds (Figure 5). Per-
fusion of some organs and tissues increased (skeletal 
muscles, stomach and adrenals), decreased (liver, 
spleen and kidneys), or was maintained (small intes-
tine, brain and skin). Decreases in flow were, with the 
exception to the liver, always less than the drop in 
mean arterial blood pressure. Therefore, vascular 
conductance in all organs and tissues, except the liver, 
increased (Figure 6). The greatest vasodilator response 
was elicited in the skeletal muscles (up to 700% 
increase), followed by the skin (140% with the highest 
dose), stomach (120%), adrenals (60%) and brain 
(50%). The increases in vascular conductance in the 
spleen and kidneys were significant only at the second 
dose. 
After j!-adrenoceptor blockade the changes in con-
ductances were less pronounced at the higher doses of 
nisoldipine, except for the brain and liver. The 
· vasodilator response remained most marked in the 
skeletal muscle as conductance still increased by 
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Figure 3 Effects of continuous 10 min infusions of nisoldipine without (open symbols) or after (closed symbols) /l-
adrenoceptor blockade on vascular conductance in the myocardium. In (a) are shown the conductances in the left 
(D.•) and right (O,e) atrium. In (b) are shown the conductances in the left (D.•) and right (O,e) ventricle. Data 
are expressed as percentage of baseline values (pre-propranolol values in the jl-blocked animals). *P<O.OS vs pre-
nisoldipinc values. 
600%, followed by the skin (70%), brain (60%) and 
stomach, small intestine and adrenals ( 40% ). Conduc-
tance in the liver again decreased. 
Discussion 
Effects of nisoldipine without /l-adrenoceptor blockade 
As reported by many investigators (Kazda et al., 1980; 
Vogtetal., 1980; Warltieretal., 198l;Vogt&Kreuzer, 
1983; Verdouw et al., 1984; Warltier et al., 1984a,b; 
Drexler et al., 1985) the major haemodynamic effect of 
nisoldipine was a reduction of the systemic vascular 
resistance leading to a decline in mean arterial blood 
pressure. Presumably due to the baroceptor reflex, 
heart rate increased, which is consistent with the 
findings of some investigators (Kazda et al., 1980; 
Vogt et al., 1980; Warltier et al., 1984a), but at 
variance with those of others (Vogt & Kreuzer, 1983; 
Verdouw et al., 1984). The absence of an increase in 
heart rate after oral administration of nisoldipine 
reported by Vogt & Kreuzer (1983) might be the result 
of the moderate decrease in mean arterial blood 
pressure reported in that study. Also the already 
enhanced sympathetic drive might have played a role, 
as the patients in their study suffered from chronic 
congestive heart failure. An explanation for the dis-
crepancy in heart rate responses with an earlier study 
performed in our laboratory (Verdouw et al., 1984), 
might be the higher infusion regimen (2 and 4 11g kg- 1 
min- 1) used in those experiments. Warltier et al. 
(1981) also reported in anaesthetized dogs dissimilar 
effects on heart rate as a 15% increase was observed 
after l~tgkg- 1 min~ 1 whereas there was virtually no 
change after 3 11g kg-• min_,_ Higher doses might lead 
to a greater direct negative chronotropic effect (Kazda 
et al., 1980, Hof & Scholtysik, 1983) and a stronger 
suppression of the baroceptor reflex (Warltier et al., 
1984b). That the experimental conditions are impor-
tant is illustrated by Warltier et al. (l984a) who found 
an increase in heart rate in conscious dogs after 
intravenous nisoldipine in doses up to 25 11g kg- 1 
min- 1, while we observed similar changes after oral 
administration up to 500 11g kg- 1 in the conscious pig 
(unpublished data). 
Nisoldipine did not affect myocardial 0 2-consump-
tion, as the elevation of heart rate was balanced by 
decreases in arterial blood pressure and preload. 
Rousseau et al. (1984) also described no effect on 
myocardial Orconsumption in angina pectoris 
patients in spite of a decline in pressure-rate product. 
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Figure 4 Effects of continuous 10 min infusiohs of nisoldipine without (open symbols) or after (closed symbols) ~ 
adrenoceptor blockade on blood flows to (a) land conductances in (b) the left ventricular epicardial (O,e) and 
endocardial (D ,•) layers. Data are expressed as percentage ofbaseline values (pre-propranolol values in the jl-blocked 
animals. • P < 0.05 vs pre-nisoldipine values. I 
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Kazda eta/. (1980), however, found that nisoldipine 
lowered myocardial 0 2-consumption in the abaesth-
etized dog, which might have been due to the decrease 
in heart rate in their experiments. I 
Augmented transmural myocardial blood flow, also 
demonstrated by other investigators (Kazda et a/., 
1980; Warltier et a/., 1981; 1984a; Roussead et a/., 
1984) was completely accounted for by the inctease in 
epicardial blood flow. Although the endo-epi blood 
flow ratio declined during infusions of higher toncen-
trations of nisoldipine, no deleterious effect was 
exerted on the endocardium as endocardial bl9od flow 
was maintained or even enhanced. Warltier et a/. 
(1981) also documented similar changes in endo-epi 
blood flow ratio, after 1 p.g kg- 1 min -I, while suben-
docardial perfusion was augmented in spite of 
tachycardia. Serruys eta/. (1985) found in man that a 
30% decrease in total systemic vascular resistance was 
accompanied by a 50% decrease in coronary vascular 
resistance. From these observations they prematurely 
concluded that nisoldipine is primarily a coronary 
vasodilator. In our study a dose of I p.gkg- 1 min- 1 
produced a 30% and 50% decrease in systemic and 
coronary vascular resistances, respectively. However, 
the various regions contributed very differently, as 
vascular conductance in skeletal muscle increased 7 
fold, while that in the kidneys, spleen and liver was 
hardly affected, or even diminished. 
The data on organ and tissue perfusion demonstrate 
that the vasodilator action of nisoldipine is most 
marked in skeletal muscle, as reported with other 
dihydropyridines (Hof, 1983; Bolt & Saxena, 1984a). 
Only in the liver was a vasoconstrictor response 
observed. Drexler et a/. (1985) reported in rats a 
general vasodilatation, although at the dose used 
(1.6 p.g kg- 1 min - 1) this was not always statistically 
significant. Higher organ and tissue conductances 
were in most cases sufficient to compensate for the loss 
of perfusion pressure. Blood flow was therefore main-
tained in most regions. The kidneys are known to 
possess an autoregulatory mechanism for maintaining 
stable blood flow, which is primarily myogenic in 
nature (Thurau & Kramer, 1959; Hashimoto et a/., 
1980). Hashimoto et al. (1980) also reported the 
capacity of calcium channel blockers to interfere with 
this autoregulation. Our data show that only with the 
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Figure 5 Effects of continuous !Omin infusions ofnisoldipine (0.25; 0.5 and 1.0 l'gkg- 1 min- 1, depicted as I, 2 and 3 
respectively) without (D) or after (•) Jl-adrenoceptor blockade on tissue blood flows. C denotes control state or, in the 
Jl-blocked group, the effect of propranolol. Data are expressed as percentage of baseline values (pre-prcipranolol values 
in the Jl-blocked animals). • P < 0.05 vs pre-nisoldipine values. 
second dose was there an increase in conductance, 
while after the highest dose renal blood flow decreased 
significantly as conductance remained constant. 
Effects of nisoldipine after P-adrenoceptor blockade 
Consistent with the findings of Kazda eta/. (1980), we 
observed that pretreatment of the animals with the P-
adrenoceptor antagonist propranolol did not atten-
uate nisoldipine-induced decreases in arterial blood 
pressure and systemic vascular resistance, but aboli-
shed the increments in heart rate and LV dP/dt max. It 
therefore appears that the latter effects are mediated 
primarily via a reflex augmentation of the sympathetic 
nervous system (Grosset a/., 1979; Spedding, 1982; 
Bolt & Saxena, 1984a). However, in certain circum-
stances, an additional mechanism resistant to P-adren-
oceptor blockade, namely a withdrawal of parasym-
pathetic tone, may also be involved (Nakaya et al., 
1983; Warltier eta/., 1984a). 
After propranolol, nisoldipine caused a slight de-
crease in myocardial 0,-consumption and a less 
marked increase in coronary blood flow. This can 
partly be explained by a decreased metabolic demand, 
as shown by Vatner & Hintze (1982). In contrast, 
Warltier eta/. (1984a) found no difference in coronary 
blood flow responses to nisoldipine under the two 
experimental conditions but, in their experiments, the 
tachycardia following nisoldipine was not completely 
eliminated by P-adrenoceptor blockade. The endo-epi 
blood flow ratio showed similar responses to nisol-
dipine irrespective of the presence or absence of 
propranolol. However, individual vasodilator respon-
ses of epi- and endocardium were attenuated by 
propranolol. Except for the liver and brain, the same 
was the case in other organs and tissues. It is interest-
ing to recall that P-adrenoceptor blockade interferes 
with vasodilator responses to another arteriolar 
vasodilator, hydralazine (Bolt & Saxena, 1984b). 
Finally, we would like to compare the effects of 
nisoldipine in the present series of experiments with 
those of another dihydropyridine analogue, 
nifedipine, which was infused directly into the left 
anterior descending coronary artery (W olffenbuttel & 
Verdouw, 1983). As can be expected, intracoronary 
infusions ofnifedipine (up to 0.5 l'gkg- 1 min- 1) seem 
to produce a greater cardiodepressant effect (arterial 
pressure, cardiac output and LV dP/dtmax decreased 
up to 23%, 18% and 35%, respectively), which was 
either unchanged or attenuated in propranolol-treated 
animals. In spite of a slight additional cardiodepres-
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sant effect of nifedipine in the presence of propranolol, 
coronary blood flow increases were similar to those 
when nifedipine was given alone. 
Conclusions 
Nisoldipine has been shown to be a potent vasodilator 
which lowers blood pressure but increases heart rate 
and coronary blood flow without changing myocar-
dial 0 2 consumption. After propranolol, the reflex 
mediated cardiostimulatory responses to nisoldipine 
are eliminated but the cardiac function is not com-
promised. Therefore, a combination of nisoldipine 
and P-adrenoceptor antagonists is an attractive pos-
sibility when the therapeutic aim is to reduce the work 
of the heart and maintain cardiac perfusion. However, 
complications have been reported when calcium chan-
nel blockers and P-adrenoceptor antagonists are ad-
ministered concurrently to patients with impaired 
cardiovascular performance (Opie & White, 1980; 
Robson & Vishwanath, 1982; Packer et a/., 1982; 
Oesterle & Schroeder, 1982). Indeed, our data, alth-
ough obtained in acute experiments in anaestheti2ed 
animals with normal cardiovascular performance, 
also show that perfusion of some organs (in particular 
adrenals, kidneys, liver, spleen and stomach) decrease 
after combined use of the two drugs. Therefore, when 
cardiovascular performance is already impaired, 
nisoldipine might better be employed without P-block-
ade as it improves myocardial 0 2-balance, while 
myocardial function is maintained. Also, the reduc-
tion of afterload facilitates left ventricular emptying, 
while organ and tissue perfusion is better preserved 
than when P-blockade is present. 
The supply of nisoldipine by Bayer AG, Wuppertal, West 
Germany and of propranolol by ICI-Farma, Rotterdam, The 
Netherlands, is gratefully acknowledged. Mr R.J. Rensen 
and Mr R.H. van Bremen are thanked for their technical 
assistance and Miss P.H. Vegter for preparing the manus-
cript. 
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The effects of nisoldipine alone and in combination with 
beta-adrenoceptor blockade on systemic haemodynamics 
and myocardial performance in conscious pigs 
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The peuk e.!Ji•cts <!( /0 mg nisoldipine p.o. ll'ith or ll'ithout 80 mg propranolol p.o. on systemic and regional 
haemc)((l'llmnics in conscious pigs ll'ere investigated. Niso/dipine increased heart rate (70%), cardiac output 
f(J7%) and maxLVdP/dt (75%), but decreased mean arterial pressure (21%) as systemic vascular 
conductance increased by 120%. Left 1•entricular systolic and end-diastolic pressures were not affected. 
I 'asodilatation occurred in most organs. The increase in left ventricular blood flow ( 150%) favoured the 
epicardial ( 195%) overt he endocardial (I 10%) layers. As a result the end~ pi blood flow ratio decreased by 
30%. 
Whennisoldipine 1\'as administered simultaneously with propranolol, heart rate (29%), cardiac output 
I 35%) allll systemic vascular conductance (65%) increased, but max LV dPfdt did not change. Mean arterial 
1 /8%) and left ventricular systo'tic ( 10%) pressure decreased; left l'entricular end-diastolic pressure was 
again unq!Ji•c1ed. In mosT organs vasodilatation 1ras al/enuated, but still present, compared to the changes 
qfier nisoldipine alone. The increase in epicardial blood flow (70%) again exceeded that in endocardial 
h/oodflmr (35%J.Izowev£'r, the endo-epi ratio decreased by only 15%. In the presence of propranolol, 
ni.wlclipine did not exert a 11£'gative inotropic action while the reflex-tachycardia was attenuated. In addition, 
no detrimemal c:ffects on pe~fusion of regionalrascu/ar beds ll'ere obserl'ed. 
Introduction 
Calcium-channel blockers and beta-adrenocep-
tor antagonists are widely used in the treatment of: 
coronary artery disease and hypertension. As they 
act through different mechanisms, the combined 
use of these drugs might be a useful. therapeutic 
tooJI'-11. In this respect a combination of beta-· 
adrenoceptor antagonists and the I A-dihydro-
pyridine derivatives seems especially attractive. The 
potent vasodilatory effect of this subgroup of 
calcium-channel blockers often induces a reflex-
mediated cardio-stimulatory response that may 
completely override their direct cardioinhibitory 
action, which is less marked than that of other 
calcium-channel blockers such as verapamil and 
Submitted for publication on 24 February 1987 and in revised form 
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diltiazem. Although beneficial effects of a combi-
nation of nifedipine and beta-adrenoceptor antag-
onists have been reportedi1.,2,41, adverse interactions 
like severe cardiodepression, which are more fre-
quently observed with verapamil'4•51 or diltiazem161, 
ha\'e also been documentedi4-Kl. 
Recently nisoldipine, another dihydropyridine 
derivative, has been shown in vitro to exert a 4-10 
times stronger vasodilatory effect and an equal 
or weaker cardiodepressant action compared to 
nifedipine at equimolar dosesi91.Jn 1•ivo, nisoldipine 
causes pronounced vasodilatation of the systemic 
and coronary bed and elicits marked reflex-
mediated increases in heart rate and myocardial 
contractility parameters19- 11 1. Although some re-
ports on systemic haemodynamic effects following 
a combination ofnisoldipine with beta-blockers are 
a\'ailab]el 11• 131, regional haemodynam1c mvesti-
gation is restricted to one report in anaesthetized 
pigs The following study was performed to 
define whether oral administration of nisoldipine, 
@ 1987 The European Society of Cardiology 
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when combined with that of propranolol, might 
have detrimental effects on myocardial perform-
ance and on perfusion of regional vascular beds in 
conscious pigs. 
Materials and methods 
GESERAL 
After an overnight fast, Yorkshire pigs (18-
20 kg, N = 7) pretreated with a mixture of pro• 
caine penicillin-G and benzathine-penicillin-G 
(Duplocillin. Gist-Brocades N.V., Delft, The 
Netherlands), both 300 000 units i.m., were sedated 
w.ith 30 mg kg- 1 ketamine HCI i,m. (Aescoket, 
Aesculaap B.V .. Boxtel, The Netherlands). The 
animals were intubated and connected to a respira-
tor for artificial ventilation with a mixture of02 and 
N20 (I :2) to which 1% halothane was added. A jugular vein and common carotid artery were can-
nulated for administration of drugs and measure-
ment of mean arterial blood pressure, respectively. 
The chest was opened via the left fifth intercostal 
space to expose the heart. A transducer (P 4 .5 , 
Konigsberg Instruments Inc. Pasedena, California, 
U.S.A.) was implanted into the apex of the left 
ventricle of the heart for recording left ventricular 
pressure. The left atrium was cannulated for record-
ing left atrial pressure which, together with the 
aortic blood pressure, was used for calibration of 
the Konigsberg transducer signals. The aorta was 
approached through the third intercostal space and 
an electromagnetic flowprobe (Skalar, Delft, The 
Netherlands) was positioned around the ascending 
aorta. Cardiac output was calculated by adding 
myocardial blood flow (see later) to ascending aorta 
blood flow. Catheters and wires were tunnelled 
subcutaneously to the back, the chest was closed 
and the animals allowed to recover. During the next 
14 days the animals received daily intravenous 
bolus injections of 500 mg amoxicilline (Clamoxil, 
Beecham Farma B.V., Amstelveen, The Nether-
lands) and in addition, during the first week, 500 mg 
kanamycin (Kamynex, Gist-Brocades N.V., Delft, 
The Netherlands) to prevent infection. The cath-
eters were flushed daily with an isotonic saline sol-
ution containing heparin (500 I.U. ml- 1 ) to avoid 
clotting of blood in the lumen. After a I week post-
operative recovery period, at least four sessions 
were·held to adapt the animals to the experimental 
and laboratory facilities. The experimental proto-
col was executed 2-3 weeks after the operation. All 
tracings were written on a Graphtec Linearcorder 
. (F WR 3701, Ankersmit, Breda, The Netherlands). 
Arterial acid-base balance and oxygenation during 
the experiments were similar to those reported for 
young Yorkshire pigs by Lagerweyf141: pH= 7 ·45 ± 
0·02, PC02 = 37 ± 3 mmHg, P02 = 81 ± 5 mmHg, 
Hb02:saturation = 92± 3%. 
MEASUREMENT OF REGIONAL BLOOD FLOWS 
Regional blood flows were measured by use of 
the radioactive microsphere technique. Although 
the microsphere technique offers the advantage of 
simultaneously measuring blood flow to a large 
number of tissues in conscious animals with rela-
tively little surgical trauma, an inherent drawback 
of this method is that only a limited number of 
isotopes can be employed. Therefore only one 
dose of nisoldipine with and without propranolol 
could be used in each individual animal; the dose 
selected was one that elicited a reasonably marked 
pharmacological response (see later). 
Microspheres(l5± I (SO) 11m diameter),labelled 
with either 141 Ce, 113Sn, 103Ru or 95Nb (NEN 
Chemicals GmbH, Dreieich, West Germany) and 
suspended in saline containing a drop of Tween 80, 
were injected in random order into the left atrium 
over a period of30-45 sf151. 
At the end of each experiment the animal was 
killed with an overdose of pentobarbitone sodium. 
The various tissues, as specified later, were dissected 
out, weighed and placed in plastic vials. The radio-
activity in the vials containing the tissues was 
counted for 5-10 min in a y-scintillation counter 
(Packard, model 5986) equipped with a multichan-
nel pulse height analyser (Conrac) using suitable 
windows for discriminating the different isotopes 
usedl 161. The microsphere and other data were pro-
cessed by a PDP-11(70 computer using a set of 
programmes especially developed for the micro-
sphere techniquel 161. The amount of blood flow dis-
tributed to the various tissues (Q.;,) was calculated 
as follows: 
Q,;,(ml min- 1) = (I,;JI,.,) x CO 
where 1,;,, I,., and CO are, respectively, radioactivi-
ties (cpm) in the individual tissues and the total 
number of microspheres injected (calculated as the 
difference in the radioactivity present in the glass 
vial before and after injection), and the cardiac out-
put (in ml min- 1 ). Tissue vascular conductance 
(flow/pressure) was calculated by dividing respect-
ive tissue blood flow values by mean arterial blood 
pressure. 
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rll . . . 
LVEDP 
~ baseline ~:::~~:ne nisoldipine 
propranolol 
Fi!!""' I Enects of nisoldipine (!Omg p.o.) without and with propranolol 
(80 mg p.o.) on systemic haemodynamics in seven conscious pigs. CO, cardiac 
nut put: HR. heart rate; SV, stroke volume; M BP, mean arterial blood pressure; 
muxl VdP.'dt. maximal rate of rise of left ventricular pressure; LVEDP, left 
ventricular end-diastolic pressure; SVC, systemic Vdscular conductance; LVSP, 
loft ventricular systolic blood pressure. Data are expressed as mean±SEM; 
?,.;0·05 rs. baseline or recovery. ••change induced by nisoldipine with pro-
pranolol si~nificantly different (P,;;0·05) from that by nisoldipine without 
propranolol. 
EXPERIMENTAL PROTOCOLS 
In pigs fasted for 24 h, 10 mg nisoldipine (equiv-
alent to 0·40 ± 0·02 mg kg- 1) was administered 
orally (p.o.) after baseline data had been recorded 
and the first batch of radioactive microspheres had 
been injected for the determination of regional 
blood flows. All measurements were repeated when 
nisoldipine-induced changes in heart rate had 
reached a stable peak level (50± 6 min after admin-
istration). As a pilot-study in eight pigs had 
revealed that, 24 h after ingestion of 10 mg of the 
drug. plasma-levels of nisoldipine could no longer 
be detected and that haemodynamic parameters 
had returned to baseline, the next day the same pro-
tocol was repeated, but now 80 mg p.o. propranolol 
(equivalent to 2·88 ± 0-44 mg kg- 1) was given along 
with the 10 ing nisoldipine tablet. This second part 
of the protocol was performed in the same animals 
to avoid inter-animal differences. Data were again 
obtained during baseline and at the peak heart rate 
effect ( 48 ± 4 min after administration). In the pilot 
study (N = 8) we had observed that peak changes in 
heart rate (from 108±5 to 160±12 beats min- 1) 
corresponded with peak plasma concentrations 
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(3·14±0·64 ng mg- 1) ofnisoldipine reached about 
I h after the drug administration. When in three 
of these animals nisoldipine and propranolol were 
administered simultaneously' the peak concen" 
tration of nisoldipine was 2·81 ±0·70 ng ml- 1 
which was not statistically significantly different 
from that obtained after nisoldipine alone. 
STATISTIC"AL ANALYSIS 
Unless otherwise stated, all data are presented as 
mean±standard error of mean. Statistical analysis 
was performed by use of Duncan's new multiple-
range test once a parametric two-way analysis of 
variance (randomized block design) had revealed 
that the samples represented different popu-
lationsP71. A P value of0·05 or Jess (two-tailed) was 
considered to be statisti~ally significant. 
DRUGS 
The only drugs used in this study were tablets of 
nisoldipine (Bay k SSS2, Bayer AG, Wuppertal, 
F.R.G.) and propranolol hydrochloride (ICI-
Farma. Rotterdam, The Netherlands). 
Results 
SYSTEMIC HAEMODYNAMICS 
Peak effects of nisoldipine (10 mg p.o.) on 
systemic haemodynamics are presented in Fig. I. 
Nisoldipine caused marked increases in cardiac 
output (67%), heart rate (70%), and maxLVdP/dt 
(7S%). Despite the increase in cardiac output, mean 
arterial blood pressure dropped by 21%. Conse-
quently, the calculated systemic vascular conduc-
tance increased considerably (120%). No changes 
were observed in left ventricular systolic or end-
diastolic pressure and stroke volume. After simulta~ 
neous administration of nisoldipine (I 0 mg p.o.) 
and propranolol(80 mg p.o.), the increases in car-
diac output (3S%), heart rate (29%) and systemic 
vascular conductance (65%) were much Jess, and 
that in maxLVdP/dt even abolished, when com-
pared to those after nisoldipine alone. Mean arterial 
blood pressure, however, decreased by a similar 
magnitude (18%), while left ventricular systolic 
pressure was now slightly reduced (I 0% ). Left ven-
tricular end-diastolic pressure and stroke volume 
were again unaffected. 
CORONARY HAEMODYNAMICS 
Administration of nisoldipine alone increased 
both the transmural left ventricular blood flow 
(I SO%) and vascular conductance (22S%) but. as 
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Figure 2 Effects ofnisoldipine (10 mg p.o.) without and w.ith 
propranolol (80 mg p.o.) on coronary haemodynamics in 
seven conscious pigs. LVBF, left ventricular blood flow; 
LVC, left ventricular conductance; endo/epi, ratio between 
endocardial and epicardial normalized blood flows; 0 2-
demand, heart rate x left ventricular systolic pressure. The 
four different columns represent, respectively, baseline, 
nisoldipiite. recovery and nisoldipine with propranolol. 
Data are expressed as mean± SEM. • P.;;O·OS ••s. baseline or 
recovery. ••changes induced by nisoldipine with proprano-
lol significantly different (P.;;O·OS) from that by nisoldipine 
without propranolol. 
the elevations in blood flow and conductance 
favoured the epicardial (195% and 280%, respec-
tively) over the endocardial (110% and 170%, 
respectively) layers, the endocardial-epicardial 
(endo-epi) blood flow ratio decreased by 30% (Fig. 
2). As the double product (left ventricular systolic 
pressure x heart rate), an index of myocardial 
oxygen demand, increased only by 60%, it would 
appear that the enhancement in coronary blood 
flow, i.e. oxygen supply, exceeded the increased 
oxygen demand. When nisoldipine was combined 
with propranolol, the elevations in transmural, epi-
cardial and endocardial blood flows (SO, 70 and 
34%, respectively) and conductances (95, 120 and 
70%, respectively) were only moderate, but still 
statistically significant (P .s;; O·OS). Furthermore, the 
reduction in endo-epi blood flow ratio (IS%) did 
not reach the level induced by treatment with the 
dihydrophyridine derivative alone,while the double 
product was only slightly ( < 10%) enhanced. 
l.liSTRIBUTIOl' OF CARDIAC OUTPUT 
The effects of nisoldipine on regional haemo-
dynamics have been presented in Figs 3 and 4. 
Nisoldipine caused the largest increase in blood 
flow to the right atrium (700%), followed by the 
right-ventricle (280%). stomach (190%),skeletal 
muscle (150%) left ventricle (150%. Fig. 2), small 
intestine (120%). adrenals (110%) and brain 
(30% ). Renal and hepatic artery blood flow as well 
as flow to the skin and spleen were not significantly 
affected. When nisoldipine was administered simul-
taneously with propranolol, increases in blood flow 
were again observed, though generally (except 
skeletal muscles) of a lesser magnitude, in the right 
;ttrium (260%), skeletal muscles (250%), stomach 
( 110%). right ventricle (105%). small iniestine 
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(70%) and left ventricle (50%). Blood flow to the 
adrenals, brain, liver and kidneys was not signifi-
.cantly affected while that to the skin (50%) and 
spleen (35%) decreased. As nisoldipine induced a 
moderate decrease in blood pressure, vascular con-
ductances increased in most organs, except the liver, 
skin and spleen (Fig. 4). The most pronounced 
increase was observed in the right atrium (900%), 
followed by the right ventricle (400%), stomach 
(280% ), skeletal muscles (230% ), left ventriCle 
(225%), small intestine (180%), adrenals (170%), 
brain (60%) and kidneys (50%). With propranolol, 
nisoldipine induced the greatest vasodilatory re-
sponse in the right atrium (360%) followed by 
skeletal muscle (300%). stomach (160%), right 
ventricle (160%), small intestine (110%), left ven-
tricle (95%) and brain (.50%). No statistically sig-
nificant changes were noted in the liver, skin, spleen, 
adrenals and kidneys. 
~ buellne nlsoldiplne recovery nlsoldiplne . 
propr•noJol 
spleen 
L
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·right 1trlum 
• Figur,· 3 Region"! blood now in seven conscious pigs after nisoldlpine (10 mg 
p.o.) without and with pmpnuiolol (80 mg p.o.). Data arc expressed as mean± 
SfM. •p,.0-05 "-'· b"$eline or recovery. ••change induced by nisoldipine with 
rr•'l'r""''lol signific.,ntly dill'crent (P<0·05) from that by nisoldipine wilhout 
prtlpr:mol<ll. 
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Figur<•4 Regional vascular conductance in seven conscious pigsafiernisoldipine 
( I 0 mg p.o.) without and with propranolol (80 mg p.o.). Data are expressed as 
mc-dn ± SEM. • P,. 0·05 •·s. baseline or recovery. **Change induced by nisoldipine 
wilh propranolol significan1ly different (P,.0·05) from that by nisoldipine 
wi1hou1 propranolol. 
Discussion 
EFFECTS OF NISOLDIPINE ALONE 
As has been reported by many investigators19· 
IJ.IM-~~1. we also observed that nisoldipine induced a 
pronounced systemic vasodilatation. This resulted 
in only a moderate fall in mean arterial blood press-
ure since cardiac output was markedly elevated. 
Due to the baroceptor-reflex, contractility and 
heart rate were augmented but stroke volume 
remained unchanged. These observations are in 
general agreement with data obtained after i.v. 
infusions of nisoldipine in anaesthetized pigsl121. 
The major difference is that cardiac output in the 
anaesthetized animals was unchanged as the reflex-
tachycardia was accompanied by a concomitant 
reduction in stroke volume. It appears that this 
reduction resulted from the use of pentobarbitone 
anaesthesia, since equal infusion rates in conscious 
pigs caused a significant increase in cardiac output 
solely due to a tachycardia as stroke volume was 
maintained (unpublished data from this labora-
tory). In most studies the elevation of cardiac out-
put results primarily from an increase in heart rate, 
with stroke volume being either unchangedl10•181 or 
increasedl10•191. In rats with high baseline heart rates 
(up to 400 beats min- 1), the elevation in cardiac 
output is primarily caused by an augmentation of 
stroke volume120•211. 
Due to the reflex-tachycardia, the oxygen 
demand (rate-pressure product) was moderately 
enhanced. The increase in coronary blood flow, 
however, exceeded this enhancement, thereby 
increasing the oxygen supply- oxygen demand 
ratio. Serruys et a/P~I reported after nisoldipine in 
humans an unchanged double product and oxygen 
consumption, while coronary blood flow was 
increased by 30%. Similar improvements of myo-
cardial oxygen balance have also been demon-
strated by other investigators19• 1 ~·' 91. The decrease in 
endocardial-epicardial blood flow ratio is probably 
due to the combination of an increased heart rate 
and hypotension'~;!. Nevertheless, an increase in 
endocardial blood flow was present, which far 
exceeded the increase in oxygen demand. 
I!FFECTS OF NISOLDIPINE AND BETA-ADRENOCEPTOR 
IILOCKADE 
Although the elevation of systemic vascular con-
ductance was reduced after combined nisoldipine 
and propranolol, the drop in blood press.ui'e was 
not different from that observed after nisoldipine 
aione. This was due to the attenuated increase in 
cardiac output, which again depended entirely on 
the increase in heart rate. An increase in heart rate 
by nisoldipine in the presence ofbeta-adrenoceptor 
blockade has also been reported by others'"·"l and 
this probably results from withdrawal of parasym-
pathetic tonel~•l, as the atria and the conductance 
tissue of the left ventricle are richly innervated by 
the parasympathetic nervous systemflSJ. The left 
ventricular myocardium is only scarcely innervated 
by the parasympathetic system and this might 
explain why maxLVdP/dt was unaffected by the 
combination. In contrast, in anaesthetized pigs1 '~1 
both heart rate and maxLVdP/dt were significantly 
decreased by the combination suggesting attenua-
tion of cardiovascular reflexes during pentobartital 
anaesihesia. . 
·Due to the beta-adrenoceptor blockade the oxy-
gen demand remained essentially unchanged, as the 
attenuated increase in heart rate was accompanied 
by a decrease in left ventriCular systolic pressure. 
Furthermore, as heart rate was only moderately 
increased, the duration of diastole, i.e. the perfusion 
time of the endocardium, was not reduced as much 
as after nisoldipine alone. As a result, the endo-epi 
blood flow ratio decreased less. As in anaesthetized 
pigsl111, vasodilatation was inhibited in almost all 
organs studied (except skeletal muscles), when 
nisoldipine was administered together with pro-
pranolol. It is known that· beta-adrenoceptor 
antagonists may generally reduce responses to vaso-
dilator drugs because beta-adrenoceptor blockade 
leads to a reflex increase in sympathetic tone, which 
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interferes with vasodilatation, and activation of 
vasoconstrictor alpha-adrenoceptors. 
We conclude that nisoldipine is a potent systemic 
and coronary vasodilator in the conscious pig. The 
combination ofnisoldipine and beta-adrenoceptor 
blockade exerted no cardiodepressant action, while 
the reflex-tachycardia was attenuated. Our data, 
obtained in conscious pigs with a normal coronary 
circulation, support the recent findings of Silke 
et a/.1'31 in patients with stable angina pectoris. In 
addition, we observed no detrimental effects of the 
combination on perfusion of regional vascular 
beds. 
Nisoldipine was generously supplied by Bayer A.G. 
(Wuppertal), West Germany), while propranolol was pro· 
vided by ICI Farma (Rotterdam, The Netherlands). We 
would like to thank the Laboratory for Experimental Surgery 
for their skilful assistance during surgery and the post-
surgical period and Mr J.P. C. Heiligers for technical assist-
ance during the experiments. Our special thanks go· to Ms 
P. H. Vegter for her assistance in the preparation of this 
manuscript. 
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Nimodipine-induced changes in the distribution of 
carotid blood flow and cardiac output in 
pentobarbitone-anaesthetized pigs 
D.J. Duncker*·**, J. Heiligers**, E.J. Mylechl:!-rane**2, P.R. Saxena**1 & 
P.D. Verdouw* 
Departments of Experimental Cardiology (Thorax Center)* and Pharmacology**, Erasmus University 
Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands 
1 In .view of the claimed effectiveness of nimodipine in migraine and its possible selectivity for 
cerebral vessels, we investigated the effects of nimodipine in anaesthetized pigs on the fractionation of 
carotid arterial blood flow into non-nutrient (arteriovenous anastomoses; AVAs) and nutrient 
(capillary) parts, and on regional tissue blood flows and vascular conductances. 
2 Intracarotid infusions of nimodipine (0.05-1.25 j.lg kg- 1 min-') redistributed carotid blood flow in 
favour of its nutrient compartment, particularly to the skeletal muscles and tongue. Vascular 
conductance in the non-nutrient (A VAs) compartment decreased (40%), most likely, as a result of 
'steal' following profound (5.5 fold) arteriolar dilatation. 
3 Intravenous infusions of nimodipine (0.05-6.25 j.lg kg- 1 min- 1) caused hypotension, bradycardia, 
a decrease in conduction in the non-nutrient fraction, and an increase in conduction in the nutrient 
fraction (mostly in the skeletal muscles, but also in the gastrointestinal tract, cerebral hemispheres, 
heart and adrenals). 
4 Probably due to the hypotensive effect, only skeletal muscle blood flow increased. The nimodipine-
induced increase in vascular conductance in the skeletal muscles showed regional variation; the effect 
wasmost pronounced in the cheek muscles, followed by the muscles of the chest, abdominal, trunk and 
gluteal regions. 
5 We conclude that: (i) A VA flow seems to represent a 'reserve' perfusion which can be readily 
diverted to tissues in the case of increased metabolism and/or vasodilatation, (ii) though the overall 
response to nimodipine of carotid blood flow distribution qualitatively resembles that to some anti-
migraine drugs, the relevance of such acute effects in the prophylactic usefulness of nimodipine in 
migraine remains to be ascertained, and (iii) nirnodipine lacks a selective cerebral vasodilator action in 
the anaesthetized pig. 
Introduction 
63 
One of the most significant recent advances in drug 
development has been the discovery of agents interfer-
ing with calcium (Ca2+) channels. These drugs are now 
being used for the treatment of cardiovascular disor-
ders such as angina pectoris, cardiac arrhythmias and 
hypertension (see Fleckenstein, 1983). The Ca2+ chan-
nel antagonists exhibit considerable heterogeneity 
with respect to their effects on the heart and different 
vascular smooth muscle preparations (Cauvin et a/., 
1983; Fleckenstein, 1983; Nayler, 1983; Peroutka, 
1 Author for correspondence at Department of Phar-
macology. 
2Present Address: Department of Pharmacology, University 
of Sydney, Sydney, NSW 2006, Australia. 
1983). The dihydropyridine derivative nimodipine 
appears to have a preferential action on cerebral 
vessels; it antagonizes vasoconstrictor effects of 5-
hydroxytryptamine · (5-HT), blood and carboxylic 
thromboxane A2 on the rabbit basilar artery more 
effectively than on the rabbit saphenous artery 
(Towart, 1981; Towart & Perzbom, 1981; Towart et 
a/., 1982). Clinically, nimodipine bas shown potential 
in the therapy of cerebral vascular spasm following 
subarachnoid haemorrhage (Aueret a/., 1982; Groten-
huis et a/., 1984; Kostron et a/., 1984) and in the 
treatment of migrainous headaches (Gelmers, 1983; 
Meyer & Hardenberg, 1983). 
In the present investigation we have addressed 
©The Macmillan Press Ltd 1986 
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ourselves to two questions. Firstly, in view of the 
possible involvement of cephalic arteriovenous anas-
tomoses (A VAs) in the pathophysiology of migraine 
(Heyck, 1969; Saxena, 1978; 1984), we have studied 
the effects of local infusions of nimodipine on the 
fractionation of carotid blood flow into nutrient 
(capillary) and non-nutrient (AVA) parts in the anaes-
thetized pig. The second part of this study deals with 
regional haemodynamics. Though several studies have 
shown that basal cerebral blood flow may increase in 
some species (Harper et al., 1981; Kazda et al., 1982; 
McCalden et al., 1984; Mohamed et al., 1984), only 
Haws et al. (1983), using rabbits, have directly com-
pared the cerebrovascular effects of nimodipine with 
those on some other tissues. Therefore, the effects of 
intravenous (i.v.) infusions of nimodipine have been 
studied on regional tissue blood flows and vascular 
conductances to determine whether the drug causes a 
selective vasodilatation in the cerebral vascular bed of 
another species (pig). 
Methods 
Three series of experiments were performed. In the 
first series, intracarotid administration of the drug 
solvent was used as a control for evaluation of the 
stability of the preparation. In a second group of 
animals, the effects oflocal infusions of nimodipine on 
the total common carotid artery blood flow and its 
distribution were determined. Finally, i.v. infusions 
were used to evaluate the effects of nimodipine on 
cardiac output and its distribution. A wide range of 
doses of nimodipine was selected; the difference 
between the first and last infusion rate was 25 and 125 
fold in the intracarotid and i.v. experiments, respec-
tively. 
Experimental preparation 
After an overnight fast, 25 Yorkshire pigs (mean body 
weight± s.e.mean, 25.7 ± 0.8kg; age 12-16 weeks) 
were initially sedated with 120mg (i.m.) azaperone 
(Stresnil) and 150mg (i.v.) metomidate (Hypnodil). 
After the animals had been intubated, they were 
connected to a respirator for intermittent positive 
pressure ventilation with oxygen and nitrous oxide 
(1 :2). Respiratory rate and tidal volume were adjusted 
to keep arterial blood gases, measured with an ABL-3 
(Radiometer, Copenhagen), within normal limits (pH, 
7.35-7.45; Po2, 90-150 mmHg, Pco2, 35-45 mmHg); 
sodium bicarbonate (8.4%, wfv) was infused, if neces-
sary, until base excess was near zero. An electric 
blanket was used to maintain the animal's temperature 
around 37•c. A continuous i.v. infusion of pentobar-
bitone sodium(15-25mgkg- 1 h- 1) and an i.v. bolus 
of 4 mg pancuronium bromide (Pavulon) were used to 
maintain anaesthesia. Arterial blood pressure 
(obtained via a 7F catheter placed in the left femoral 
artery and connected to a Statham pressure trans-
ducer) and heart rate (counted from ECG signals) 
were monitored on a Gould Brush recorder. Catheters 
in both femoral veins and the other femoral artery 
were used for i.v. administration of drugs and fluids, 
and for monitoring arterial blood gases. 
In the animals which received intracarotid infusions 
of nimodipine, both common carotid arteries were 
dissected free in the neck and bilateral cervical 
vagosympathectomy was performed to avoid reflex 
influences on the carotid circulation. Two 0.5 mm 
(external diameter) needles, connected to suitable 
polyethylene tubings, were inserted directly into one of 
the common carotid arteries for the infusion of 
nimodipine and the injection ofmicrospheres, respec-
tively. Blood flow in this artery was measured with a 
2.5 or 3 mm (i.d.) calibrated flow probe connected to a 
sine wave electromagnetic blood flowmeter (Skalar, 
Delft). In the animals used to study the effects ofi.v. 
administration of nimodipine on the distribution of 
cardiac output, a mid-sternal thoracotomy was perfor-
med. A cannula was inserted into the left atrial 
appendage for injection of the microspheres and a 
catheter in the femoral artery was · employed to 
withdraw a reference blood sample during micro-
sphere injection (Saxena et al., 1980). Ascending aorta 
blood flow was measured with a suitable electromag-
netic flow probe placed around the vessel. Cardiac 
output was derived by adding myocardial blood flow 
(measured with radioactive microspheres; see below) 
to the ascending aorta blood flow. 
Distribution of common carotid blood flow and cardiac 
output 
Injection of radioactive microspheres Radioactive 
microspheres (15 ± 1 rs.d.]jtm diameter), labelled with 
141Ce, 113Sn, 103Ru, 9'"sNb or 46Sc (NEN Chemicals 
GmbH, Dreieich, West Germany) and suspended in 
saline containing a drop of Tween 80, were used (for 
details, see Saxena & Verdouw, 1982, 1984). Prior to 
use, the spheres were deaggregated by mechanical 
agitation. The distribution of common carotid arterial 
blood flow was determined by injecting 1-2 x 105 
microspheres into the artery against the direction of 
blood flow over a period of 15-20 s. The distribution 
of cardiac output was determined similarly except that 
1-2 x 106 microspheres were injected into the left 
atrium. Starting about 5 s before the injection of 
microspheres, blood was withdrawn (rate: 
12mlmin-1) from a femoral artery for a total period 
of 60-65 s. 
Counting of radioactivity At the end of each ex-
periment the animal was killed with an overdose of 
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pentobarbitone sodium and the various tissues, as 
specified later, were dissected out, weighed and placed 
in vials. The radioactivity in the vials containing the 
tissues and blood samples was counted for 5-10 min in 
a y-scintillation counter (Packard, model 5986) equip-
ped with a multichannel pulse height analyser (Con-
rae) using suitable windows for discriminating the 
different isotopes used (Saxena et a/., 1980). 
Calculations The microsphere and other data were 
processed by a PDP-11/70 computer using a set of 
programmes especially developed for the microsphere 
technique (Saxena et al., 1980). The amount of carotid 
blood distribut~d to the individual tissues (Qu'!fa'J) was 
calculated by: Qus[carJ (ml min- 1) = (IuJI.oJ x ~.lear and 
Ous[carJ (%) = (IuJI,0 ,) X 100, where 1,;, and 1,0 , are, 
respectively, the radioactivity (c. p.m.) in a particular 
tissue and that detected in all tissues (i.e. tissues of the 
head, including the compl~te brain, and the neck and 
lungs) collectively, and Qcar is carotid blood flow 
(ml min- 1) (see Saxena & Verdouw, 1982). The 
amount pf cardiac output distriputed to the various 
tissues !Q,;,) was. calculated ~s: Q,;, (mlmin- 1) = (1,;,/ 
I,.,) x Qan and Q,;, (%) = (Q,;JCO) x 100, where 1,;, 
and Ian are, respectively, the radioactivity (c. p.m.) in a 
particqlar tissue and that of the arterial blood sample, 
while Q." is the rate of withdrawal of blood samples 
and CO is cardiac output in mlmin-•. The various 
tissues selected were: heart, kidneys, ·adrenal glands, 
skeletal muscles from several regions, skin, spleen, 
liver, small and large intestine, including caecum and 
rectum (gastrointestinal tract), eyes and a large part of 
the brain (cerebral hemispheres). Tissue vascular 
conductance was calculated by dividing respective 
blood flow values by mean arterial blood pressure. 
The values determined for lungs, when micro-
spheres were injected into the carotid artery, represent 
the AVA part of the carotid circulation (see Johnston 
& Saxena, 1978; Saxena & Verdouw, 1982). In the case 
of left atrial injection, the lungs receive microspheres 
via both peripheral A VAs and bronchial arteries; 
however, the contribution via the latter route appears 
to be only about l% (Baile et al., 1982). Thus, even in 
this case, the values for 'lung blood flow' can be used 
as an index of peripheral AVA flow (i.e. the non-
nutrient part of cardiac output). The nutrient part of 
cardiac output was calculated by subtracting 'lung 
blood flow' from cardiac output. 
Experimental protocol 
In all experiments, the baseline values were obtained 
following a stabilization period of 60 min after com-
pletion of the surgical procedures. The measurements 
consisted of recordings of the heart rate, mean arterial 
blood pressure and common carotid artery blood flow 
(or cardiac output), while a batch of microspheres was· 
injected into the carotid artery (or into the left atrium). 
In the common carotid blood flow distribution ex-
periments, three successively increasing intracarotid 
infusions of nimodipine (0.05, 0.25 and 1.25 11g kg- 1 
min- 1) were then administered for lOmin each. 
Microspheres were injected at the end (l 0 min) of the 
0.05 and 0.25 11g kg- 1 min- 1 infusions, and 2 and 
lOmin after the last infusion step (l.25~tgkg- 1 min- 1 ). 
In the cardiac output distribution experiments, succes-
sively increasing i. v. doses of 0.05, 0.25, 1.25 and 
6.25 Jtgkg- 1 min-• of nimodipine were infused for a 
period of 10 min each; microspheres were injected at 
the end of each i.v. infusion period. Control ex-
periments were performed with the drug solvent which 
was injected into the common carotid artery in 
amounts (0.5, 2.5 and 12.5 ~tl kg- 1 min- 1) which corre-
sponded to the three intracarotid doses of nimodipine; 
l 0 min after each infusion, microspheres were injected 
into the carotid artery. 
Data presentation and statistical analysis 
Except as mentioned otherwise, all data in the text and 
Table 1 Effects ofintracarotid administration of nimodipine (n = 9) and eqnivalent amounts of its solvent (n = 6) on 
mean arterial blood pressure and heart rate in pigs 
Solvent 
Nimodipine 
Solvent 
Nimodipine 
Baseline 
values 
104±7 
105±4 
100±4 
114± 8 
% change by nimodipine (JJgkg- 1 min- 1) or solvent' 
1.25 1.25 
0.05 0.25 (2 min) (10 min) 
Mean arterial pressure (mmHg) 
-2±1 -3±1 
-14± 3•'•• 
-8± 1• 
-7±2 
-24±4•' .. -34±4• 
Heart rate (beats min-t) 
-11 ± t• 
-17±5• -18±4• 
-4± 1° 
-47± 5•••• 
-12±2• 
-23±4•' .. 
'The corresponding doses of solvent were 0.5, 2.5 and 12.5 ,.I kg-• min-•; •Significantly different from the respective 
baseline value; .. Change significantly more than the respective change caused by the drug solvent. 
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illustrations are presented as means ± s.e.mean. In 
general absolute values have been given but in order 
to facilitate comparison between the effects of 
nimodipine and its solvent (carotid blood flow dis-
tribution experiments), we have presented data in 
Tables 1 and 2 as % changes from the respective 
baseline values. These values are means of the % 
changes in each animal, as are the other %. changes 
included in the text. The significance of the effects of 
the solvent or nimodipine on the different variables 
was evaluated by Duncan's new multiple-range test 
once an analysis of variance (randomized block 
design) had . revealed that the samples represented 
different populations. The baseline values and the 
effects of the solvent were compared similarly but, in 
this case, one-way analysis of variance was used 
(Saxena, 1985). A P value of 0.05 or less (two-tailed) 
was considered statistically significant. 
Drugs 
No drugs other than the anaesthetics and nimodipine 
(Bay e 9736; Bayer, Wuppertal) were used in this 
study. The nimodipine solvent used was a mixture of 
polyethylene glycol 400, glycerol and water. The 
nimodipine solution (0.1 mgml- 1) and the solvent 
were diluted with 0.9% w /v NaCl solution immediate-
ly before use. 
Results 
Effects of intracarotid infusions of solvent and 
nimodipine 
Arterial blood pressure and heart rate Baseline mean 
arterial blood pressure and heart rate did not differ 
Table 2 Effects of intracarotid administration of nimodipine (n = 9) and equivalent amount of its solvent (n = 6) on 
total carotid blood liow and its distribution in pigs 
A VA-fraction 
Solvent 
Nimodipine 
Nutrient-fractionb 
Solvent 
Nimodipine 
Total carotid 
Solvent 
Nimodipine 
AVA-fraction 
Solvent 
Nimodipine 
Nutrient-fraction 
Solvent 
Nimodipine 
Total carotid 
Solvent 
Nimodipine 
AVA-fraction 
Solvent 
Nimodipine 
Nutrient-fraction 
Solvent 
Nimodipine 
Baseline 
values 
82± I 
82± 2 
18± I 
18± 2 
166± 17 
232± 20 
137 ±IS 
190 ± 18 
29± 3 
40± 5 
1.6 ±0.2 
2.2 ±0.2 
1.3 ±0.2 
1.8 ±0.2 
0.28±0.02 
0.38 ± 0.04 
% change by nimodipine ( p.g kg -I min- 1) or solvent" 
/.25 1.25 
0.05 0.25 (2min) (/Omin) 
Blood flow(% carotid liow) 
3± 2 
-31 ± 6*'** 
-13± 9 
i22 ± 18*'*0 
2± I 
4± 8 
6± 2 
-31± 4*'** 
-II± 10 
135± 34*'** 
2± 3 
-48 ± s•·•• 
-11±13 
232 ± 23*'** 
Blood flow (ml min- 1) 
3± 2 
10± 7 
S± 3 
-44± 5*'** 
~8± 13 
264± 29*'** 
-63 ± s• 
323 ± 32* 
9± 7 
-60± 6* 
323 ± 32* 
Conductance (mlmin- 1 mmHg- 1) 
5± I 7± 3* 
21± 10 47 ± 10*'** 67± 8* 
8± 2* 8± 4* 
-20± 4*'** -27± 4*'** -40± 7* 
-9± 10 -5± 13 
175 ± 42*'** 385 ± 48*'** 551 ±53* 
I± 3 
-65 ± s•·•• 
-I± 16 
268 ± 29*'*0 
2± 2 
-14± 7* 
3± 3 
-70± 4*'** 
I± 18 
208± 14*'"* 
7± 3* 
68 ± 16*'•• 
7± 3* 
-44± S*"** 
6±20 
512 ± 68*'** 
"The corresponding doses of solvent were 0.5, 2.5 and 12.5 p.l kg- 1 min -I; blncludes botb extracerebral and cerebral 
(2%) components. *Significantly different from tbe respective baseline value; **Change significantly more tban tbe 
respective change caused by tbe drug solvent. 
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significantly in the animals subsequently treated with 
the solvent or nimodipine (Table 1). Intracarotid 
administration of the solvent had little or no effect on 
mean arterial blood pressure but caused slight de-
creases in heart rate. Nimodipine produced substan-
tial decreases in arterial blood pressure at all three 
infusion rates, but heart rate decreased significantly 
more than that with the equivalent amount of solvent 
only at the highest rate (1.25 !Lg kg- 1 min - 1) of in-
fusion (Table 1). 
Fractionation of carotid blood flow into non-nutrient 
and nutrient parts The effects of nimodipine and its 
solvent on the distribution of carotid blood flow are 
shown in Table 2. Though the baseline values of total 
carotid blood flows in the two series differed sig-
nificantly, none of the other baseline values was 
significantly different. Infusions of the solvent caused 
little or no change in either the blood flow to or the 
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conductance in the carotid vascular bed (both in non-
nutrient and nutrient parts). On the other hand, there 
was a marked redistribution of blood flow with 
nimodipine. AVA blood flow and conductance de-
creased dose-dependently by up to 70 and 44%, 
respectively, but these decreases were associated with 
marked increases in nutrient blood flow and conduc-
tance (Table 2). Therefore, total carotid artery blood 
flow was not affected until! 0 min after the infusion of 
the highest dose when flow had significantly decreased 
by 14%. Since mean arterial blood pressure had 
decreased with nimodipine, there were increases in the 
calculated total carotid conductance, but these were 
much smaller than the increases observed in the 
nutrient part. 
Tissue distribution of the nutrient part of carotid blood 
flow Figures l and 2 show that the various tissues in 
the head were not equally affected by nimodipine. The 
* 
~* -::. • " Eyes Fat 20 
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Tongue 0 Salivary glands 
Bones 
Figure 1 Effects of intracarotid administration of nimodipine on tissue distribution of carotid nutrient blood flow in 
pigs (n = 9). The five columns represent values at baseline (open columns), and after nimodipine {l&gkg-1 min- 1) 
infusions of 0.05 (stippled columns), 0.25 (hatched, dark lines on white background, columns) and 1.25 at 2 min 
(hatched, white lines on dark background columns) and at 10 min (solid columns). *Significantly different from the 
respective baseline value. 
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contribution via the carotid artery to nutrient blood 
supply of the eyes and bones decreased, but that to the 
fat, skeletal muscles, tongue, salivary glands and skin 
increased. The increases in the blood flow to the 
skeletal muscles (6-14 fold) and tongue (2-12 fold) 
were particularly marked. No significant change was 
noticed in the brain and ears (Figure 1). 
Vascular conductance increased in all tissues except 
the eyes and bones (Figure 2). The magnitude of the 
vasodilator response varied greatly. The largest in-
crease in conductance (20 fold) was observed in 
skeletal muscles and tongue, followed by fat (9 fold), 
skin (4 fold) and salivary glands (3 fold). Conductance 
of the cerebral vascular bed showed the least increase 
(1.6 fold) and that, too, only after 10 min of the highest 
infusion rate. 
Effects of i. v. infusions of nimodipine 
Systemic haemodynamics The effects of nimodipine 
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on systemic haemodynamic variables are shown in 
Table 3. The drug decreased mean arterial blood 
pressure and heart rate dose-dependently (by up to 
60 ± 4 and 36 ± 5%, respectively). During baseline 
condition,·· 55± 2% of cardiac output (2.9lmin- 1) 
was used for the nutrition of tissues, while 45 ± 2% 
bypassed tissues via A VAs. Nunodipine decreased 
cardiac output but, except for the highest dose 
(38 ± 7%), these effects were relatively minor 
(<15%). The decrease in cardiac output was entirely 
in the AVA-part which was reduced by 12 ± 3, 41 ± 5, 
70 ± 4 and 87 ± 3%, respectively, by the four infusion 
rates (0.05, 0.25, 1.25 and 6.25 flg kg- 1 min -I) used. 
The nutrient part of cardiac output remained unchan-
ged, or even increased (after 1.25 Jlgkg- 1 min- 1 of 
nimodipine). Systemic vascular conductance increased 
(up to 65 ± 13%) after the two highest doses of the 
drug. This increase in the systemic conductance (Table 
3) was due to the increase in conductance of the 
nutrient part of the vascular beds of the various tissues 
~ 
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Figure 2 Effects of intracarotid administration of nimodipine on tissue conductance in the nutrient part of carotid 
vascular bed of pigs (n= 9). The five columns represent values at baseline (open columns), and after nimodipine 
(f.lgkg- 1 min- 1) infusions of0.05 (stippled columns), 0.25 (hatched, dark on white background, columns) and 1.25 at 
2 min (hatched, white lines on dark background, columns) and at 10 min (solid columns). *Significantly different from 
the respective baseline value. 
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Table 3 Systemic haemodynamic effects ofi.v. administration ofnimodipine in pigs (n = 10) 
Baseline 
values 0.05 0.25 1.25 6.25 
MAP(mmHg) 84±4 78±4 63±4• 45±2• 34± 3• 
HR (beatsmin- 1) 98± 3 95±3 92±4 87± s• 63± s• 
CO(Imin- 1) 2.9 ±0.2 2.5 ±0.1 2.4 ± 0.1• 2.4 ± 0.1• 1.7 ± 0.2• 
AVA ftow (I min- 1) 1.3 ± 0.1 1.1 ±0.1 ... o.1 ±o.I• 0.3 ± 0.04• 0.2 ± 0.04• 
NCO (I min- 1) , 1.6 ± 0.1 1.4 ± 0.1 1.7 ± 0.1 2.1 ±o.1• 1.5 ± 0.2 
SVC (mlmin- 1mmHg- 1) 35± 3 34± 3 41 ±3 54±3' s1 ±s• 
AVAC (mlmin- 1mmHg- 1) 16± I 15± 2 12± •• 8± •• 5± •• 
NYC (mlmin- 1mmHg- 1) 19±2 19±2 29±3• 46±3• 46± s• 
MAP, mean arterial blood pressure; HR, heart rate; CO, cardiac output; AVA flow, peripheral arteriovenous 
anastomoses blood ftow; NCO, nutrient part of cardiac output. SVC, AVAC and NYC are conductances of, 
respectively, total systemic, peripheral AVA and nutrient channels. 
•Significantly different from the respective baseline value. 
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(2.4 fold with the highest dose), as the conductance of 
A VAs decreased dose-dependently to 30% of baseline 
values. 
Tzssue blood flow and conductance The changes in 
nutrient cardiac output were not equally distributed 
(Figure 3). The perfusion of the skeletal muscles 
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Figore3 Effects ofi.v. administration ofnimodipine on tissue distribution of nutrient cardiac output in pigs (n = 10). 
The five columns represent values at baseline (open columns), and after infusions of 0.05 (stippled columns), 0.25 
(hatched, dark lines on white background, columns), 1.25 (hatched, white lines on dark background, columns) and 6.25 
(solid columns) 11g kg- 1 min-t of nimodipine. •significantly different from the respective baseline value. 
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increased, while that of other organs either did not 
change (heart, adrenal glands, skin and gastrointes-
tinal tract) or even decreased (kidneys, spleen, liver, 
eyes and cerebral hemispheres). Consequently, 
nutrient vascular conductance (Figure 4) of some 
organs increased (heart, adrenal glands, skeletal mus-
cles, gastrointestinal tract and cerebral hemispheres) 
and of others either remained unchanged (skin. and 
liver) or decreased (kidneys, spleen and eyes). The 
most pronounced increase was in the conductance of 
skeletal muscles (271 ±57%) which was followed by 
gastrointestinal tract ( 124 ± 19%) and cerebral hemis-
pheres(98 ± 16%).0n theotherhand,conductanceof 
the vascular bed of the eye was reduced by 49 ± 7%, 
which was followed by the renal vascular bed 
(41 ± 6%). 
Skeletal muscles of different regions As shown in 
Table 4, the effects of nimodipine varied in the skeletal 
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muscles obtained from different regions. With the 
highest dose the average increase in vascular conduc-
tance was 9 fold in the cheek muscles, 4 fold in the 
chest muscles, 3 fold in the abdominal muscles and 
only 2 fold in the trunk and gluteal muscles. 
Diseussion 
Systemic haemodynamics 
Both intracarotid and i.v. administration of 
nimodipine caused a fall in arterial blood pressure. 
Since even the local intracarotid infusions of the drug 
substantially lowered blood pressure, it would appear 
that the drug quickly appeated in the systemic circula-
tion. Whether th.:: cervical vagosympathetic nerves 
were sectioned (intracarotid infusions) or not (i.v. 
infusions), the hypotensive effect of nimodipine was 
0.20 
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Figure 4 Effects ofi.v. administration of nimodipine on nutrient regional vascular conductance in pigs (n = 10). The 
five columns represent values at baseline (open columns), and after infusions of0.05 (stippled columns), 0.25 (hatched, 
dark lines on white background, columns), 1.25 (hatched, white lines on dark background, columns) and 6.25 (solid 
columns) 1'8 kg- 1 min- 1 of nimodipine. •Significantly different from the respective baseline value. 
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Table 4 Effect of i.v. administration of nimodipine on skeletal muscles ~f different regions of pigs (n = 10) 
Baseline 
values 0.05 0.25 1.25 6.25 
Blood flow (mlmin- 1 100g- 1) 
Cheek 3.5 ± 0.6 
2.6 ± 0.4 
2.0 ± 0.2 
5.5 ± 0.5 
5.9 ± 0.8 
4.4 ± 0.5 
5.3 ± 0.4 
3.1 ± 0.4 4.5 ± 1.2 14 ± 2* II± 2* 
4.3 ± 1.1* 
2.7 ± 0.8 
6.6 ± 1.8 
6.1 ± 1.8 
5.4 ± 1.6 
6.6 ± 1.4 
Chest 
Abdomen 
Right trunk 
Left trunk 
Right gluteus 
Left gluteus 
2.1 ± 0.4 2.9 ± 0.5 4.8 ± 0.7* 
1.7 ± 0.2 1.7 ± 0.3 3.2 ± 0.4* 
4.6 ± 0.9 5.3 ± 1.0 9.0 ± 1.3* 
4.4 ± 0.8 5.4 ± 1.0 8.9 ± 1.9* 
3.7 ± 0.5 5.0 ± 0.7 6.9 ± 1.2* 
4.5 ± 0.6 6.7 ± 0.8 9.6 ± 1.3* 
Conductance (mlmin- 1 mmHg- 1 Ioog- 1) 
Cheek 0.04± 0.01 
0.03 ± 0.01 
0.02± 0.004 
O.o7 ± O.oi 
O.o7 ± 0.01 
0.05 ± 0.01 
0.06± 0.01 
0.04 ± O.ot O.o7 ± O.o2 0.31 ± 0.05* 0.32± 0.04* 
0.12± 0.02* 
O.o7 ± 0.02* 
0.19 ± 0.03* 
0.17 ± 0.03* 
0.15 ± 0.04* 
0.19 ± 0.03* 
Chest 
Abdomen 
Right trunk 
Left trunk 
Right gluteus 
Left gluteus 
0.03 ± 0.01 0.05 ± 0.01 O.ll ± 0.01* 
0.02 ± 0.004 0.03 ± 0.005 0.07 ± 0.1* 
0.06 ± O.ot 0.09 ± 0.01 0.19 ± 0.02* 
0.06 ± 0.01 0.08 ± 0.01 0.19 ± 0.03* 
0.05 ± 0.01 0.08 ± 0.01 0.15 ± 0.03* 
0.06 ± 0.01 0.11 ± 0.01* 0.21 ± 0.02* 
*Significantly different from tbe respective baseline value. 
not accompanied by any evidence of reflex activation 
of the sympathetic nervous system via the barorecep-
tors; both heart rate and cardiac output decreased in 
the present experiments (Tables 1 and 3). The decrease 
in cardiac output Oargely, if not entirely, confined to 
the non-nutrient part) was moderate and, therefore, 
the hypotensive effect of nimodipine was mainly due 
to an increase in systemic vascular conductance, 
The lack of reflex effects during nimodipine-in-
duced hypotension in anaesthetized pigs is in contrast 
to the effects of the structurally related Ca2+ channel 
antagonists nifedipine (Gross et a/., 1979) and 
felodipine (Bolt & Saxena, 1984) in conscious animals, 
where both heart rate and cardiac output increase 
prominently. This discrepancy appears to be, at least 
partly, due to the anaesthetic agents used in the present 
experiments; in conscious or anaesthetized (fentanyl 
plus etomidate) patients undergoing cardiac bypass 
surgery, nimodipine increases cardiac output (Boldt et 
a/., 1985), and therefore causes less hypotension. 
However, heart rate is not or only slightly elevated by 
nimodipine, even in conscious rabbits (Haws et a/., 
1983) or man (Boldt eta/., 1985), but is increased by 
nisoldipine, another related Ca2+ channel antagonist, 
in anaesthetized pigs (Duncker et a/., 1986). 
Carotid haemodynamics 
The results obtained in the present experiments con-
firm our previous observations that a large (about 
80%) fraction of common carotid blood flow in the pig 
is shunted via A VAs (Saxena & Verdouw, 1982; 1984; 
Verdouw eta/., 1984a,b), which are mainly located in 
the skin and ears (Saxena & Verdouw, 1985). Local 
infusions of nimodipine, but not of its solvent, redis-
tributed carotid arterial blood flow in favour of the 
nutrient (tissue, arteriolar) component at the expense 
of the non-nutrient (A VA) component. Unlike 5-HT 
where the increased nutrient flow is mainly distributed 
to the skin and ears (Saxena and Verdouw, 1982; 
1984), nimodipine enhanced primarily that to the 
skeletal muscles and tongue. 
The dilatation of arterioles by nimodipine is 
apparently due to Ca2+ channel blockade, but the 
mechanism responsible for the decrease in AVA flow 
and conductance needs further examination. A 
baroreceptor reflex-mediated stimulation of the sym-
pathetic nervous system seems unlikely for the reasons 
discussed above and, moreover, in young pigs as used 
in the present experiments, A VAs are only poorly 
constricted via noradrenergic mechanisms (Verdouw 
et a/., 1984b). Another possibility may be that 
nimodipine in some way interferes with the release of 
an endogenous substance responsible for opening up 
A VAs in the pig. Though the formation of endoth-
elium-derived relaxing factor (EDRF) in some arterial 
preparations in vitro is Ca2+ -dependent (Singer & 
Peach, 1982; Rubanyi et at., 1985), and can be 
inhibited by Ca2+ channel antagonists (Singer & 
Peach, 1982), it is not yet known if such an effect of 
Ca2+ channel antagonists is observed in vivo or if 
EDRF can indeed relax A VAs. Thus, it follows that 
the reduction in AVA flow and conductance most 
probably results from 'steal' as a consequence of 
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profound dilatation in the nutrient vascular channels 
. caused by nimodipine. This suggestion is indirectly 
supported by comparing similar data found with 5-
IIT,.which.elicits..an 'active' constriction of A VAs. In 
the face of a 3 fold increase in nutrient vascular 
conductance, 5-HT reduces AVA conductance by over 
80% (Saxena & Verdouw, 1982), whereas in associa-
tion with an even greater increase (5.5 fold) in nutrient 
conductance, nimodipine decreased AVA conduc-
tance by only about 40% (Table 2). This haemodyn-
amic redistribution as observed with nimodipine may 
be of physiological significance; the data in this study 
reinforce the idea ·that, in situations .of increased 
-metabolism and/or vasodilatation, nutrient blood 
supply to tissues can be readily made available from 
arteriovenous shunting which apparently represents 
'reserve' perfusion. 
Arteriovenous shunting has been implicated in the 
pathophysiology of migraine where profound 
vasodilatation in these large shunt vessels may lead to 
a reverse 'steal' (Heyck, 1969; Saxena, 1978; 1984). 
Indeed anti-migraine drugs, particularly the ergot 
alkaloids effective in the treatinent of individual 
attacks (Johnston & Saxena, 1978; Schamhardt eta/., 
1979; Spierings & Saxena, 1980), as well as 5-HT 
(Saxena & Verdouw, 1982) which may also alleviate 
migraine attacks (Kimball eta/., 1960; Lance, 1982), 
cause an .'active' constriction of A VAs. Though the 
overall effect of nimodipine on the distribution of 
carotid artery blood flow into nutrient and non-
nutrient fractions qualitatively resembles that of the 
above drugs, nimodipine is less efficacious and, as 
discussed above, has a 'passive' effect on A VAs. 
Probably because of this passive and moderate effect 
of A VAs, in contrast to the ergot alkaloids, 
nimodipine has recently been found to be ineffective in 
the treatment of individual attacks of classic migraine 
(Jensen et a/., 1985). Whether the acute effects of 
nimodipine on carotid haemodynamics, as observed in 
this study, are related to the beneficial properties of the 
drug reported after long term prophylactic use in 
migraine (Gelmers, 1983; Meyer & Hardenberg, 1983) 
remains to be ascertained. 
Regional haemodynamics 
The regional haemodynamic effects ofnimodipine on 
the nutrient fraction were not uniform. Only skeletal 
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muscle blood flow increased. Since arterial blood 
pressure decreased, conductance increases (i.e. 
vasodilatation) were observed (in decreasing order of 
magnitude) in the skeletal muscles, the gastrointestinal· 
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Enhancement of vasoconstrictor and attenuation of vasodilator effects 
of 5-hydroxytryptamine by the calcium channel blockers nimodipine 
and nifedipine in the pig 
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As calcium (Ca2+) channel blockers are effective against the vasoconstrictor responses to 5-hydroxytryptamine 
(5-HT) in vitro, and a favourable response is claimed for these drugs in migraine prophylaxis, we studied the 
interaction between ni.modipine or nifedipine, and 5-HT for effects on carotid haemodynamics in the anaesthetized 
pig. Intracarotid infusions of ni.modipine (0.25 p.g · kg-1 • min- 1), nifedipine (0.75 p.g · kg- 1 • min-1) or 5-HT (2.0 
p.g · kg-1 · min-1) caused a redistribution of carotid blood flow in favour of the nutrient (capillary) fraction at the 
expense of the non-nutrient (arteriovenous anastomoses; AVA) fraction. Compared to those of 5-HT, the effects of the 
Ca 2+ channel blockers on cranial A VAs were much weaker and the increase in the capillary fraction was observed 
mainly in the skeletal muscles, rather than in the skin. and ears as with 5-HT. When 5-HT was infused in the presence 
of ni.modipine or nifedipine, the amine-induced vasoconstrictor responses in the total carotid vascular bed and its 
AVA fraction were either not attenuated or were increased while the vasodilator responses were reduced. We conclude 
that: (i) in contrast to what was found in vitro, the 5-HT-induced vasoconstriction in vivo, involving either ''5-HT1-like' 
{AV As) or 5-HT2 (arterioles) receptors, was not antagoni2ed by ni.modipine or nifedipine; (ii) the attenuation of the 
5-HT-induced dermal vasodilatation by the two Ca2+ channel blockers is most likely to.be the result of a 'steal' due to 
the profound vasodilatation in the skeletal muscle region; and (iii) the comparatively mild reduction in A VA 
conductance caused by the Ca2 + channel blockers may be one of the reasons for their inability to abort acute attacks 
of migraine. The increase in nutrient blood flow is of. potential benefit, but whether this property of the Ca 2+ channel 
blockers is linked to their usefulness in migraine prophylaxis remains to be ascertained. 
Arteriovenous anastomosis; Calcium channel blockers; Carotid artery; 5-Hydroxytryptamine; Migraine; Nifedipine; 
Ninlodipine; Radioactive microspheres; Blood flow (regional) 
1. Introduction 
Though the magnitude of the effect varies with 
individual drugs, calcium (Ca2+) channel blockers 
inhibit the influx of extracellular Ca2+ into cardiac 
and vascular smooth muscle cells. These drugs are 
• To whom all correspondence should be addressed: Erasmus 
University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, 
The Netherlands. ' 
primarily effective in the treatment of cardiovas-
cular disorders such as hypertension, cardiac 
arrhythmias md angina pectoris. 
Recently, some Ca2+ channel blockers were 
reported to show therapeutic promise in cerebral 
vascular spasm following subarachnoid haemor-
rhage and in migraine prophylaxis (Louis, 1981; 
Auer et al., 1982; Gelmers, 1983; Meyer and 
Hardenberg, 1983). These beneficial.effects claini-
ed for Ca2+ channel blockers in migraine, and 
0014-2999/87/$03.50 © 1987 Elsevier Science Publishers B.V. (Biomedical Division) 
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perhaps also in subarachnoid haemorrhage, may 
be related to 5-hydroxytryptarnine (5-HT). It is 
known that, after an initial increase in the pre-
headache period, the concentration of 5-HT in 
blood decreases (together with increased urinary 
excretion of 5-hydroxyindole acetic acid) during 
migraine headaches (see Lance, 1978; Fozard, 
1982). Therefore, while headache itself seems to be 
associated with vasodilatation in the non-nutrient 
(arteriovenous anastomoses; AVAs) part of the 
cranial non-cerebral circulation, possibly linked to 
a low blood 5-HT concentration (Heyck, 1969; 
Saxena, 1978), an enhanced release of 5-HT could 
be involved in the initial cerebral vasoconstriction. 
Indeed, in vitro studies have shown convincingly 
that the drugs which block Ca2+ channels can also 
attenuate the vascular smooth muscle contractions 
elicited by 5-HT (Towart, 1981; Miiller-Schwei-
nitzer and Neuman, 1983; Van Nueten, 1984). The 
present series of experiments were designed to 
study the interaction between 5-HT and two dihy-
dropyridine Ca2 + channel blockers, nimodipine 
and nifedipine, on the distribution of common 
carotid artery blood flow in the anaesthetized pig. 
2. Materials and methods 
2.1. General 
Three series of experiments were performed in 
young Yorkshire pigs (22-28 kg). In the first series 
(n = 6), infusions into the co=on carotid artery 
were used to evaluate the effects of 5-HT on the 
distribution of total co=on carotid artery blood 
flow, before and during local infusions of 
nirnodipine. A similar protocol was followed in 
the second series (n = 5) but now we used nifedi-
pine instead of nirnodipine. A third group of 
animals (n = 6), served to study the carotid hemo-
dynamic effects of intracarotid infusion of 
nifedipine alone. 
2.2. Experimental set-up 
After an overnight fast the pigs were initially 
sedated with 120 mg azaperone (Stresnil) i.m., and 
120-150 mg metomidate (Hypnodil) i.v., intubated 
and connected to a respirator for intermittent 
positive pressure ventilation with a mixture (1 : 2) 
of oxygen and nitrous oxide. A continuous i.v. 
infusion of pentobarbitone sodium (20 mg · kg- 1 • 
h - 1) was administered throughout the experiment 
to mai:il.tain anesthesia. Respiratory rate and tidal 
volume were adjusted or sodium bicarbonate (8.4% 
wjv) was infused (until base excess was near zero) 
to keep arterial blood gases within normal limits 
(pH, 7.35-7.45; P0 ,, 90~150 rnrnHg; Pc0 ,, 35-45 
=Hg). Body temperature was kept around 37 o C 
with an electric blanket. Aortic blood pressure was 
monitored with a microtipped Millar catheter in-
serted into the left femoral artery. Both carotid 
arteries were dissected free in all animals and 
bilateral vagosyrnpathectomy was performed to 
avoid reflex effects on the carotid circulation. 
Blood flow in one of the co=on carotid arteries 
was measured with a precalibrated flow probe 
connected to a sine wave electromagnetic blood 
flowmeter (Skalar, Delft, The Netherlands). Three 
0.5 = (external diameter) hubless needles, con-
nected to suitable polyethylene tubing, were in-
serted directly into the main artery for intracaro-
tid infusions of 5-HT, nirnodipine or nifedipine 
and injection of radioactive microspheres. 
2.3. Distribution of common carotid artery blood 
flow 
2.3.1. Injection of radioactive microspheres 
The distribution of carotid blood flow into 
nutrient (tissue; capillary) and non-nutrient (A VA) 
fractions was determined by injecting into the 
co=on carotid artery a batch of 1-2 X 105 (15 ± 1 
(s.d.) pm) microspheres, labeled with 141 Ce, 113Sn, 
103 Ru, 95 NB, or 46 Sc (NEN Chemicals GmbH, 
Dreieich, West Germany) over a 15-20 s period, 
against the direction of blood flow (Saxena and 
Verdouw, 1982). 
2.3.2. Counting of the radioactivity 
The animals were killed at the end of each 
experiment with an overdose of pentobarbitone 
sodium. The various tissues of the head, and the 
lungs, heart and kidneys were dissected out, 
weighed and placed in vials. The radioactivity in 
these vials was counted for 5-10 min in a y-scintil-
lation counter (Packard, model 5986) equipped 
with a multichannel analyser (Contrac) using sui-
table windows for discriminating the different iso-
topes (Saxena et a!., 1980). 
2.3.3. Calculations 
The microsphere and other data were processed 
by a PDP-11/70 computer with a set of specially 
developed programmes (Saxena et a!., 1980). The 
fraction of common carotid blood flow distributed 
to the various organs (Qtis{carJ) was calculated as: 
Q,*.,1(ml·min- 1)- (Iti,/!,0 ,) XQ~, and 
Q,;*"'i(%) = (I,;,/1 10,) XlOO 
where I tis and Ito, are, respectively, the radioactiv-
ity (c.p.m.) in a particular tissue and that detected 
in all tissues collectively, and Qcar is total carotid 
blood flow (ml · min -I). Vascular conductance was 
calculated by dividing the respective blood flow 
values by the mean arterial blood pressure. The 
values obtained for lungs when microspheres were 
injected into the carotid artery represent the AVA 
part of the carotid circulation (see Saxena and 
Verdouw, 1982). 
2.4. Experimental protocols 
Baseline values were obtained for all experi-
ments after the preparation had been in a stable 
hemodynamic condition for at least 30 min after 
completion of the surgical procedures. The mea-
surements consisted of the recording of heart rate, 
mean arterial blood pressure and common carotid 
artery blood flow, while a batch of microspheres 
was injected for the determination of nutrient 
(tissue; capillary) and non-nutrient (AVA) blood 
flow. In the first and second series, the measure-
ments were repeated following a 10 min in-
tracarotid infusion of 5-HT (2.0 p.g · kg- 1 · min- 1) 
and again, in the first series, after a recovery 
period of 20 min. An intracarotid infusion of 0.25 
p. g · kg- 1 • min - 1 of nimodipine (first series) or 
0.75 p.g · kg- 1 • min- 1 of nifedipine (second series) 
was then started and was continued for 20 min; 
the doses of the Ca2 + channel blockers were cho-
sen after preliminary experiments and approxi-
mated those used in patients (for example, see 
Gelmers, 1983; Hugenholtz eta!., 1984; Jensen et 
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a!., 1985). All measurements were repeated 10 min 
after the start of infusion of either Ca2+ channel 
blocker, both before and 10 min after another 
infusion of 5-HT (2.0 p.g·kg- 1 -min- 1). In the 
third series data were recorded before and 10 and 
20 min after an infusion of nifedipine (0.75 p.g · 
kg -I · min - 1) had been started and once again 30 
min after the infusion had been stopped. 
2.5. Data presentation and statistical evaluation 
Unless stated otherwise, all data in the text and 
illustrations are presented as means ± S.E.M. The 
significance of the differences between the varia-
bles was evaluated by Duncan's new multiple-
range test after an analysis of variance (rando-
mized block design) had revealed that the samples 
represented different populations (Steel and Tor-
rie, 1980). The paired t-test was used to compare 
the 5-HT-induced changes during the infusion of 
nimodipine or nifedipine to the 5-HT-induced 
changes observed before the Ca2+ channel block-
ers. A P value of less than 0.05 (two-tailed) was 
considered to be statistically significant. 
2.6. Drugs 
The drugs, other than anaesthetics, used in this 
study were 5-hydroxytryptarnine creatinine sul-
phate (Janssen Chimica, Beerse, Belgium), 
nimodipine and nifedipine (Bayer A.G., Wup-
pertal, F.R.G.). The doses refer to the base of the 
substances. The Ca2 + channel blockers were dis-
solved in a mixture of glycerol (60 g), H 20 (100 g) 
and polyethylene glycol (ad 1129 g), and the stock 
solution (nimodipine: 0.2 mg · ml-\ nifedipine: 
0.1 mg · mi -I) was diluted with 0.9% N aCl to the 
concentrations used (nimodipine: 0.25 p.g · kg- 1 • 
min- 1; nifedipine: 0.75 p.g·kg- 1 -min- 1). The 
above solvent mixture has no effect on systemic or 
carotid haemodynarnics (Duncker eta!., 1986b). 
3. Results 
3.1. Systemic hemodynamics 
Neither heart rate nor mean arterial blood pres-
sure was affected by intracarotid infusions of 2.0 
80 
J.!g·kg- 1 ·min- 1 of 5-HT in the control period 
(fig. 1). Intracarotid administration of nimodipine 
(0.25 J.!g·kg- 1 ·min-1) or nifedipine (0.75 J.!g· 
kg- 1 · min- 1 ) did not change the heart rate but 
diminished blood pressure by 21 ± 3 and 20 ± 3%, 
respectively. In the presence of either Ca2+ chan-
nel blocker, 5-HT was again unable to induce 
major changes in these hemodynamics parame-
ters; only an 18 ± 5% increase in heart rate was 
noticed with 5-HT during treatment with nimodi-
pine. The heart rate was unchanged during a 20 
min infusion of 0.75 J.!g · kg- 1 • min-1 of nifedi-
pine (series 3), while the mean arterial blood pres-
sure decreased by 22 ± 1 and 32 ± 3% after 10 and 
20 min, respectively. The values at baseline, at 10 
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Fig. 1. Heart rate (HR) and mean arterial blood pressure 
(:MAP) values in pigs before and after infusions of 5-HT (2.0 
f'g·kg- 1·min-1 ) given during the control period and during 
intracarotid infusions of nimodipine (0.25 f'g·kg- 1·min- 1; 
left panels) or nifedipine (0.75 f'g·kg- 1·min-l, right panels). 
Note that while 5-HT did not cause any change in MAP and 
increased HR only slightly during nimodipine infusion, both 
Ca 2+ channel blockers decreased MAP without affecting HR. 
• P < 0.05 vs. baseline or recovery; • • P < 0.05 vs. nimodi-
pine or nifedipine. D Baseline; liD 5-HT; D recovery; D nimodi-
pine (left) or nifedipine (right); 1!11 5-HT + nimodipine (left) or 
nifedipine (right). 
and 20 min infusion of nifedipine and at 30 min 
after the end of the infuson were: 93 ± 4, 72 ± 3, 
63 ± 2 and 75 ± 2 =Hg, respectively. 
3.2. Carotid hemodynamics 
3.2.1. Distribution of common carotid artery blood 
flow during baseline 
As found earlier (Saxena and Verdouw, 1982; 
Verdouw et al., 1984b), under control (baseline) 
conCiitions, a major fraction of the total co=on 
carotid artery blood flow (244 ± 21 ml · min-\ 
n = 17) was shunted via A VAs because 86 ± 2% of 
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Fig. · 2. Effect of intracarotid infusion of nimodipine (0.25 
f<g·kg- 1·min- 1) on the changes induced by intracarotid infu-
sions of 5-HT (2.0 ,..g·kg- 1·min-1) in the total carotid blood 
flow and its distribution into non-nutrient (A VA) and nutrient 
(tissue; capillary) parts in pigs. Nimodipine, like 5-HT, re-
duced blood flow, and vascular conductance in the A VA 
fraction but increased the capillary fraction. Total carotid 
conductance was increased by nimodipine but was decreased 
by 5-HT. The 5-HT-induced vasoconstriction in the total caro-
tid bed and its AVA fraction was not affected by nimodipine, 
but the tissue vasodilatation was reduced. • P < 0.05 vs. base-
line or recovery; •• P < 0.05 vs. nimodipine; ••• the 5-HT-
induced change during nimodipine infusion was significantly 
different cP < 0.05) from the 5-HT -induced change before 
nimodipine. D Baseline; D 5-HT; D recovery; !l3 nimodipine; Ill 
5-HT + nimodipine. 
the injected microspheres was detected in the lungs 
whereas only a very minor fraction (1.6 ± 0.4%) 
was used to supply the brain. The blood flow to 
the extracerebral tissues was: skin, 1.5 ± 0.2 ml · 
min- 1 (0.6 ± 0.1%); skeletal muscles, 6.1 ± 0.6 ml 
· min - 1 (2.6 ± 0.2%) ears, 0.9 ± 0.2 ml· min - 1 (0.4 
± 0.1%); tongue, 2.0 ± 0.5 ml· min- 1 (0.9 ± 0.2%); 
salivary glands, 5.8 ± 1.1 ml· min - 1 (2.6 ± 0.5%); 
eyes, 2.0 ± 0.3 ml· min- 1 (0.9 ± 0.1%) and bone, 
9.2 ± 1.3 ml· min- 1 (4.2 ± 0.6%). Finally, less than 
2% of the carotid blood flow was distributed to 
the contralateral half of the head and less than 
0.1% of the microspheres was detected in the heart 
and kidneys, signifying an efficient entrapment of 
the spheres in the lung vasculature after their 
escape via the cranial A VAs. 
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3.2.2. Effects of ~imodipine on the 5-HT-induced 
changes in the distribution of common carotid artery 
blood flow and vascular conductance 
The effects of intracarotid infusions of 5-HT, 
before and during nimodipine infusion, on the 
distribution of carotid blood flow into nutrient 
(tissue; capillary) and non-nutrient (AVA) frac-
tions are shown in fig. 2. 5-HT caused a decrease 
in total common carotid artery blood flow (54± 
14%), which was entirely due to a reduction (75 ± 
14%) in AVA blood flow; nutrient flow more than 
doubled. Similar changes were observed in vascu-
lar conductances, as the blood pressure was not 
much affected by 5-HT. In spite of a reduction in 
blood pressure by nimodipine, the total carotid 
blood flow was maintained· as the total carotid 
Tongue Salivary 
glands 
Brain 
Fig. 3. Effect of intracarotid infusion of nimodipine (0.25 JLg·kg" 1·min" 1) on the vasodilatation induced in various tissues by 
intracarotid infusions of 5-HT (2.0 JLg·kg" 1·min" 1). While 5-HT produced its most prominent vasodilator effect in the skin and 
ears, nimodipine selectively and potently increased blood flow to and vascular conductance in the skeletal muscles. During 
nimodipine infusion, 5-HT caused vasoconstriction in the skeletal muscles, and its vasodilator response in the tissues was reduced. 
• P < 0.05 vs. baseline or recovery; • • P < 0.05 vs. nimodipine; • • • the 5-HT-induced change during nimodipine infusion was 
significantly different (P < 0.05) from the 5-HT-induced change before nimodipine. 0 Baseline; 0 5-HT; 0 recovery; !ll nimodipine: !II 
5-HT + nimodipine. 
82 
conductance increased (41 ± 9%). 1bis was accom-
panied by a large elevation (300 ± 25%) in vascu-
lar conductance in the nutrient part, which out-
weighed the 19 ± 7% reduction in vascular con-
ductance in A VAs. Although nimodipine markedly 
affected vascular conductance in both the total 
carotid vascular bed and its AVA fraction, it had 
no influence on 5-HT-induced vasoconstrictor re-
sponses. In contrast, nimodipine converted the 
amine-evoked vasodilatation into vasoconstriction 
in the nutrient part. 
Of all tissues and organs, the skin and ears 
showed the largest vasodilator response to 5-HT 
(18- and 12-fold increase in vascular conductance, 
respectively). Skeletal muscles exhibited a marked 
vasodilatation (15-fold increase in vascular con-
ductance) during nimodipine infusion. Vascular 
conductance was also increased, but only mod-
erately so in the salivary glands (fig. 3). In the 
presence of nimodipine, the 5-HT-induced vaso-
dilatation in the skin and ears tended to be less 
marked. However, in the skeletal muscles ~-HT 
now elicited a marked vasoconstriction which re-
duced the nimodipine-induced vasodilatation by 
more than 50%. Although the carotid artery con-
tribution to the blood supply of the brain de-
creased slightly in response to both 5-HT and 
nimodipine, vascular conductance in the brain did 
not change significantly. Tongue vessels were not 
affected by either drug. 
3.2.3. Effects of nifedipine on the 5-HT-induced 
changes in the distribution of common carotid artery 
blood flow and vascular conductance 
5-HT induced vasodilatation in the nutrient 
fraction of the carotid vascular bed (conductance 
increased by 350 ± 85%). 1bis vasodilatation was 
unable to compensate for the decline (by 80 ± 5%) 
in A VA conductance, resulting in a 24 ± 3% re-
duction in vascular conductance of the total caro-
tid bed (fig. 4). The decrease in mean arterial 
blood pressure during intracarotid nifedipine infu-
sion was compensated for by a 4-fold elevation in 
vascular conductance of the capillary fraction 
which, by compensating for the slight decrease in 
AVA conductance, enhanced total carotid conduc-
tance. As a result, total carotid blood flow was 
maintained during nifedipine infusion. The 5-HT-
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Fig. 4. Effect of intracarotid infusion of nifedipine (0.75 l'g· 
kg" 1·min-1) on the changes induced by intracarotid infusions 
of 5-HT (2.0 l'g·kg- 1·min-1) in the total carotid blood flow 
and its distribution into non-nutrient (AVA) and nutrient 
(tissue; capillary) parts in pigs. Nifedipine, like 5-HT, reduced 
blood flow to and vascular conductance in the AVA fraction 
but increased the capillary fraction. Total carotid conductance 
was increased by nifedipine but was decreased by 5-HT. The 
5-HT-induced vasoconstriction was either not affected (AVA 
fraction) or was even enhanced (total carotid vascular bed) by 
nifedipine, but the 5-HT-induced tissue vasodilatation was 
reduced. • P < 0.05 vs. baseline; • • P < 0.05 vs. nifedipine; 
• • • the 5-HT-induced change during nifedipine infusion was 
significantly different (P < 0.05) from the 5-HT-induced change 
before nifedipine. D Baseline; lill 5-HT; D recovery; Ell nifedi-
pine; Ell 5-HT + nifedipine. 
induced vasoconstriction in the total carotid vas-
cular bed was enhanced in the presence of nifedi-
pine but that in the AVA part was unchanged. On 
the contrary, the vasodilator response to 5-HT in 
the nutrient (tissue; capillary) fraction was com-
pletely abolished (fig. 4). 
5-HT caused a 30-fold increase in vascular con-
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Fig. 5. Effect of intracarotid infusion of nifedipine (0.75 l'g·kg-1·min- 1) on the vasodilatation induced in various tissues by 
intracarotid infusions of 5-HT (2.0 I'S·kg- 1·min- 1). While 5-HT produced its most prominent vasodilator effect in the skin and 
ears, nifedipine selectively increased blood flow to, and vascular conductance in the skeletal muscles. During rtifedipine infusion, 
5-HT caused vasoconstriction in the skeletal muscles and the vasodilator response in the tissues was reduced. • P < 0.05 vs. baseline; 
• • P < 0.05 vs. nifedipine; • • • the 5-HT-induced change during nifedipine infusion was significantly different (P < 0.05) from the 
5-HT-induced change before nifedipine. 0 Baseline; iilJ 5-HT; 12 nlfedipine; !II 5-HT+ rtifedipine. 
TABLE 1 
Effects of 20 min intracarotid infusions of 0.751'g·min- 1·kg-1 rtifedipine on carotid haemodynamics. 
Blood flow (ml· min 1) 
Total carotid 
AVA fraction c 
Tissue fraction 
Skeletal muscles 
Baseline 
value 
272 ±31 
244 ±28 
28 ± 5 
7.4 ± 1.4 
Vascular conductance (ml· min- 1 • mmHg- 1) 
Total carotid 3.00 ± 0.43 
AVA fraction 2.69 ± 0.40 
Tissue fraction 0.30± 0.05 
Skeletal muscles 0.08 ± 0.02 
Nifedipine 
10min 20min 
270 ±37 227 ±31a.b 
154 ±26 a 134 ±25 a 
115 ±26 a 92 ±26 a 
84 ±24 a 60 ±21a 
3.80± 0.56 a 3.71± 0.58 a 
2.19± 0.41a 2.21 ± 0.49 a 
1.59± 0.35 a 1.50± 0.44 a 
1.18± 0.33 a 0.97± 0.35. 
a P < 0.05 vs. baseline; b P < 0.05 min vs. 10 min observations. cAVA, arteriovenous anastomotic. 
30 min of 
recovery 
224 ±30 a 
193 ±29 a 
31 ± 6 
10 ± 2 
3.03± 0.47 
2.61± 0.46 
0.41± 0.08 
0.13± 0.03 
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ductance in the skin (fig. 5), which was signifi-
cantly attenuated when the animals were treated 
with nifedipine. Vasodilator responses to 5-HT 
(12- and 4-fold increase in vascular conductance, 
respectively) in the ears and tongue were also 
attenuated. 5-HT reduced the nifedipine-induced 
elevation (almost 16-fold) in vascular conductance 
in the skeletal muscles by approximately 50%. 
3.2.4. Effects of nifedipine infusions alone 
Table 1 shows the changes in the distribution of 
common carotid artery blood flow observed dur-
ing a 20 min intracarotid infusion of nifedipine 
(0.75 j.tg·kg-1 ·min- 1) without concomitant ad-
ministration of 5-HT. As described above, nifedi-
pine decreased AVA flow and vascular conduc-
tance but increased capillary blood flow and vas-
cular conductance, particularly to the skeletal 
muscles. There were no differences between the 
effects of nifedipine at the 10 and the 20 min 
period, except that the total carotid blood flow 
was decreased significantly after 20 min. The 
carotid hemodynamic variables returned towards 
baseline values (except total carotid blood flow) 
30 min after the nifedipine infusion was stopped. 
4. Discussion 
4.1. Carotid vascular responses to 5-HT 
As reported previously (Saxena and Verdouw, 
1982; Verdouw et al., 1984a,b), a large fraction 
(about 80%) of the total common carotid blood 
flow in the anesthetized pig was shunted via A VAs 
located in the skin and ears (Saxena and Verdouw, 
1985a). Infusion of 5-HT drastically changed the 
distribution of carotid blood flow so that, with or 
without a concomitant decrease in total carotid 
blood flow, the non-nutrient (AVA) fraction de-
creased and the nutrient (tissue; capillary) frac-
tion, particularly that to the skin and ears, in-
creased; recovery from the effects of 5-HT was 
observed within 20 min (Saxena and Verdouw, 
1982; Verdouw et al., 1984b). These hemodynamic 
effects are due to activation of vascular 5-HT2 
receptors causing constriction, mainly of the 'large' 
conductance vessels (Heistad et al., 1976; Saxena 
and Verdouw, 1982), and vascular '5-HTclike' 
receptors mediating constriction of A VAs and re-
laxation of arterioles (Saxena and Verdouw, 1985b; 
Saxena et al., 1986). Besides confirming the above 
findings with 5-HT, we now report the carotid 
vascular effects of two Ca2 + channel blockers of 
the dihydropyridine type (nimodipine and nifedi-
pine) and their influence on the responses to 5-HT. 
4.2. Carotid vascular effects of nimodipine and 
nifedipine 
Local intracarotid infusions of both nimodipine 
and nifedipine resulted in a redistribution of 
carotid blood flow in favour of the nutrient frac-
tion and at the expense of the non-nutrient frac-
tion. While in the case of 5-HT the increased 
nutrient flow was distributed mainly to the skin 
and ears (Saxena and Verdouw, 1982; Verdouw et 
al., 1984b; present results), nimodipine and 
nifedipine selectively affected the skeletal muscles. 
It is of interest to recall that vascular conductance 
in, and blood flow to the skeletal muscles is also 
increased by other dihydropyridine-type Ca2+ 
channeJ blockers ( darodipine, felodipine and 
nisoldipine), but not by veraparnil or diltiazem 
(Hof, 1983; Bolt and Saxena, 1984; Duncker et al., 
1986a,b). Low affinity but high capacity dihydro-
pyridine binding sites, as yet unassociated with 
any specific functional response, have recently 
been described in the skeletal muscles (Miller and 
Freedman, 1984). It is tempting to suggest that the 
vascular effects in the skeletal muscles may be 
related in some way to the above binding sites. 
The relaxation of arterioles is apparently due to 
Ca2+ channel blockade but the mechanism re-
sponsible for the decrease in AVA flow and con-
ductance is less obvious. It is unlikely to be a 
baroreceptor reflex-mediated stimulation of the 
sympathetic nervous system since the animals were 
bilaterally vagosympathectomized. Moreover, in 
young pigs A VAs are only poorly constricted via 
noradrenergic mechanisms (Verdouw et al., 1984a). 
Thus, the reduction in AVA flow most likely 
results from 'steal' due to the profound vasodila-
tation in the nutrient vascular channels. This im-
pression is enhanced when the data for nimodi-
pine and nifedipine are compared to those for 
5-HT. While 5-HT reduced the vascular conduc-
tance of A VAs by approximately 85% in the face 
of a 3-fold increase in conductance of the nutrient 
fraction, nimodipine and nifedipine reduced AVA 
conductance by, respectively, only 25 and 18%. 
These latter effects were accompanied by even 
greater increases in nutrient conductance (4.6- and 
5.3-fold, respectively). It therefore seems that, in 
contrast to 5-HT which actively constricts A VAs, 
the Ca2 + channel blockers cause a 'passive' reduc-
tion in AVA flow and conductance. 
4.3. Modification of carotid vascular responses to 
5-HT by nimodipine and nifedipine 
When nifedipine was infused alone for 20 min 
(series 3 experiments), the effects of the drug were 
not much different whether measured at 10 or 20 
min. This suggests that the changes (from values 
after 10 min nifedipine infusion) obtained after 
simultaneous infusions of nifedipine and 5-HT 
(series 2 experiments) were in fact due to 5-HT 
and not to a major change in the effects of 
nifedipine with a longer period of infusion. The 
same may also hold true for nimodipine, though 
this drug was not infused alone for the full 20 miit 
period. 
A comparison of the responses to 5-HT before 
and after the infusions of the two Ca2+ channel 
blockers revealed three interesting facts: (i) the 
vasoconstrictor response in the total carotid vascu-
lar bed not only remained unattenuated but 
seemed to be enhanced; (ii) the increase in the 
tissue fraction due to 5-HT was completely 
eliminated (total capillary flow) or reduced (skin 
and ears); and (iii) blood vessels in the skeletal 
muscles - strongly dilated under the influence of 
the Ca2+ channel blockers - responded to 5-HT 
with a marked vasoconstriction. 
The lack of attenuation by the Ca2+ channel 
blockers, nimodipine and nifedipine, of the 5-HT-
induced constrictions in vivo of A VAs (mediated 
by '5-HT1-like' receptors) or of 'small' resistance 
vessel (arterioles; mediated by 5-HT2 receptors) 
suggests that, in contrast to the 5-HT-induced 
constrictions of 'large' conducting arteries in vitro 
(Towart, 1981; Miiller-Schweinitzer and Neuman, 
1983; Van Nueten, 1984), these responses are not 
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dependent on influx of extracellular Ca2+. A simi-
lar conclusion has recently been reached by others. 
Except for verapamil which has some affinity for 
5-HT2 binding sites (see Kalkman et a!., 1984), a 
number of Ca2+ channel blockers (diltiazem, 
flunarizine, nimodipine or darodipine) failed to 
antagonize the 5-HT-induced elevations of perfu-
sion and arterial blood pressures in the rat (Cavero 
and Lefevre-Borg, 1981; Kalkman et a!., 1984) 
and the decrease in total peripheral AVA flow in 
the cat (Hof et a!., 1985). Hof et a!. (1985) also 
observed that 5-HT, which did not significantly 
alter coronary haemodynamics, caused an unmis-
takable coronary vasoconstriction when given after 
darodipine. 
Unlike the vasoconstrictor responses, the 5-
HT-induced vasodilatation, particularly that in the 
skin vasculature, was reduced by the two Ca2+ 
channel blockers. It appears to us that the at-
tenuated increase in flow to, and the vascular 
conductance in the skin is secondary to the strong 
vasodilatation elicited by the two Ca2+ channel 
blockers in other parts of the nutrient bed mainly 
of the skeletal muscles. When the blood vessels of 
skeletal muscles were strongly relaxed under the 
influence of the Ca2+ channel blockers, it is logi-
cal to expect that 5-HT elicited no further vasodi-
latation but caused arterial vasoconstriction which 
is mediated by 5-HT2 receptors (Verdouw et a!., 
1984b; Saxena and Lawang, 1985; Meschig eta!., 
1985). Unlike the vasoconstriction in 'large' ves-
sels in vitro, this vasoconstriction was not in-
hibited by nifedipine and nimodipine in vivo (see 
above). 
4.4. Possible implications in migraine 
Cerebral blood flow has been reported to de-
crease, probably as a result of 'spreading depres-
sion of Leao', in 'classical' but not in 'non-classi-
cal' migraine patients (Lauritzen and Olesen, 
1984). If the release of 5-HT is involved, Ca2+ 
channel blockers probably do not act via this 
mechanism as shown by their ineffectiveness 
against the vasoconstrictor responses to 5-HT in 
vivo. 
As mentioned at the outset, sudden opening of 
cranial A VAs in the headache phase (Heyclc, 1969; 
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Saxena, 1978), probably associated with the de-
crease in blood 5-HT level (Lance, 1978; Fozard, 
1982), has also been pathophysiologically im-
plicated in migraine. Compatible with this sugges-
tion, antimigraine drugs - particularly the ergot 
alkaloids - effective in the treatment of individual 
attacks (Johnson and Saxena, 1978; Spierings and 
Saxena, 1980) as well as 5-HT (Saxena and 
Verdouw, 1982; Verdouw et al., 1984b) which has 
been reported to alleviate acute attacks (Kimball 
et al., 1960) decrease AVA shunting by eliciting an 
'active' constriction of· cranial A VAs. The 'pas-
sive' reduction of AVA flow induced by the two 
Ca2+ channel blockers may be one of the reasons 
for their inability to abort acute attacks of migraine 
(Jensen et al., 1985). The redistribution of carotid 
blood flow towards the nutrient compartment, as 
observed in the present study, should obviously be 
considered as potentially beneficial. Whether this. 
property of Ca2+ channel blockers is linked to the 
usefulness of these drugs in the prophylactic ther-
apy of migraine (Gelmers, 1983; Meyer and 
Hardenberg, 1983) remains to be ascertained. 
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126 (1986) 21-30. 
Intravenous infusions of 0.01-0.1 mg · kg - 1 • min -I of pimobendan, a benzirnidazole-pyridazinone derivative in pigs 
with normal coronary circulation caused dose-dependent changes in heart rate (10-35%), left. ventricular systolic 
pressure (- 5 to - 45% ), left ventricular filling pressure (- 20 to -40%) but had only a minor effect on the maximum 
rate of rise of left ventricular pressure (max LVdPidt; 10-20%). The decrease in mean arterial blood pressure was 
primarily due to systemic vasodilation; peripheral resistance and cardiac output decreased by ·up to 40 and 14%, 
respectively. Vasodilation occurred in several vascular beds, but was particularly pronounced in the adrenals, stomach, 
small intestine and myocardium. Although the increase in myocardial blood flow favoured the epicardium, vascular 
conductance in both the endo- and epicardial layers was significantly increased. Myocardial 0 2 consumption (MV02 ) 
was not affected despite the increase in heart rate. Bolus injections of 0.1-0.5 mg · kg- 1 pimobendan produced similar 
changes in all haemodynamic variables, except max LV dP I dt which now increased by 30-70%. As in the infusion 
experiments, cardiac output tended to decrease due to a pronounced reduction in ventricular preload probably as a 
result of venodilation and the consequent reduction in cardiac filling. However, in animals where max LV dP 1 dt and 
cardiac output were reduced and pre- andjor after-load were increased by partial occlusion of the left anterior 
descending coronary artery, pimobendan clearly increased both max LV dP 1 dt and cardiac output. Pretreatment with 
propranolol did not modify any of the cardiovascular responses to pimobendan, thereby excluding the involvement of 
a ,8-adrenoceptor mechanism. Pimobendan is thus a compound with vasodilator and positive inotropic properties that 
improves cardiac output in animals with severe myocardial ischaemia. The finding that the mild tachycardia caused by 
pimobendan was not accompanied by an increase in MV02 warrants investigation to evaluate its usefulness in the 
treatment of heart failure. 
Distribution of cardiac output 
,8-Adrenoceptor blockade 
Myocardial ischaemia 
Myocardial 0 2 consumption 
Phosphodiesterase inhibitor 
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t_ Introduction 
Heart failure is a pathophysiological state in 
which the heart is unable to pump blood at a rate 
* To whom all correspondence should be addressed: Labora-
tory for Experimental Cardiology (Thoraxcenter), Erasmus 
University Rotterdam, 3000 DR Rotterdam, The 
Netherlands. 
0014-2999j86j$03.50 © 1986 Elsevier Science p;,blishers B.V. 
commensurate with the metabolic needs of body 
tissues. Although myocardial dysfunction is often 
the cause of heart failure, other conditions (for 
example, a sudden overload of the heart or a 
reduction of cardiac filling) can lead to heart 
failure even in the presence of a normal myo-
cardium (Braunwald, 1984). Thus, in dealing with 
heart failure one should consider not only the 
myocardium but also the peripheral circulation as, 
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Fig. 1. Chemical structure of pirnobendan (UD-CG 115 BS). 
in addition to a depressed myocardial contractil-
ity, elevated left ventricular filling pressure and 
systemic vascular resistance are among prominent 
characteristics of heart failure. It is therefore obvi-
ous that positive inotropic agents which also cause 
peripheral vasodilation may be useful in the treat-
ment of heart failure. 
In an attempt to provide efficient substitutes 
for cardiac glycosides, which have a narrow ther-
apeutic margin, many positive inotropic agents 
acting via different mechanisms including inhibi-
tion of cardiac phosphodiesterases, have been de-
scribed during the past several years (see Farah et 
al., 1984). One such compound, pimobendan 
(UD-CG 115 BS; fig. 1) has been shown to in-
crease myocardial contractility and cause periph-
eral vasodilation (Diederen et al., 1982; Van Meel, 
1985) possibly due to elevation of cyclic A~P 
levels following inhibition of myocardial phos-
phodiesterase (Honerjager et a!., 1984). In this 
report we give a detailed description of the 
cardiovascular profile of the drug, including its 
effects on regional vascular beds and myocardial 
performance. 
2. Materials and methods 
2.1. Experimental set-up 
After an overnight fast Yorkshire pigs (22-28 
kg) were sedated with 120 mg azaperone i.m. and 
anaesthetized with 150 mg i.v. metomidate. The 
levels of arterial blood gases (ABL-3, Acid-Base 
Laboratory, Radiometer, Copenhagen) were con-
trolled by artificial ventilation with a mixture of 
0 2 : N20 (1 : 2). Catheters were placed in the su-
perior vena cava for administration of pentobar-
bital (20 mg · kg- 1 • h- 1), sodium bicarbonate 
(8.4%, when needed), pimobendan and haemaccel; 
the latter was given to replace blood loss. Micro-
tipped Millar catheters were used for measure-
ments of the left ventricular and central aortic 
blood pressures. An 8 F catheter was positioned in 
the descending aorta for the withdrawal of arterial 
blood samples. The muscle relaxant pancuronium 
( 4 mg) was administered before the heart was 
exposed via a midstemal split. Electromagnetic 
flow probes (Skalar, Delft, The Netherlands) were 
placed around the ascending aorta and the left 
anterior descending coronary artery (LAD). The 
great cardiac vein was cannulated and the left 
atrial appendage was catheterized for the injection 
of microspheres. 
Myocardial wall thickness was monitored with 
a 5 MHz ultrasonic transducer (Krautkramer-
Branson, Lewistown, PA, USA). The wall thick~ 
ness at end-diastole (EDT) and end-systole (EST) 
was used to calculate systolic wall thickening (swt) 
as: 
swt (%) = 100 x (EST-EDT)/EDT 
and the mean velocity of swt (V,w,) as: 
Y,w, = (EST-EDT)jDS 
where DS is the duration of the isovolumic con-
traction phase and the ejection time. 
The distribution of cardiac output was mea-
sured using the microsphere technique (see Saxena 
and Verdouw, 1985; Verdouw et al., 1985). About 
2 X 106 microspheres (15 ± 1 (S.D.)p.m diameter, 
NEN Company, Dreieich, West Germany), la-
belled with either 46Sc, 103 Ru, 141 Ce, 95 Nb or 
113Sn, were injected via a cannula placed in the 
left atrium of the heart. A reference arterial blood 
sample was withdrawn (flow rate, 10 ml· min- 1 ) 
starting just before and continuing for a period of 
about 1 min after the injection of microspheres. 
At the end of the experiment several organs (see 
later) were excised, weighed and placed in vials. 
The heart was removed and fixed in 4% formalin 
for at least 24 h. The details of the counting of 
radioactivity and processing of data have been 
described previously (Saxena et a!., 1980). 
Myocardial oxygen consumption (MV02 ) was 
estimated by multiplying the difference in the 0 2 
content of the arterial and coronary venous blood 
by coronary blood flow. 
2.2. Experimental protocols 
Four series of experiments were performed to 
characterize the cardiovascular actions of pirno-
bendan. In the first series (n = 8), four consecutive 
10 min infusions (0.01, 0.025, 0.05 and 0.10 rng · 
kg- 1 -min- 1 ) were used. At the end of each infu-
sion all cardiovascular variables were recorded 
and arterial blood was drawn for the determina-
tion of plasma concentrations of the parent corn-
pound and its major metabolite (UD-CG 212 BS). 
In the second series (n = 9), each animal received 
three consecutive bolus injections of pirnobendan 
at 10 min intervals. The doses (0.1, 0.25 and 0.5 
rng · kg -I) were chosen such that the animals re-
ceived the same amount of drug as administered 
during each comparable infusion period in the 
first series. 
To evaluate cardiac pump function during 
pathological conditions, blood flow in the left 
anterior descending coronary artery was reduced 
in 4 animals (third series) by tightening a J-shaped 
clamp placed around the vessel until the systolic 
wall thickening was reduced to 20-30% of the 
baseline value. After the haernodynamic values 
had been stable for at least 15 min these animals 
were given pirnobendan (0.25 rng · kg- 1 + 0.05 rng 
· kg- 1 . min- 1). Lastly, in order to establish 
whether or not some of the actions of pirnobendan 
were caused via ,8-adrenoceptor stimulation, the 
cardiovascular effects of the drug were studied in 
5 pigs (fourth series) before and after pretreatment 
with propranolol (0.5 rng · kg- 1 followed by 0.5 
rng · kg -I · h-I). This dose regimen of propranolol 
provides adequate ,8-adrenoceptor blockade in ·pigs 
(Wolffenbuttel and Verdouw, 1983). 
2.3. Determination of plasma concentrations 
The plasma concentrations of pirnobendan and 
its 0-dernethylrnetabolite, UD-CG 212 BS were 
determined using an HPLC assay with fully auto-
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mated drug preconcentration on solid supports 
(Roth, 1983). Briefly, the drugs were extracted on 
a reverse phase column and simultaneously pre-
concentrated after injection of whole plasma. The 
compounds were measured by means of fluores-
cence detection (332 nrn/405 nrn) after HPLC 
separation on reversed phase ODS-hypersil (par-
ticle size: 5 JLm). The eluent composition was 
methanol/water 590/460 (v/v) + 2.5 g ammoni-
um acetate per liter eluent (total amount 2.625 g). 
Post column, a mixture of rnethanol/orthophos-
phoric acid 85%/water (300/100/100, vjv/v) was 
added with a flow rate of 0.2 rnl · min -I via a 
T-fitting in order to optimize the fluorescence 
(increase in fluorescence by a factor of 2). The 
lower limit of detection for both compounds was 
about 1 ng/rnl. Pirnobendan and UD-CG 212 BS 
themselves were used as external standards. 
2.4. Data presentation and statistical analysis 
All data are presented as means ± S.E.M. Ab-
solute values are given in the tables and in fig. 3, 
but % changes from baseline values are shown in 
the other figures to facilitate comparison between 
different variables. However, all statistical analyses 
were performed on the actual data values. The 
significance of the difference between the means 
of any two groups was compared by applying 
Duncan's new multiple range test once an analysis 
of variance (randomized block design) had re-
vealed that the samples represented different 
populations (Saxena, 1985). Statistical significance 
was accepted at P < 0.05 (two-tailed). 
2.5. Drugs 
The only drugs used in this study were the 
anaesthetics, haernaccel, propranolol hydrochlo-
ride and pirnobendan ( 4,5-dihydro-6-[2-( 4-rnetho-
xypheny 1)-1 H-benzimidazol-5-yl]-5-rnethyl-3(2H)-
pyridazinone; UD-CG 115 BS). Pirnobendan was 
dissolved in a mixture of polyethylene glycol 200 
and saline (1 : 1 ). 
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3. Results 
3.1. Intravenous infusion of pimobendan in animals 
with normal coronary circulation 
3.1.1. Plasma concentrations of pimobendan and 
UD-CG212 BS 
The plasma concentrations of the parent drug 
increased rapidly during intravenous infusions of 
pimobendan. There was a more than 14-fold dif-
ference between the concentrations noted at the 
end of the first and the last infusion period. The 
concentration of the major metabolite, UD-CG 
212 BS, increased only 6-fold during the same 
period (table 1) suggesting saturation of the en-
zymes metabolizing pimobendan during higher in-
fusion rates. 
3.1.2. Systemic haemodynamics 
The most pronounced effect of pirnobendan 
was the vasodilation in systemic vascular beds as 
the dose-dependent decreases in arterial blood 
pressure (up to 45%) agreed very closely with 
those in systemic vascular resistance (table 1 ). 
Diastolic arterial pressure declined slightly more 
than systolic arterial blood pressure (up to 52 and 
44%, respectively). Pimobendan also decreased the 
TABLE 1 
left ventricular filling pressure, ·indicating reduced 
venous return and, therefore, venodilation. This 
probably accounts for the slight decrease in cardiac 
output at the two highest infusion rates. Max 
LVdP/dt was moderately enhanced (up to 20%) 
with the two lowest doses, but was not different 
from baseline during the two highest infusion 
rates. 
3.1.3. Regional haemodynamics 
Table 2 shows that, despite the reduction in 
cardiac output, pimobendan increased blood flow 
to the adrenals, stomach, small intestine and brain, 
but decreased that to the kidneys and spleen. 
Hepatic arterial (liver) and skeletal muscle blood 
flow did not change significantly after pimoben-
dan. Since arterial blood pressure was decreased 
by the drug, vascular conductance increased dose 
dependently in most organs (fig. 2). The most 
marked effect was on the stomach (up to 325%) 
followed by adrenals (200%), small intestine 
(190%), myocardium (160%; see following section), 
skeletal muscles (140%) and brain (130%). No 
differences existed between the effects of pimo-
bendan on different brain areas (cerebral hemi-
sphe;:es, diencephalon, cerebellum and brainstem; 
data not shown in the figure). Vascular conduc-
Cardiovascular actions of continuous 10 min pirnobendan infusions in 8 anaesthetized open-chest pigs. Abbreviations: CO, cardiac 
output; HR, heart rate; SV, stroke volume; LVEDP, left ventricular end-diastolic pressure; LVdP /dt, maximal rate of rise of left 
ventricular pressure; SVR, systemic vascular resistance; SAP, systolic arterial pressure (mm Hg); DAP, diastolic arterial pressure 
(mm Hg). All data were obtained after 10 min of infusions. All data are presented as means± S.E.M. • P < 0.05 vs. baseline. 
Baseline Pimobendan (mg·kg 1-min- 1) 
O.Ql 0.025 0.05 0.1 
Total dose injected 
(mg·kg- 1) 0.1 0.35 0.85 1.85 
Plasma concentration (1'&·1- 1 ) 
Pimobendan 100 ± 10 274 ± 19 689 ± 35 1441 ± 61 
UD-CG212 BS 3.1 ± 0.3 9.1 ± 0.6 14.4 ± 1.2 20.2 ± 1.8 
CO(l·min- 1) 2.16± 0.11 2.15± 0.11 2.01± 0.12 1.90± 0.11* 1.85± 0.14. 
HR (beats· min_, ) 84 ± 4 92 ± 4* 104 ± 5 • 112 ± 6. 114 ± 7. 
SV(ml) 26 ± 2 24 ± 1 20 ± 2* 17 ± 2* 17 ± 2* 
LVEDP (mm Hg) 10 ± 1 ± 1* 6 ± 1* 6 ± 1* 6 ± 1. 
LVdP /dt (mm Hg·s- 1) 1460 ±160 1680 ±170. 1770 ±210. 1620 ±210 1570 ±230 
SVR (mm Hgr 1·min) 39 ± 3 37 ± 3 30 ± 2* 25 ± 1* 22 ± 1. 
SAP(mmHg) 102 ± 4 95 ± 5. 79 ± 3* 64 ± 3. 57 ± 2* 
DAP(mmHg) 63 ± 4 59 ± 4 49 ± 4* 37 ± 3. 30 ± 2* 
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TABLE 2 
Effect of continuous 10 min pimobendan infusions on organ blood flow (ml· min - 1·100 g - 1) in 8 anaesthetized open-chest pigs. All 
data are presented as means± S.E.M.; • P- < 0.05 vs. baseline. 
Baseline Pimobendan (mg. kg - 1• min- 1) 
Kidneys 
Liver 
Spleen 
Adrenals 
Stomach 
Small intestine 
Skeletal muscles 
Brain 
(!,%) KIDNEY 
100~ 
-4~ . 
(6%) STOMACH 
(6%) MUSCLE 
200Li* 100 
0 
322±27 
30± 9 
80±13 
136±22 
14± 1 
21± 
7± 
22± 2 
(6%) LIVER 
(6%) SM INTESTINE 
200LJ~ 100 
. 
0 
(t.%) BRAIN 
J : ... 
aLA 
0.01 
351±22 
27± 8 
101±20 
166±24. 
17± 2 
22± 2 
7± 1 
22± 1 
(6%) SPLEEN 
100r . ~ ..i. 
-4~~ 
(!,%) ADRENALS 
:::ld 
100 .. 
0 -~· j~; 
PlMOBENDAN 
(mg·k9!mili1) 
Fig. 2. Effect of intravenous infusion of pimobendan on re-
gional vascular conductances. Pre-infusion values of vascular 
conductances (in ml·min- 1·mm Hg- 1·100 g- 1) were: kid-
neys: 3.98±0.39; liver: 0.37±0.10; spleen: 0.94±0.13; stomach 
0.18 ± 0.02; small intestine: 0.25 ± 0.03; adrenals: 1.68 ± 0.29; 
skeletal muscles 0.08 ± 0.02 and brain: 0.27 ± 0.02. Data are 
presented as percentage changes from baseJine, but the statisti-
cal analysis was performed on the actual data. • P < 0.05 vs. 
baseline. 
O.Q25 0.05 0.1 
318±32 217±28. 156±23. 
24± 6 22± 4 21± 5 
84±17 51± 11. 33± 8. 
189±29. 194± 19 • 181±20. 
19± 2* 24± 3* 27± 3. 
22± 1 26± 2. 28± 2* 
6± 7±2 8± 
22± 2 23± 1 25± 2* 
tance in the kidneys, liver and spleen was much 
less affected. All three showed increases at lower 
doses (<50%) but the effect tended to decrease as 
perfusion pressure started to drop severely. 
3.1.4. Myocardial blood flow and performance 
Coronary blood flow increased up to 30% in 
spite of the decline in arterial blood pressure (fig. 
3). This increase in flow was not evenly distrib-
uted transmurally as the epicardium benefited 
more (up to 43%) than the endocardial layers (up 
to 15%) during the first three infusion rates. There 
was even a slight decrease in the endocardial 
blood flow at the highest infusion rate (0.1 mg · 
kg- 1 • min- 1). Consequently, the endo-epi flow 
ratio decreased gradually from 0.99 ± 0.03 to 0.70 
± 0.02 (P < 0.05) at the end of the highest infu-
sion rate. Coronary venous 0 2 saturation in-
creased dose dependently from 37 ± 5 to 58± 3% 
(P < 0.05). Hence MV02 was not significantly af-
fected (fig. 3). Regional myocardial function 
showed no changes for systolic wall thickening but 
a gradual increase in the velocity of thickening 
was noticed. Figure 4 shows that, although the 
vasodilator response to pimobendan in the epicar-
dial layers exceeded that in the endocardial layers, 
vascular conductance in the latter was also dou-
bled at the end of the highest infusion rate. Though 
not shown in the figure, the increases in vascular 
conductance in the right ventricle (up to 180 ± 
12%) and left atrium (up to 110 ± 20%) were very 
similar to those in the left ventricle. 
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Fig. 3. Left ventricular performance after intravenous infusions 
of pimobendan at increasing rates. From top to bottom: trans-
mural left ventricular blood flow, the endo-epi blood flow 
ratio, left ventricular 0 2 consumption (MV02 ), regional sys-
tolic wall thickening (swt) and the mean velocity of wall 
thickening cY,w, ). • P < 0.05 vs. baseline. 
3.2. Bolus injections in animals with normal coronary 
circulation 
3.2.1. Plasma concentrations of pimobendan and 
UD-CG212 BS 
Following each bolus injection of pimobendan, 
the plasma levels of the parent drug increased 
sharply but, at 10 min, they were considerably 
lower than those after infusions of the correspond-
ing amounts. As was the case in the infusion 
experiments, the plasma concentration of the 
metabolite UD-CG 212 BS increased but less 
steeply than that of. the parent drug (table 3). 
(6%) TRANSMURAL 
20l ~ 
101AJ 
(6%) ENDO 
~ 
PIMOBENDAN 
(mg.kg1.min") 
I O.Q1 0025 . 0.05 0.1 
(6%) EPI 
200~: 100 
0 
Fig. 4. Effect of intravenous infusion of pimobendan on left 
ventricular vascular conductance. Vasodilation of the epicar-
dial vessels exceeded that of the endocardial vessels, which 
explains the decrease in the endo-epi blood flow ratio. Pre-
infusion transmural conductance was 1.26 ± 0.22 mhnin -I. 
mm Hg- 1·100 g- 1• • P < 0.05 vs. baseline. Data are presented 
as percentage changes from baseline but the statistical analysis 
was performed on the actual data -' 
3.2.2. Systemic haemodynamics 
As in the infusion experiments, a pronounced 
vasodilation accompanied by tachycardia occurred 
after bolus injections of pimobendan (table 3). 
Cardiac output decreased slightly (19%) after the 
highest dose as the increase in heart rate (up to 
35%) was not sufficient to balance the decrease in 
stroke volume (up to 40%). The latter appeared to 
be caused by the fall in left ventricular filling 
pressure (up to 62%) as systemic vascular resis-
tance decreased (up to 40%) and max LVdPjdt 
increased by almost 70% in spite of the fall in 
diastolic arterial blood pressure (table 3). The 
substantial increase in max LV dP / dt after the 
bolus injections contrasts sharply with the minor 
changes observed when the drug was infused (series 
1). This is best illustrated in fig. 5 which shows 
that the larger increases occurred at comparable 
reductions in systemic vascular resistance. Another 
striking feature was that the increase in max 
LVdPjdt was lower with 0.5 mg·kg- 1 than with 
0.25 mg · kg- 1 despite similar after- and preload 
reductions. 
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TABLE 3 
Cardiovascular actions of cumulative bolus injections of pimobendan in 9 anaesthetiZed open-chest pigs. Abbreviations: CO, cardiac 
output; HR. heart rate; SV, stroke volume; LVEDP, left ventricular end-diastolic pressure; LVdP/dt, maximal rate of rise of left 
ventricular pressure; SVR, systemic vascular resistance; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; a peak refers 
to the time at which the effect on max LVdP/dt was maximum. All data are presented as means±S.E.M.; * P < 0.05 vs. baseline. 
Baseline Pimobendan (mg·kg~ 1 ) 
0.1 (n = 9) 
Peak' 10min 
Total dose injected 
(mg·kg- 1) 0.1 
Plasma concentration 
(p.gr'> 
Pimobendan 124 ±22 34 ± 
UD-CG212BS 1.7 ± 0.4 5.4 ± 1.6 
CO(l·min- 1) 2.46± 0.18 2.46± 0.16 2.37± 0.15 
HR (beats·min- 1) 102 ± 5 110 ± 5 * 114 ± 6 * 
SV(ml) 24 ± 1 24 ± 1 21 ± 1. 
LVEDP (rom Hg) 9 ± 1 6 ± 1* ± 1. 
LVdP/dt 
(mm Hg·s- 1) 1750 ±20 2230 ±20. 2080 ±20. 
SVR(mmHgr 1 
·min) 38 ± 5 32 ± 4* 36 ± 4 
SAP(mmHg) 107 ± 5 98 ± 5* 96 ± s• 
DAP(mmHg) 71 ± 4 63 ± 5* 66 ± 5 
75 
j\0 50 
'*' ...s- 0 
: 1 i~~ 
. -------· 
0 
0 
0 
-so 
500 1000 1500 
PtMOBENOAN ("gll 
0.25 (n = 9) 0.5 (n -7) 
Peak lOmin Peak 10min 
0.35 0.85 
484 ±59 129 ±12 757 ±68 273 ±26 
7.8 ± 1.6 11.2 ± 1.4 12.4 ± 1.9 17.4 ± 1.8 
2.47± 0.12 2.21± 0.17 2.40± 0.20 2.06± 0.16. 
121 ± 7. 128 ± s• 127 ± s• 135 ± 6. 
21 ± 1 17 ± 1. 19 ± 1. 15 ± 1. 
± 1* ± 1* 4 ± 1* 4 ± 1. 
3100 ±30 * 2540 ±20. 2690 ±30. 2570 ±20. 
26 ± 4* 31 ± 3 * 25 ± 3. 29 ± 3* 
80 ± s• 81 ± s• 77 ± 4* 76 ± 3• 
47 ± 4* 53 ± 4* 45 ± 4* 48 ± 4* 
3.3. Bolus injections in animals with ischaemic hearts 
Reduction of the lumen of the left anterior 
descending coronary artery did not affect heart 
rate but led to an increase in the left ventricular 
end-diastolic pressure (from 8.4 ± 1.4 to 19.6 ± 1.7 
mm Hg) and diminutions in max LVdP jdt (25%), 
cardiac output (by 26%), stroke volume (23%) and 
regional systolic wall thickening (from 24 ± 2 to 
9 ± 2%). A large fall in mean arterial blood pres-
sure (9%) was prevented by the vasoconstriction 
(23%) in systemic vascular beds. After the pre-
paration had been stable for 15 min, pimobendan 
(0.25 mg · kg- 1 over 2 min+ 0.05 mg · kg- 1 · 
Fig. 5. Changes in max LVdP /dt (top) and total systemic 
vascular resistance (SVR, bottom) as a function of arterial 
plasma concentrations of pimobendan after infusions or bolus 
injections (peak and 10 min later). Notice that the changes in 
SVR but not those in max LVdP /dt depend on the plasma 
concentrations. The latter is true even when ·th:e effects on 
heart rate and preM and afterload are taken into account 
(compare tables 1 and 3). • P < 0.05 vs. baseline. 0 Pimoben-
dan bolus (peak); 0 pimobendan bolus (10 min); • pimoben-
dan infusion. 
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Fig. 6. Effect of pimobendan (0.25 mg-kg- 1 +0.05 mg·kg- 1• 
min- 1) in 4 pigs with a partial stanosis in the left anterior 
descending coronary artery. The ischemia (D) and pimobendan 
(•) induced changes are given as percentage change from 
baseline. Baseline values were: cardiac output (CO, 2.44±0.25 
l·min- 1 ); mean arterial blood pressure (MAP, 74±5 mm Hg); 
systemic vascular resistance (SVR, 31±5 mm Hg·l- 1-min); 
heart rate (HR, 81±1 beats·min- 1); max LYdP/dt (1630± 
220 mm Hg · s -l) and left ventricular end-diastolic blood pres-
sure (LVEDP, 8.4± 1.4 mm Hg). • P < 0.05 vs. baseline; + P 
< 0.05 vs. ischaemia. Data are presented as percent changes 
from baseline but the statistical analysis was performed on the 
actual data. 
min -I for 5 min) was administered. The drug 
lowered left ventricular filling pressure to 12.6 ± 
1.8 mm Hg and systemic vascular resistance (45%), 
but increased heart rate (20%) and max LVdPidt 
(30%). Stroke volume did not change significantly, 
perhaps due to a reduction in left ventricular 
filling following the increase in heart rate. These 
observations are akin to those in the animals with 
a normal coronary circulation. However, the in-
crease in cardiac output in the ischaemic prepara-
tion (20%, fig. 6) was at variance with the results 
of these experiments. 
3.4. Cardiovascular actions of pimobendan after /3-
adrenoceptor blockade 
A bolus of 0.5 mg · kg- 1 propranolol followed 
by an infusion of 0.5 mg · kg- 1 · h-I lowered heart 
rate (from 89 ± 14 to 75 ± 7 beats · min -I), max 
LV dP I dt (from 1 930 ± 290 to 1 280 ± 110 rnm 
Hg · s- 1) and mean arterial blood pressure (from 
83 ± 2 to 74 ± 4 mm Hg). Cardiac output was 
reduced to the same extent as arterial blood pres-
sure so that peripheral resistance did not change. 
Pimobendan-induced tachycardia, increase in 
cardiac contractility and systemic vasodilation 
were not modified in the presence of /3-blockade. 
The changes caused by 0.5 mg · kg- 1 pimobendan 
before and after propranolol, respectively, were 
27 ± 6 and 27 ± 5% (heart rate), 49 ± 13 and 47 ± 
14% (max LVdPidt) and -32 ± 6 and -38 ± 5% 
(systemic vascular resistance). Coronary venous 
0 2 saturation, which had decreased from 18 ± 3 to 
13 ± 3% after /3-blockade, increased dose depen-
dently to 39 ± 7% (P < 0.05) during pimobendan 
administration, a response again not different from 
that observed with pimobendan alone. 
4. Discussion 
The investigation showed that pimobendan 
caused a vasodilation and cardiac stimulation 
which were not mediated by /3-adrenoceptors. The 
vasodilator activity of pimobendan was demon-
strated in animals that received the drug either as 
infusions or as bolus injections. The magnitude of 
the effect was closely related to the arterial plasma 
concentrations and appeared to be independent of 
the rate of drug administration. In contrast, the 
inotropic effects of pimobendan, evaluated by 
changes in max LV dP I dt, were less obvious. Bolus 
injections caused marked increases, but when the 
plasma levels were raised gradually by infusion, 
the changes in max LV dP I dt were only minimal. 
One must, however, be careful when using max 
LVdPidt as an index of contractility as this 
parameter also depends on heart rate and pre- and 
afterload, all of which changed considerably with 
the drug. In pigs, an increase in heart rate from 60 
to 100 beats· min- 1 causes a 15% increase in max 
LV dP I dt, but further increases have no additional 
effect (Verdouw et al., 1980a,b; Scheffer and 
Verdouw, 1983). Since the heart rate ranged from 
80 to 140 beats· min -I in the present study, it is 
unlikely that tachycardia alone could account for 
the increase in max LVdPidt. Moreover, because 
of the fall in left ventricular end-diastolic (prob-
ably due to venodilation) and arterial blood pres-
sures, the increases in inotropic state were under-
estimated by the changes in max LVdPidt. At 
variance with the changes in total systemic vascu-
lar resistance, the effects of pimobendan on max 
LV dP I dt were not related to the plasma con-
centrations of the drug (fig. 5). During the infu-
sion experiments higher concentrations were 
accompanied by lower max LV dP I dt increments, 
even at comparable changes in heart rate, pre- and 
afterload. It has been suggested that the metabo-
lite UD-CG 212 BS possesses positive inotropic 
properties (Meyer, unpublished data). However, in 
our study the concentrations of UD-CG 212 BS 
increased at a similar rate after infusion or bolus 
injections of pimobendan (see tables 1 and 3), yet 
the pattern of max LV dP 1 dt changes differed 
widely. Therefore, our data do not suggest a posi-
tive inotropic action of UD-CG 212 BS in the 
concentration range attained in this investigation. 
A combination of vasodilation and positive in-
otropy increases cardiac output by facilitation of 
ventricular emptying and augmentation of the 
velocity of wall thickening (Cohn and Franciosa, 
1978; Miller et a!., 1977; 1981; Verdouw et a!., 
1981). The results obtained with pimobendan dur-
ing coronary artery occlusion-induced myocardial 
ischemia show that, in a setting where cardiac 
contractility and output are depressed in the pres-
ence of a high pre- andlor afterload, the pimo-
bendan-induced increase in cardiac inotropy is 
translated into a salutary effect on the pump 
function of the heart. It would appear, therefore, 
that the drug may be useful in clinical heart 
failure where a similar pathophysiological state is 
encountered. The finding that cardiac output did 
not increase in the animals with normal hearts 
emphasizes the role of left ventricular filling and 
systemic vascular resistance. 
The effects of pimobendan on regional vascular 
beds are relevant to the therapy of congestive 
heart failure. Vasodilation occurred in all beds 
but, for the kidneys and spleen, this happened 
only with the lowest doses. When perfusion pres-
sure started to fall severely, the vascular beds of 
these organs tended to constrict. For some other 
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organs (stomach, adrenals, heart, brain) the vaso-
dilator response increased dose dependently. In 
the heart, vasodilation was more marked in the 
epicardium than in the endocardium ( endo-epi 
ratio was reduced) and, as a result, perfusion of 
the epicardium increased and that of the endo-
cardium was maintained despite a marked reduc-
tion in perfusion pressure. The smaller effect on 
the endocardial blood flow may have been at least 
partly due to an increase in heart rate and the 
consequent reduction of the duration of diastole 
caused by pimobendan. Moreover, the vasodilator 
capacity of the endocardial vessels appears to be 
less than that of the epicardial vessels (Winbury 
and Howe, 1979). The reduction in endo-epi ratio 
does not appear to be deleterious because myocar-
dial function was improved by the drug, even in 
the animals with an ischaemic heart. 
A potential disadvantage of cardiotonic agents 
is that they may increase MV02 , not least by the 
accompanying tachycardia. In the case of pimo-
bendan, these untoward effects were apparently 
balanced by reductions in pre- and afterload since 
MV02 did not change following drug administra-
tion. The data on MV02 also confirm that vasodi-
lation in the coronary vascular bed was due to a 
direct action of pirnobendan and was not the 
consequence of an increased myocardial metabolic 
demand. 
In summary, pimobendan presents itself as a 
compound with vasodilator and positive inotropic 
properties that improves cardiac output in a model 
of severe ischaemia. The finding that the mild 
tachycardia elicited by the drug was not accompa-
nied by an increase in MV02 warrants investiga-
tion to evaluate its usefulness in the treatment of 
heart failure. This is especially true since, in the 
clinical setting, the heart rate may even be reduced 
because of a reduction in reflex sympathetic activ-
ity as a consequence of an improvement in left 
ventricular function. 
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Usefulness ofPimobendan in the Treatment of Heart Failure 
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Summary: The effects of the benzimidazole-pyridazinone pi-
mobendan (UD-CG 115 BS) on systemic haemodynamics, 
myocardial performance and the distribution of cardiac out-
put were studied in open-chest anaesthetized'pigs. After in-
travenous bolus injections (0.1-0.5 mg- kg-1, n = 7) increases 
in heart rate (up to 37%), LVdPidtmax (up to 54%) and de-
creases in systemic vascular resistance (up to 33%) and left 
ventricular filling pressure (up to 50%) were observed, while 
cardiac output was unchanged. Vasodilation occurred in 
nearly all regional vascular beds, but was most pronounced 
in the adrenals (200%), followed by stomach ( 1 50%), small 
intestines (130%), heart (1 25%) and brain (110%). o,-
consumption was not ajfocted in spite of the increases in 
heart rate and myocardial inotropy. To evaluate the direct 
ejfocts on the myocardium, pimobendan was also infosed 
(1-5 llg. kg-L mirr-1, n = 7) directly into the left anterior des-
cending coronary artery. In addition to a marked vasodila-
tion of the coronary bed (140%), also a lowertng of the left 
ventricular filling pressure (up to 20%) and cardiac output 
(15%) was observed, but no changes in regional myocardial 
function, LVdP/dtmax and systemic vascular resistance 
occurred. Immediately after intracoronary bolus injections 
(1 mg · kg-1, n = 4), vasodilation of the coronary vessels was 
apparent, but myocardial contractility was not affected. This 
may explain that cyclic AMP content, determined in biopsies 
excised 30 s after injection, was unaltered. it may be con-
cluded that pimobendan e;,;erts actions on the cardiovascular 
,system which may be useful in the treatment of heart failure. 
Zusammenfassung: Nutzlichkeit von Pimobendan bei der 
Behandlung der Herzinsuffizienz 
Die Wirkungen des Benzimidazol-pyridazinons Pimob.en-
dan (UD-CG 115 BS) aufsystemische Htimodynamik, myo-
kardiale Leistung und_Verteilung des Herzminutenvolumens 
wurden an narkotisierten Schweinen mit eriJjfoetem Brust-
korb untersucht. Nach intraveniisen Bolusinjektionen 
(0,1-0,5 mg. kg-1, n = 7) wurde eine Zunahme der Herzfre-
quenz (bis 37%) und der LVdPidtmax (bis 54%) sowie eine 
Abnahine des systemischen Gefiif3widerstandes (bis 33%) 
und des linksventrikultiren Fiillungsdruckes (bis 50%) beob-
achtet, wtihrend das Herzminutenvolumen unvertindert 
blieb. Eine Vasodilatation war in fast allen regionalen Ge-
fiij3betten zu verzeichnen, jedoch war sie besonders augenfiil-
lig in den Nebennieren (200%), gefolgt vom Magen (150%), 
dem Dunndarm (130%), dem Herzen (125%) und Gehim 
(110%). Der 0,- Verbrauch blieb trotz der Steigerung der 
Herzfrequenz und des myokardialen Inotropismus unbeein-
jluj3t. Urn die unmittelbaren Effokte auf das Myokard zu be-
werten, wurde Pimobendan direkt in die Iinke vordere ab-
steigende Koronararterie infondiert (1-5 Jlg- kg-1 · mirr-1, 
n = 7). Auj3er einer deutlichen Vasodilatation in den 
Kranzgefiij3betten (140%) wurde auch eine Abnahme des 
linksventrikultiren Fullungsdruckes (bis 20%) und des Herz-
minutenvolumens (1 5%) beobachtet, doch es traten keine 
Vertinderungen bei der regiona/en myokardialen Funktion, 
der LV dP ldtmax und dem systemischen Gefiij3widerstand ein. 
Unmittelbar nach intrakoronaren Bolusinjektionen (1 mg . 
kg-1, n = 4) war die Erweiterung) der Herzkranzgefiij3e 
augenfiillig, die Kontraktilittit des Myokards wurde jedoch 
nicht beeinj/uj3t. Dies kiJnnte eine Erk/tirung dafiir sein, daj3 
der Gehalt an zyklischem AMP, der in 30 s nach Injektion 
exzidiertem Biopsiematerial bestimmt wurde, unvertindert 
war. Daraus kann geschlossen werden, daj3 die Effekte, die 
Pimobendan auf das kardiovaskultire System ausiibt, bei der 
Behandlung der Herzinsuffiziertz nutzlich sein kiJnnten. 
Key words: Cardiotonic drugs· Pimobendan, pharmacology· UD-CG 115 BS 
1. Introduction 
The ideal drug for the treatment of heart failure should aug-
ment cardiac pump function by improving myocardial con-
tractility, and (or) reducing left yentricular pre- and after-
load, without increasing myocardial 0 2-demand. In recent 
years a large series of new compounds (i.e. sulmazole, am-
rinone, milrinone) has been shown to meet the above men-
tioned requirements in the experimental animaL In clinical 
practice; however, the high incidence of side effects has pre-
vented these drugs from totally replacing cardiac glycosides, 
despite the unwanted properties of the latter. In this study 
we describe some investigations with the benzimidazole-
pyridazinone pimobendan (UD-CG 115 BS*), see formula 
•l Manufacturer: Dr. Karl Thomae GmbH, Biberach an der Riss 
(Federal Republic of Germany). 
diagram), which is structurally related to sulmazole [1]. 
Pimobendan increases myocardial contractility in the canine 
preparation [1, 2], possibly due to phosphodiesterase inhibi-
tion [3]. Diederen et aL also provided evidence that 
the drug is active on the venous vasculature [2]. We have 
shown that intravenous infusion of the drug also causes a 
marked systemic vasodilation in the pig [3a]. However, in 
these experiments the positive inotropic potency of pimo-
106 
bendan was of relatively minor importance. This discte-
pancy in inotropy between our study and those reported by 
others [1, 2] could not only be due to differences in the spe-
cies used and experimental model but also be caused by dif-
ferences in the administration: intravenous bolus injections 
versus infusions. In an attempt to reconcile these differences 
we studied the effect of pimobendan after intravenous bolus 
injections in anaesthetized pigs. Radioactively labelled mi-
crospheres were used to determine the effects on organ blood 
flow. In a second series of experiments we also infused the 
drug directly into a coronary artery to separate the direct ac-
tions on the myocardium from those on the vascular beds. 
Finally, the effects on myocardial cAMP levels were eval-
uated after selective coronary artery bolus injections. 
2; Materials and methods 
2.1. ~rimen131 set-up 
After an overnight fast Yorkshire pigs (22-28 kg) were sedated with 
120 mg azaperone i.m., and anaesthetized with 150 mg iotravenous 
metomidate [4]. Arterial blood gases (ABL-3, Acid-Base Laboratory, 
Radiometer, Copenhagen, Denmark) were controlled by artificial 
ventilation with a mixture of 0, : N,O (I : 2). Catheters were placed 
in the superior vena cava for administration of pentobarbital (20 mg · 
kg-1 • h-1), sodium bicarbonate (8.4%, when needed), pimobendan 
and polygelioe (Haemaccel"', Behringwerke AG, Mahtbwg!Lahn, 
FR Germany) to replace blood loss. Microtipped Millar catheters 
(Millar, lnstr., Houston, TX, USA) were used for measurement of 
the blood pressures in the left ventricular cavity and central aorta. 
An 8 F catheter was positioned in the aorta descendens for the with-
drawal of blood samples. Before the heart was exposed via a mid-
sternal split, 4 mg of the muscle relaxant pancuronium bromide was 
administered. A precalibrated electromagnetic flow probe (Skalar, 
Delft, The Netherlands) was placed around the ascending aorta. The 
great cardiac vein was cannulated and the left atrial appendage was 
catheterized for the injection of microspheres. In some animals the 
left anterior descending coronary artery (LADCA) was cannulated 
for intracoronary administration of pimobendan. 
Myocardial wall thickness tracings, monitored with a 5 MHz ultra-
sonic transducer (Krautkramer-Branson, Lewistown, PA, USA), 
were used to evaluate regional myocardial performance. The wall 
thickness at end-diastolic (EDT) and end-systole (ES'D were used to 
calculate systolic wall thickening (swt) as 
swt (%) = 100 X (EST -EDT)/EDT 
and the mean velocity of swt (fl swiJ as 
V"" =(EST -EDT)/DS 
where DS is the duration of the isovolumic contraction phase and 
the ejection time [4). In some experiments (n = 3) regional function 
was estimated from segment length changes obtained from a pair of 
ultrasonic dimension gauges (5 MHz), placed subendocardially [5) 
and connected to a 4-channel ultrasonic dimension system (Model 
40 I, Schuessler and associates, Cardiff by the Sea, CA, USA). The 
segment length at end-diastole' (EDSL) and at end-systole (ESSL) 
were used to calculate systolic segment length shortening (sis) as 
sis(%)= 100 x (EDSL-ESSL)/EDSL 
and the mean velocity of sis (fl sts) as 
Vsts= (EDSL-ESSL)IDS. 
Distribution of cardiac output was measured usiog the radioactive 
microsphere technique [4]. Just before the injection of about 2 x 106 
microspheres (15 ± 1 p.m diameter, NEN Company, Dreieich, FR 
Germany) labelled with either 46Sc, 103Ru, '"Ce, "Nb or "'Sn, into 
the left atrium, the withdrawal of an arterial reference sample was 
started (flow rate 10 m1 • min-I) and continued for a period of about 
1 min ,after injection of the microspheres was completed. After the 
experiment organs and tissues were excised, weighed and placed in 
vials. Details of the counting of the radioactivity and processing of 
the data have.been described in detail [6, 7]. 
2.2. Experimen131 protocols 
Three series of experiments were performed. In the first series (n = 
7) 3 consecutive i.v. bolus injections (0.1, 0.25 and 0.5 mg. kg-1) 
were used at 10-min intervals. Haemodynamic data were obtained 
duriog peak response and 10 min ·after· administration of the bolus. 
At this time radioactive microspheres were injected to determine re-
gional blood flows. In a second series of experiments (n = 7) pimo-
bendan was directly iofused into the left anterior descending coro-
nary artery at increasing iofusion rates (1, 2.5 and 5 p.g · kg-1 · 
min-I), each rate again laSting 10 min. In the last series (n = 4) the 
role of cAMP was studied. To minimize the effect of the systemic 
circulation on myocardial performance pimobendan was adminis-
tered directly into the left anterior descendiog coronary artery. Cy-
clic AMP and cyclic GMP levels were, determined in segments per, 
fused by the LADCA and remote from this artery. To this end 0.5 g 
biopsies were rapidly taken from the ventricle areas, and directly 
frozen in isopentane cooled in liquid N,. The frozen tissue was pul-
varized in a mortar while liquid N, was continuously added. The 
powder was mixed with 2.5 m1 0.9% perchloric acid (PCA), thawed 
and centrifuged thereafter. The PCA pellet was washed once more 
with 2.5 m1 0.9% PCA and further used for protein estimation. Cy-
clic AMP and cyclic GMP were determined, using the Amersham's 
cyclic AMP and cyclic GMP assay kits (Amersharn, UK), in the 
combined supernatants after neutralization with 0. 7 mol/1 K,PO, 
and 10 min centrifugation at 12,000 g [8]. 
2.3. Statistical analysis 
Statistical analysis was performed using parametric tests [9]. After 
each dose of pimobendan, changes from baseline were calculated se-
parately in each experiment and the significance of these changes 
was determined by using the Duncan ·new multiple-range test, once 
an analysis of variance had established that the data represented dif-
ferent populations. Statistical significance was accepted at· p < 0.05 
(two-tailed). All data have been expressed as mean ± standard error 
of mean (mean± SEM),. 
2.4. Drugs 
The only drugs used in this study were the anaesthetics, Haemaccel 
and pimobendan (supplied by'Dr. Karl' Thomae GmbH, Biberach 
an der Riss, FR Germany) which was dissolved in a mixture of po-
lye,tbylene glyco1400 and saline (I : 1). 
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Fig. t: Haemodynamic effects of cumulative bolus i:njections (mg · Icg-1) of 
pim.obendan (blank columns= i.v. bolus peak; dark columns= i.v. bolus 10 
min). The following parameters are shown: heart rate (HR: baseline 99 ± 6 
beats · m.m-1); ·maximum rate of rise of left ventricular pressure 
(LVdP/dtmax: 1680: 140 mmHg ·,-I); mean arterial blood pressure (MAP: 
92 ± S mmHg); systemic vascular resistance (SVR: 41 ± 5 mmlfg · 
1-1 ·min); left ventricular end-diastolic pressure (LVEDP: 9.7 ± 1.0 mmHg); 
stroke volume (SV: 24.2: 1.7 mi) and cardiac output (CD: 2.39: 0.23 I· 
min-). All data are presented as percentage change from baseline (mean ± 
SEM). • p < 0.05 vs baseline. 
3. Results 
3.1. Intravenous bolus injections in pigs 
3.1.1. Haemodynamics 
Within minutes after each bolus injection ·mean arterial 
blood press\rre decreased up to 36o/o in a dose-dependent 
manner. This was caused by arterial vasodilation as cardiac 
output was not significantly affected (Fig, 1). From the deter-
minants of cardiac output, heart rate increased up to 37o/o 
but stroke volume decreased to 62o/o of baseline. This oc-
curred in. spite of the reduction in afterload and tbe increase 
in LVdP/dtmax (44o/o, Fig. 1). Therefore tbe 50o/o decrease in 
left .ventricular· filling pressure must have been responsible 
for tbe decline in stroke volume. 
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3.1.2. Distribution of cardiac output 
10 min after administration of the lowest dose (0.1 
mg . kg-I), none of the conductances of the regional vascular 
beds differed from their respective baseline values (Table I), 
but after 0.25 and 0.50 mg. kg-t, a profound vasodilation of 
tbe regional beds not only prevented a significant fall in per-
fuSion of most organs and tissues but even caused sligbt in-
creases in that of tbe myocardium (40o/o, Table 2). The in-
creases in conductance were in declining order: adrenals 
(200o/o), stomach (150%), small intestine (130o/o), heart 
(125o/o) and brain· (IIOo/o). In Table I tbe results for total 
brain are presented because only minor differences existed 
between tbe effects on tbe hemispheres (IOOo/o), diencepha-
Table 1: Conductance of regional vascUlar beds after cumulatiVe intravenous bolus injections ofpimobendan in 7 anaesthetized pigs. 
Baseline 
Pimobendan (mg · kg- 1) 
.o.t 0.25 0.5 
svc 27.7 ±3.0 30.0 ±3.3 35.3 :1:4.6" 37.5 ±3.7" 
Kidneys 4.05 ±0.86 4.34 ±1.02 4.28 ±0.52 5.66 ±0.75 
Liver 0.50 ±0.19 0.50 ±0.19 0.42 ±0.18 0.64 ±0.18 
Spleen 1.52 ±0.17 1.70' ±0.18 2.01 ±0.43 1.87 ±0.21 
Adrenals 2.01 ±0.41 2.47 ±0.45 2.92 ±0.46" 4.31 ±0.31" 
Stomach 0.22 ±0.06 0.22 ±0.05 0.30 ±0.05° 0.38 ±0.05° 
Small intestine 0.23 ±.0.03 0.24 ±0.03 0.31' ±0.04° 0.40 ±0.04~ 
Muscle 0.050±0.015 0.045 ±0.009 0.051 ±0.014 0.067±0.014" 
Skin 0.015±0.005 0.049±0.011* 0.054±0.022" 0.044±0.011" 
Left atrium 1.05 ±0.24 1.30 ±0.27 1.69 ±0.28° 2.15 ±0.33° 
Left ventricle 1.26 ±0.22 1.44 ±0.27 1.85 ±0.37" 2.59 ±0.50" 
Right ventricle 1.27 ±0.30 1.53 ±0.35 2.26 ±0.50" 3.07 ±0.63" 
Total brain 0.28 ±0.05 0.32 ±0.05 0.39 ±0.05° 0.50 ±0.05" 
All conductances are in mJ. min-I· mmHg-1 · 100 g-1, ~cept those of the systemic vascular tree (SVC. ml· min-I· mmHg-1). All data are presented as mean 
± SEM. "' p < 0.05 vs baseline. · 
·Table 2: Perfusion of regional vascular beds after cumulative intravenous bo-
lus injections ofpimobendan in 7 anaesthetized pigs. 
Baseline 
Pimobendan (mg. kg-!) 
0.1 0.25 0.5 
co 2.49± 0.24. 2.44± 0.20 2.37± 0.23 2.26± 0.20 
Kidrieys 359±72 343±63 310±56 351±59 
Liver 45.2 ±16.7 40.7 ±13.8 29.8 ±11:7 38.0 ±10.2 
Spleen 139±18 141±17 141±31 113±12 
Adrenals 182±39 203±35 206±32 259± 11 
Stomach 19.6 ± 5.3 17.9 ± 3.7 20.5 ± 3.8 23.0 ± 3.6 
Small intestine 19.9 ± 2.7 19.7 ± 1.8 21'.1 ± 2.4 23.7 ± 1.7 
Muscle 4.45± 1.34 3.67± 0.73 3.48± 0.94 3.94± 0.72 
Skin 1.32± 0.37 4.19± 1.12 3.95± 1.95 2.68± 0.67 
Left atrium 93±20 104±17 115±18 130±19 
Left ventricle 113±20 118± 19 128±23 157±29 
Right ventricle 112±24 123±22 155±32° 183±34" 
Total brain 25.3 ± 3.8 26.1 ± 3.1 26.0 ± 2.6 29.5 ± 2.2 
.. 
-All flow data are m '1'1· mm 1 · 100 g 1, except cardiac output (CO) which IS 
presented in I · min- . All data are presented as mean ± SEM. • p < 0.05 vs 
baseline. 
Table 3: Haemodyna.rirlc effects of cumulative 10-min intracoronary infu-
sions of pimobendan in 7 anaesthetized pigs. 
Baseline 
Pimobendan (Jlg · kg-1 · min-1) 
1 2.5 5 
co 2.10±0.25 1.99±0.22" 1.88±0.22° 1.82±0.22° 
HR 82±4 85±4 87±4 92±5° 
sv 26±3 23±3' 22±3' 20±3° 
LVdP/dtmax 1690±70 1730±100 1780±120 1990±200 
.LVEDP 10.0 ±0.4 9.3 ±0.7 8.6 ±0.9 8.0 ±0.9' 
MAP 84±5 79±5° 76±5" 69±5° 
SVR 43±4 43±5 43±5 40±4 
Abb~vations: CO = cardiac output 0 · min-1); HR = heart rate (beats· 
min-_); SV =stroke volume (ml)i LVdP/dt"""' = maximw:n rate ofris~ ofleft 
ventricular pressure (mmHg · ,- ); L VEDP = left ventricular end-diastolic 
~;:;::c ~;~~em(~·~~·= AJf~ ~.~~ ~ 
mean ± SEM. • P< 0.05 vs baseline. 
Jon ( 11 Oo/o ), cerebellum ( 130o/o) and brainstem (150o/o ). The 
vasodilatory response of the vascular beds of the kidneys, 
liver and spleen did not reach levels of significance. 
3.1.3. Myocardial perfonnance 
Coronary blood flow increased dose-dependently up to 
140o/o of the pre-treatment value (113 ± 20 ml. min·! . 100 
g-1) because of a doubling oftbe coronary vascular conduct-
ance. The increase in flow was most beneficial for tbe epi-
cardial layers as perfusion of tbe endocardial layers re-
mained unchanged (not shown). Consequently tbe endo-epi 
blood flow ratio decreased from L06 ±' 0.04 to 0.83 ± 0.03 
(p < 0.05). The oxygen content in the coromiry venous 
blood rose as tbe oxygen saturation in tbe great cardiac vein 
increased from 26 ± 4 to 44 ± 3o/o (p < 0.05). Myocardial 
Oz·consumption was not significantly affected, which is not 
surprising because tbe double product (heart rate x systolic 
arterial· blood pressure) was also not affected as tbe eleva-
tions in heart rate were balanced by tbe decreases in arterial 
blood pressure. 
3.2. Intracoronary infusions 
3.2.1. Haemodynamics 
In spite oftbe low doses (1-5 pg · kg-1. min·') the intracor-
onary infuSions caused dose-dependent decreases in arterial 
blood pressure (up to 18o/o, p < 0.05) because of a fall in 
cardiac output (up to 15o/o, p < 0.05) as systemic vascular 
resistance was not affected (Table 3). This decrease in car-
diac output occurred despite a moderate dose-dependent in-
crease in heart rate.' Consequently stroke volume was de-
creased. Of its determinants only left ventricular filling was 
reduced, reflected by a 20o/o decrease in LVEDP, while sys-
temic vascular resistance was not affected ·and LV dP I dtmax 
tended to increase. Although arterial blood pressure de-
creased, no redistribution of cardiac output occurred as the 
conductances of tbe regional vascular beds were not signif-
icantly affected (Table 4). 
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Table 4: Conductance of regional vascular-beds after cumulative 10-min intracoronary infusions ofpimobendan in 7 anaesthetized pigs. 
Pimobendan (Jlg · ~cg- 1 · min-1) 
Baseline 
I 2.5 5 
svc 25.0 ±2.6 25.1 ±2.6 24.8 ±2.6 26.3 ±2.4· 
KidneY. 4.23 ±0.56 3.77 ±0.30 4.52 ±0.85 4.65 ±1.10 
Liver 0.43 ±0.13 0.44 ±0.17 0.49 ±0.15 0.47 ±0.17 
Spleen 1.74 ±0.38 1.78 ±0.39 2.00 ±0.54 1.46 ±0.36 
Adrenals 2.51 ±0.26 2.70 ±0.37 3.03 ±0.47 3.32 ±0.67 
Stomach (n = 3) 0.18 ±0.05 0.19 ±0.06 0.18 ±0.06 0.19 ±0.06 
Muscle 0.038±0.006 0.036±0.007 0.041 ±0.008 0.039±0.009 
Left atrium 1.14±0.13. 1.16 ±0.15 1.33 ±0.19 1.47 ±0.18 
-All conductances are m ml· m.m-1. mmHg-1 · 100 g-1, except of the systemic vascular tree (SVC, ml· nun 1 • mmHg 1}. All data are presented as mean ± 
SEM. 
Table 5: Myocardial performance after cumulative I 0-min intra coronary AMP and cyclic GMP detemrinations. Cyclic AMP in the 
(LADCA) infusions ofpimobendan in 7 anaesthetized pigs. ·LADCA-perfused myocardium tended to he slightly lower 
Pimobendan (Jlg · kg- 1 · min-1) 
Baseline 
1 2.5 5 
Control segment 
Flow 
epi 125± II 118± 10 129±18 122±14 
endo 138± 14 128±12 127± 13 124±11 
endo/epi 1.07±0.06 1.09±0.06 1.02±0.08 1.04±0.06 
Conductance 
epi 1.48±0.07 1.49±0.07 1.66±0.17 1.77±0.15 
en do 1.62±0.13 1.62±0.11 1.67±0.13 1.81±0.10 
LADCA segment 
Flow 
epi 132± 17 143±16 163±19 172±27 
endo 143±17 154±19 179±18 191±25 
.endo/epi 1.18±0.09 1.16±0.12 1.18±0.09 1.21±0.09 
Conductance 
epi · 1.57±0.16 1.81±0.16' 2.13±0.16' 2.53±0.34' 
endo 1.68±0.16 1.93±0.16 2.32±0.12' 2.77±0.26' 
Cor ven 01-sat 24±4" 44±5* 51±5"' 63±6' 
0 2.-consumption 0.53±().07 0.40±0.05 0.39±0.07 0.30±0.03' 
~~~~~~~~Oo r:P;~ndu~n~~~nn:l ~:eEF~;~EJ~o~11:~~ ~~rwv! 
02-sat in%; 02-consumption in mmol· min~· 100 g- . All data are present-
ed as mean ± SEM. "' p < 0.05 vs baseline. 
3.2.2. Myocardial performance 
Because of the fall in perfusion pressure, a slight decrease in 
perfusion of the myocardium adjacent to the LADCA per-
fused segment was observed (Table 5). A minor increase in 
conductance prevented that ·this decrease in perfusion 
reached levels of significance. The increase in the conduct-
ance of both the endo- and epicardial layers from the area 
perfused by the LADCA prevented that the fall in perfusion 
pressure was detrimental to their perfusion. Systolic wall 
thickening (swt), mean velocity of swt, systolic segment 
length shortening (sis) and mean velocity of sis did not 
change significantly from their respective baseline values of 
25 ± 4%, 19.8 ± 3.4 mm. s-', 24 ± 5% and 5.6 ± !'.! mm 
· s-1. The most marked changes were again in the coronary 
venous 0,-content, as the saturation in the great cardiac vein 
increased from 24 ± 4 to. 63 ± 6% (p < 0.05). These in-
creases in coronary venous Q,-saturation were caused by a 
lowering· in regional myocardial o,-consumption (Table 5), 
which occurred although the double product was hardly af-
fected. 
3.3. Myocardial cyclic AMP and cyclic GMP levels after 
intracorooary pimobendan administration 
Within seconds after intracoronary bol~s injections (I mg · 
kg-') a very pronounced vasodilation of the coronary vascu-
lar bed occurred (visible by a bright red colour of the myo-
cardium and confirmed by the extreme high o,-saturations 
in the great cardiac vein (up to 75%)), but LVdP/dt...,. and 
regional myocardial wall thickening of the area perfused by 
the LADCA were not significantly affected. At that mo-
ment the heart was excised rapidly and treated for cyclic 
(6.13 ± 0.42 vs 7.27 ± 0.50 pmoVmg protein, p > 0.05), 
while cyclic GMP was slightly higher (0.343 ± 0.115 vs 
0.143 ± 0.24 pmoVmg protein) compared to respective data 
obtained from a segment remote from the myocardium per-
fuSed by the LADCA. 
4. Discussion 
Intracoronary infusions were used to minimize the extracar-
dial effects of pimobendan to enable us to evaluate more di-
rectly the drug's inotropic potency. In spite of the low doses 
(1-5 llg . kg-' . min-I) the intracoronary infusions caused a 
decrease in cardiac output, as the decrease in stroke 
volume was not compensated by the acceleration of heart 
rate. This diminution in stroke volume was the result 
of a reduction in preload as the responses of afterload and 
myocardial contractility did not favor such a reduction. Be-
cause no dilation of the systemic arterial bed was noted, our 
data suggest that at these low doses a larger sensitivity. exists 
. for the venous than for the arterial vessels, confirming the 
earlier observations reported by Diederen et a!. [2]. Higher 
doses (0.1-0.5 mg ·kg-I i. v.) caused a marked systemic arte-
rial vasodilation in addition to the venodilation. It is note-
worthy that the effects on the arterial vessels appear to be 
shorter lasting than on the veins, as after I 0 min the effects 
on the arterial ·vessels were considerably lower than the peak 
effects obtained after 2 min, while the effects on the venous 
vasculature persisted. The arterial vasodilation is one of the 
factors that prevented a fall in cardiac output during the in-
travenous bolus injections. Another was the significant rise 
in myocardial contractility, reflected by the increase in 
LVdP/dtmax· Although the latter is not a true index for myo-
.cardial contractility because of its dependence on heart rate 
and pre· and afterload, the experimental evidence in this 
study warrants such a conclusion as the pre- and afterload 
induced-changes in LVdP/dtmax tend to underestimate the 
inotropic changes [10, 11]. Moreover, we have repeatedly 
shown that in the anaesthetized pig LVdP/dt.n.x is only 
slightly modified when heart rate varies between I 00 and 
140 beatS • min-I [12, 13]. While intravenous bolus injec-
tions (0.1-0.5 mg . kg-') revealed increases in myocardial 
inotropy, such an action was not noticeable during the intra-
coronary infusions. That the intracoronary infusion rates 
were too low is ruled out when one takes into account that 
after intravenous administration only about 2o/o of the pimo-
bendan passes through the coronary circulation. Moreover, 
intracoronary bolus injections (up to I mg . kg-1) were also 
unable to elicit a positive inotropic action, while arterial va-
sodilation was remarkably present. In these experiments, we 
excised the hearts approximately 30 s after administration, 
to avoid extracardial influences of pimobendan on myocar-
dial performance, The absence of significant changes in 
myocardial cAMP content therefore does not exclude the 
possibility of phosphodiesterase inhibition as a mechanism 
for the drug's inotropic potency [3), but rather indicates that 
the vessels respond much more rapidly (within seconds) than 
the tissue. 
After intravenous bolus injection· vasodilation occ~ed in 
all regional vascular beds. The increase in conductance was 
enough to maintain or even augment regional blood flow in 
spite of the fall in perfusion pressure. In the myocardium, 
the epicardial layers benefited more than the endocardial 
layers yielding a 20% decrease in the endo-epi blood flow ra-
tio. Domenech and Goich [14] reported tbat tachycardia 
does not affect the endo-epi blood flow ratio in normoten-
sive ammals because of the endocardial vasodilatory ·re-
serve capacity, but in dilated coronary vascular beds raising 
the heart rate resulted in a decrease of the endo-epi blood 
flow ratio [14]. Therefore, the pimobendan-induced tachy-
cardia and decrease in perfusion pressure are very likely the 
responsible factors for the uneven distribution of the flow 
after administration of the drug. The intracoronary infusions 
of pimobendan were accompamed by smaller changes in 
heart rate and arterial blood pressure, which explains why 
the different myocardial layers were now equally affected. 
Since the myocardial 0,-consumption was not increased 
after the intravenous and even decreased during the intracor-
onary experiments we conclude that the increase in flow was 
not the result of an autoregulatory response mediated by an 
increased 0,-demand. The decrease in 0,-consumption after 
the intracoronary infusions probably underestimates the 
true vasodilatory response to the pimoberidan infusions be-
cause of a metabolic-induced vasoconstriction. Since the 
double product of heart rate and left ventricular systolic 
pressure was unchanged in the intracoronary experiments, 
other factors may have played a role in the lowering of the 
myocardial 0,-consumption: A decrease in left ventricular 
wall tension due to the decrease in LVEDP seems to be such 
a factor. In the intravenous experiments the double product 
was also unchanged, but now the decrease in L VEDP was 
balanced by an increase in LVdP/dtm .. resulting in an un-
changed myocardial o,-consumption. 
In conclusion, our data suggest that pimobendan at low 
doses acts primarily on the venous system but at higher 
doses the effects on the arterial vessels are also prominent. 
Depending on the rate of administration, a significant posi-
tive inotropic response can be elicited. In view of our obser-
vations with pimobendan, ii is of interest that Wilmshurst 
et al. [15] reported amrinone to be devoid of any beneficial 
effect in patients with cardiac failure when administered di-
rectly into the coronary artery. Intravenous administration, 
on the other hand, improved cardiovascular performance 
due to vasodilation of the venous and arterial beds. Only in 
a small number of patients myocardial contractility in-
creased probably due to catecholamine release. These ob-
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servations -suggest that the beneficial actions of some of the 
so-called positive inotropic agents might be due to normali-
zation of left ventricular dimensions as a result of a reduc-
tion in both preload and afterload rather than to a signif-
icant increase in myocardial contractility. However, the 
above described properties of pimobendan are useful in the 
treatment of heart failure and side effects permitting, clinical 
studies appear to be warranted. 
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Cardiovascular effects of UD-CG 212 CL, a metabolite of pimobendan, 
in anaesthetized pigs 
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Systemic and regional haemodynamic effects of UD-CG 212 CL (0.5-16 p.g · kg- 1 • min- 1), the major metabolite of 
the vasodilator and cardiotonic drug pimobendan, were studied in anaesthetized pigs. The drug caused a dose-depen-
dent decrease in left ventricular (LV) end-diastolic and arterial blood pressures while it increased systemic vascular 
conductance, heart rate and maxLVdP/dt. The decrease in LV end-diastolic pressure was observed at lower plasma 
concentrations than the increase in systemic vascular conductance. Cardiac output tended to decrease but statistical 
significance was achieved only with the highest concentration. These effects of UD-CG 212 CL were not altered by the 
blockade of ,8-adrenoceptors with propranolol. The vasodilator action of UD-CG 212 CL was noticed in several 
organs but the effects were relatively more marked (in decreasing order of magnitude) in the adrenals, kidneys, 
gastrointestinal tract, brain and LV epicardium. Since both arterial pressure and cardiac output decreased, the blood 
flow increased significantly only in the adrenals and decreased moderately in the spleen, LV endocardium and skeletal 
muscles. The effects of UD-CG 212 CL on the renal and skeletal muscle haemodynamics were different from those of 
pimobendan, which causes vasodilatation in the skeletal muscles but not in the kidneys. The results of this study show 
that, like the parent compound pimobendan, UD-CG 212 CL has independent cardiotonic and vasodilator actions; 
the latter being more pronounced on the venous side. However, the contribution of this metabolite to the overall 
pharmacological activity of pimobendan appears to be limited. 
UD-CG 212 CL; Pimobendan; Phosphodiesterase inhibitors; Vasodilatation; Regional blood flow; 
,8-Adrenoceptor blockade; Myocardial 0 2 consumption; Tachycardia; Inotropic agents (positive); (Pig) 
l. Introduction 
The last decade has seen considerable attention 
focused on a new type of cardioactive drugs which 
could be useful in the treatment of congestive 
heart failure. These agents are thought to dilate 
• To whom all correspondence should be addressed: Labora-
tory for Experimental Cardiology, Erasmus University Rot-
terdam, P.O. Box 1738, 3000 DR Rotterdam, The Nether-
lands. 
1 Present address: Dept. of Thoracic and Cardiovascular 
Surgery, Beilinson Hospital Medical Centre, Petah Tikva, 
IsraeL 
peripheral vascular beds and increase myocardial 
contractility by elevating cyclic AMP levels fol-
lowing inhibition of phosphodiesterases (Honer-
jager et a!., 1984; Scholz and Meyer, 1986). One 
such drug is pimobendan (UD-CG 115 BS) which 
in vivo experiments have shown to act more 
potently on the venous than on the arterial side; 
the positive inotropic action is only moderate 
(Diederen et a!., 1982; Van Meel, 1985; Verdouw 
et a!., 1986; Duncker et a!., 1986c). Recently, the 
major metabolite of pimobendan, UD-CG 212 CL 
(fig. 1), was found in in vitro studies to increase 
cardiac contractile force (Meyer eta!., 1985; Scholz 
0014-2999/87/$03.50 © 1987 Elsevier Science Publishers B.V. (Biomedical Division) 
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Fig. 1. Chemical structure of pimobendan and its major 
metabolite UD-CG 212 CL. 
and Meyer, 1986). The major goal of the present 
study was to investigate the complete systemic and 
regional haemodynamic profile of UD-CG 212 
CL. Additionally, in view of the possible contribu-
tion of UD-CG · 212 CL to the systemic 
haemodynamic effects of pimobendan (Meyer et 
al., 1985; Scholz and Meyer, 1986), we have mea-
sured the plasma concentrations of UD-CG 212 
CL and compared them with concentrations 
achieved following infusions of the parent drug 
pimobendan (Verdouw et al., 1986) to assess the 
extent of such a contribution. 
2. Materials and methods 
2.1. Experimental set-up 
After a 24 h fast, Yorkshire pigs (23-28 kg) 
were sedated with 120 mg azaperone (Stresnil®) 
i.m., anaesthetized with 150 mg metomidate (Hyp-
nodil®), intubated and ventilated with a mixture 
of 0 2 and N20 (1 : 2). Respiratory rate and tidal 
volume were set to keep arterial blood gases, 
measured with an ABL-3 (Radiometer, Copenha-
gen, Denmark), within normal limits (7.35 <pH 
< 7.45; 35 =Hg < PC02 < 45 =Hg; 90 mmHg 
< P02 < 150 =Hg). Cathethers placed in the 
superior vena cava were used for administration of 
a-chloralose (100 mg · kg- 1) and pentobarbital 
sodium (5 mg · kg- 1 • h- 1) for anaesthesia, 
Haemaccel® (Behringwerke AG, Marburg, FRG) 
to replace blood loss, and UD-CG 212 CL. An 8F 
catheter was positioned in the descending aorta 
for withdrawal of blood samples. Left ventricular 
and aortic blood pressures were obtained with 8F 
Millar microtipped catheters (Millar Instruments 
Houston, Texas, USA). Prior to exposing the heart 
via a midstemal split, 4 mg of the muscle relaxant 
pancuronium bromide (Pavulon®) was adminis-
tered. Ascending aortic blood flow was measured 
with an electromagnetic flow probe (Skalar, Delft, 
The Netherlands). Blood samples were collected 
from the great cardiac vein for the determination 
of haemoglobin and 0 2 saturation. Myocardial 0 2 
consumption was calculated by multiplying left 
ventricular blood flow by the arterial-coronary 
venous Oz content difference. 
The distribution of cardiac output was 
determined using the radioactive microsphere 
technique. Microspheres of 15 ± 1 JLm (mean± 
S.D.) diameter labeled with either 103Ru, 113Sn, 
46Sc, 95 Nb or 141Ce (NEN Chemicals GmbH, 
Dreieich, FRG), were injected in random order 
via a cannula inserted into the left atrial appen-
dage. Flow measurements were calibrated by 
withdrawal of an arterial reference blood sample 
at a rate of 10 ml· min - 1 starting just before and 
continuing for 1 min after each injection of micro-
spheres. The aruma! was killed at the end of the 
experiment and several organs and tissues were 
excised and treated as described elsewhere (Saxena 
and Verdouw, 1985). The data were processed 
using computer progra=es developed for the 
purpose (Saxena et al., 1980). 
2.2. Experimental protocols 
Two series of experiments· were performed. In 
both series pre-drug systemic haemodynamic data 
were collected after a stabilisation period of 30-45 
min. In the first group (n = 9) this was followed 
by six consecutive 15 min infusions of 0.5, 1, 2, 4, 
8 and 16 JLg-kg- 1 -min- 1 of UD-CG 212 CL. 
Measurements were repeated at the end of each 
infusion at a given rate. Radioactive microspheres 
were injected at baseline and at the end of the 
four highest 'infusion rates' (2, 4, 8 and 16 p.g · 
kg- 1 • min- 1), because of the limited number of 
isotopes available. Since increases in heart rate 
and maxL V dP I dt in these experinlents were 
accompanied by a fall in mean arterial blood 
pressure, the same infusion rates were repeated in 
a second group of 5 animals after pretreatment 
with propranolol (0.5 mg · kg -I followed by an 
infusion of 0.5 mg · kg- 1 ·h-I) to exclude effects 
of a direct or indirect ,8-adrenoceptor mechanism. 
Regional blood flows and plasma concentrations 
were not determined in this series of experinlents. 
An earlier study from our laboratory (W olffenbut-
tel and Verdouw, 1983) had shown that the 
above-mentioned dose regimen for propranolol 
provides adequate ,8-adrenoceptor blockade and 
that systemic haemodynamic parameters change 
less than 5% over a period of 90 min. 
2.3. Determination of plasma drug concentrations 
The concentration of UD-CG 212 CL in the 
plasma was measured using high-performance 
liquid chromatography (HPLC). The details of the 
HPLC assay have been described earlier (Roth, 
1983; Verdouw et a!., 1986). The lower limit for 
detection of the compound is 1 ng · ml- 1. 
2.4. Statistical analysis 
Data are presented as means ± S.E.M. Statisti-
cal analysis was performed by use of a parametric 
two-way analysis of variance (randomized block 
design), followed by Duncan's new multiple range 
test (Steel and Torrie, 1980). Statistical signifi-
cance was accepted at P < 0.05 (two-tailed). 
2.5. Drugs 
The substances used were the anaesthetics, 
Haemaccel, propranolol hydrochloride (ICI-
Pharma, Rotterdam, The netherlands) and UD-CG 
212 CL (Dr. Karl Thomas GmBH, Biberach ajd 
Riss, FRG). The latter was dissolved in a mixture 
of polyethylene glycol and saline, such that the 
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infusion rates of polyethylene glycol ranged be-
tween 0.5 and 1.0 mi · min- 1• The infusion of the 
solvent of these rates has no cardiovascular effects 
(Verdouw eta!., 1983). 
3. Results 
3.1. Cardiovascular actions of UD-CG 212 CL 
without ,8-adrenoceptor blockade 
3.1.1. Plasma concentrations of UD-CG 212 CL 
As the infusion rates (0.5, 1, 2, 4, 8 and 16 
p.g·kg- 1 ·min- 1) of UD-CG 212 CL were in-
creased, the plasma concentrations reached levels 
of 9±1 ng·ml-\ 21±2 ng·ml-\ 44±5 ng· 
ml-\ 87 ± 8 ng · ml- 1; 170 ± 16 ng · ml- 1 and 
361 ± 32 ng · mi- \ respectively. The latter was 
approximately 20 tinies the highest UD-CG 212 
CL concentration obtained in pimobendan infu-
sion experiments (Verdouw eta!., 1986). 
HR (beats.min- 1 } maxLVdP/dt (mmHg.s -l) 
* 
170 3800 ~/ * 130 ~~ 3000 
90 2200 
MAP (mmHgl 
: l
LVEDP (mmHg) 
·j ~~ ~ * * * * * * 
" 
CO (l.min- 1) SVC (ml.min - ~mmHg) 
3.0 l 
... ~ 50 j ~~ 2.2 30 
...... 
0 10 30 TOO 300 0 10 30 100 300 
UD-CC 212 CL (ng.ml- 1 ) UD-CG 212 CL (ng.mJ-ll 
Fig. 2. Systemic haemodynamics at increasing UD-CG 212 CL 
plasma concentrations. HR, heart rate; maxL VdP jdt, maximal 
rate of rise of left ventricular pressure; MAP, mean arterial 
pressure; L VEDP, left ventricular end-diastolic pressure; CO, 
cardiac output; SVC, systemic vascular conductance. Data are 
presented as means± S.E.M. • P < 0.05 vs. pre-drug values. 
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3.1.2. Systemic haemodynamics 
UD-CG 212 CL caused dose-related decreases 
in mean arterial blood pressure (fig. 2), without 
affecting pulse pressure (not shown). Although the 
hypotensive action of UD-CG 212 CL was accom-
panied by a positive chronotropic action (heart 
rate increased up to 40%) it was not sufficient to 
prevent a fall in cardiac output, as stroke volume 
decreased dose dependently from a pre-drug value 
of 29 ± 2 to 17 ± 2 ml (not shown). For concentra-
tions less than 30 ng · ml- 1 this decrease in stroke 
volume was primarily due to a reduced left 
ventricular filling (left· ventricular end-diastolic 
pressure decreased up to SO%), as the increases in 
systemic vascular conductance (flow 1 pressure) by 
10% and maxLVdP I dt (15%) would facilitate left 
ventricular emptying. No additional effects on left 
ventricular end-diastolic pressure were seen for 
concentrations higher than 50 ng · ml-I, while 
maxL V dP I dt increased gradually up to 60% and 
systemic vascular conductance increased by 45% 
(fig. 2). 
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Fig. 3. Effects of i. v. infusions of UD-CG 212 CL on regional 
blood flows. Data are presented as means± S.E.M. * P < 0.05 
vs. pre-drug values. 
3.1.3. Regional blood flows and vascular conduc-
tances 
Because of the limited number of microspheres 
available with different radioactive labels, regional 
blood flows were determined before the start of 
the infusion of UD-CG 212 CL and at the end of 
the four highest infusion rates. Figure 3 shows 
that the decrease in cardiac output was not equally 
distributed over all organs. Blood flow to the 
adrenals was increased at each plasma concentra-
tion (up to 100%). Renal blood flow initially tended 
to increase, but started to decrease at concentra-
tions higher than 40 ng · ml- 1 and bad fallen to 
below pre-drug values at 360 ng · ml- 1• At con-
centrations higher than 40 ng · ml-I, splenic (up 
to 45%), skeletal muscle (up to 40%) and left 
ventricular (up to 20%, for further details see 
below) blood flow decreased but no significant 
changes were observed at any concentration in 
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Fig. 4. Effects of i.v. infusions of UD-CG 212 CL on regional 
vascular conductances. Data are presented as means± S.E.M. 
• P < 0.05 vs. pre-drug values. 
any of the other organs studied (stomach, small 
intestine, brain, liver and skin (not shown)). 
Dose-related increases in vascular conductance 
were observed in the adrenals (up to 300%), 
stomach (up to 100%), brain (up to 60%) and 
small intestine (up to 60%; fig. 4). The increase in 
conductance in the renal bed was independent of 
the dose, whereas vasodilatation in the spleen only 
occurred at the lowest two doses. The changes in 
vascular conductance in skeletal muscle, liver and 
skin (not shown) did not reach significance. 
3.1.4. Coronary circulation 
As shown in fig. 5 the blood flow to the two 
atria and the right ventricle did not change after 
the administration of UD-CG 212 CL. Since a 
right atrium left atrium 
100 
flow 
(ml.min-1 .1 oog-1) 
conductance 
(ml.min-1 .mmHg-1 .1 OQg-1) 
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decrease in arterial blood pressure was observed, 
vascular conductance in these organs increased 
dose dependently. Transmural left ventricular 
blood flow decreased by 12% when UD-CG 212 
CL reached arterial plasma levels of 40 ng · mi- 1. 
A further decline (28%) was observed at 170 ng· 
ml- 1 (fig. 5). The decreases were confined to the 
subendocardial layers, yielding a moderately de-
creased endo-epi blood flow ratio (from 1.23 ± 0.04 
to 0.95 ± 0.03, P < 0.05, not shown). Vascular con-
ductances of the subendocardial and subepicardial 
layers were, respectively, virtually unchanged and 
increased dose dependently (up to 55%). 
The 0 2 saturation in the great cardiac vein 
increased from 15 ± 2 to 21 ± 1% (P < 0.05) at 40 
ng · ml- 1 but was not further affected at higher 
right ventricle 
total endocard epicard 
flow 
(ml.min-1.10og-1) 
conductance 
(ml.min-1 .mmHg-1 .1 Oog-1) 
100 
left ventricle 
llrll 
~rnl~ 
02'1816 02tl816 024816 
UD·CG 212 CL (!.<g.kg.-1.min-1) 
Fig. 5. Myocardial blood flows and vascular conductances with increasing rate of UD-CG 212 CL i.v. infusion. The plasma 
concentrations at baseline and at the end of the infusions at each rate were: 0 ng·ml-', 44±5 ng·ml-', 87±8 ng·ml-', 170±16 
ng·ml- 1 and 361 ±32 ng·ml-', respectively. Data.are presented as means±S.E.M. • P < 0.05 vs. pre-drug values. 
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concentrations (not shown). Myocardial 0 2 con-
sumption therefore decreased gradually from 5.1 
±0.4!1mol· min-1 . g- 1 to 3.6 ± 0.51'mol· min- 1 
. g- 1 (P < 0.05; not shown). 
3.2. Cardiovascular actions of UD-CG 212 CL after 
/3-adrenoceptor blockade 
When UD-CG 212 CL was infused at rates up 
to 8 l'g·kg- 1 ·min- 1 neither the responses of 
heart rate nor those of maxL V dP I dt, mean arterial 
blood pressure, cardiac output and left ventricular 
end-diastolic pressure were significantly modified 
by the presence of propranolol (not shown). 
4. Discussion 
In the study just described UD-CG 212 CL. 
dilated both arterial and venous vascular beds and 
increased myocardial contractility. The data in fig. 
2 reveal that at concentrations lower than 30 
ng · mi-l· UD-CG 212 CL is primarily a venodila-
tor (decrease in left ventricular end-diastolic pres-
sure) and that the arterial vasodilator and 
maxL V dP I dt increasing properties only become 
apparent at higher concentrations. Because 
maxLVdPidt depends on heart rate and pre- and 
afterload, its use as an index of inotropy demands 
caution. In this study the heart rate increased, 
which could be a factor contributing to the aug-
mentation of maxL V dP I dt (Higgins et al., 1973). 
However, in the anaesthetized pig, maxL V dP I dt 
is not significantly affected by a heart rate in the 
range of 100-150 beats·min-1 (Scheffer and 
Verdouw, 1983). Furthermore, the decreases in 
diastolic arterial blood pressure and left ventricu-
lar end-diastolic pressure tend to reduce 
maxL V dP I dt (Mason, 1969). It thus seems that 
the enhancement of maxL V dP I dt by UD-CG 212 
CL represents its positive inotropic effect. The 
increases in heart rate and maxL V dP I dt induced 
by UD-CG 212 CL were not modified by pro-
pranolol. We therefore conclude that these effects 
are not mediated by /3-adrenoceptors, either di-
rectly or via enhancement of sympathetic nerve 
activity (due to baroreceptor reflex) but the possi-
bility of withdrawal of vagal tone cannot be ex-
eluded. With respect to the positive inotropic ef-
fects of UD-CG 212 CL as well as of pimoben-
dan, evidence from in vitro studies suggests that 
inlribition of phosphodiesterase is involved, but 
the extent of this involvement is less than in the 
case of bipyridine derivatives such as amrinone 
and milrinone (Scholz and Meyer, 1986). 
UD-CG 212 CL caused a pronounced vasodila-
tation of the systemic arterial bed. Although 
vasodilatation occurred in most regional beds it 
was conspicuously absent in skeletal muscle and 
was of only limited magnitude in the left ventricle. 
In this respect the effects of UD-CG 212 CL are 
similar to those of a.Duinone (Hartog et al., 1986), 
but quite different from those of other vasodila-
tors such as the calcium channel blockers 
nimodipine and nisoldipine (Duncker et al., 
1986a,b; Verdouw et al., in press), the nitrate-like 
drug nicorandil (unpublished data from our 
laboratory)· or even pimobendan (Verdouw et al., 
1986; Duncker et al., 1986c), which were all 
evaluated in the same experimental model and 
elicited moderate to pronounced vasodilatation in 
these regions. The vasodilatation that occurred in 
the left ventricle was not sufficient to prevent a 
reduction in transmural blood flow. As the 
coronary venous 0 2 content increased slightly it is 
likely that the reduction in flow reflects the di-
minished metabolic needs (myocardial ~ con-
sumption decreased up to 30% ). The transmural 
vasodilatation was almost solely confined to the 
subepicardial layers; endocardial blood flow and 
the endolepi ratio decreased. It is known that 
endocardial blood flow is more susceptible to a 
decrease in diastolic perfusion time (due to 
tachycardia in this case) and systemic perfusion 
pressure (see Feigl, 1983). Alternatively, though 
less likely, there is the possibility that UD-CG 212 
CL has a more potent vasodilator effect on the 
epicardial layers whereby a 'steal' of endocardial 
blood flow may take place. Interestingly, a reduc-
tion in endo-epi ratio has also been observed for 
the phosphodiesterase inhibitor amrinone in the 
same animal model (Hartog et al., 1986), but in 
animals with ischaemic hearts amrinone signifi-
cantly increased endocardial blood flow and the 
endo-epi ratio (Hartog et al., 1987). It therefore 
appears that the decrease in endocardial blood 
flow and endo-epi ratio by UD-CG 212 CL found 
in this study in animals with a normal heart may 
not be of much consequence for the clinical situa-
tion. Furthermore, in congestive heart failure, the 
heart rate is usually already high and vasodilator 
drugs are likely to reduce heart rate, while blood 
pressure is maintained (due to an increase in 
cardiac output). 
Of particular interest in the treatment of con-
gestive heart failure are the renal and skeletal 
muscle blood flows. With UD-CG 212 CL 
vasodilatation occurred in the renal vascular bed 
at all concentrations. There was even an increase 
in blood flow at the lower doses despite the fall in 
arterial blood pressure and cardiac output. How-
ever, no vasodilatation occurred in skeletal muscle. 
In this respect the actions of UD-CG 212 CL were 
quite different from those of pimobendan which 
did not affect renal vascular conductance but in-
creased skeletal muscle conductance by 40% at 
comparable changes in mean arterial blood pres-
sure and cardiac output (Verdouw et al., 1986). 
The maximum concentration of UD-CG 212 
CL after administration of pharmacologically ac-
tive doses (10, 25, 50 and 100 p.g · kg- 1 · min- 1 ) of 
pimobendan did not exceed 20 ng · ml- 1 (Verdouw 
et al., 1986). Around ~his concentration, UD-CG 
212 CL caused only small but significant reduc-
tions in left ventricular end-diastolic and mean 
arterial pressures and increases in heart rate. These 
effects may partly contribute to the systemic ef-
fects of pimobendan. However, in view of the 
much higher plasma concentrations of UD-CG 
212 CL required to cause major haemodynarnic 
effects, it would appear that most cardiovascular 
changes observed after the administration of 
pimobendan in the original study (Verdouw et al., 
1986) were induced by the parent drug itself. 
In summary, the present experiments show that 
UD-CG 212 CL is a vasodilator agent with posi-
tive inotropic actions. The vasodilator effect of the 
drug is more marked on the venous than on the 
arterial vascular bed. In addition, the positive 
inotropic action of UD-CG 212 CL seems to be 
more potent than that of its parent compound 
pimobendan. 
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Nicorandil-induced changes. in the distribution of cardiac output 
and coronary blood flow in pigs 
Pieter D. Venloow 1, Loes M.A. Sassen 1, Dirk J. Doncker 1, Dona 0. L. Scbmeets 1, Rob J. Reoseo 1, and Pramod R. Saxena 1 
1 Laboratory for Experimental Cardiology and 2 Department of Pharmacology, Erasmus University Rotterdam, 
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Summary. The present investigation was conducted to study 
systemic and regional haemodynamic effects of nicoraodil, 
a potent coronary vasodilator, after intravenous or local 
intracoronary administration in anaesthetized or conscious 
pigs. Intravenous infusions ofnicoraodil for 10 min in both 
anaesthetized (15, 30, 75 and 150 )J.g ·.kg- 1 • min- 1) and 
conscious (20, 40 and 80 )J.g · kg -• · min -•) pigs reduced 
arterial blood pressure, stroke volume, left ventricular end-
diastolic pressure (L VEDP) and systemic vascular resis-
tance, but increased heart rate and maxLVdP/dt. Since 
nicoraodil decreased LVEDP at doses' which did not affect 
arterial blood pressure, the drug may be considered as a 
more potent venodilator than arterial dilator. Nicoraodil 
increased cardiac output only in conscious animals due to a 
more marked tachycardia (85% after 80 )J.g · kg-• · min- 1) 
than in anaesthetized animals (30% after 7 5 )J.g · kg -• 
· min- 1). The nicorandil-induced increase in heart rate and 
maxL VdP/dt, being substantially attenuated in conscious 
pigs after treatment with propranolol, can be ascribed to a 
reflex activation of the sympathetic nervous system 
following the fall in arterial pressure. Although cardiac 
output did not change in anaesthetized animals, intravenous 
infusions of nicorandil did cause a redistribution of blood 
flow in favour of organs such as the heart, adrenals, spleen, 
small intestine and brain at the expense of that to the stom-
ach and kidneys; hepatic artery and skeletal muscle blood 
flow did not change. The increase in myocardial blood flow, 
primarily to the subepicardial layers, was associated with an 
enhancement in coronary venous oxygen content and was 
also noticed after intracoronary infusions ofnicorandil (0.6, 
1.5, 3 and 6 )J.g · kg- 1 · min -•). The above cardiovascular 
proftle suggests a possible usefulness of nicorandil in angina 
pectoris as well as congestive heart failure. However, caution 
is needed because the strong hypotensive action and reflex-
mediated tachycardia may under certain conditions 
aggravate myocardial ischaemia, particularly in the sub-
endocardial layers. 
Key words: Nicorandil - Systemic haemodynamics -
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Introduction 
Nicorandil (N-(2-hydroxyethyl) nicotinamide nitrate; SG-
75) is a potent directly-acting coronary vasodilator (Uchida 
Send offprint requests toP. D. Verdouw 
et a!. 1978). Upon intra-arterial injection the di-ug also in-
creases blood flow in the femoral, mesenteric and, to a lesser 
extent, renal vessels (Sakai'et a!. 1981). The results obtained 
in several models of myocardial ischaemia (Aono eta!. 1981; 
Lamping and Gross 1984a, b; Lamping eta!. 1984a, b) and 
in angina pectoris (Uchida 1978; Thormann et a!. 1982, 
1983) have focused special attention on the potential 
usefulness of the drug as an anti-anginal agent (Sakai et 
a!. 1983). In addition, since nicorandil decreases both left 
ventricular end-diastolic and end-systolic volumes and 
possesses only a negligible negative inotropic action in the 
therapeutic dose-range, the drug might also be useful in the 
treatment of heart failure (Belz eta!. 1984). In this condition 
the decrease in cardiac output leads to cardiovascular 
adjustments often at th.e expense of renal and skeletal muscle 
blood flow (Drexler eta!. 1986). Therefore, normalization of 
perfusion of these organs is particularly beneficial. However, 
few data on the effects ofnicoraodil on regional blood flows, 
other than that of the coronary circulation, have so far been 
reported. 
With respect to regional myocardial blood flow, using 
the radioactive microsphere technique, Gross et a!. 
(Lamping and Gross 1984a; Lamping eta!. 1984a, b; Preuss 
et a!. 1985) have reported that, both in anaesthetized and 
conscious dogs, nicorandil dose-dependently increases 
transmural left ventricular blood flow with the greatest in-
creases occurring in the subepicardium and mid-
myocardium. As a result the subendocardial-subepicardial 
blood flow ratio (endofepi) decreases but even then sub-
endocardial blood flow is elevated by more than two-fold 
(Preuss eta!. 1985). Moreover, if the fall in aortic pressure 
after nicorandil is prevented by use of a cuff around the 
descending thoracic aorta, collateral blood flow to the sub-
endocardial layers of an ischaernic area increases to a similar 
extent as (Lamping and Gross 1984b) or in excess of 
(Lamping and Gross 1984a) that to the subepicardial layers. 
The object of the present investigation, performed in 
young Yorkshire pigs, is three-fold. Firstly, we have studied 
the regional haemodynamic effects of nicoraodil on various 
tissues. Secondly, an attempt has been made to delineate 
direct and indirect (secondary to systemic haemodynamic 
changes) effects of nicorandil on blood flow to different 
layers of the myocardium. For this purpose the drug was 
infused directly into a coronary artery. Lastly, since 
a combination of nicorandil and beta-adrenoceptor 
antagonists is clinically important, we also report on the 
systemic haemodynamic effects of nicorandil with or 
without propranolol in conscious pigs. 
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Materials and methods 
Anaesthetized pigs. After an overnight fast Yorkshire pigs 
of either sex (24-26 kg, n = 17), were sedated with 120 mg 
azaperone (Stresnil) i. m., anaesthetized with 150 mg 
metomidate (Hypnodil) i. v., intubated and connected to a 
respirator for intermittent positive pressure ventilation with 
a mixture of oxygen and nitrous oxide (1 : 2). Respiratory 
rate and tidal volume were set to keep arterial blood gases 
within the normal range: 7.35 <pH< 7.45; 35 mm Hg < 
PC0 2 < 45 mm Hg and 90 mm Hg < P0 2 < 150 mm Hg. 
SF catheters were placed in the superior caval·vein for ad-
ministration of 100 mg · kg- 1 alpha-chloralose followed by 
an infusion of low dose pentobarbital (5 mg · kg- 1 • h- 1), 
administration of the muscle relaxant pancuronium bromide 
( 4 mg) prior to thoracotomy, and Haemaceel (Behringwerke 
A. G., Marburg, FRG) to replace blood loss. Catheters were 
also positioned in the inferior caval vein for infusion of 
nicorandil and in the femoral artery for withdrawal of blood 
samples. Microtipped catheters (SF Millar) were used to 
measure left ventricular and central aortic blood pressures. 
After thoracotomy, an electromagnetic flow probe (Skalar, 
Delft, The Netherlands) was placed around the ascending 
aorta, while the great cardiac vein was cannulated for collec-
tion of blood in which haemoglobin concentration and oxy-
gen saturation were determined (OSM2, Radiometer, 
Copeu!Iagen, Denmark). In some animals the left anterior 
descending coronary artery was also cannulated with a 4F 
catheter for intracoronary infusions of nicorandil. Myo-
cardial oxygen consumption (M V02), was calculated as the 
product of coronary blood flow and the difference in the 
oxygen contents of the arterial and coronary venous blood. 
To determine regional blood flows, the left atrial 
appendage was cannulated for injection of a batch of 1-
2.106 carbonized plastic microspheres [15 ± 1 IJll1 (SD) in 
diameter] labeled with either 46Sc, 95Nb, 103Ru, 113Sn or 
141Ce. Full details of the procedures and the calculation of 
flow data have been reported earlier (Saxena et aj. 19SO; 
Saxena and Verdouw 19S5). 
Conscious pigs. After an overnight fast Yorkshire pigs (1S-
20 kg, n = 6), pretreated with a mixture of procaine 
penicilline-G and benzathinepenicilline-G (Duplocilline) 
both 300.000 U i.m., were sedated with 30 mg · kg- 1 
ketarnine · HCl i.m., intubated and connected to a res-
pirator for artificial ventilation with a mixture of oxygen 
and nitrous oxide (1: 2) to which 1% halothane was added. 
After the jugular vein and common carotid artery had been 
cannulated for infusion of drugs and measurement of mean 
arterial blood pressure, the chest was opened via the left 
filth intercostal space, the heart exposed and a Konigsberg 
transducer (Konigsberg Instrument Inc., Pasadena, CA, 
USA) implanted near the apex for recording ofleft ventricu-
lar pressure. The left atrium was cannulated for recording 
ofleft atrial pressure, used for calibration of the Konigsberg 
transducer signals. The aorta was approached through the 
third intercostal space and an electromagnetic flow probe 
was positioned around the ascending aorta. Catheters and 
wires were tunneled subcutaneously to the back, the chest 
was closed and the animals allowed to recover. During the 
next days the animals received i. v. 500 mg an10xicilline 
(Clamoxil) and 500 mg kanamycine (Kamynex) to prevent 
infection. Daily flushment of the catheters was performed 
to prevent clotting of blood in the lumen. After recovery of 
surgery at least 4 sessions were held to adapt the animals to 
the experimental and laboratory facilities. The experimental 
protocol was executed 2-3 weeks after surgery. 
Experimental protocols. In the anaesthetized animals four 
consecutive 10 minintravenous(15, 30, ?Sand 150 J.lg · kg- 1 
·min -I; n = 12) or coronary (0.6, 1.5, 3.0 and 6.0 J.lg · kg- 1 
· min_,; n = 5) infusions were administered. Systemic 
haemodynarnics were measured and the distribution of coro-
nary blood flow was determined in both series of experi-
ments, but the distribution of cardiac output was ouly deter-
mined during the intravenous infusion experiments. In the 
conscious pigs the systemic haemodynarnic effects of three 
successive 10-mininfusions (20,40and SO 11g · kg- 1 · min- 1) 
without (n = 6) and after (n = 4) beta-adrenoceptor 
blockade with propranolol (0.5 mg · kg- 1 + 0.5 mg · kg- 1 
· h- 1) were employed. Regional blood flows were not deter-
mined in these animals. 
Drugs. The substances used in this study were the 
anaesthetics, propranolol (ICI-Pharma, Rotterdam, The 
Netherlands) and nicorandil (Rhone-Poulenc, Amstelveen, 
The Netherlands). Nicorandil was dissolved in 1.5 ml 
ethylalcohol and o:s ml polyethylene glycol and sub-
sequently fmal volume was reached by adding isotonic 
saline. The solvent has no effect on cardiovascular perform-
ance in the pig (Duncker eta!. 19S6b). 
Statistical analysis. Analysis was performed by using a 
parametric two-way analysis of variance (randomized block 
design) followed by Duncan's new multiple range test (Steel 
and Torrie 19SO). P-Values less than 0.05 were considered 
to be statistically significant. 
Results 
Intravenous infusions of nicorandil in anaesthetized animals 
Systemic circulation. The haemodynarnic effects of 
nicorandil are summarized in Table 1. Mean arterial blood 
pressure decreased dose-dependently to 55% of the pre-drug 
value without affecting pulse pressure. This was due to a 
reduction in systemic vascular resistance, as cardiac output 
remained unchanged. The maintenance of cardiac output 
resulted from a reflex-induced tachycardia (heart rate in-
creased up to 30% ), as stroke volume decreased from 
24 ± 2 ml to 20 ± 1 mi. This decline in stroke volume must 
have been the result ofthe reduction in left ventricular filling 
pressure from 7 ± 1 mm Hg to 4 ± 1 mm Hg as the reduc-
tion in arterial blood pressure and the slight increase in 
maxLVdPfdt would facilitate left ventricular ejection. 
Coronary circulation. Although left ventricular transmural 
blood flow was not affected, its distribution over the myo-
cardium changed in favour of the subepicardial layers, as 
flow to the subendocardium decreased by 30% of the pre-
drug value of 144 ± 9 mi · min- 1 • 100 g- 1 , whereas that to 
the subepicardium increased by 65% of its pre-drug value 
of 120 ± S ml· min- 1 • 100 g- 1 (Fig.1). Transmural blood 
flow was maintained despite the nicorandil-induced 
hypotension and, therefore, coronary vasodilation must 
have taken place; the calculated transmural resistance de-
creased by up to 45%. The vasodilatation was only limited 
to the subepicardial layers (60% decrease in vascular resis-
tance) as the resistance of the subendocardial layers was not 
significantly affected (Fig. 1). 
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Table 1. Systemic haemodynamics after continuous 10 min intravenous infusions ofnicorandil in 12 open-chest anaesthetized pigs 
Cumulative total dose (Jlg · kg- 1) 
co 
HR 
SV 
LVSP 
LVEDP 
maxLVdP/dt 
DAP 
MAP 
SVR 
Baseline 
2.5 ± 0.2 
104 + 5 
24 ± 2 
101 ± 5 
7.1 ± 0.7 
2630 ± 190 
69 ± 4 
87 ± 4 
37 ± 3 
Nicorandil (!lg · kg- 1 • min- 1) 
15 30 
150 450 
2.4± 0.3 2.7± 0.2 
114 ± 6• 120 ± s• 
21 ± 2 21 ± 2• 
94 ± s• 86 ± 4• 
5.6± 0.6• 5.0± 0.6• 
'3030 ±3oo• 3040 ±260• 
64 ± 4• 56 ± 4• 
81 ± s• 70 ± s• 
37 ± 5 29 ± 2• 
75 150 
1200 2700 
2.6± 0.2 2.6± 0.2 
126 ± 6• 135 ± 7• 
21 ± z• 20 ± 1• 
78 ± 3• 69 ± 2• 
3.6± o.s• 4.2± o.s• 
3120 ±38o• 3000 ±350 
47 ± 3• 37 ± 3• 
70 ± 4• 48 ± 3• 
24 ± 2• 19 ± t• 
CO =cardiac output (1 ·min-'); HR = heart ate (beats· min- 1); SV = stroke volume (rul); LVSP and LVEDP are the left ventricular 
systolic and end-diastolic pressure, respectively (mm Hg); maxLVdP/dt =maximum rate of rise ofleft ventricular pressure (mmHg · s- 1); 
DAP and MAP are the diastolic and mean arterial blood pressure (mm Hg), respectively; SVR = systemic vascular resistance (mm Hg · 1- 1 
· min); all data are mean ± SEM; • P < 0.05 vs. baseline 
Table 2. Myocardial blood flows and resistances after continuous 10 min intravenous infusions ofnicorandil in 11 open-chest anaesthetized 
pigs 
Baseline Nicorandil (!lg · kg_, . min_,) 
15 30 75 !SO 
Cumulative total dose (llg · kg- 1) !SO 450 1200 2700 
Blood flows 
left ventricle 133 ± 8 142 ± 15 149 ±17 177 ±19• 148 ±23 
right ventricle 99 ±15 122 ±10 134 ± 15 169 ±20• 164 ±26• 
left atrium 99 ±17 119 ±11 119 ±16 133 ±14 113 ±14 
right atrium 104 ±22 113 ±10 123 ±16 113 ±11 88 ±11 
Resistances 
left ventricle 0.66± 0.05 0.57± 0.06 0.51 ± O.Q7 0.36± o.os• 0.36± o.o5• 
right ventricle 1.03± 0.16 0.66± 0.07• 0.57± O.Q9• 0.41 ± 0.07• 0.37± o.o8• 
left atrium 1.00± 0.16 0.69± 0.09• 0.72± 0.17• 0.51 ± 0.09• 0.45 ± 0.06• 
right atrium 1.01 ± 0.17 0.74± 0.09 0.62± O.Q7 0.56± 0.06• 0.59 ± 0.09• 
Blood flows are in rut · min_, · 100 g _, and resistances in mm Hg · ml- 1 min · 100 g- 1 ; all data are mean ± ~EM; • P < 0.05 vs. baseline 
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Fig. 1. Left ventricular blood flow and coronary vascular resistance 
after consecutive 10 min intravenous infusions of nicorandil in 11 
anaesthetized pigs. Although transmural blood flow did not change, 
there was a redistribution in favour of the epicardium. All data have 
been presented as means ± SEM. • P < 0.05 vs. pre-nicorandil 
,'t 
Although left ventricular transmural blood flow did not 
change, myocardial oxygen consumption decreased from 
5.5 ± 0.3 to 4.1 ± 0. 7 J.lffiOl ·min - 1 · g- 1. This was reflected 
by the decrease in myocardial oxygen extraction as coronary 
venous oxygen saturation increased from 21% ± 3% to 
36% ± 4% (P < 0.05). 
Right ventricular blood flow increased dose-dependently 
up to 55%, but perfusion of the left and right atrium were 
not significantly affected (Table 2). Consequently, the de-
crease in vascular resistance was more prominent in the right 
ventricle (up to 65%) than in the right (up to 40%) or left 
atrium (up to 55%). 
Regional blood flows. Although cardiac output did not 
change during the nicorandil infusions, blood flow to some 
organs (adrenals, spleen, small intestine and brain) increased 
whereas that to others was minimally affected (liver and 
skeletal muscle) or decreased (kidneys and stomach) (Fig. 2). 
Blood flow to the stomach decreased at the lowest two con-
centrations (up to 22%), but returned towards the pre-drug 
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Fig. 2. Regional blood flows after consecutive 10 min intravenous 
infusions of nicorandil in 12 anaesthetized pigs. All data have been 
presented as means ± SEM. • P < 0.05 vs. pre-nicorandil 
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Fig. 3. Regional vascular resistances after consecutive 10 min intra-
venous infusions of nicorandil in 12 anaesthetized pigs. All data 
have been presented as means ± SEM. • P < 0.05 vs. pre-nicorandil 
Table 3. Systemic haemodynamics after consecutive 10 min intracoronary infusions of nicorandil in 5 open-<:hest anaesthetized pigs 
Baseline Nicorandil (llg · kg- 1 • min- 1) 
0.6 1.5 3.0 6.0 
co 2.9± 0.3 2.9± 0.3 2.8± 0.2 2.8± 0.2 2.9± 0.2 
HR 104 ± 7 102 ± 7 101 ± 8 106 ± 7 114 ± 9* 
sv 28 ± 3 29 ± 3 28 ± 3 27 ± 4 26 ± 4* 
LVSP 114 ± 9 110 ± 8 106 ± 6* 104 ± 6* 101 ± 6* 
LVEDP 8.3+ 0.8 7.7± 1.1 6.9± 1.1* 5.7± 1.0* 5.5± 0.8* 
maxLVdPjdt 2400 ±220 2310 ±200 2360 ±200 2400 ±190 2550 ±220 
MAP 96 ± 9 93 ± 8 90 ± 6* 89 ± 7* 86 ± 7* 
SVR 35 ± 5 34 ± 5 34 ± 4 33 ± 3 31 ± 3 
CO =cardiac output (I· min-'); HR = heart rate (beats· min- 1); SV = stroke volume (ml); LVSP and LVEDP are the left ventricular 
systolic and end-diastolic pressure (mm Hg), respectively; maxLVdP/dt =maximum rate of rise ofleft ventricular pressure (mmHg · s- 1); 
SVR =systemic vascular resistance (mm Hg ·1-1 ·min); all data are mean ± SEM; * P < 0.05 vs. baseline 
value at higher concentrations. In the small intestine, blood 
flow was significantly elevated at the highest concentration. 
In view of the hypotensive action of nicorandil, 
vasodilatation must have occurred in all organs in which 
flow was increased or remained unchanged (Fig. 3). The 
resistance of the renal vascular bed was unchanged because 
the decrease in renal blood flow paralleled the fall in 
perfusion pressure. The biphasic pattern in flow to the stom-
ach was also reflected by a vasoconstriction at low and a 
vasodilatation at high concentrations. For the small intestine 
the increase in resistance at low concentrations was not 
statistically significant. 
lntracoronary infusions ofnicorandil in anaesthetized animals 
Systemic circulation. Infusion rates up to 3 Jlg · kg- 1 • min- 1 
did not affect cardiac output, heart rate, stroke volume, 
maxL V dP fdt and systemic vascular resistance, while a slight 
( < 10%) decrease in blood pressure was observed (fable 3). 
Only left ventricular end-diastolic pressure was markedly 
affected as there was a drop from 8.3 ± 0.8 mm Hg to 
5.7 ± 1.0 mm Hg. At the highest infusion rate (6 J.Lg · kg- 1 
· min - 1) cardiac output was maintained because the slight 
increase in heart rate (10%) compensated for a similar de-
crease in stroke volume. 
Coronary circulation. In the left anterior descending coro-
nary artery (LADCA) perfused area subepicardial blood 
flow increased with the highest two infusion rates, but sub-
endocardial blood flow remained unchanged (Fig. 4). 
Consequently, the endofepi decreased dose-dependently 
from 1.15 ± 0.11 to 0.91 ± 0.08 (P < 0.05). Transmural 
myocardial resistance decreased slightly which was primarily 
due to vasodilatation in the subepicardial layers. Because the 
blood flow 
(ml.mln.-1 100g-1) 
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Fig. 4. Myocardial blood flow and coronary vascular resistance 
after intracoronary infusions of nicorandil into tbe left anterior 
descending coronary artery (LADCA) of 5 anaesthetized pigs. No 
changes were observed in tbe area adjacent to the LADCA perfused 
myocardium. The intracoronary infusion rates (1'8 · kg - 1 • min - 1) 
were: 0 = 0, ~ = 0.6; 111'1 = 1.5; ~ = 3.0 and • = 6.0. All data 
have been preseo.ted as means ± SEM. • P < 0.05 vs. pre-nicorandil 
slight increase in transmural blood flow was accompanied by 
a decreased coronary arterio-venous oxygen content 
difference, oxygen consumption of the LADCA-perfused 
area remained unchanged. In the different layers of the 
myocardium not perfused by the LADCA no significant 
changes in either blood flow or vascular resistance were 
observed. · 
Intravenous infusions of nicorandil in conscious pigs 
Systemic circulation. Cardiac output increased dose-de-
pendently from 3.0 ± 0.21· min- 1 to 4.0 ± 0.21· min- 1 
(P < 0.05) due to an increase in heart rate (up to 80%, 
Fig. 5), which completely negated the dose-related diminu-
tion in stroke volume from 24 ± 2 m1 to 19 ± 2 m1 
(P < 0.05, not shown). The reason for the decrease in stroke 
volume was the reduction in left ventricular end-diastolic 
pressure from 10.6 ± 0.8 mm Hg to 4.6 ± 1.0 mm Hg 
(P < 0.05) as both the reduction in blood pressure (up to 
20%) and the increase in maxLVdP/dt (up to 80%) would 
augment stroke volume. Since the decrease in blood pressure 
occurred despite an increase in cardiac output, nicorandil 
caused a vasodilatation of the systemic vascular bed. 
The immediate effects of propranolol were similar to 
those described for pentobarbital-anaesthetized pigs 
(Wolffenbuttel and Verdouw 1983): decreases in cardiac 
output (22%), heart rate (19%) and maxLVdP/dt (40%), 
increases in left ventricular filling pressure (from 10 to 
15 mm Hg) and systemic vascular resistance (27%) and no 
change in mean arterial blood pressure. After beta-
adrenoceptor blockade with propranolol, the responses of 
heart rate and maxLVdP/dt to nicorandil infusions were 
markedly attenuated, whereas those of the other variables 
were not significantly affected. 
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Fig. 5. The effects of continuous 10 min intravenous infusions of 
nicorandil witbout (0; n = 6) and after (e; n = 4) beta-
adrenoceptor blockade in conscious pigs. All data have been pre-
sented as mean ± SEM. • P < 0.05 vs. pre-nicorandil ( 0 ). 
+ P < 0.05 vs. pre-propranolol (PP) 
Discussion 
Systemic haemodynamics 
The present study in conscious and anaesthetized pigs 
confirms the potent vasodilating properties of nicorandil 
already reported by others (Uchida et al. 1978; Sakai et al. 
1981). At lower concentrations nicorandil exerted a more 
pronounced effect on preload (left ventricular end-diastolic 
pressure; LVEDP) than on afterload (systemic arterial pres-
sure) suggesting that the drug is a more potent venodilator 
than arterial dilator. This is also supported by the results 
obtained in the intracoronary infusion experiments where 
doses were increased in small steps and L VEDP already 
decreased at doses which had a negligible effect on systemic 
arterial pressure. 
In general nicorandil produced similar effects in both the 
anaesthetized and the conscious pigs. Apart from the fact 
that cardiac output increased in the conscious but not in 
the anaesthetized animals, in both conditions intravenous 
administration of nicorandil increased heart rate and 
maxLVdP/dt and decreased stroke volume, LVEDP, 
systemic vascular resistance and a:terial pressure. The 
increase in cardiac output was due to the more marked 
tachycardia in the conscious (85% after 80 J.Lg 
· kg- 1 ·min_,) than in the anaesthetized (30% after 
75 J.Lg · kg- 1 • min- 1) animals. The nicorandil-induced 
tachycardia and increase in maxLVdP/dt can be ascribed 
to a reflex activation of the sympathetic nervous system 
following the fall in arterial pressure elicited by nicorandil. 
It is to be appreciated that reflex-activity can be attenuated 
by anaesthetic agents and, therefore, the magnitude of 
tachycardia was less in the anaesthetized animals. Moreover, 
positive chronotropic and inotropic effects were sub-
stantially reduced, though tachycardia was not completely 
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eliminated, when nicorandil was administered to the con-
scious animals after beta-adrenoceptor blockade with pro-
pranolol. The propranolol-resistant tachycardia, as already 
described with a number of other vasodilators in different 
species, including man (Man in 't Veld et al. 1978; Reid 1979; 
Nakaya et al. 1983; Bolt and Saxena 1984a; Warltier et 
al. 1984), are most likely due to a withdrawal of 
parasympathetic tone. The fall in stroke volume in both 
conscious and anaesthetized pigs was apparently caused by 
the decrease in L VEDP as the nicorandil-induced reduction 
in arterial pressure and enhancement in maxL V dP/dt would 
tend to facilitate left ventricular ejection. 
Regional haemodynamics 
Although cardiac output did not change, at lower concentra-
tions there was a redistribution of blood flow in favour of 
organs such as the adrenals, spleen and brain at the expense 
of that to the stomach, small intestine and kidneys. At the 
highest concentration increases in blood flow were observed 
in the small intestine and brain, while renal blood flow was 
diminished. Except the kidneys, vascular resistance de-
creased to different degrees in all organs studied. From a 
number of studies it is abundantly clear that the direct 
vascular effects of vasodilators are modified to different 
extents by counter-regulatory mechanisms, such as tissue 
autoregulation and baroreceptor activation and, therefore, 
each vasodilating agent seems to produce a characteristic 
haemodynamic profile (see Saxena and Bolt 1987). 
The reduction in renal blood flow with nicorandil is 
similar to our previous observations with the dihydro-
pyridine calcium channel blockers nisoldipine (Dunk-
ker et al. 1986a) and nimodipine (Duncker et al. 1986b) as 
well as the pyridazi.none derivative pimobendan (V erdouw 
et a!. 1986; Duncker et al. 1986c) which were studied in 
the same animal model (anaesthetized pigs). However, in 
contrast, another dihydropyridine calcium channel blocker 
felodipine, studied in conscious renal hypertensive rabbits, 
increased renal blood flow (Bolt and Saxena 1984b). 
The effects of nicorandil and the calcium channel 
blockers on skeletal muscle blood flow also differ. Whereas 
nicorandil and pimobendan (Verdouw et al. 1986; Duncker 
et al. 1986c) did not affect muscle blood flow, it was mark-
edly increased (100% to 400%) by the calcium channel 
blockers, felodipine (Bolt and Saxena 1984b), nisoldipine 
(Duncker et a!. 1986a) and nimodipine (Duncker et al. 
1986b). 
Myocardial oxygen consumption and haemodynamics 
Although myocardial oxygen consumption decreased 
slightly left ventricular blood flow tended to increase which, 
in view of the increased coronary venous oxygen content, 
points towards a vasodilatory action of nicorandil on the 
coronary arterial bed. Despite the unchanged transmural 
blood flow there was a redistribution in favour of the sub-
epicardium which is in agreement with the observation by 
other investigators (Preuss et al. 1985). To investigate 
whether the decrease in endojepi was due to the hypotension 
and tachycardia (Domenech and Goich 1976) or to a prefer-
ence of nicorandil for the subepicardial layers, we infused 
the substance directly into a coronary artery in order to 
minimize systemic haemodynamic responses. Except for 
the highest intracoronary infusion rate, the systemic 
haemodynamic changes were minimal and transmural 
myocardial blood flow, and its distribution, of the control 
area were not affected. However, nicorandil again selectively 
increased epicardial blood flow suggesting a preferential 
susceptibility of the subepicardium to the vasodilatory ac-
tion of nicorandil. 
In conclusion, the cardiovascular profile of nicorandil 
suggests that the drug may be useful during myocardial 
ischaemia, but caution is warranted because the strong 
hypotensive action and the reflex-mediated tachycardia 
might under certain conditions, especially when the 
vasodilatory reserve of the subendocardial layers is ex-
hausted, aggravate rather than ameliorate myocardial 
ischaemia by a coronary steal. Administration of the drug 
to patients with heart failllre might also be considered. Be-
cause of the high activity of the sympathetic nervous system 
in a large number of these patients, reflex tachycardia is less 
likely to occur. Furthermore, reduction of both pre- and 
afterload by nicorandil might normalize dimensions of the 
heart and thereby reduce myocardial oxygen consumption. 
Data on renal and skeletal muscle blood flows do not show 
such a favourable action of the drug, but it is possible that 
when vascular tone of these beds is increased during heart 
failure, vasodilatation in these beds may become more prom-
inent. 
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Chapter 10 
Comparison of the systemic hemodynamic actions of dihydropyridine calcium-
channel blockers in conscious pigs with or without ~-adrenoceptor blockade. 
Introduction 
Though the calcium-channel blockers, nifedipine, nisoldipine and 
nimodipine, have greater vascular than direct cardiac actions, these drugs may 
show variations in the extent of their preferences for vascular versus cardiac 
musculature and for venous versus arterial vasculature. Nisoldipine has been 
reported to be 4 to 10 times more potent on vascular smooth muscle than 
nifedipine, while it is equipotent or less potent with respect to inhibition of 
cardiac muscle contraction (Kazda et al., 1980). Nimodipine has been claimed 
to cause vasodilation in the cerebral bed with very little effect on arterial 
blood pressure (Kazda et al., 1982). In this investigation in conscious pigs 
the effects of these calcium-channel blockers on systemic hemodynamic 
variables have been compared using cumulative intravenous infusions. Since 
these drugs often induce reflex-mediated cardiostimulation (Warltier et al., 
1984; Duncker et al., 1986, 1987b), combination of calcium antagonists with 
13-adrenoceptor antagonists may be superior to monotherapy in the treatment 
of coronary artery disease (Dargie et al., 1981; Fox et al., 1981). Therefore, 
the effects of these dihydropyridine-derivatives have also been studied in 
animals after pretreatment with propranolol. 
Materials and methods 
General 
The instrumentation of the animals has been described in detail in an 
earlier publication (Duncker et al., 1987a). After recovery from surgery at 
least 4 sessions were held to adapt the animals to the experimental and 
laboratory facilities, before the experimental protocol was executed. 
Experimental protocols 
Three consecutive 10 min intravenous infusions were used with each drug: 
0.5, 1 and 2 IJg.kg-t.min-1 for nisoldipine (n=7) and 1, 2 and 4 1Jg.kg-1.min-1 
for nimodipine (n=6) and nifedipine (n=6). At least 24 hours later these 
experiments were repeated 10 min after 13-adrenoceptor blockade with 
intravenous 0.5 mg.kg-1 + 0.5 mg.kg-1.h-1 propranolol. This dose-regimen 
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provides adequate ~-adrenoceptor blockade in conscious pigs (Duncker et al., 
1987c). 
In another series of experiments (n=9) we studied the cardiovascular 
actions of the dihydropyridine solvent to evaluate the hemodynamic stability 
of our experimental model. The amount of solvent (intravenous 10 min 
infusions of 0.1, 0.2 and 0.4 ml.min-1) corresponded with the amount of 
solvent infused during the nimodipine experiments and was twice the volume 
administered during nifedipine and nisoldipine infusions. Finally, we evaluated 
the hemodynamic stability of ~-adrenoceptor blockade after intravenous 
administration of 0.5 mg.kg-1 + 0.05 mg.kg-1.h-1 propranolol (n=6). 
In each case data were obtained at baseline and at the end (10 min) of 
each infusion period. In the propranolol-treated animals data were also 
recorded 10 min after administration of the ~-adrenoceptor antagonist at 
which time cardiovascular parameters had reached a new stable level. 
Data presentation and statistical analysis 
Data have been presented as mean ± S.E. of the mean. In general data 
have been presented as absolute values, except for the control experiments 
(Tables and 2) which have been presented in percentage changes. 
Statistical analysis was performed by use of Duncan's new multiple-range test 
once an analysis of variance (randomized block design) had revealed that the 
samples represented different populations (Steel and Torrie, 1980). P values 
of 0.05 or less (two-tailed) were considered to be statistically significant. 
Drugs 
Apart from the anesthetics during surgery and the antibiotics and heparin 
during the post-surgical period, the drugs used in this study were nisoldipine, 
nifedipine and nimodipine (Bayer AG, Wuppertal, FRG) and propranolol 
hydrochloride (ICI Farma, Rotterdam, the Netherlands). 
Results 
Hemodynamic stability of' solvent and propranolol treated animals 
Intravenous infusions of solvent did not affect any of the measured 
systemic hemodynamic parameters (Table 1). Intravenous treatment with 
propranolol reduced heart rate by 15 ± 2%, LVdP/dtmax by 26 ± 4% and 
cardiac output by 17 ± 3%, while left ventricular end -diastolic blood pressure 
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Table 1. Systemic hemodynamics during 10 min solvent infusions in 9 
conscious pigs. 
% by solvent (ml.min-1) 
baseline 0.1 0.2 0.4 
co 2.4 ± 0.1 -3 ± 2 -1 ± 3 1 ± 3 
HR 118±6 -1 ± 1 -2 ± 2 -1 ± 2 
SV 21 ± 1 -2 ± 2 1 ±2 2 ± 2 
LVdP/dtmax 3060 ± 240 -2 ± 2 2 ±3 5 ± 4 
LVEDP1 11.0 ± 1.3 0.9 ± 0.7 1.0 ± 0.4 1.0 ± 0.9 
SAP 118±2 -1 ± 1 0 ± 1 0 ± 1 
MAP 89 ± 3 -1 ± 1 0 ± 1 0 ± 1 
DAP 76 ± 3 -1 ± 1 0 ± 2 2 ± 2 
SVR 37 ± 2 3 ± 2 ±3 0 ±2 
1changes have been expressed in absolute values. CO = cardiac output (l.min-
1); HR = heart rate (beats.min-1); SV = stroke volume (ml); LVdP/dtmax = 
maximal rate of rise of left ventricular pressure (mmHg.s-1); LVEDP = left 
ventricular end-diastolic blood pressure (mmHg); SAP = systolic arterial blood 
pressure (mmHg); MAP = mean arterial blood pressure (mmHg); DAP = 
diastolic arterial blood pressure (mmHg); SVR = systemic vascular resistance 
(mmHg.l-l.min). 
increased by 4.6 ± 0.9 mmHg within 10 min after injection of the bolus. 
Mean arterial blood pressure did not change due to an increase in systemic 
vascular resistance (19 ± 6%). The propranolol-induced effects did not further 
change during the remainder of the 40 min period (Table 2). 
Nisoldipine with or without [3-adrenoceptor blockade 
Nisoldipine (0.5, 1 and 2 !Jg.kg-1.min-1) caused a dose-dependent increase 
in cardiac output (up to 71 ± 8% with the highest dose) which was entirely 
due to the increase in heart rate (up to 86 ± 12%) as stroke volume did not 
change with the lower doses and even slightly decreased after the highest 
dose (Fig. 1). In spite of the increase in cardiac output, systolic, mean and 
diastolic arterial blood pressure decreased up to 12 ± 3%, 19 ± 2% and 
23 ± 2%, respectively, due to systemic vasodilation (systemic vascular 
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Table 2. Systemic hemodynamics during propranolol infusions in 6 conscious 
pigs 
---------------------------------------------------------------------------
% by propranolol (0.5 mg.kg-1 + 0.5 mg.kg-1.h-1) 
----------------------------------------------------
baseline propranolol 10' 20' 30' 
----------------------------------------------------------------
co 2.6 ± 0.1 2.2 ± 0.1+ 0 ± 2 -1 ± 1 -1 ± 1 
HR 127 ± 7 108 ± 5+ -2 ± 1 -2 ± 1 -2 ± 2 
sv 21 ± 1 20 ± 1 3 ± 1 1 ± 1 0 ± 2 
LVdP/dtmax 3280 ± 430 2400 ± 240+ -2 ± 3 -1 ± 3 -2 ± 3 
LVEDP1 12.2 ± 0.9 16.8 ± 1.2+ -0.7 ± 0.5 0.5 ± 0.4 -0.3 ± 0.8 
SAP 122 ± 12 119 ± 10 0 ± 2 -3 ± 2 -2 ± 2 
MAP 96 ± 9 93 ± 7 0 ± 2 -4 ± 3 -2 ± 3 
DAP 84 ± 8 82 ± 6 -1 ± 2 -4 ± 4 -3 ± 3 
SVR 37 ± 4 44 ± 5• 0 ± 3 -2 ± 2 0 ± 3 
---------------------------------------------------------------------------
1changes have been expressed in absolute values. CO = cardiac output 
(l.min-1); HR = heart rate (beats.min-1); SV = stroke volume (ml); 
LVdP/dtmax =maximal rate of rise of left ventricular pressure (mmHg.s- 1); 
LVEDP =left ventricular end-diastolic blood pressure (mmHg); SAP= 
systolic arterial blood pressure (mmHg); MAP =mean arterial blood 
pressure (mmHg); DAP = diastolic arterial blood pressure (mmHg); SVR = 
systemic vascular resistance (mmHg.l-1.min). 
resistance decreased by 52 ± 3%). Since the increase in LVdP/dtmax 
(105 ± 10%) and the decrease in systemic vascular resistance would favour an 
increase in stroke volume, the slight decrease in left . ventricular 
end-diastolic pressure (-2.7 ± 1.1 mmHg) must have been responsible for the 
reduction in stroke volume after the highest dose. 
~-Adrenoceptor blockade did not much affect the nisoldipine-induced 
increases in cardiac output, despite an attenuation of the positive inotropic 
response (increase in LVdP/dtmax; Fig. I). At the highest dose the increase 
in stroke volume partly compensated for the attenuated heart rate response. 
Arterial blood pressure responses were not affected by pretreatment with 
propranolol, nor was the response of the calculated systemic vascular 
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Figure 1. 
The effects of consecutive 10 min intravenous infusions of 0.5, 1 and 
2 1Jg.kg-1.min-1 nisoldipine without ( 0; n=7) and after (e; n=6) 
13-adrenoceptor blockade with 0.5 mg.kg-1 + 0.5 mg.kg-1.h-1 propranolol in 
conscious pigs. CO = cardiac output; LVdP/dtmax. = maximal rate of rise of 
left ventricular pressure; HR = heart rate; LVEDP = left ventricular 
end-diastolic blood pressure; SV = stroke volume; MAP = mean arterial blood 
pressure; SVR = systemic vascular resistance; SAP = systolic arterial blood 
pressure; DAP = diastolic arterial blood pressure; PP = Pre-propranolol. Data 
have been presented as mean ± S.E.M.; "nisoldipine-induced changes 
statistically significant (P<0.05); •propranolol-induced changes statistically 
significant (P<0.05). 
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resistance. 13-adrenoceptor blockade abolished the reduction in left 
ventricular end-diastolic blood pressure caused by nisoldipine. 
Nimodipine with or without {3-adrenoceptor blockade 
Nimodipine (1, 2 and 4 1Jg.kg-1.min-1) caused dose-related hemodynamic 
effects that were similar to those induced by nisoldipine (Fig. 2). Only the 
responses of stroke volume and left ventricular end-diastolic pressure were 
slightly different as these parameters did not change with nimodipine. 
After 13-adrenoceptor blockade responses of cardiac output and heart rate 
were attenuated and that of LVdP/dtmax abolished. Changes in arterial blood 
pressure were not affected, nor were the actions of nimodipine on stroke 
volume. Left ventricular end-diastolic pressure tended to increase but this 
did not reach levels of statistical significance. Finally the systemic 
vasodilation was slightly attenuated. 
Ni:fedipine with or without {3-adrenoceptor blockade 
The dose-dependent actions of nifedipine (1, 2 and 4 1Jg.kg-1.min-1) were 
similar to that of the other two dihydropyridines. Increases in cardiac 
output, heart rate, LVdP/dtmax were observed, and decreases in arterial blood 
pressure and calculated systemic vascular resistance. Like nimodipine, 
nifedipine did not affect stroke volume and left ventricular end -diastolic 
pressure. After 13-adrenoceptor blockade responses of cardiac output and 
heart rate were minimally affected but that of LVdP/dtmax was blunted. The 
responses of the other variables were not affected by the presence of 
propranolol. 
Discussion 
The most prominent of the hemodynamic responses of the dihydropyridines 
was systemic vasodilation, with nisoldipine as the most potent of the three 
drugs. Probably due to the pronounced vasodilation, nisoldipine elicited also 
the most prominent cardiostimulatory action. The increase in heart rate 
might have contributed to the increase in LVdP/dtmax. However, it has been 
shown that in pigs, although under anesthesia, raising heart rate from 100 to 
160 beats.min-1 by left atrial pacing has only a minor effect on LVdP/dtmax 
(Scheffer and Verdouw, 1983). Moreover, preliminary observations from our 
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Figure 2. 
The effects of consecutive 10 min intravenous infusions of 1, 2 and 
4 IJg.kg-t.min-1 nimodipine without ( o ; n=6) or after ( e ; n=6) propranolol in 
conscious pigs. See legends of Fig. 1 for further details. 
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Figure 3. 
The effects of consecutive 10 min intravenous infusion of 1, 2 aJ 
4 iJg.kg-t.min-1 nifedipine without ( o; n=6) or after (e; n=6) propranolol 
conscious pigs. See legends of Fig. 1 for further details. 
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laboratory in conscious pigs, showed that the negative chronotropic compound 
UL-FS 49 ( 1,3,4,5-tetrahydro-7 ,8-dimethoxy-3-[3-[2-(3,4-dimethoxyphenyl)-
ethyl]methylimino]propyl]-2H -3-benzazepin -2-on hydrochloride; Kobinger and 
Lillie, 1984) reduced heart rate from 140 to 90 beats.min-1 without affecting 
LVdP/dtmax. It is therefore likely that the increase in LVdP/dtmax is 
predominantly due to direct sympathetic stimulation of the left ventricle 
rather than mediated by the increase in heart rate. Left ventricular filling 
pressure was only minimally affected by the three drugs although the 
nisoldipine-induced decrease was statistically significant. However, this 
finding has probably no major clinical implication as other substances, like 
the pyridazinone-derivatives pimobendan and UD-CG 212 Cl and the 
nitrate-like substance nicorandil which have been studied in the same model, 
reduced left ventricular filling pressure to a greater extent, while increments 
in heart rate were less (Duncker et al., 1987a) or equal (Verdouw et al., 
1987). Furthermore, when preload was elevated by propranolol none of the 
three dihydropyridines affected this parameter, in contrast to the above 
mentioned other substances. 
13-Adrenoceptor blockade did not significantly affect the vasodilatory 
responses. The increases in LVdP/dtmax were more potently attenuated than 
those in heart rate and cardiac output. An increase in heart rate in the 
presence of 13-adrenoceptor blockade has also been reported by other 
investigators (Warltier et al., 1984; Silke et al., 1986) and may be due to 
parasympathetic withdrawal (Nakaya et al., 1983). Since the left ventricle is 
only scarcely innervated by the parasympathetic system (Higgins et al., 1973), 
myocardial contractility is unable to increase through such a mechanism. Of 
the three drugs, the effects of nimodipine were affected to a greater extent 
by the presence of propranolol than were the effects of the two other 
calcium-channel blockers. 
In conclusion, the dihydropyridine calcium channel blockers (nifedipine, 
nisoldipine and nimodipine) appear potent arterial vasodilators with negligible 
cardiodepressant actions. The systemic hemodynamical profiles were very 
similar for all three drugs. In view of the reflex-tachycardia and the 
negligible negative inotropic actions these substances can be safely combined 
with 13-adrenoceptor blockade without compromising left ventricular pump 
function. 
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Systemic haemodynamic actions of pimobendan 
(UD-CG 115 BS) and its 0-demethylmetabolite 
UD-CG 212 Cl in the conscious pig 
Dirk J. Duncker, Johannes M. Hartog, 1Leon Levinsky & iPieter D. Verdouw 
Laboratory for Experimental Cardiology, Thoraxcentre, Erasmus University Rotterdam, Rotterdam, The 
Netherlands · 
1 The cardiovascular effects of the pyridazinone-derivatives pimobendan and its 0-demethyl-
metabolite UD-CG 212 Cl (2-( 4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl) 
benzimidazole HCl) were studied in conscious pigs, employing consecutive intravenous 10 min 
infusions of 10, 25; 50 and IOOJ!gkg-• min-• and 2, 4 and 8J!gkg-• min-• respectively. 
2 Pimobendan caused dose-dependent increases in LVdP/dt"""' (up to 115%) and heart rate (up to 
30%), while cardiac output was slightly elevated (up to 15%) and stroke volume decreased by 12%. 
Left ventricular end-diastolic pressure decreased in a dose-related manner from 8. 7 ± 1.0 mmHg to 
2. 7 ± 1. 7 mmHg. Mean arterial blood pressure was not signific.antly affected because systemic vascular 
resistance decreased dose-dependently up to 15%. 
3 After jJ-adrenoceptor blockade, the pimobendan-induced increases in heart rate and cardiac output 
were attenuated and the increase in LV dPfdt"""' almost abolished. The responses ofleft ventricular end-
diastolic and mean arterial blood pressure, systemic vascular resistance and stroke volume were not 
modified. 
4 UD-CG 212Cl caused dose-related increases in LVdPfdt"""' (up to 100%) and heart rate (up to 
25%). Cardiac output was minimally elevated (up tQ 8%) as stroke volume decreased dose-
dependently up to 15%. As systemic vascular resistance decreased up to 12%, mean arterial blood 
pressure was slightly reduced (5%). Left ventricular end-diastolic blood pressure decreased dose-
dependently from 9.0 ± 0.8 mmHg to 3.8 ± 1.3 mmHg. 
5 After IJ-adrenoceptor blockade, the UD-CG 212 Cl-induced increases in heart rate and LV dPfdtmax 
were attenuated and almost abolished and amounted up to 15% and 20%, respectively. The responses 
of the other systemic haemodynamic parameters were not significantly modified. 
6 We conclude that pimobendan and UD-CG 212 Clare compounds with marked positive inotropic 
and venodilator properties in the conscious pig. The attenuation of 'the inotropic effects by 
pretreatment with propranolol strongly suggests that, in the conscious pig, the jJ-adrenergic system is 
significantly involved in the positive inotropic actions. The lack of effect of jJ-adrenoceptor blockade 
on the vasodilator responses to both compounds suggest a mechanism not related to jJ-adrenergic 
activity. 
Introduction 
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The pyridazinone-derivative pimobendan (UD-
CG 115 BS) has been shown to possess veno- and 
arteriodilator as well as positive inotropic properties 
in a number of animal models (Diederen eta/., 1982; 
van Meel, 1985; Verdouw eta/., 1986; Duncker et al., 
1986). Although the precise mechanism of action of 
' Present address: Dept. of Thoracic and Cardiovascular 
Surgery, Beilinson Hospital Medical Centre, Petah Tikva, 
Israel. 
2 Author for correspondence. 
pimobendan is still largely unknown, phosphodies-
terase inhibition and an increased sensitivity of con-
tractile proteins to calcium may contribute to its 
cardiovascular actions (Riiegg eta/., 1984; Honeljiiger 
eta/., 1984; Scholz & Meyer, 1986). It has also been 
reported that UD-CG212CI (2-(4-hydroxy-phenyl)-
5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl) 
benzimidazole HCI), the 0-demethylmetabolite of 
pimobendan, is more potent at increasing myocardial 
contractile force than the parent drug itself (Scholz & 
Meyer, 1986). Confusion therefore exists as to what 
©The Macmillan Press Ltd 1987 
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extent the cardiovascular actions ascribed to pimoben-
dan are in fact secondary to the presence of the 
metabolite. In the present study we describe the 
cardiovascular actions of pimobendan and UD-
CG212Cl in the conscious pig and on the possible 
contribution of UD-CG 212 Cl to the actions of 
pimobendan. In addition, to obtain information on 
the relative contribution of factors other than those 
involving the j!-adrenergic system, we also studied the 
effects of pimobendan and UD-CG 212 Cl after 
pretreatment with propranolol. 
Methods 
General 
After an overnight fast, Yorkshire pigs (18-20 kg, 
n = 6), pretreated with a mixture of procaine pen-
icillin-G and benzathinepenicillin-G (Duplocillin, 
Gist-Brocades N.V., Delft, The Netherlands)' both 
300000units i.m., were sedated with 30mgkg- 1 
ketamine HCI i.m. (Aescoket, Aesculaap B.V., Boxtel, 
The Netherlands). The animals were intubated and 
connected to a respirator for artificial ventilation with 
a mixture of 0 2 and N20 (I : 2) to which 1% halothane 
was added. A jugular vein and common carotid artery 
were cannulated for infusion of drugs and 
measurement of mean arterial blood pressure, respec-
tively. The chest was opened via the left fifth intercos-
tal space to expose the heart. A transducer (P._,, 
Konigsberg Instruments Inc. Pasadena, California, 
USA) was implanted into the left ventricle ofthe heart 
through its apex for recording of left ventricular 
pressure. The left atrium was cannulated for recording 
of left atrial pressure which, together with the aortic 
blood pressure, was used for calibration of the Konigs-
berg transducer signals. The aorta was approached 
through the third intercostal space and an electromag-
netic flowprobe (Skalar, Delft, The Netherlands) was 
positioned around the ascending aorta. Catheters and 
wires were tunnelled subcutaneously to the back, the 
chest was closed and the animals allowed to recover. 
During the next 14 days the animals received daily 
intravenous bolus injections of 500 mg amoxicilline 
(Clamoxil; Beecham Farma B.V., Amstelveen, The 
Netherlands) and in addition, during the first week, 
500mg kanamycin (Kamynex; Gist-Brocades N.V., 
Delft, The Netherlands) to prevent infection. Daily 
flushing of catheters with an isotonic saline solution 
containing 500 iu heparin per ml (Thromboliquine; 
Organon Teknika B.V., Boxtel, The Netherlands) was 
performed to avoid clotting of blood in the lumen. 
After one week for recovery from surgery, at least 4 
sessions were held to adapt the animals to the 
experimental and laboratory facilities. The experimen-
tal protocol was executed 2-3 weeks after the opera-
tion. All tracings were on a Graphtec Linearcorder 
(F WR 3701; Ankersmit, Breda, The Netherlands). 
Arterial acid-base balance and oxygenation during the 
experiments were not significantly different from 
those observed for young conscious Yorkshire pigs by 
Lagerwey (1973): pH= 7.41 ± 0.04, Pco2 = 44 
± 4mmHg, Po2 = 87 ± 6 mmHg and Hb02-sat-
uration of 91 ± 2%. 
Experimental protocols 
Four series of experiments (6 pigs in each series) were 
performed. In two series, consecutive I 0 min infusions 
of either drug were administered. For pimobendan the 
infusion rates were 10, 25, 50 and 100!'gkg-1 min- 1 
and for UD-CG212Cl, 2, 4 and 8!'gkg- 1min- 1• 
Corresponding volumes were 0.2, 0.5, 1.0 and 
2.0mlmin- 1 and 0.5, 1.0 and 2.0mlmin- 1 for the 
pimobendan and UD-CG212Cl infusions, respec-
tively. At the end of each 10 min infusion period, when 
parameters .had reached a stable level, tracings of left 
ventricular pressure and its first derivative (LV dP/dt; 
obtained by electronic differentiation), arterial blood 
pressure, stroke volume and cardiac output were 
recorded and arterial blood samples were withdrawn 
for the determination of plasma concentrations of 
pimobendan and UD-CG212Cl. In the other two 
series of experiments the same protocols were repeated 
after jl-adrenoceptor blockade with propranolol. The 
latter was dissolved in isotonic saline and administered 
intravenously as a bolus injection of0.5 mg kg- 1 (given 
over 2 min), immediately followed by a continuous 
infusion of0.5mgkg- 1 h- 1 at a rate of0.2mlmin- 1• 
The infusions of the pyridazinone-derivatives were 
started 10 min after the bolus administration of 
propranolol. At this time haemodynamic parameters 
had reached a stable level. In other experiments we 
have shown that the isoprenaline dose-ratio for heart 
rate and LVdP/dt'""" for this dose of propranolol is 
more than 20 (unpublished data from this laboratory). 
Since the volume that was infused during propranolol 
administration was small (0.2 m1 min - 1), isotonic 
saline was not administered to the animals which did 
not receive propranolol. 
Determination of plasma concentrations 
The plasma concentrations of pimobendan and UD-
CG 212 Cl were determined by use of an h.p.l.c. assay 
with fully automated drug preconcentration on solid 
support (Roth, 1983). Briefly, the drugs were extracted 
on a reverse phase column and simultaneously precon-
centrated after injection of whole plasma. The com-
pounds were measured by means of fluorescence 
detection (332 nm/405 nm) after h.p.l.c separation on 
reversed phase ODS-hypersil (particle size; 5 I'm). The 
eluent composition was methanol/water (590/460, v/ 
v) + 2.5 g ammonium acetate per litre eluent (total 
amount 2.625 g). Post column, a mixture of methanol/ 
orthophosphoric acid 85%/water (300/100/100,vfv/v) 
was added with a flow rate of 0.2 m1 min -• via a T-
fitting in order to optimize the fluorescence (increase 
in fluorescence by a factor of 2). The lower limit of 
detection for both compounds was about I ngml- 1• 
Pimobendan and UD-CG212CI themselves were 
used as external standards. 
Statistical analysis 
Data have been presented as mean of 6 experiments ± 
s.e.mean. Statistical analysis was performed by use of 
a parametric two-way analysis of variance (ran-
domized block design), followed by the Duncan new 
multiple range test (Steel & Torrie, 1980). Statistical 
significance was accepted at P<O.OS (two-tailed). 
Drugs 
The only substances used were propranolol hydro-
chloride (ICI-Pharma, Rotterdam, The Netherlands), 
pimobendan and its 0-demethylmetabolite (2-(4-
hydroxy-phenyl)-5-(5-methyl -3-oxo-4,5-dihydro-2H-
6- pyridazinyl)benzimidazole HCI). Both of the latter 
compounds were kind gifts from Dr Karl Thomae 
GmBH, Biberach afd Riss, FRG and they were 
dissolved in a mixture of polyethylene glycol 200 and 
saline (1: 1 ). 
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Results 
Plasma concentrations ofpimobendan and UD-
CG212Cl 
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Although duration and rate of infusion of pimoben-
dan were the same as for the anaesthetized pigs 
(Verdouw eta/., 1986), the arterial plasma concentra-
tions ofpimobendan were considerably less (30- 50%) 
in the conscious animals. On the other hand, the 
concentrations of UD-CG 212 Cl were very similar in 
the two preparations. With the lowest two infusion 
rates of UD-CG 212 Cl, UD-CG 212 Cl plasma con-
centrations were similar to the UD-CG 212 Cl plasma 
concentrations measured after the highest two 
infusion rates of pimobendan (Table 1). 
Effects of pimobendan 
Pimobendan caused a mild increase in cardiac output 
(up to IS%) due to a moderate tachycardia (heart rate 
increased up to 30%), as stroke volume decreased by 
12% (Figure 1). LV dPfdt~ increased dose-dependen-
tly and was more than doubled after the highest 
infusion rate. Since mean arterial blood pressure was 
unchanged in the presence of an increased cardiac 
output, systemic arterial vasodilatation (reflected by a 
decrease in systemic vascular resistance up to 15%) 
must have occurred. The effect on the systemic venous 
Table 1 Plasma concentrations ofpimobendan and UD-CG 212 Cl after continuous intravenous IOmin infusions of 
pimobendan and UD-CG212Cl in conscious pigs 
Pimobendan {l!gkg- 1 min-') 
10 25 so 100 
Total dose administered {l!g kg-') tOO 350 850 1850 
Plasma concentration (ngml- 1) 
Pimobendan 65 ± 3* 157± 7* 364 ± 16* 828 ± 32* 
Pimobendan + 66± 3* 172± 6* 399 ± 17* 918 ± 35* 
UD-CG212CI 0±0 9± t• 14±2* 22±4* 
UD-CG212Cl + I± 1 7±2* 13 ± 2* 20± 3* 
UD-CG212Cl {l!gkg-• min-') 
2 4 8 
Total dose administered {l!g kg-') 20 60 140 
Plasma concentration (ng mJ- 1) 
UD-CG212Cl 14± t• 29± I* 62±2* 
UD-CG2t2Cl + 18 ± 2*t 33 ± t•t 70 ± 2*t 
Values are given as mean of6experiments ± s.e.mean; (-)indicates that propranolol was not present and (+)that the 
animals were pretreated with propranolol (0.5 mg kg- 1 + 0.5 nig kg- 1 h- '); • P < 0.05 versus each of the lower plasma 
concentrations in the same series of experiments. t P < 0.05 versus plasma level at comparable infusion rate without /l-
adrenoceptor blockade. 
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Figure 1 Effects of continuous intravenous 10 min infusions ofpimobendan, before (0) or after (e) jl-adrenoceptor 
blockade with propranolol, on systemic haemodynamics in conscious pigs. CO = cardiac output; HR = heart rate; 
SV =stroke volume; MAP= mean arterial blood pressure; LVdP/dt_= maximal rate of rise of left ventricular 
pressure; SVR = systemic vascular resistance. Data have been presented as mean of6 experiments with s.e.mean shown 
by vertical lines; t P < 0.05 vs pre-propranolol (PP) values; • P < 0.05 vs baseline (0). 
vasculature was, however, much more pronounced as 
left ventricular end-diastolic pressure was reduced 
from 8.7± l.OmmHg to 2.7± 1.7mmHg. 
Pretreatment with propranolol attenuated the 
increases in heart rate and cardiac output, almost 
abolished the response of LV dPfdtm~ but had no effect 
on the reductions in pre- and afterload (Figure I). 
Effects of UD-CG 212 Cl 
UD-CG212Cl (0-60ngml- 1) produced cardiovas-
cular effects similar, both qualitatively and quan-
titatively, to pimobendan (0-900ngml-'), as shown 
in Figure 2. After J;l-adrenoceptor blockade the UD-
CG212Cl-induced increases in heart rate and LVdP/ 
dtm~ were attenuated and almost abolished, respec-
tively, whereas there was no effect on the changes in 
systemic vascular resistance, mean arterial blood 
pressure or left ventricular end-diastolic pressure. 
Discussion 
In a number of animal models, pimobendan has been 
shown to dilate the venous and arterial vasculature, as 
well as exert positive inotropic and chronotropic 
effects. However, differences in the potency of this 
drug with respect to the vasodilator and cardiac 
stimulatory effects have been reported, which may be 
due to the absence or presence of anaesthesia as well as 
to differences in species. Diederen et a/. (1982) repor-
ted that in conscious dogs there was a more potent 
effect on the myocardium than on the vasculature, 
while in anaesthetized baboons prominent effects on 
both the vasculature and the myocardium were 
observed. Van Meel (1985) described in anaesthetized 
cats a strong venodilator effect besides a potent 
positive inotropic action. In anaesthetized pigs, 
pimobendan proved to be a more potent vasodilator, 
in particular of the venous bed, than a positive 
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Figure 2 Effects of continuous intravenous 10 min infusions of UD-CG 212 Cl, before (0) or after (e) fl-
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otropic agent (Verdouw et al., 1986; Duncker et al., 
186). In the present study pimobendan caused a 
·amatic increase in LV dP/dt_, while the vasodilator 
feet was primarily confined to the venous vas-
ilature. 
The use of LVdPfdt .... , as an index of myocardial 
ontractility is often subject to criticism because of its 
:pendence on heart rate, preload and afterload 
lfason, 1969). The question therefore remains to 
nat extent the increase in LVdPjdtmax induced by 
.ese pyridazinone derivatives reflects true positive 
otropy. In anaesthetized pigs we have shown that 
creasing heart rate, by atrial pacing, from I 00 beats 
in-• to 160beatsmin-• has no effect on LVdPjdtmd< 
icheffer & Verdouw, 1983). Although we have no 
1ch data in the conscious animal, it appears unlikely 
that LVdPjdt_ would more than double when heart 
rate increases only by 30%. Furthermore, the reduc-
tion in left ventricular filling pressure leads to a 
underestimation of myocardial contractility changes 
by using LVdPjdt_. 
The precise mechanism of action of the pyridazin-
one derivatives is still largely unknown. However, 
phosphodiesterase inhibition, an increased sensitivity 
of contractile proteins to calcium and a prolongation 
of duration of the action potential, allowing more 
calcium to enter the cell, have been demonstrated to be 
involved in their actions in a number of in vitro 
preparations (Riiegg et al., 1984; Honerjiiger et a/., 
1984; Berger eta/., 1985; Scholz & Meyer, 1986). The 
marked attenuation of the pyridazinones-induced 
increases in LVdPjdtmd< after pretreatment with 
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propranolol implies that in the present study the p.. 
adrenergic system, possibly via phosphodiesterase 
inhibition, contributed significantly to the actions of 
these drugs. In contrast, in pentobarbitone-anaesth-
etized pigs, JJ-adrenoceptor blockade did not modify 
the responses to pimobendan (Verdouw eta/., 1986). 
One must keep in mind, however, that in the anaesth-
etized animals, pimobendan caused not only much 
smaller increases in LVdPfdt_ compared to the 
effects in conscious animals, but also that LVdPfdt .... 
was already severely depressed (baseline 1500 mmHg s- 1 
by the presence of pentobarbitone. Barbiturates have 
been reported to decrease sympathetic outflow 
(Roberts, 1980) and this would render phosphodies-
terase inhibition less effective than in the conscious 
state with a higher JJ-adrenergic activity. Therefore, in 
the conscious pigs phosphodiesterase inhibition might 
be involved in the positive inotropic action of 
pimobendan and UD-CG 212 Cl. However, the 
increase in LVdPfdt,..,. which was insensitive to P-
adrenoceptor blockade in the anaesthetized animals as 
well as the pyridazinone-induced increase in LVdP/ 
dt .... after fj-adrenoceptor blockade in the conscious 
animals, strongly suggest that other mechanisms are 
also involved in the inotropic actions of these drugs. It 
is of interest that another pyridazinone-derivative 
(sulmazole) increased LVdPfdt,... by 75% from its 
baseline value of 2400 mmHg s- 1 in anaesthetized pigs 
(Verdouw et a/., 1981). Surprisingly the vasodilator 
actions of pimobendan and UD-CG 212 Cl were not 
affected by propranolol suggesting that these effects 
are not mediated by a fj-adrenergic mechanism. 
UD-CG 212 Cl is more potent at increasing contrac-
tile force than its parent compound (Scholz & Meyer, 
1986). In the present study UD-CG 212 Cl exerted a 
cardiovascular action similar to that of pimobendan, 
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Chapter 12 
Nisoldipine and perfusion of post-stenotic myocardium in conscious pigs with 
different degrees of concentric stenosis. 
Summary 
The effects of oral nisoldipine on the perfusion and wall function of a 
myocardial segment distal to a fixed coronary artery stenosis were studied in 
2 groups of conscious pigs with different degrees of stenosis. In group 1 
(n=S) systolic wall thickening (SWT) of the post-stenotic segment was more 
than 15% (27 ± 4%); in group 2 (n=7) SWT was less than 10% (7 ± 1%). 
The systemic hemodynamic profiles at baseline and during nisoldipine were 
similar in both groups. Dose-titrations of nisoldipine (0.24 ± 0.02 mg.kg-1 and 
0.47 ± 0.04 mg.kg-1) were performed to obtain increases in heart rate of 25% 
and 50%, respectively. These increases were accompanied by increases in 
cardiac output (up to 50%) and LVdP/dtmax (60%), while systemic vascular 
resistance (35%) and mean arterial blood pressure (10%) were reduced. Left 
ventricular systolic and end-diastolic blood pressure and stroke volume were 
not affected. 
In both groups, nisoldipine caused increases in blood flow to the 
non-stenotic area which favoured the subepicardium more than the 
subendocardium. Blood flow to the post-stenotic area of group 1 was normal 
at baseline and was only slightly enhanced (preferentially to the 
subepicardium) by nisoldipine. In the post-stenotic area of group 2 
transmural and subendocardial blood flow were lower at baseline compared to 
the control area. Nisoldipine did not affect subepicardial blood flow but 
reduced subendocardial blood flow. 
In spite of the reflex-mediated positive chronotropic actions of nisoldipine 
the acute post-stenotic systolic wall thickening was not affected by 
nisoldipine in either group. 
We conclude that, under the experimental conditions employed (concentric 
stenosis, no coronary collaterals and acute drug administration), nisoldipine 
does not have a useful effect on post-stenotic myocardial blood flow, 
particularly in animals with severe stenosis. In view of a possible resetting 
of the baroreceptors (subsiding of the tachycardia) with chronic treatment 
and the presence of eccentric stenosis in many patients, additional studies are 
warranted. 
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Introduction 
Since the myocardial vasculature possesses a great capacity for 
autoregulation, a coronary artery stenosis reduces coronary perfusion pressure 
but not necessarily perfusion (Berne and Rubio, 1979; Feigl, 1983). The 
autoregulatory capacity is most pronounced in the subepicardial layers of the 
myocardium as vasodilator reserve in these layers is greater than that in the 
subendocardium. Consequently, progressive narrowing of a coronary artery 
affects perfusion and causes ischemia in the subendocardium earlier than in 
the subepicardium. 
Until recently it was believed that during myocardial ischemia, coronary 
vasodilator reserve is completely exhausted as vasodilation in the 
post-stenotic segment is maximal (Berne and Rubio, 1979). Pharmacological 
interventions were therefore primarily aimed at reducing myocardial oxygen 
demand and at increasing myocardial oxygen supply by elevation of perfusion 
pressure or prolongation of diastolic perfusion time. Unless vasodilation at 
the site of stenosis is possible (eccentric stenosis or spasm), vasodilation is 
generally regarded as being potentially harmful since it may induce "coronary 
steal" from ischemic to non-ischemic transmurium (Warltier et al., 1980) or 
from post-stenotic subendocardium to subepicardium (Weintraub et al., 1981; 
Gewirtz et al., 1984). However, evidence is now emerging that coronary 
vasodilation may not be maximal in ischemic myocardium. In dogs (Aversano 
& Becker, 1985; Canty and Klocke, 1985) as well as in pigs (Pantely et al., 
1985) with myocardial ischemia resulting from a fixed stenosis in a coronary 
artery, intracoronary administration of adenosine can increase myocardial 
blood flow. Furthermore, during exercise-induced ischemia in dogs, both 
a2-adrenoceptor blockade (Seitelberger et al., 1986) and nifedipine (Heusch et 
al., 1987) improve blood flow to and function of the myocardium distal to the 
stenosis. 
In the present investigation we studied the effects of the dihydropyridine 
calcium channel blocker nisoldipine on regional myocardial blood flow 
distribution and function of the post-stenotic myocardium in conscious pigs 
with a fixed chronic coronary artery stenosis. To investigate the possible 
dependency of these effects upon the severity of the stenosis the animals 
were divided into two groups, one with slight or almost no and the other 
with marked attenuation of myocardial wall motion. Nisoldipine was 
administered orally in doses up to 0.5 mg.kg-1 which corresponds with doses 
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used in the clinical setting (Lam et al., 1985; Lopez et al., 1985). 
Furthermore, Drexler et al. (1986) showed that after oral administration of 
nisoldipine a more pronounced vasodilation of the coronary bed is obtained 
than after intravenous application. 
Materials and Methods 
General 
After an overnight fast Yorkshire pigs (18-20 kg), pretreated with a 
mixture of procaine penicillin-G and benzathine penicillin-G (Duplocillin, 
Gist-Brocades N.V., Delft, The Netherlands) both 300,000 units i.m., were 
sedated with 30 mg.kg-1 ketamine HCl i.m. (Aescoket, Aesculaap B.V., Boxtel, 
The Netherlands). The animals were intubated and connected to a respirator 
for artificial ventilation with a mixture of oxygen and nitrous oxide (1 :2) to 
which 1% halothane was added. A jugular vein and a common carotid artery 
were cannulated for infusion of drugs and measurement of mean arterial blood 
pressure, respectively. The chest was opened via the left fifth intercostal 
space to expose the heart. A transducer (PM, Konigsberg Instruments Inc. 
Pasadena, California, USA) was implanted into the left ventricle of the heart 
through its apex for recording of left ventricular blood pressure. The left 
atrium was cannulated for the injection of radioactive microspheres (see 
later) and for recording of left atrial pressure which, together with the aortic 
blood pressure, was used for calibration of the Konigsberg transducer signals. 
Regional myocardial function was assessed by sonomicrometry (Triton 
Technology, San Diego, Ca, USA). One pair of ultrasonic crystals (5 MHz) 
was implanted in the myocardial area perfused by the left anterior descending 
coronary artery (LADCA) to measure regional myocardial wall thickness. The 
wall thicknesses at end-diastole (EDT) and end-systole (EST) were used to 
calculate systolic wall thickening (SWT) as: 
SWT (%) = (EST - EDT)/ EDT x 100% 
and the mean velocity of SWT (Vswt) as: 
Vswt (mm.s-1) = (EST - EDT) I DS 
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where DS is the duration of systole (isovolumic contraction phase and 
ejection time). Systolic wall thickening at the time of surgery (open-chest 
state) was 32 ± 4%. 
The aorta was approached through the third intercostal space and an 
electromagnetic flow probe (Skalar, Delft, The Netherlands) was positioned 
around the ascending aorta. The proximal segment of the LADCA was 
dissected free from its surrounding tissue and a teflon constrictor, with an 
internal diameter varying from 1.0 to 2.0 rnrn, was positioned around the 
LADCA which resulted in different degrees of loss of systolic wall 
thickening. Catheters and wires were tunnelled subcutaneously to the back. 
The chest was closed and the animals allowed to recover. During the next 
two days the animals received intravenous bolus injections of 500 mg 
amoxicilline per day (Clamoxil, Beecham Farma B.V., Amstelveen, The 
Netherlands) to prevent infection. Catheters were flushed daily with an 
isotonic saline solution containing 500 I.U. heparin per ml (Thromboliquine, 
Organon Teknika B.V., Boxtel, The Netherlands) to avoid blood clotting. Prior 
to surgery the animals had been adapted to the laboratory and experimental 
facilities. An additional adaptation procedure was performed on the second 
day after surgery to confirm hemodynamic stability. This was the case in all 
but two animals showing ventricular arrhythmias (see results). On the next 
day the arrhythmias had disappeared and the experimental protocol could be 
executed. The animals were fasted for 18 hours prior to the experiments. 
All tracings were written on a Graphtec Linearcorder (F WR 3701, Ankersmit, 
Breda, The Netherlands). Arterial acid-base balance and oxygenation during 
the experiments were within the following limits: 7.37 < pH < 7.49; 
35 mmHg < PC02 < 45 mmHg; 75 rnrnHg < P02 < 95 mmHg. These values are 
in accordance with earlier reports (see Tumbleson and Schmidt, 1986). 
Regional myocardial blood flows 
Carbonized plastic microspheres (15 ± 1 (s.d) 1Jm in diameter) labelled with 
141Ce, uasn, toaRn or 90Nb (NEN Chemicals GmbH, Dreieich, FRG) and 
suspended in saline containing a drop of Tween 80, were injected in random 
order into the left atrium over a period of 30 seconds, while an arterial 
reference sample was drawn for calibration of the microsphere data. 
At the end of each experiment the animal was killed with an overdose of 
pentobarbitone sodium, the heart excised, the left anterior descending 
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Fig. 1. 
Systemic haemodynamics of untreated animals of group 1 (SWT>15%; n=6) and 
group 2 (SWT<10%; n=6). The four bars represent: baseline, 30 min, 90 min 
and 150 min after baseline, respectively. HR=heart rate; CO=cardiac output; 
LVdP/dt.,ax=maximal rate of rise of left ventricular blood pressure; 
MAP=mean arterial blood pressure; SWT=systolic wall thickening; SVR=systemic 
vascular resistance; Data have been presented as mean ± SEM. 
coronary artery (LADCA) cannulated for injection of methylene blue dye to 
delineate between LADCA and non-LADCA perfused areas, and the heart fixed 
in 10% formalin for at least 48 hours. The left ventricle was then divided 
into LADCA and non-LADCA perfused areas. To avoid mixture of both areas, 
border zone tissue was not sampled. Both areas were separated into three 
layers of equal thickness from endocardium to epicardium. Details of the 
radioactive microsphere method and of the calculation of flow data have been 
reported earlier (Saxena et al., 1980; Verdouw et al., 1985). 
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Experimental protocols 
The experiments were performed in 18 instrumented pigs. In 12 of these 
animals stability of systemic hemodynamic variables and regional myocardial 
wall function was evaluated over a 150 min period. The effects of orally 
administered nisoldipine on systemic hemodynamics, myocardial blood flows 
and regional left ventricular wall function of the LADCA perfused segment 
were studied in 15 pigs. The two doses of nisoldipine (0.24 ± 0.02 and 
0.47 ± 0.04 mg.kg-1 ) were selected in each animal prior to surgery and were 
such that elicited peak tachycardia (30-60 min after drug administration) of 
approximately 30 and 60 beats.min-1 , respectively. Measurements consisting of 
systemic hemodynamics and regional myocardial wall function were made and a 
batch of microspheres injected at baseline and at peak heart rate effect of 
the first dose of nisoldipine. In all but the first three animals systemic 
hemodynamic measurements were repeated at 30 min, 60 min and 120 min 
after peak-effect. Twentyfour hours later, when it is known that previously 
administered nisoldipine is no longer detectable in the plasma (see Duncker et 
al., 1987) the same protocol was performed, but now employing the higher 
dose of the drug. 
Data presentation and statistical analysis 
Animals were categorized into two groups defined by the loss of systolic 
wall thickening of the post-stenotic segment at the time of the experiment; 
each group was analyzed separately. Group 1 consisted of animals with a 
systolic wall thickening of 15% or more; group 2 consisted of animals with a 
systolic wall thickening of 10% or less. No animals with a systolic wall 
thickening between 10% and 15% were present. 
All data have been presented as mean ± SE of mean. Statistical analysis 
was performed using Duncan's New Multiple range-test once a parametric 
two-way analysis of variance (randomized block design) had revealed that the 
samples represented different populations. 
Drugs 
Except for the anesthetics during surgery and the antibiotics during the 
post-surgical period the only drug used in this study was nisoldipine 
(Bayer A.G., Wuppertal, F.R.G.). 
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Fig. 2. 
Effects of nisoldipine on systemic haemodynamics in group 1 (SWT>I5%; n=8) 
and in group 2 (SWT<IO%; n=7). The five bars represent: baseline <0>. 
peak-response to nisoldipine ( .) and 30 min (~). 60 min (~) and 120 min 
(rffij) after peak-response, respectively. HR = heart rate; LVdP/dtmax = maximal 
rate of rise of left ventricular blood pressure; MAP = mean arterial blood 
pressure; CO = cardiac output; SVR = systemic vascular resistance. Data have 
been presented as mean ± SEM; "P<0.05 vs baseline. 
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Results 
Arrhythmias during the post-surgical period 
Two animals died the night following surgery. Because post-mortem 
examination was negative ventricular fibrillation might have been the cause of 
death. In two other animals ventricular arrhythmias (>5 premature ventricular 
contractions.min-1) were observed during the first adaptation session after 
surgery, but not on the following days. Arrhythmias were not observed in 
any of the other animals, neither during adaptation, nor during the course of 
the experiments. 
Stability of systemic hemodynamics and regional myocardial wall function 
Hemodynamical data obtained during 150 min in which the animals received 
no treatment have been presented in Fig. 1. In both group 1 and group 2 
none of the parameters changed significantly from its baseline value during 
the course of the experiment. Moreover, there were no differences between 
the systemic hemodynamic parameters of the two groups despite the 
difference in regional systolic wall function. 
Nisoldipine-induced responses 
Systemic hemodynamics. The nisoldipine-induced increases in heart rate 
were accompanied by responses that were very similar in both groups (Fig. 2). 
Calculated systemic vascular resistance decreased dose-dependently (up to 
36 ± 4% and 37 ± 4% after the highest dose in group 1 and 2, respectively), 
-as mean arterial blood pressure was reduced from 98 ± 5 to 88 ± 5 mmHg and 
from 95 ± 4 to 83 ± 5 mmHg after the highest dose and cardiac output 
increased considerably (43 ± 5% and 46 ± 7%). The increase in cardiac output 
resulted primarily from a dose-dependent increase in heart rate (up to 
53 ± 6% and 50 ± 7%, in group 1 and 2, respectively) as stroke volume was 
unchanged from its baseline value (21 ± 1 ml and 19 ± 2 ml). Left 
ventricular systolic (124 ± 8 mmHg and 122 ± 2 mmHg) and end-diastolic 
(12.1 ± 1.0 mmHg and 12.8 ± 1.9 mmHg) blood pressure were also unchanged 
from their respective baseline values. Finally LVdP/dtmax increased 
dose-dependently up to 67 ± 8% and 53 ± 7% in group 1 and 2 respectively. 
The doses needed to elicit these responses were 
(0.22 ± 0.03 mg.kg-1 and 0.44 ± 0.05 mg.kg-1, 
(0.25 ± 0.02 mg.kg-1 and 0.51 ± 0.05 mg.kg-1, p.o.). 
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Regional myocardial blood flow (ml.min-1.100 g-1 ) responses to nisoldipine of 
the control and post-stenotic areas of group 1 (SWT>15%; n=8) and group 2 
(SWT<10%; n=7). The four columns represent: control (0), peak-response to 
nisoldipine (0.22 ± 0.03 mg.kg-1 and 0.25 ± 0.02 mg.kg-1 p.o. in group 1 and 
2, respectively; ~ ), control ( D ) and peak-response to nisoldipine 
(0.44 ± 0.05 mg.kg-1 and 0.51 ± 0.05 mg.kg-1 p.o. in group 1 and 2, 
respectively; • ). Data have been presented as mean ± SEM; ·p<o.o5 vs 
baseline; • • nisoldipine-induced response significantly different (P<0.05) from 
that in the corresponding control area; • • • nisoldipine-induced response in 
group 2 significantly (P<0.05) different from that in group 1. •P<0.05 vs 
corresponding control area. 
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Regional myocardial blood flows. Baseline myocardial blood flow values 
and the nisoldipine-induced responses in the control area of both groups were 
similar (Fig. 3). Myocardial blood flow to the control areas was 
dose-dependently enhanced in both groups (up to 76 ± 18% and 64 ± 12% after 
the highest dose in group 1 and 2, respectively). The increase in transmural 
blood flow favoured the subepicardial (96 ± 22% and 88 ± 13%, respectively) 
over the subendocardial (70 ± 21% and 40 ± 13%) layers. In the post-stenotic 
area of group 1 baseline blood flow values were very similar to those in the 
control segment, but the nisoldipine-induced responses were markedly 
different. Nisoldipine caused only slight increases in transmural (25%) and 
subepicardial (40%) blood flows; however, subendocardial flow remained 
unchanged (Fig. 3). In the post-stenotic segment of group 2 transmural and 
subendocardial blood flows at baseline were significantly lower compared with 
flows of the control area. Nisoldipine did not affect transmural and 
subepicardial blood flow but reduced subendocardial blood flow by 30% with 
the highest dose. 
Regional myocardial wall function. The effects of nisoldipine on regional 
wall function are shown in Fig. 4. In neither of the two groups myocardial 
wall thickness at end-diastole and at end-systole (baseline values: 
10.0 ± 0.8 mm and 12.8 ± 0.9 mm in group 1; 10.6 ± 1.1 mm and 
11.3 ± 1.2 mm in group 2) was affected. Systolic wall thickening (27 ± 4% for 
group 1 and 7 ± 1% for group 2 during baseline) was also not affected by the 
drug in either group. Velocity of wall thickening was enhanced in group 1 
but unaffected in group 2. 
Discussion 
In this investigation nisoldipine was administered orally at two doses which 
were titrated in each animal based on peak heart rate responses of 30 and 
60 beats.min-1, respectively. The tachycardiac effect of the lower dose (25% 
of baseline value) corresponds well with heart rate changes observed in the 
clinical setting (Silke et al., 1985; Serruys et al., 1985). Moreover, the peak 
tachycardiac responses to nisoldipine correlate with peak drug concentrations 
in the plasma (Duncker et al., 1987). 
As reported by many investigators (see Verdouw et al., 1988) we also 
observed that nisoldipine induced a pronounced systemic vasodilation, which 
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0.51 ±0.05 
Regional left ventricular myocardial wall function responses to nisoldipine of 
pigs in group 1 (SWT>15%; n=8) and group 2 (SWT<10%; n=7). The five columns 
represent: baseline CO>. peak re!Ponse to nisoldipine (•) and 30 min (l§§j), 
60 min (~) and 120 min (~) after peak-response, respectively. 
SWT = normalized systolic wall thickening; Vswt = mean velocity of wall 
thickening. Data have been presented as mean ± SEM; "P<0.05 vs baseline. 
resulted in only a moderate reduction in mean arterial blood pressure as 
cardiac output was markedly elevated. The increase in cardiac output was the 
result of a reflex-mediated increase in heart rate as stroke volume was 
maintained. Due to the baroreceptor reflex LVdP/dtmax was also .enhanced. 
Left ventricular end-diastolic blood pressure was unchanged, which is in 
accordance with reported earlier findings (see Verdouw et al., 1988). 
Nisoldipine, like other dihydropyridine calcium channel-blockers, does not have 
an effect on preload unless elevated end-diastolic pressures are present 
(Verdouw et al., 1984; Kimchi et al., 1985). In both groups the cardiovascular 
profile of nisoldipine was not different from that observed in conscious pigs 
with a normal coronary circulation (Duncker et al., 1987), which implies that 
the myocardial ischemia in the present study was not severe enough to 
produce chronic reduction in global left ventricular pump function. 
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Nisoldipine potently enhanced myocardial blood flow to the normally 
perfused areas which is in agreement with data obtained in animals with a 
normal coronary circulation (for reference see Verdouw et al., 1988) or in the 
control area of ischemic canine hearts (Warltier et al., 1981). The increase in 
blood flow favoured the subepicardial layers, a finding observed with many 
vasodilators (Verdouw et al., 1986, 1987a,b), arid this most likely resulted from 
the moderate hypotension and the reflex-mediated tachycardia (see Feigl, 
1983). 
In group 1 the stenosis did not affect basal blood flow which correlates 
well with the almost normal systolic wall thickening of the post-stenotic 
area. In group 2, however, the stenosis severely reduced systolic wall 
thickening, while basal transmural and subendocardial but not subepicardial 
blood flow were decreased. These findings are supported by Gallagher et al. 
(1985) who reported a severe impairment of systolic wall thickening in the 
presence of a coronary stenosis despite a normal subepicardial blood flow 
and subepicardial function. In the post-stenotic segment of group 1 in 
.which the stenosis caused almost no or slight loss of wall function, 
nisoldipine caused a moderate increase in transmural blood flow which was 
solely confined to the subepicardial layers. In the post-stenotic myocardial 
area of the animals in which the stenosis caused marked loss of wall function 
(group 2), nisoldipine failed to cause an increase in blood flow to the 
subepicardial layers whereas subendocardial blood flow was decreased. This 
decrease probably resulted from the hypotension and increase in heart rate. 
Although subepicardial blood flow was not affected by the drug vasodilation 
must have occurred as mean aortic blood pressure and hence perfusion 
pressure was decreased. 
Our findings lend further support to the concept that during myocardial 
ischemia due to a fixed concentric coronary artery stenosis, vasodilators, 
may not be beneficial (Weintraub et al., 1981; Gross and Warltier, 1981; 
Gewirtz et al., 1984). However, recent reports have shown that vasodilator 
reserve may be present in ischemic myocardium distal to a severe coronary 
artery stenosis and that vasodilators may improve myocardial blood flow and 
myocardial function (Heusch and Deussen, 1984; Aversano and Becker, 1985, 
Seitelberger et al., 1986; Heusch et al., 1987). The different observations in 
those studies and in the present one might be the result of (i) different 
routes of administration, (ii) absence or presence of collateral circulation and 
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(iii) different duration of ischemia. In most studies intracoronary 
administration of drugs was used to minimize systemic effects (Heusch and 
Deussen, 1984; Aversano and Becker, 1985; Canty and Klocke, 1985; Pantely et 
al., 1985; Seitelberger et al., 1986). We, on the other hand, used oral 
administration like in the clinical situation. Systemic administration of a 
vasodilator results in hypotension which together with a reflex-tachycardia 
reduces autoregulatory capacity of the myocardial vasculature especially in the 
subendocardial layers (see Feigl, 1983). Only in the study of Heusch et al. 
(1987) intravenous administration of nifedipine was employed. However, 
during exercise-induced ischemia, systemic hemodynamics of the untreated and 
the nifedipine-treated group did not differ. Furthermore, systemic 
administration of nifedipine might have enhanced blood flow through 
collateral vessels, which may be abundantly present in canine hearts. For 
example, Warltier et al (1981) observed an increase in flow to a totally 
collateral-dependent area in acutely ischemic dog hearts after intravenous 
administration of nisoldipine. Since pigs possess very few collaterals and it is 
unlikely that after induction of ischemia extensive collateral formation has 
taken place within 5 days (Ramo et al., 1970), such a beneficial effect of 
nisoldipine was not to be expected in our study. Finally, in all previous 
studies measurements were made up to maximally 3 hours after induction of 
ischemia, whereas in our study ischemia was present for more than 2 days 
when the protocol was executed. To our knowledge, no information is 
available on the extent of vasodilator reserve during prolonged (more than 3 
hours) ischemia. Therefore, it might be that in our animals vasodilator 
reserve was no longer present at the time of the experiment. 
The nisoldipine-induced responses of myocardial blood flow were not 
accompanied by a worsening of wall function in group 1 and, surprisingly, 
also not in group 2. An explanation for this observation is not readily 
found. Nisoldipine might have decreased oxygen demand of the post-stenotic 
area although the increase in heart rate suggests an increase in oxygen 
demand rather than a reduction. Another possibility arises from the 
investigation of Berdeaux et al (1984} who observed an increase in wall 
function of severely ischemic myocardium after a low dose of prenalterol, a 
13-adrenoceptor agonist, causing an increase in heart rate of 15 beats.min-1, 
while after a high dose of prenalterol an increase in heart rate of 40 
beats.min-1 was accompanied by an unchanged wall function. This suggests 
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that the reflex-mediated increase in sympathetic activity can cause an 
increase in wall function even in severely ischemic myocardium, provided that 
the increase in heart rate is minimal. In our experiments it is possible that 
these reflex-mediated chronotropic and inotropic actions of nisoldipine balance 
one another with respect to their effects on wall function. 
In conclusion, the findings in the present study, although obtained in 
normotensive animals with a normal cardiac pump function, suggest that in 
patients with myocardial ischemia caused by a concentric coronary artery 
stenosis and with few collaterals, vasodilators may not be beneficial. 
Therefore, it is important to stratify patients according to the status of their 
coronary circulation, i.e. presence or absence of collaterals and severity and 
type of stenosis. Because of its potent systemic vasodilator properties, the 
drug will most likely also be used in patients with hypertension. In view of 
this and the probable resetting of the baroreceptors, long-term studies in 
models with hypertension and myocardial ischemia appear to be worth-while. 
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Chapter 13 
Exercise-induced myocardial ischemia in pigs: cardiovascular actions of 
nisoldipine with or without ~-adrenoceptor blockade. 
Summary 
We evaluated the effects of oral nisoldipine with or without propranolol on 
exercise-induced myocardial ischemia in conscious pigs with a coronary artery 
stenosis. Treadmill-running up to 4 km.h-1 increased cardiac output (90%), 
heart rate {90%), LVdP/dtmax (80%), left ventricular systolic (15%) and 
end-diastolic blood pressure (13 ± 3 mmHg), while systolic wall thickening of 
the post-stenotic left ventricular myocardium was reduced from 29 ± 8% to 
19 ± 6%. Nisoldipine neither affected the systemic hemodynamic profile 
during exercise nor the exercise-induced reductions in myocardial wall 
function. Propranolol attenuated both the positive chronotropic and inotropic 
effects and the deterioration of wall function caused by the 
treadmill-exercise. Combined treatment with the two drugs resulted in a 
cardiovascular profile similar to propranolol during exercise, but the loss of 
wall function was now completely prevented. We conclude that, unlike 
propranolol, nisoldipine was not effective against the exercise-induced 
ischemia but may have beneficial actions when combined with [3-adrenoceptor 
antagonists. 
Introduction 
In clinical studies both [3-adrenoceptor antagonists and calcium-channel 
blockers are effective as anti -anginal agents (Prichard et al., 1970; Livesly 
et al., 1973; Kaltenbach et al., 1979). These two classes of drugs act through 
different mechanisms and in a number of studies their combination has proven 
superior to monotherapy with either class (Leon at al., 1980; Dargie et al., 
1981; Fox et al., 1981). In this respect the dihydropyridine calcium-channel 
blockers appear particularly attractive to combine with [3-adrenoceptor 
antagonists since the latter drugs block the baroreceptor reflex-mediated 
tachycardia. However, the effects of the dihydropyridines are not always 
predictable as vasodilation per se, depending on the experimental set-up and 
dose of the vasodilator used, may either induce "coronary steal" (Warltier 
et al., 1980; Weintraub et al., 1981) or increase blood flow to ischemic regions 
(Canty and Klocke, 1985; Pantely et al., 1985; Heusch et al., 1987). In the 
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present study we evaluated the effects of nisoldipine, a dihydropyridine-
derivative with potent vasodilator and minimal direct negative inotropic 
properties (Kazda et al., 1980; Duncker et al., 1987a), on systemic 
hemodynamics and post-stenotic myocardial wall function during 
exercise-induced myocardial ischemia in pigs with a subacute coronary artery 
obstruction. Since nisoldipine may be used in the clinical setting in 
combination with ~-adrenoceptor antagonists, we also investigated the actions 
of nisoldipine in the presence of propranolol. 
employed in view of the clinical use of these drugs. 
Methods and Materials 
Oral administration was 
Surgical procedure for instrumentation and coronary artery stenosis 
After an overnight fast 9 Yorkshire pigs (18-20 kg), pretreated with a 
mixture of procaine penicillin-G and benzathine-penicillin-G (Duplocillin, 
Gist-Brocades N.V., Delft, The Netherlands) both 300,000 units i.m., were 
sedated with 30 mg.kg-1 ketamine HCl i.m. (Aescoket, Aesculaap B.V., Boxtel, 
The Netherlands). The animals were intubated and connected to a respirator 
for artificial ventilation with a mixture of oxygen and nitrous oxide ( 1 :2) to 
which 1% halothane was added. A jugular vein and common carotid artery 
were cannulated for infusion of drugs and measurement of arterial blood 
pressure, respectively. The chest was opened via the left fifth intercostal 
space to expose the heart. A transducer (P4.~, Konigsberg Instruments Inc. 
Pasadena, California, USA) was implanted into the left ventricle of the heart 
through its apex for recording of left ventricular pressure. The left atrium 
was cannulated for recording of left atrial pressure which, together with the 
arterial blood pressure, was used for calibration of the Konigsberg transducer 
signals. Regional myocardial function was assessed by sonomicrometry (Triton 
Technology, San Diego, Ca, USA). A pair of ultrasonic crystals (5 MHz) was 
implanted in the left ventricular myocardial segment perfused by the left 
anterior descending coronary artery (LADCA) to measure regional myocardial 
wall thickness. The wall thickness at end-diastole (EDT) and end-systole 
(EST) were used to calculate percentual systolic wall thickening (SWT) as 
reported earlier (Verdouw et al., 1983). Subsequently, the aorta was 
approached through the third intercostal space and an electromagnetic flow 
probe (Skalar, Delft, The Netherlands) was positioned around the ascending 
aorta. The proximal segment of the LADCA was dissected free from its 
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surrounding tissue and a teflon constrictor with an internal diameter varying 
from 1.0 to 2.0 mm was positioned around the LADCA which resulted in a loss 
of systolic wall thickening to different degrees. Lastly, catheters and wires 
were tunnelled subcutaneously to the back and the chest was closed. The 
animals were allowed to recover from the surgery for 7-8 days during which 
they were adapted to the laboratory facilities. 
During the postoperative period the animals received daily intravenous 
bolus injections of 500 mg amoxicilline (Clamoxil, Beecham Parma B.V., 
Amstelveen, The Netherlands) to prevent infection. The catheters were 
flushed daily with an isotonic saline solution containing 500 I.U. per ml 
heparin (Thromboliquine, Organon Teknika B.V., Boxtel, The Netherlands) to 
avoid clotting of blood in the lumen. 
Experimental protocol 
This study in conscious instrumented pigs with a fixed coronary artery 
stenosis was conducted in two parts: one part dealt with the effects of 
nisoldipine on exercise-induced changes in systemic hemodynamic variables and 
post-stenotic myocardial wall motion in control (untreated) animals and the 
other part dealt with similar effects of nisoldipine in animals treated with 
propranolol. For the first part of the study the animals were placed on a 
treadmill and systemic hemodynamic variables and post-stenotic myocardial 
wall motion were recorded. The speed of the treadmill was gradually 
increased first to 3 km.h-1 and then to 4 km.h-1. These speeds were 
maintained for a period of 2 min each during which hemodynamic variables 
became stable and data were collected. Both systemic hemodynamics and wall 
thickness variables returned towards baseline values within 60 min after 
cessation of the treadmill-running. Subsequently, the animals were orally 
administered 10 mg (0.54 ± 0.01 mg.kg-1) of nisoldipine and, at the 
drug-induced peak-response of systemic hemodynamic parameters (30-60 min 
after administration), measurements were made and the exercise protocol 
repeated. 
For the second part of the study the first exercise-test was performed 
60 min after treating the animals with 80 mg (4.36 ± 0.10 mg.kg-1) 
propranolol. In a pilot-study (n=3) we established the extent of 
~-adrenoceptor blockade at various times after oral administration of 80 mg of 
propranolol; the tachycardiac responses to isoprenaline (0.1 ~g.kg-1; i. v.) were 
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37 ± 3 beats.min-1 at baseline and 26 ± 6, 14 ± 1, 6 ± 4, 14 ± 7 and 
7 ± 4 beats.min-1 at 30, 60, 120, 180 and 240 min after propranolol 
administration. After a 60 min period of recovery from treadmill-exercise 
nisoldipine (10 mg) was administered and, approximately 30-60 min later (at 
nisoldipine peak-effect), exercise-tests were again performed. The two parts 
of the study, as outlined above, were executed on consecutive days, but the 
order of the two parts was varied. We have shown earlier that nisoldipine 
(10 mg orally) is completely eliminated from the plasma within 24 hours after 
administration (Duncker et al., 1987a). Furthermore, the isoprenaline-induced 
increases in heart rate had returned to baseline levels 24 hours after 
administration of 80 mg of propranolol orally: 37 ± 3 beats.min-1 at baseline 
versus 33 ± 4 beats.min-1 24 hours after propranolol. We did not perform 
control experiments to establish the reproducibility of the exercise-induced 
responses, but studies in dogs (Matsuzaki et al., 1984a) reveal that the 
responses are identical during exercise performed 3 hours after the first 
exercise test. 
Two of the 9 animals, which did not run on the treadmill satisfactorily, 
were excluded from the study protocol. Arterial blood pressure measured with 
a fluid-filled catheter could not be obtained during the exercise period due to 
disturbances in the signals induced by the running; this parameter was 
therefore excluded from analysis. 
Drugs 
Except for the anesthetics during surgery and the antibiotics, the only 
drugs used in this study were nisoldipine (Bayer A.G., Wuppertal, F.R.G.) and 
propranolol hydrochloride (ICI-Farma, Rotterdam, The Netherlands). 
Data presentation and statistical analysis 
All data have been presented as mean ± SE of mean. Statistical analysis 
was performed using Duncan's New Multiple range test once a parametric 
two-way analysis of variance (randomized block design) had revealed that the 
samples represented different populations. 
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Fig. 1. 
Systemic haemodynamic effects of exercise without and after medication with 
nisoldipine, propranolol or their combination. HR=heart rate; CO=cardiac 
output; SV=stroke volume. *P<0.05 vs corresponding pre-exercise; *"P<0.05 
pre-exercise after medication vs pre-exercise without medication; +,x,o 
exercise-induced response after medication significantly different (P<0.05) from 
exercise without treatment (+), after nisoldipine (x), or propranolol (O). 
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Results 
Blood chemistry 
Arterial acid-base balance and oxygenation at the time of the experiments 
were within the following limits: 7.37 < pH < 7.50; 35 mmHg < PC02 < 
45 mmHg; 75 mmHg < P02 <95 mmHg, corresponding well with earlier reports 
(Tumbleson and Schmidt, 1986). 
Arrhythmias during the post-surgical period 
In two animals ventricular arrhythmias (>5 min-1) were observed during 
the first adaptation session after surgery but not on the following days. 
Arrhythmias were not observed in any of the other animals, neither during 
adaptation, nor during the course of the experiments. 
Exercise without treatment 
The exercise-induced changes observed in our study are very similar to 
those reported by other investigators (Sanders et al., 1977). Treadmill 
exercise up to 4 km.h-1 almost doubled heart rate, cardiac output and 
LVdP/dtmax as those parameters had increased at the highest running speed 
by 91 ± 6%, 92 ± 8% and 83 ± 11%, respectively. Increases were also observed 
in left ventricular end-diastolic blood pressure (from 7 ± 1 to 20 ± 4 mmHg) 
and left ventricular systolic pressure (15 ± 3%), while stroke volume was 
minimally affected (Figs. 1 and 2). Treadmill-running caused speed-dependent 
reductions in systolic wall thickening (from 29 ± 8% to 19 ± 6% at 4 km.h-1 ) 
which were primarily due to the decrease in end-systolic wall thickness as 
end-diastolic wall thickness was not significantly affected (Fig. 3). 
Exercise in the presence of nisoldipine 
During exercise in the presence of nisoldipine the hemodynamic parameters 
reached levels very similar to those obtained during the control run, except 
for left ventricular end-diastolic pressure which was, at both running speeds, 
consistently lower than in the untreated animals (Figs. 1 and 2). Since 
nisoldipine increased pre-exercise levels of heart rate, cardiac output and 
LVdP/dtmax, the exercise-induced changes in these variables after nisoldipine 
were less than those observed in the control period. Nisoldipine tended to 
reduce the exercise-induced decrease in systolic wall thickening (from 26 ± 8% 
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Systemic haemodynamic effects of exercise without and after medication with 
nisoldipine, propranolol, or their combination. LVdP/dtmax=maximal rate of 
rise of left ventricular pressure; LVSP=left ventricular systolic blood pressure; 
LVEDP=left ventricular end -diastolic blood pressure. *P<0.05 vs corresponding 
pre-exercise; **P<0.05 pre-exercise after medication vs pre-exercise without 
medication; +,x.o exercise-induced responses after medication significantly 
(P<0.05) different from exercise-induced responses without treatment (+), after 
nisoldipine (x), or propranolol (0). 
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to 19 ± 8%) but this effect did not reach levels of statistical significance 
(Fig. 3). 
Exercise in the presence of propranolol 
After ~-adrenoceptor blockade with propranolol the exercise-induced 
increases in heart rate (up to 81 ± 11 %), cardiac output (82 ± 13%) and 
LVdP/dtmax (38 ± 5%) were lower than those observed during exercise without 
medication. Stroke volume increased more (P<0.05) than in the untreated 
animals, while the responses of left ventricular end-diastolic pressures were 
similar (Figs. 1 and 2). Propranolol also significantly reduced the 
exercise-induced loss of wall function as systolic wall thickening decreased 
only from 29 ± 8% to 24 ± 7% (Fig. 3). 
Exercise in the presence of propranolol and nisoldipine 
Systemic hemodynamic parameters reached levels similar to those obtained 
during exercise-tests in propranolol-treated animals (Figs. 1 and 2). However, 
the combination completely prevented the exercise-induced loss of wall 
function of the post-stenotic segment (Fig. 3). 
Discussion 
Systemic hemodynamics 
The exercise-induced responses of systemic hemodynamics were very similar 
to those described for exercising pigs with a normal coronary circulation 
(Sanders et al., 1977; Scheffer and Verdouw, 1983) or with a gradually 
occluded coronary artery (Bloor et al., 1984; White and Bloor, 1986). The 
increase in cardiac output was almost exclusively due to the tachycardia as 
stroke volume remained virtually unchanged. LVdP/dtmax was markedly 
enhanced indicating that global left ventricular function increased. Left 
ventricular systolic pressure was slightly elevated, while a pronounced 
increase in left ventricular end-diastolic pressure was observed. 
The pre-exercise cardiovascular actions of nisoldipine, propranolol or their 
combination under resting conditions are in accordance with the findings of 
other investigators (Warltier et al., 1984; Scriabine and Taylor, 1984; Silke 
et al., 1985, 1986) as well as those from our laboratory (Duncker et al., 
1987a,b). Despite the changes induced by nisoldipine at rest, during exercise 
the systemic hemodynamic variables reached levels that were similar in 
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Effects of exercise on post-stenotic wall function in the absence or presence 
of medication with nisoldipine, propranolol, or their combination. MWT=left 
ventricular myocardial wall thickness; EST = end-systolic thickness; EDT = 
end-diastolic thickness; SWT= normalized systolic wall thickening. *P<O.OS vs 
corresponding pre-exercise; **P<O.OS pre-exercise after medication vs 
pre-exercise without treatment; +,x exercise-induced responses after 
medication significantly (P<O.OS) different from exercise-induced responses 
without treatment (+), or after nisoldipine (x). 
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untreated and nisoldipine-treated animals. Only left ventricular systolic and 
end-diastolic pressures were lower when compared to the group without 
medication. Another dihydropyridine-derivative, nifedipine, has also been 
shown not to modify the changes in systemic hemodynamic variables during 
exercise in dogs with critical coronary stenosis (Heusch et al., 1987). In 
contrast, Silke et al. (1985, 1986} reported that during exercise 
nisoldipine-treated patients with coronary artery disease achieved higher heart 
rate levels but had a lower arterial blood pressure than untreated control 
patients. These patients were apparently subjected to a mild exercise, as 
heart rates of only 100 beats.min-1 were reached during the control-exercise 
period. At such a low level of exercise the baroreceptor-reflex is still 
operative so that nisoldipine could induce further tachycardia. 
Pretreatment with propranolol attenuated but not completely eliminated the 
exercise-induced increases in heart rate, cardiac output, LVdP/dtmax and left 
ventricular systolic blood pressure. These findings, suggesting the 
involvement, at least in part, of the withdrawal of parasympathetic tone 
during exercise, are in agreement with data reported earlier in dogs with 
propranolol (Heyndrickx et al., 1980) and atenolol (Matsuzaki et al., 1984b). 
Combined treatment with nisoldipine and propranolol resulted during exercise 
in a hemodynamic state similar to that obtained after propranolol alone. 
Silke et al. (1986) observed in their patients that addition of nisoldipine to 
metoprolol caused an increase in cardiac output, heart rate and stroke volume. 
The reason for this observation might again be the low exercise level to 
which their patients were subjected and at which the baroreceptor-reflex 
(parasympathetic withdrawal) is still operative. 
Regional myocardial wall function 
None of the drug regimen caused a significant increase in wall function at 
rest, but different patterns emerged during exercise. In our study nisoldipine 
was ineffective in antagonizing the exercise-induced decrease in systolic wall 
thickening. In contrast, Heusch et al. (1987) observed an improvement of 
myocardial performance after nifedipine in exercise-induced myocardial 
ischemia in dogs. The reason for the difference in observations may be that 
pigs, unlike dogs, possess few native coronary collaterals. Our experiments 
were performed 7-9 days after implantation of a constrictor which caused 
severe impairment of wall function (systolic wall thickening less than 15%) in 
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only two out of seven animals. Since myocardial ischemia is an important 
inductor of collateral formation it is not likely that extensive collateral 
formation took place in most animals in this study. Warltier et al. (1981) 
have also shown that in anesthetized dogs nisoldipine increased blood flow to 
a myocardial area totally dependent upon collateral circulation. Therefore, 
the reason for the difference between our observations and those of Heusch 
et al. (1987) might be related to the absence of extensive coronary 
collaterals in our animals. 
As we found in this study with pigs, 13-adrenoceptor antagonists have been 
shown to be effective against myocardial ischemia induced by treadmill-
exercise in dogs (Kumada et al., 1980; Matsuzaki et al., 1984b; Tomoike et al., 
1987). This beneficial effect is most likely due to a reduction in heart rate 
(Guth et al., 1987) which not only decreases myocardial oxygen demand but 
also prolongs the diastolic coronary perfusion time to improve myocardial 
blood flow, especially to the subendocardial layers (Schamhardt et al., 1981; 
Saxena, 1983; Guth et al., 1987). Though propranolol effectively antagonized 
(but not eliminated) the exercise-induced loss of systolic wall function, 
nisoldipine did not. The reason for this difference in the efficacy of the two 
drugs may lie in their respective pharmacological profile. Propranolol can 
decrease myocardial oxygen demand (due to negative chronotropic and 
inotropic effects) as well as enhance blood supply to the jeopardized 
myocardium (due to increased diastolic perfusion time; Schamhardt et al., 
1981). In case of nisoldipine the decrease in myocardial oxygen demand (due 
to peripheral vasodilation) can be offset by an exercise-induced increase in 
sympathetic activity. Since the last effect is antagonized by propranolol, the 
combination of the two drugs may be more effective in averting the 
deterioration of systolic wall function of post-stenotic myocardium during 
exercise. Indeed, this seems to be the case in our experiments where after 
propranolol alone the animals did show some deterioration in systolic wall 
thickening in the post-stenotic myocardium during treadmill exercise; such 
changes were completely prevented after the combined treatment with 
propranolol and nisoldipine. 
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14.1 Methodological considerations 
The experimental animal 
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The experimental animal used in the studies presented in this thesis was 
the farm-bred Yorkshire pig. The use of swine in scientific research has 
increased rapidly over the last decade. Ample studies demonstrate that the 
pig is closely related to the human, anatomically and physiologically (Pond 
and Houpt, 1978; Sack, 1982; Swindle and Bobbie, 1983; Peng et al., 1983; 
Pluth, 1983; Swindle, 1984). From a cardiovascular point of view the 
similarities in size and distribution of coronary arteries (Weaver et al., 1986), 
blood pressure and heart rate (Smith et al., 1964), plasma lipoprotein profile 
(Mahley and Weisgraber, 1974) and responses to hyperlipidemic diets (Thomas 
et al., 1983) are of interest. In pigs atherosclerosis occurs spontaneously 
(Skold and Getty, 1961) and can also be easily induced (Thomas et al., 1983). 
However, for cardiovascular studies in vivo the dog is perhaps still the most 
often employed animal, partly because it is easier to handle. However, a 
disadvantage of the dog for cardiovascular research is that it has an 
extensive native collateral circulation in the heart and even complete 
occlusion of coronary arteries may result in no infarction or variable infarct 
sizes (Schaper, 1971). In contrast pigs, like humans, possess very few native 
collaterals; the formation of new collaterals can, however, be easily induced 
(Ramo, 1970; Millard, 1981). Moreover, for exercise studies, swine compare 
more favorably to human than dogs with respect to heart weight-body weight 
ratio, V02max, cardiac index, regional distribution of cardiac output and 
acid-base balance (see Mckirnan et al., 1986). 
The experiments in this thesis were performed in anesthetized as well as 
conscious animals. The anesthetized animal model can be used for acute, 
relatively short-lasting experiments with drugs administered intravenously or 
intra-arterially (intracoronary or intracarotid). However, the presence of 
anesthesia may interfere with the autonomic regulation of the cardiovascular 
system and, therefore, may alter the actions of drugs. For example, 
pentobarbital anesthesia is known to reduce inotropy of the heart (Sawyer 
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et al., 1971) which is an undesirable action especially in a model of 
myocardial ischemia. Also, the baroreceptor reflex appears to be attenuated 
in the presence of barbiturates (Roberts, 1980; Montgomery et al., 1982; 
Zimpfer et al., 1982). Although the conscious animal model is more laborious 
than the anesthetized model, it enables chronic studies, exercise studies, or 
studies in which oral administration of a drug is employed. Furthermore, in 
conscious animals there is no interference of anesthesia with circulatory 
dynamics. 
Model tor the study of myocsrdlsl lschemls 
Myocardial ischemia has been defined as the imbalance between the supply 
of oxygenated blood and the oxygen requirements of the myocardium. The 
consequence of this imbalance is: 1) a lack of oxygen and metabolic substrates 
for the production of energy in the form of high energy phosphates such as 
adenosine triphosphate (ATP) and creatine phosphate and 2) the diminished 
"wash out" of metabolites of the ensuing anaerobic glycolysis. Anaerobic 
glycolysis is insufficient to meet the energy requirements of the myocyte. 
Furthermore, the accumulation of metabolic products, such as lactate, H+ and 
purine bases in the heart inhibits anaerobic glycolysis and other metabolic 
pathways. 
Functional features of myocardial ischemia are: 1) loss of contractile 
function (within seconds after a flow reducing intervention) and 2) electrolyte 
and electrophysiological changes which may lead to rhythm disturbances (Hillis 
and Braunwald, 1977). In this thesis we used systolic wall thickening as a 
measure of regional myocardial function. Systolic wall thickening of the left 
ventricle is a good measure of local myocardial function (Sasayama et al., 
1976) which is closely related to disturbances in oxygen demand/oxygen supply 
(Kerber et al., 1975; Verdouw et al., 1980; Ross and Franklin, 1976). Another 
measure of myocardial ischemia, frequently used in the clinical setting, are 
ST-segments changes. Although ST-segment changes are used to quantitate 
infarct size (Maroko et al., 1972) poor correlations have been reported 
between ST-segment changes and infarct size or the severity of myocardial 
ischemia (Vincent et al., 1977). Metabolic markers (lactate and 
hypoxanthines) have also been used as a measure of the severity and extent 
of myocardial ischemia (Parker et al., 1969; Opie et al., 1973; Remme et al., 
1977) but they have the disadvantage of being time-dependent as their 
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production fades during prolonged ischemia (Rovetto et al., 1975; De Jong 
et al., 1977; Verdouw et al., 1979), probably due to deterioration of cell 
function. 
In chapters 12 and 13 we investigated the effects of nisoldipine on 
perfusion and/or wall function of a myocardial area distal to a coronary 
artery stenosis in the proximal part of the left anterior descending coronary 
artery. The stenosis was produced by use of a teflon ring, implantation of 
which resulted in a fixed concentric obstruction. In a clinical study by 
Vlodaver and Edwards (1971) 30% of all (200) atherosclerotic lesions studied 
at autopsy were of the concentric type, whereas 70% belonged to the 
eccentric type, either polymorphous or slit-like. In contrast to eccentric 
stenoses, the vessel in the case of concentric obstructions is circumferentially 
affected by the atherosclerotic process and responds less well to vasodilatory 
interventions than eccentric stenoses (see Lichtlen and Ebner, 1986). 
Another important factor that determines the effectiveness of vasodilatory 
treatment is the presence or absence of collateral vessels supplying the 
post-stenotic myocardium. In the experiments described in chapter 12 the 
stenosis in the animals was present for a period of 5 days which is not 
sufficient to allow significant collateral formation (Ramo et al., 1970). In 
pigs with a longer period of stenosis (7-9 days) as used in chapter 13, 5 out 
of 7 animals showed no signs of myocardial ischemia under resting conditions. 
Since myocardial ischemia is a potent inductor of collateral formation 
(Schaper, 1971), it is not likely that an extensive collateral circulation was 
present in that group of animals. In a clinical study by Schwartz et al. 
(1978) collaterals were not observed when the stenosis obstructed less than 
90% of the cross-sectional area of the coronary arterial lumen. With a 
stenosis of 90% to 99% of the luminal area, 22% of the patients demonstrated 
collaterals; of patients with a complete occlusion, 83% showed collateral 
supply. In another study {Kober et al., 1978) collaterals were not present 
when the stenosis was less than 60%; half the patients, with a stenosis of 
90% to 99%, showed collaterals and again with complete coronary occlusion 
collateral vessels were apparent in nearly all patients. These clinical data 
correspond well with experimental findings (Schaper and Wusten, 1979; 
Marcus, 1983) in which collateral formation becomes apparent when the 
stenosis has reduced the luminal area for more than 80%-90%. At this stage 
the vasodilator reserve of the post-stenotic bed is exhausted even at rest {see 
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Klocke et al., 1987) and myocardial ischemia will ensue, reflected by a loss of 
wall function (Schwartz et al., 1978), thereby promoting collateral-formation. 
In the above mentioned clinical studies (Schwartz et al., 1978; Kober et al., 
1978) no collaterals could be visualized in approximately 30% of all patients. 
In the study of Kober et al. (1978) 30% of all patients had an obstruction in 
the left anterior descending coronary artery, without concomitant 
atherosclerotic processes in other coronary vessels, or collaterals. In the 
study by Schwartz et al. (1978), 50% of patients with one-vessel disease had 
no collaterals. In view of the above findings in patients with coronary artery 
disease, our model seems to correlate well with a subgroup of patients who 
have one-vessel disease and no or few collaterals. 
In chapter 13 acute myocardial ischemia was induced by exercise on a 
treadmill one week after surgery. The animals were adapted to the laboratory 
facilities prior to the operation and during the post-surgical period but were 
not trained on the treadmill to avoid a training-effect per se. We know 
from earlier experiments in our laboratory (Scheffer and Verdouw, 1983) as 
well as from other reports (Sanders et al., 1978; Moores et al., 1986) that 
pigs can be easily trained to perform treadmill exercise. Six out of 9 animals 
performed the complete exercise protocol on the first day, while in one 
animal the first day exercise-adaptation was necessary. In two animals no 
exercise-protocol could be executed because the animals were incapable of 
running at a constant pace and they were excluded from further study. In 
only two out of the seven animals employed in the exercise-protocol the fixed 
stenosis caused a significant loss of systolic wall· function at rest and 
therefore collateral circulation may have been present in these two animals. 
However, based on the findings by Ramo et al. (1970) the collateral 
circulation would probably not have been extensive after 1 week of 
implantation of the constrictor. This also suggests that our animal 
experimental model mimics patients with one-vessel disease with only poor or 
no collateral formation. 
14.2 Systemic hemodynamic actions of vasodllating drugs in conscious pigs. 
In order to facilitate the comparison of the systemic hemodynamic actions 
of the substances studied in this thesis the relative changes of the different 
systemic hemodynamics have been depicted along the diagonals of a hexagon 
(Fig. 1). One must be careful when using percentage changes from baseline 
SVR 
(- .6. O/o) 
MAP 
(- ~ 0/o) 
Fig. 1 
HR 
(~ O/o) 
LVEDP 
(- .0. mmHg) 
co 
(.6. O/o) 
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LVdP/dtmax 
(.6. o/o) 
Schematic representation of the effects on systemic hemodynamic parameters 
as used in Figs 2 and 3. HR = heart rate; CO = cardiac output; LVdP/dtmaz = 
maximal rate of rise in left ventricular pressure; LVEDP= left ventricular 
end-diastolic pressure; MAP = mean arterial pressure; SVR = systemic vascular 
resistance. All changes have been expressed as percentage change from 
baseline (as specified for heart rate), except LVEDP. The changes in the 
latter have been expressed in absolute values because of the marked effect 
of 13-adrenoceptor blockade on this parameter. 
as an indicator of the magnitude of the response of a parameter because such 
changes depend on the baseline values. Therefore a minimum requirement is 
that the respective baseline values of a parameter are similar for each drug. 
No significant differences between any of the baseline values of the 
parameters existed before 13-adrenoceptor blockade. 13-adrenoceptor blockade 
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Fig. 2 
Without 
beta·adrenoceptor blockade 
(1) (2) 
(2) (4) 
(2) (4) 
Nisoldipine 
Nifedipine 
Nimodipine 
After 
beta·adrenoceptor blockade 
(1) (2) 
(2) 
(2) (4) 
Systemic hemodynamic responses to three dihydropyridines without and after 
13-adrenoceptor blockade in conscious pigs. See Fig. 1 for explanation of the 
diagrams. The numbers in parenthesis indicate the infusion rate of the drugs 
in !Jg.kg-l.min-1. 
had a relatively minor effect on all parameters except for LVEDP. The 
changes in the latter have therefore been expressed in absolute values to 
allow comparison between the hemodynamic actions of a drug without and 
after 13-adrenoceptor blockade. Inspection of Fig. 2 reveals that in conscious 
pigs the dlhydropyridines nisoldipine, nimodipine and nifedipine have simi.lar 
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systemic hemodynamic profiles, with arteriodilation (indicated by the decrease 
in systemic vascular resistance) being the most prominent feature, but that 
Fig. 3 
Without 
beta·adrenoceptor blockade 
(40) (80) 
(25) (100) 
(2) (8) 
Nicorandil 
Pimobendan 
UD·CG 212 Cl 
After 
beta·adrenoceptor blockade 
(40) (80) 
(25) (100) 
(2) (8) 
Systemic hemodynamic responses to nicorandil, pimobendan and UD-CG 212 Cl 
without and after 1)-adrenoceptor blockade in conscious pigs. See Fig. 1 for 
explanation of the diagrams. The number in parenthesis indicate the infusion 
rate of the drugs in IJg.kg-l,min-1 • 
they differ somewhat in potency. At variance with the data of the 
dihydropyridines are those of the three substances presented in Fig. 3. 
Nicorandil as well as pimobendan and UD-CG 212 Cl markedly decreased left 
ventricular filling pressure, indicating venodilation. Because of this action 
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the increase in cardiac output was consistently less than the increase in heart 
rate with these drugs. 
c. HR C. LVdP/dtmax 
(beats/min) (mmHg/s) 
100 4000 
so 
3000 
60 
2000 
40 
1000 
20 
0 0 
0 -10 -20 -30 0 -10 -20 -30 
c. MAP (mmHg) c. MAP (mmHg) 
Fig. 4 
Changes in heart rate ( HR) and the rate of rise in left ventricular pressure 
( LVdP/dtmax) are plotted as a function of the decrease in mean arterial 
blood pressure ( MAP) for conscious pigs (open symbols) and dogs (closed 
symbols). The vasodilatory drugs were nifedipine (tJ •• ) nisoldipine (0,.) and 
nicorandil ( V , T ). The data on pigs and dogs were obtained in the 
laboratories of Dr. Verdouw (Verdouw et al., 1987, chapter 10 this thesis) and 
Dr. Gross (Warltier et al., 1984; Preuss et al., 1985), respectively. 
13-adrenoceptor blockade had no major effects on the arterio- and 
venodilatory responses of the compounds (Figs. 2 and 3), but attenuated in 
all cases the positive inotropic and also, to a large extent, the positive 
chronotropic actions. 
If we compare the actions of vasodilating drugs in conscious pigs to those 
in conscious dogs, it is clear that in both species the drop in blood pressure 
elicits a similar marked baroreceptor reflex-mediated tachycardia (Fig. 4). In 
contrast, a reflex-mediated increase in myocardial contractility is much more 
pronounced in pigs than in dogs. An explanation for this observation is not 
readily found but one of the possibilities is a denser sympathetic innervation 
in left ventricular porcine myocardium resulting in a more pronounced 
reflex-mediated increase in LVdP/dtmax. It is unlikely that these drugs exert 
a greater negative inotropic action in dogs than in pigs since after 
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pretreatment with 13-adrenoceptor blockade no significant reductions in 
LVdP/dtmax were observed in conscious dogs (not shown in Fig. 4). 
14.3 Influence of anesthesia on the systemic hemodynamic profile of 
vasodllatlng drugs. 
The influence of anesthesia on systemic hemodynamic responses to 
vasodilators are indicated in Table 1. In anesthetized animals a certain 
degree of systemic vasodilation resulted in a much greater fall in arterial 
blood pressure, apparently due to an attenuation of the baroreceptor reflex 
which prevented an increase in cardiac output. It is known for some time 
that pentobarbital anesthesia attenuates the baroreceptor-reflex (Roberts, 
1980; Montgomery et al., 1982; Zimpfer et al., 1982). In an earlier study 
TABLE 1 
Systematic hemodynamic responses induced by intravenously administered vasodilating drugs 
at comparable reductions in systemic vascular resistance1 in pigs. 
·-· lpg/kg{mln) MAP SVR co HR sv LVdP/dtmu LVEDP 
Nisoldipine A 0.25-1.0 . ' H • t ~ c 0.5-1.0 ! H • • t tt • 
Nimodipine A 0.25-1.25 H • ! ~ ! 
c 1.0-2.0 ~ H • • tt 
Nicorandil A 15-75 ., H • ! • . 'c 20-80 
• H tt tH • Ht H+ 
Pimobendan A 10-100 • • ·~ • t • t ., c 10-100 ! • ! Ht +H 
UD·CG 212CI A 0.5-8 
. ' ·~ • t ., • t .. , c 2-8 ~ • ' tH H! Abbreviations: A = anesthetized; C = conscious; MAP = mean arterial pressure; SVR = systemic 
vascular resistance; CO = cardiac output; HR =heart rate; SV = stroke volume; 
LVdP/dtmax =maximal rate of rise of left ventricular pressure; LVEDP =left ventricular 
end-diastolic pressure. 
1 Pimobendan and UD-CG 212 Cl administration in conscious pigs induced only a slight 
reduction in systemic vascular resistance. 
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Booth et al. (1960) had shown that a-chloralose anesthesia, which we 
employed in the nicorandil and UD-CG 212 Cl studies, did not affect the 
baroreceptor-reflex in pigs. The low dose of pentobarbital (5 mg.kg-1.h-1 ) 
which we added to the a-chloralose anesthesia may therefore be responsible 
for the attenuated positive chronotropic responses to nicorandil. 
At variance with the other three compounds presented in Table 1 the 
pyridazinone-derivatives showed a somewhat larger percentage increase in 
heart rate in anesthetized animals. The slightly lower baseline value in 
anesthetized pigs only partly explains this observation. Another contributing 
factor might be the minimal systemic vasodilation in conscious animals, which 
in anesthetized animals was prominent, inducing therefore only a slight 
increase in heart rate. Furthermore, it cannot be excluded that the positive 
chronotropic action of these drugs in anesthetized pigs were di.rect rather 
than reflex-mediated. The increments in heart rate were, namely, not 
affected by pretreatment with propranolol. 
Finally, in contrast with the similarities between the systemic hemodynamic 
profiles of nisoldipine and nimodipine in conscious pigs, nimodipine exerted in 
anesthetized pigs a direct cardiodepressant action while nisoldipine did not. 
Similar differences in action between nimodipine and nisoldipine have been 
reported in pentobarbital anesthetized dogs (Maxwell et al., 1982; Satoh et al., 
1984). 
14.4 Vasodllatory profile of vasodllating drugs. 
The responses of regional vascular conductances induced by five 
vasodilating drugs have been presented along the diagonals of a hexagon 
(Fig. 5). As can be seen in Fig. 6, the dihydropyridines nisoldipine and 
nimodipine caused their greatest vasodilatory response in skeletal muscles. 
Nicorandil, at the middle dose having a profile similar to nimodipine, elicited 
at the highest dose a more evenly distributed vasodilation in the peripheral 
beds. This profile at the highest dose was similar to that after the highest 
dose of pimobendan. Despite the similarity to pimobendan with respect to the 
systemic hemodynamic actions, UD-CG 212 Cl did not cause significant 
vasodilation in the left ventricular myocardium and the skeletal muscle 
vasculature. However, of all drugs studied this compound was the only 
substance that caused a slight increase in renal vascular conductance. 
Kidneys 
(.6 °/o} 
Left 
ventricle 
(.6 °/o) 
Fig. 5 
Brain 
(.6 °/o} 
400 
Skeletal 
muscle 
(.6 °/o} 
Small 
intestine 
(.6 °/o} 
Skin 
(.6 °/o} 
20S 
Schematic representation of the effects on six regional vascular conductances 
as used in Fig. 5. All changes have been expressed as percentage change from 
baseline. 
In the carotid circulation, intra-arterial infusions of nimodipine and 
nifedipine produced almost identical vasodilatory profiles (Fig. 7). Here again, 
the dihydropyridines induced the greatest response in the skeletal muscles. 
When the vasodilatory actions of nisoldipine after intravenous 
administration in anesthetized animals are compared with those of the drug 
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Nisoldipine Nimodipine Nicorandil Pimobendan UD-CG 212 Cl 
(0.25) (0.25) (30) (25) (4) 
@@@@@ 
(0.5) (1.25) (75) (50) (B) 
@@@@@ 
(1.0) 
Fig. 6 
Regional vasodilatory responses to five vasodilators. See Fig. 5 for explanation 
of the diagrams. The numbers in parenthesis indicate the infusion rates of the 
drugs in i-Jg.kg-1 .min-1 • Blood pressure reductions at each dose were, 
respectively, for nisoldipine 5, 15 and 25 mmHg, for nimodipine 21, 38 and 52 
mmHg, for nicorandil 18, 28 and 40 mmHg, for pimobendan 21, 35 and 43 
mmHg and for UD-CG 212 Cl 28, 34 and 39 mmHg. 
after oral administration in conscious pigs (Fig. 8), the most striking feature 
is the absence of preferential vasodilation in skeletal muscles in the conscious 
animals. Based on the responses of systemic vascular conductance, the 
gastrointestinal tract, left ventricle and brain responded dose-dependently. It 
is not clear whether the differences with regard to vascular conductance 
responses in the skeletal muscle, and also skin, are due to the anesthesia or 
the route of administration. A slight response of the skin vasculature to a 
vasodilator agent in conscious animals is a finding also observed with 
nisoldipine in rats (Drexler et al., 1985, 1986) and felodipine in rabbits (Bolt 
and Saxena, 1984) and is possibly due to reflex-mediated sympathetic 
vasoconstriction. Although the skeletal muscle responses might also be due to 
the absence of anesthesia, Drexler et al. (1985, 1986) also observed that in 
Fat 
Salivary 
glands 
Fig. 7 
Nimodipine 
Skeletal 
muscle 
Brain 
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Nifedipine 
Ears 
Skin 
Effects of intracarotid infusions of nimodipine (0.25 (.Jg.kg-l.min-1) and 
nifedipine (0.75 (Jg.kg-1 .min-1 ) on regional vascular conductances of ipsilateral 
tissues and organs in the pig head. Data have been expressed as percentage 
change from baseline. 
conscious rats the largest vasodilatory response in the skeletal muscle 
occurred after intravenous administration of nisoldipine. In contrast, after an 
oral dose eliciting similar systemic hemodynamic actions. the greatest 
vasodilatory response was observed in the gastrointestinal tract. These 
findings are in agreement with our data and it is therefore possible that the 
differences that we observed are due to different routes of administration 
rather than absence or presence of anesthesia. 
Finally, in contrast to some reports claiming selectivity of nisoldipine and 
nimodipine for the coronary and cerebral vascular beds, respectively (Kazda 
et al.. 1980, 1982; Serruys et al.. 1985). we observed that all three 
dihydropyridines exerted their most potent vasodilating action on skeletal 
muscle vasculature. 
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14.6 Conclusions and perspectives 
The cardiovascular responses ~nduced by the vasodilating drugs studied in 
this thesis indicate that these drugs might play a role in the treatment of 
800 1 
700* 
b.% 
400 
300 
200 
100 
0 
Fig. 8 
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Muscle Skin 
~ 0.25 0.5 1.0 0.4 
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cardiovascular disorders, in particular, coronary artery disease, hypertension 
and heart failure. 
With respect to coronary artery disease and hypertension, the 
dihydropyridines and nicorandil caused systemic and coronary arteriolar 
vasodilation. The acute administration of nicorandil and the dihydropyridines 
induced a baroreceptor reflex-tachycardia which may limit their usefulness, 
since the combination of hypotension and an increase in heart rate may lead 
to an underperfusion of the subendocardial layers in the myocardium distal to 
a coronary artery stenosis. However, during prolonged treatment with 
vasodilators the baroreceptors usually reset and the reflex-tachycardia fades 
(Kiowski et al., 1983). But, since pretreatment with the 13-adrenoceptor 
antagonist propranolol attenuated the reflex-tachycardia and in addition 
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detrimental effects on cardiac pump function and contractility were not 
observed, a combination of vasodilators and 13-adrenoceptor blockade might be 
more attractive than monotherapy with either drug. Furthermore, during 
chronic treatment with 13-adrenoceptor antagonists, after an initial 
reflex-mediated compensatory increase in systemic vascular resistance, blood 
pressure is decreased and this effect may add to the hypotensive actions of 
vasodilating drugs. 
Though most vasodilators, in particular after acute administration, cause a 
greater vasodilation in the subepicardial than in the subendocardial layers due 
to their systemic actions and the smaller vasodilatory reserve in the 
subendocardial layers, they do not seem to have an intrinsic preference for 
either layer. In this respect, an interesting observation was recently made by 
Gross and co-workers (Pelc et al., 1987) who reported that so called 
"endothelium-dependent" vasodilators (acetylcholine and ATP) preferentially 
caused vasodilation in the subendocardial regions after intracoronary 
administration whereas "endothelium-independent" vasodilators like nifedipine 
did not have such a preference. We found that the "endothelium-independent" 
vasodilator pimobendan did not have a preference, while nicorandil even 
favoured the subepicardial layers after intracoronary infusions. It might be 
speculated that, provided the systemic actions are mild, "endothelium-
dependent" vasodilators are less likely to inpuce so called "steal" distal to a 
coronary artery stenosis due to vasodilation in subepicardial layers and that 
they may favorably influence myocardial oxygen balance preferentially in the 
subendocardial layer where ischemia occurs first. Other factors that may 
determine the possible benefits of vasodilators in coronary artery disease are 
the nature of the coronary artery stenosis and the absence or presence of a 
collateral circulation. In this thesis, like in all other experimental models 
with a coronary artery stenosis, a concentric (fixed) stenosis which is not 
amenable to vasodilation was used. In the present experiments in pigs, where 
only few collaterals could have been present, nisoldipine caused an impairment 
of blood flow to the subendocardial layers during rest, whereas the drug was 
ineffective against exercise-induced ischemia. It seems therefore important to 
stratify patients on the basis of the nature of coronary stenosis (concentric 
or eccentric) and the presence of a collateral circulation in order to obtain a 
patient population that is most likely to benefit from vasodilating therapy. 
Furthermore, studies in experimental models with eccentric stenoses and/or 
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collaterals employing chronic treatment with vasodilators are necessary to 
obtain more detailed information on the possible usefulness of a certain drug 
in a particular patient population. 
In patients with heart failure a reduction in left ventricular filling 
pressure is associated with a reduction in mortality (see Packer et al., 1987). 
Therefore, it appears that nicorandil and the pyridazinone-derivatives are of 
greater promise in this disorder than are the dihydropyridines of which 
nisoldipine only after i. v. administration caused a slight decrease in filling 
pressure. The use of calcium-channel blockers has also not been advised for 
treatment of congestive heart failure in a recent review article (Packer et al., 
1987). Although the "unloading" of the heart by the pyridazinone-derivatives 
and nicorandil caused a reduction in stroke volume and/or cardiac output in 
animals with a normal circulation, in animals with failing hearts pimobendan 
unloaded the left ventricle and increased cardiac pump function, thereby 
normalizing these parameters (chapter 6). Reflex-tachycardia does not seem 
to be important in heart failure since the reduction in afterload is often 
unaccompanied by increases in heart rate due to the already enhanced 
sympathetic drive (Higgins et al., 1972; Levine et al., 1982). Furthermore, the 
increase in cardiac pump function prevents a fall in blood pressure. 
Another aspect of heart failure is the systemic arteriolar vasoconstriction 
in the peripheral vascular beds especially in the kidneys, skin, skeletal muscle 
and gastro-intestinal tract. Nicorandil and pimobendan caused vasodilation in 
the latter three beds, but failed to increase vascular conductance in the renal 
bed. On the other hand UD-CG 212 Cl increased renal vascular conductance, 
but was relatively ineffective on the skeletal muscle vasculature. 
Interpretation of these regional vasodilatory profiles of drugs that are of 
potential usefulness in the treatment of congestive heart failure must be done 
with caution since the vasodilatory profile of a drug in a normal circulation 
may not be the same as in a circulation with high vascular tone (Hof, 1983; 
Hof et al., 1985). Further research in experimental models of congestive 
heart failure seems therefore necessary to elucidate whether the drugs studied 
in this thesis still exert their potentially beneficial actions. 
Finally, marked effects of anesthesia on circulatory control mechanisms 
suggest that conscious rather than anesthetized animals should be employed in 
cardiovascular research. This seems particularly true for animal models 
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dealing with myocardial ischemia and heart failure where counterregulatory or 
compensatory mechanisms are integral parts of the profile of the disease. 
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SUMMARY 
Chapter 1 presents a brief review of literature concerning the mechanism 
of action, the vasodilator profile and some clinical uses of vasodilating drugs. 
Thereafter, this thesis describes an investigation in anesthetized or conscious 
pigs dealing with the cardiovascular pharmacology of representatives of three 
groups of vasodilating drugs. The selected drugs were: the dihydropyridine 
calcium-channel blockers nisoldipine, nimodipine and nifedipine, the 
pyridazinone-derivatives pimobendan and UD-CG 212 Cl (which may act via 
phosphodiesterase-inhibition), and the nitrate-like drug nicorandil (which also 
opens potassium-channels). 
The Vasodilator Profile of Dihydropyridine Calcium-channel Blockers 
Nisoldipine has been described as having a particularly pronounced and 
selective vasodilator action on the coronary circulation. In order to evaluate 
this claim we studied the effects of this substance on distribution of cardiac 
output. In anesthetized pigs intravenous infusions of nisoldipine caused dose-
dependent coronary and systemic vasodilation and increases in heart rate and 
LVdP/dtmax as a result of baroreceptor reflex activation (Chapter 2). 
Systemic vasodilation was most pronounced in the skeletal muscle vasculature. 
Coronary vasodilation occurred particularly in the subepicardial layers of the 
left ventricle. After pretreatment with the 13-adrenoceptor antagonist 
propranolol, vasodilator responses to nisoldipine were relatively unaffected, 
but the reflex -mediated responses were abolished. In conscious pigs 
(Chapter 3) oral administration of nisoldipine resulted in marked systemic 
vasodilation which was most pronounced in the gastrointestinal tract and 
skeletal muscles. The increase in cardiac output (reflex-mediated) prevented a 
major drop in arterial blood pressure. Probably due to the attenuated 
increase in heart rate after combined treatment with propranolol and 
nisoldipine, the subendocardial-subepicardial blood flow ratio was better 
maintained than after nisoldipine alone. 
We conclude that: (i) nisoldipine is a substance with a potent vasodilator 
action, (ii) this vasodilation is most pronounced in the skeletal muscles and, 
(iii) the drug can be safely combined with 13-adrenoceptor antagonists 
without compromising left ventricular pump function. 
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In view of the claimed selectivity for cerebral vessels and effectiveness in 
migraine, the effects of nimodipine on the distribution of cardiac output and 
carotid artery blood flow as well as on the vascular responses to 
5-hydroxytryptamine (5-HT) were evaluated (Chapters 4 and 5). Intravenous 
infusion of nimodipine caused hypotension, bradycardia and a vasodilator 
response that was most marked in the skeletal muscles. Upon intracarotid 
administration, both nimodipine and nifedipine redistributed carotid blood flow 
in favor of the capillary compartment, again particularly to the skeletal 
muscles. Intracarotid infusion of 5-HT also redistributed carotid artery blood 
flow, but in favor of the capillary blood flow to the skin. Arteriovenous 
anastomotic (AVA) blood flow was severely reduced by 5-HT, while the 
calcium-channel blockers affected it only mildly. The vasoconstrictor 
response to 5-HT was not affected by the two calcium-channel blocking drugs. 
In conclusion: (i) nimodipine lacks selectivity for the cerebral vasculature, 
(ii) the vasodilator actions of nimodipine and nifedipine are most pronounced 
in the skeletal muscles, (iii) the comparatively mild reductions in AVA 
conductance may be one of the reasons for the inability of dihydropyridine-
derivatives to abort acute attacks of migraine and (iv) in contrast to 
'in-vitro' studies, 5-HT induced vasoconstriction 'in-vivo' is antagonized 
neither by nimodipine nor by nifedipine. 
Vasodilator Profile of Pyrldazlnone-derlvatives 
In heart failure peripheral vasoconstriction may play an important role in 
maintaining or aggravating the failing state of the heart. Vasoconstriction 
may be particularly pronounced in the renal, dermal, gastrointestinal and 
skeletal muscle vasculature. We therefore evaluated the effects of the 
pyridazinone-derivatives pimobendan and UD-CG 212 Cl on cardiovascular 
dynamics, in particular the distribution of cardiac output. Intravenous 
infusions of pimobendan in anesthetized pigs caused venous and arterial 
dilation and an increase in heart rate but had only a minor effect on 
LVdP/dtmax (Chapter 6). Arterial vasodilation was most pronounced in the 
adrenals, gastrointestinal tract, skeletal muscles and myocardium 
(subepicardium > subendocardium). Intravenous bolus injection of pimobendan 
produced similar changes in all systemic and regional hemodynamic variables 
except that LVdP/dtmax now increased markedly (Chapter 7). Cardiac output 
was slightly reduced in animals with a normal coronary circulation. 
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However, in animals with an ischemic heart, the drug clearly increased both 
LVdP/dtmax and cardiac output while pre- and afterload were reduced. 
During intracoronary infusion no preference for the subepicardial layer was 
observed and the endo-epi blood flow ratio was unaffected. 
Intravenous infusion of the 0-demethyl metabolite of pimobendan, 
UD-CG 212 Cl, caused nearly similar systemic hemodynamic actions as the 
parent drug but at much lower doses (Chapter 8). The plasma concentrations 
of UD-CG 212 Cl obtained during pimobendan infusions were however too low 
to ascribe the actions of the parent drug to the formation of the metabolite. 
The regional arterial vasodilation was most pronounced in the adrenals, 
kidneys and gastrointestinal tract but was conspicuously absent in the 
skeletal muscles. 
It is concluded that: (i) the pyridazinone-derivatives exert vasodilator and 
positive inotropic actions which improve cardiac pump function in pigs with 
severe myocardial ischemia, (ii) although the contribution of the metabolite 
to the actions of pimobendan seems negligible during acute experiments, it is 
conceded that it may become important during prolonged treatment; this is 
particularly interesting in view of the vasodilation by pimobendan in the 
skeletal muscles and gastrointestinal tract and the vasodilation by UD-CG 
212 Cl in the renal vasculature. 
Vasodilator Profile of Nlcorandll 
The vasodilator pro,file of the nitrate-like substance nicorandil was 
evaluated in the light of its potential usefulness in coronary artery disease, 
hypertension and congestive heart failure. Intravenous infusions of nicorandil 
in anesthetized pigs reduced arterial blood pressure, stroke volume, left 
ventricular end-diastolic pressure and systemic vascular resistance, but 
increased heart rate and LVdP/dtmax (Chapter 9). Cardiac output was not 
affected as the increase in heart rate was balanced by the reduction in stroke 
volume. The nicorandil-induced increases in heart rate and LVdP/dtmax were 
most likely due to a reflex activation of the sympathetic nervous system 
following the fall in arterial blood pressure. Although cardiac output did not 
change in animals, intravenous infusions of nicorandil did cause a 
redistribution of blood flow in favor of organs such as the heart, adrenals, 
spleen, small intestine and brain at the expense of that to the stomach and 
kidneys. The increase in myocardial blood flow, primarily to the subepicardial 
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layers, was associate4 with an enhancement in coronary venous oxygen 
content and was also noticed after intracoronary infusions of nicorandil. 
We conclude that the cardiovascular profile of nicorandil suggests possible 
usefulness of the drug in coronary artery disease as well as in congestive 
heart failure and hypertension. However, the combination of the marked 
hypotensive effect and reflex-mediated tachycardia may, under certain 
conditions, aggravate rather than ameliorate myocardial ischemia, particularly 
in the subendocardial layers. 
Systemic hemodynamic actions of vasodllating drugs in the conscious pig in 
the absence or presence of ~-adrenoceptor blockade 
Since vasodilating drugs induce reflex-mediated cardiostimulatory 
responses which may partially offset their beneficial actions, these agents are 
often combined with ~-adrenoceptor blockade. Furthermore, patients with 
hypertension and/or coronary artery disease which are considered for 
treatment with vasodilator therapy may already be on ~-adrenoceptor 
antagonist medication. Therefore, we studied the hemodynamic effects of the 
vasodilators nicorandil, nisoldipine, nimodipine and nifedipine in combination 
with propranolol. 
Intravenous infusions of nicorandil caused a marked systemic vasodilation 
which led, however, to only a moderate fall in arterial blood pressure due to 
an increase in cardiac output (Chapter 9). This increase in cardiac output 
was due to tachycardia as stroke volume and left ventricular filling pressure 
were reduced. After pretreatment with propranolol the vasodilation was not 
affected but increases in heart rate and LVdP/dtmax were attenuated. 
Intravenous infusions of nisoldipine, nimodipine and nifedipine resulted in 
similar systemic hemodynamic profiles. Of the three dihydropyridines 
nisoldipine was the most potent substance (Chapter 10). Dose-dependent 
reduction in systemic vascular resistance induced marked baroreceptor reflex-
mediated counterregulation. Systemic vasodilation was not affected by 
pretreatment with propranolol, but reflex-mediated actions were attenuated 
(cardiac output and heart rate) or abolished (LVdP/dtmax). The effects of 
the dihydropyridines on left ventricular filling pressure were minimal and 
independent of pretreatment with propranolol. 
To evaluate the importance of 13-adrenergic tone for the cardiovascular 
actions of the pyridazinone-derivatives, we studied the effects of pimobendan 
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and its 0-demethyl metabolite UD-CG 212 Cl in combination with propranolol 
in conscious pigs (Chapter 11). Intravenous infusions of both compounds 
caused prominent dose-dependent increases in LVdP/dtmax and, to a far lesser 
extent, in heart rate and cardiac output. Stroke volume was slightly reduced 
due to the decrease in left ventricular end-diastolic pressure. Mean arterial 
blood pressure was not significantly affected. In contrast to the observations 
in anesthetized pigs there was a slight decrease in the systemic vascular 
resistance slightly decreased of the conscious animals. After ~-adrenoceptor 
blockade, increases in heart rate and cardiac output induced by the 
pyridazinone-derivatives were attenuated and those in LVdP/dtmax were 
almost abolished. The responses of left ventricular end-diastolic and mean 
arterial blood pressure, systemic vascular resistance and stroke volume were 
not modified. 
In conclusion: (i) combination treatment of nicorandil or the 
dihydropyridines with ~-adrenoceptor blockade seems useful as it attenuates 
the reflex-mediated cardiostimulatory responses, (ii) these reflex responses 
are much more pronounced in conscious than in anesthetized animals, and (iii) 
13-adrenergic tone seems to be necessary for the cardiostimulatory actions of 
pyridazinone-deri va ti ves. 
Vasodllator therapy and myocardial ischemia 
Recent studies indicate that vasodilator reserve may still be present 
despite severe myocardial ischemia. Thus we investigated the effects of 
nisoldipine on the performance of the myocardium distal to a fixed coronary 
artery stenosis in conscious pigs at rest (Chapter 12) and during exercise 
(Chapter 13). 
In Chapter 12 the animals studied at rest were divided into two groups 
depending upon the severity of stenosis as judged by systolic wall thickening 
(SWT) of the post-stenotic segment: Group 1 (SWT>l5%) and Group 2 
(SWT<10%). The systemic hemodynamic profiles at baseline and after oral 
administration of nisoldipine were similar in both groups. Increases in heart 
rate were accompanied by increases in cardiac output and LVdP/dtmax, while 
systemic vascular resistance and mean arterial blood pressure were reduced. 
Left ventricular systolic and end -diastolic blood pressure and stroke volume 
were not affected. In both groups, nisoldipine caused increases in blood flow 
to the control (non-stenotic) myocardial area which favored the subepicardium 
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over the subendocardium. Blood flow to the post-stenotic area in group 1 
animals was normal at baseline but was only slightly enhanced (preferentially 
to the subepicardium) by nisoldipine. In the post-stenotic area of group 2 
animals, transmural and subendocardial blood flows were lower at baseline as 
compared to the control area. Nisoldipine did not affect subepicardial blood 
flow but reduced subendocardial blood flow. It is concluded that, under the 
experimental conditions employed (concentric stenosis, no coronary collaterals 
and acute drug administration) nisoldipine does not have a beneficial effect 
on post-stenotic myocardial blood flow, particularly in animals with severe 
stenosis. 
In Chapter 13 the effects of oral nisoldipine with or without propranolol 
on exercise-induced myocardial ischemia in pigs with a coronary artery 
stenosis were evaluated. Treadmill-running up to 4 km.h-1 increased cardiac 
output, heart rate, LVdP/dtmax, left ventricular systolic and end-diastolic 
blood pressure, while systolic wall thickening of the post-stenotic left 
ventricular myocardium was reduced. Nisoldipine neither affected the 
systemic hemodynamic profile during exercise nor the exercise-induced 
reductions in myocardial wall function. Propranolol attenuated both the 
positive chronotropic and inotropic effects and the deterioration of wall 
function caused by the treadmill-exercise. Combined treatment with the two 
drugs resulted in a cardiovascular profile during exercise similar to that with 
propranolol alone, but the loss of wall function was now completely 
prevented. Thus, unlike propranolol, nisoldipine was not effective against the 
exercise-induced ischemia but may have beneficial actions when combined with 
13-adrenoceptor antagonists. 
overall conclusions 
The pharmacological responses induced by the vasodilating drugs studied in 
this thesis indicate that these drugs have a hemodynamic. profile 
commensurate with their therapeutic use in cardiovascular disorders like 
coronary artery disease, hypertension and heart failure. However there are 
certain aspects which should be further elaborated. Firstly, with respect to 
the first two disease entities, the baroreceptor reflex mediated actions may 
potentially offset the benefits of nicorandil and the dihydropyridines. To 
circumvent these negative effects a combination with 13-adrenoceptor 
blockade appears useful. Secondly, based on the findings with nisoldipine in 
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our model of myocardial ischemia, nisoldipine may not be effective in patients 
with concentric stenosis lacking coronary collaterals. It may therefore be 
important to select patients for therapy with such drug on the basis of the 
nature of their stenosis and the state of their coronary collateral circulation. 
Also, chronic studies in experimental models with eccentric stenoses and/or 
coronary collaterals are necessary to obtain more detailed information on 
possible benefits from these drugs in a particular patient population. Thirdly, 
with respect to heart failure the pyridazinone-derlvatives present greater 
promise than other vasodilator drugs studied in this thesis. These drugs 
reduce preload and enhance myocardial contractility which, in animals with 
ischemic hearts, normalized cardiac pump function. Finally, the marked 
effects of anesthesia on circulatory control mechanisms shows that conscious 
rather than anesthetized animals should be preferred in cardiovascular 
research especially in experimental models dealing with myocardial ischemia 
and heart failure. 
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SAMENV ATTING 
In hoofdstuk 1 is een kort overzicht gegeven van het 
werkingsmechanisme, het vasodilator profiel en een aantal klinische 
toepassingen van vasodilatantia. Hierna volgt een beschrljving van onderzoek 
naar de cardiovasculaire pharmacologie van drie groepen van vasodilatantia in 
genarcotiseerde en niet-genarcotiseerde varkens. De geselecteerde stoffen 
waren: de dihydropyridine calcium-kanaal blokkeerders nisoldipine, nlmodipine 
and nifedipine, de pyridazinone-derivaten pimobendan en UD-CG 212 Cl 
(werkingsmechanisme mogelijkerwijs via phosphodiesterase-inhibitie) en de 
nitraat-achtige stof nicorandil (werkingsmechanisme tevens via kalium-
kanalen). 
Het vasodilator profiel van dihydropyridine calcium-kanaal blokkeerders 
Van nisoldipine is beschreven dat het een selectieve verwljding geeft van 
het coronaire vaatbed. Teneinde deze eigenschap te toetsen, bestudeerden we 
de effecten van deze stof op de verdeling van het hartminuutvolume. In 
genarcotiseerde varkens veroorzaakten intraveneuze infusies van nisoldipine 
dosis afhankelljke verwijding van zowel het coronaire alsook het systemische 
vaatbed. Tevens namen tengevolge van activatie van de baroreceptor reflex 
hartfrequentie en LVdP/dtmax toe (Hoofdstuk 2). In het systemische vaatbed 
trad de dilatatie voornamelijk op in de skeletspieren. In de linker ventrikel 
was de dilatatie van het coronaire vaatbed grater in de subepicardiale dan in 
de subendocardiale lagen. Voorbehandeling met de 15-adrenoceptor antagonist 
propranolol, had geen invloed op de vasodilator responsies van nisoldipine 
maar de reflectoire responsies waren sterk verminderd. Orale toediening van 
nisoldipine aan varkens (Hoofdstuk 3) leidde in het systemische vaatbed vooral 
tot dilatatie van de tractus gastro-intestinalis en de skeletspieren. De 
reflectoire toename in het hartminuutvolume (reflectoir) voorkwam een grate 
daling van de arteriele bloeddruk. De subendocardiale-subepicardiale perfusie 
ratio nam minder af na gecombineerde behandeling met propranolol en 
nisoldipine dan na nisoldipine aileen, ten gevolge van de geringere toename in 
hartfrequentie. 
Concluderend: (i) nisoldipine is een stof met een potent vasodilaterende 
werking, (ii) deze vasodilatatie is niet-selectief en het meest uitgesproken in 
de skeletspier en (iii) de stof kan gecombineerd worden met 13-adrenoceptor 
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antagonisten zonder de pompfunctie van de linker ventrikel nadelig te 
beinvloeden. 
In het licht van de gepropageerde selectiviteit voor de cerebrale vaten en 
effectiviteit in migraine, werden de effecten van nimodipine op de distributie 
van het hartminuutvolume en de bloedstroom door de arteria carotis communis 
zonder en tijdens infusies van 5-hydroxytryptamine (5-HT) bestudeerd in 
genarcotiseerde varkens (Hoofdstukken 4 en 5). Intraveneuze infusie van 
nimodipine veroorzaakte hypotensie, bradycardie en een vaatverwijding welke 
het meest uitgesproken was in de skeletspieren. Na toediening in de arteria 
carotis induceerden nimodipine en nifedipine een redistributie van de carotis 
bloedstroom ten gunste van het capillaire compartiment, en in het bijzonder 
van de skeletspieren. Infusie van 5-HT in de carotis gaf een redistributie van 
de carotis bloedstroom, waarvan nu vrijwel uitsluitend de huid profiteerde. 
De bloedstroom door de arterioveneuze anastomosen (AVA) werd sterk 
gereduceerd door 5-HT, terwijl de calcium-kanaal blokkeerders de AVA 
doorbloeding slechts in geringe mate beinvloedden. De vasoconstrictor 
responsie na infusie van 5-HT werd niet door de calcium-kanaal blokkeerders 
geantagoneerd. 
We concluderen dat: (i) nimodipine geen selectiviteit ten opzichte van de 
cerebrale vasculatuur bezit, (ii) de vasodilator effecten van nimodipine en 
nifedipine het meest uitgesproken zijn in de skeletspieren, (iii) de relatief 
mil de afnamen van de AVA geleiding na toediening van nifedpine en 
nimodipine wellicht een van de mogelijke verklaringen is voor het onvermogen 
van dihydropyridine-derivaten om acute aanvallen van migraine te couperen, 
en (iv) in tegenstellig tot 'in-vitro' studies, de vasoconstrictie door 5-HT 
'in-vivo' niet door nimodipine en nifedipine geantagoneerd wordt. 
Het vasodilator proflel van pyrldazlnone-derlvaten 
Bij hartfalen kan een toename in periphere vaatweerstand leiden tot een 
verslechtering van de pompfunctie van het hart. Vasoconstrictie is dan vooral 
sterk in de circulatie van de nier, skeletspier, huid en tractus gastro-
intestinalis. We evalueerden daarom de effecten van de pyridazinone-
derivaten pimobendan en UD-CG 212 Cl op de cardiovasculaire dynamica en in 
het bijzonder op de distributie van het hartminuutvolume. Intraveneuze 
infusies van pimobendan in genarcotiseerde varkens veroorzaakten veneuze en 
arteriele dilatatie en een toename in hartfrequentie, maar hadden slechts een 
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gering effect op LVdP/dtmax (Hoofdstuk 6). Arteriele vasodilatatie was het 
meest uitgesproken in de bijnieren, tractus gastro-intestinalis, skeletspieren 
en myocardium (subepicardium > subendocardium). Intraveneuze bolus injecties 
van pimobendan produceerden dezelfde veranderingen in aile systemische en 
regionaal haemodynamische variabelen met uitzondering van LVdP/dtmax die 
nu sterk toenam (Hoofdstuk 7). In dieren met een normale coronair circulatie 
was er een geringe daling van het hartminuutvolume. Daarentegen leidde 
toediening van pimobendan aan dieren met een ischaemisch hart tot een 
stijging van het hartminuutvolume en de LVdP/dtmax. Gedurende 
intracoronaire infusies nam de myocard doorbloeding toe zonder voorkeur voor 
de subepicardiale lagen. 
Intraveneuze infusie van UD-CG 212 Cl, de O-demethyl metaboliet van 
pimobendan, veroorzaakte systemisch haemodynamische veranderingen die 
vrijwel gelijk waren aan die van pimobendan. UD-CG 212 Cl veroorzaakte 
deze veranderingen echter al bij veel lagere doseringen (Hoofdstuk 8). De 
plasma concentraties van het geformeerde UD-CG 212 Cl tijdens pimobendan 
infusies zijn echter te laag om de effecten van pimobendan toe te schrijven 
aan de formatie van de metaboliet. De perifere vasodilatatie was het meest 
uitgesproken in de bijnieren, nieren en tractus gastro-intestinalis maar 
opvallend afwezig in de skeletspieren. 
Concluderend: (i) de pyridazinone-derivaten bezitten een vasodilator en 
een positief inotrope werking, (ii) in varkens met een ischaemisch hart leidt 
dit tot een verbetering van het hartminuutvolume, (iii) hoewel de bijdrage 
van de metaboliet aan de werking van pimobendan verwaarloosbaar is 
gedurende acute experimenten, wordt deze wellicht belangrijk bij chronische 
toediening. Dit is vooral interessant indien men bedenkt dat pimobendan 
vaatverwijding induceert in de skeletspieren en tractus gastro-intestinalis en 
UD-CG 212 Cl in de nieren. 
Het vasodilator proflel van nlcorandU 
Het vasodilator profiel van de nitraat-achtige stof nicorandil werd 
geevalueerd vanwege mogelijke toepassing in coronaire hartziekten, 
hypertensie en hartfalen. Intraveneuze infusies van nicorandil in 
genarcotiseerde varkens reduceerde de arteriele bloeddruk, slagvolume, linker 
ventrikel eind-diastolische bloeddruk en de systemische vasculaire weerstand, 
maar induceerde een toename in hartfrequentie en LVdP/dtmax (Hoofdstuk 9). 
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Het hartminuutvolume veranderde niet omdat de afname in slagvolume werd 
gecompenseerd door de toename in hartfrequentie. Er was wel een 
verandering in de distributie van het hartminuutvolume ten gunste van het 
hart, dunne darm en hersenen ten koste van de maag en nieren. De toename 
in de linker ventrikel doorbloeding, voornamelijk naar de subepicardiale lagen, 
ging gepaard met een toename in de coronair veneuze zuurstof saturatie. Na 
intracoronaire toediening van nicorandil werden dezelfde resultaten voor het 
hart gevonden. 
Concluderend: het cardiovasculaire profiel van nicorandil suggereert een 
mogelijke toepassing in coronaire hartziekten, hartfalen en hypertensie. De 
combinatie van een sterke bloeddruk daling en een reflectoire tachycardie kan 
onder bepaalde condities, vooral in de subendocardiale lagen, ischaemia 
induceren. 
Systemische haemodynamische werking van vasodilatantia in het niet-
genarcotiseerde varken voor en tijdens 13-adrenoceptor blokkade. 
Aangezien vaatverwijders reflex-gemedieerde cardiostimulerende responsies 
kunnen induceren die de gunstige effecten geheel of gedeeltelijk opheffen, 
worden deze stoffen vaak gecombineerd . met 13-adrenoceptor antagonisten. 
Tevens worden patienten met een ischaemisch hartziekte en/of hypertensie 
die voor behandeling met vaatverwijders in aanmerking komen al vaak 
behandeld met 13-adrenoceptor antagonisten. Wij bestudeerden daarom de 
haemodynamische effecten van de vaatverwijders nicorandil, nisoldipine, 
nimodipine en nifedipine na voorbehandeling met propranolol. Om mogelijke 
effecten van anaesthesie uit te sluiten werden de experimenten in niet-
genarcotiseerde dieren uitgevoerd. 
In traveneuze infusies van nicorandil induceerden een opmerkelijke 
systemische vasodilatatie met slechts een geringe daling in de arteriele 
bloeddruk, omdat het hartminuutvolume toenam (Hoofdstuk 9). Deze toename 
was het gevolg van een tachycardie omdat het slagvolume afnam. Na 
voorbehandeling met propranolol was de systemische vasodilatatie ongewijzigd 
maar de toenamen in hartfrequentie en LVdP/dtmax verminderd. 
Nisoldipine, nimodipine en nifedipine vertoonden na intraveneuze toediening 
een overeenkomstig systemisch haemodynamisch profiel met nisoldipine als de 
meest potente stof (Hoofdstuk 10). Dosis afhankelijke reducties in 
systemische vasculaire weerstand leidden tot opmerkelijke baroreceptor reflex 
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gemedieerde effecten. Systemische vasodilatatie werd niet beinvloed door 
voorbehandeling met propranolol, maar de reflectoir geinduceerde effecten 
waren verminderd (hartminuutvolume en hartfrequentie) of zelfs volledig 
geinhibeerd (LVdP/dt~aax). De effecten van de dihydropyridines op de 
vullingsdruk van de linker ventrikel waren zeer gering en onafhankelijk van 
voorbehandeling met propranolol. 
Om de invloed van de 13-adrenerge tonus op de cardiovasculaire werking 
van de pyridazinone-derivaten te evalueren, bestudeerden we de effecten van 
pimobendan en UD-CG 212 Cl in niet-genarcotiseerde varkens in combinatie 
met propranolol (Hoofdstuk 11). Intraveneuze infusies van beide pyridazinone-
derivaten veroorzaakten sterke toenamen in LVdP/dtmax en in mindere mate 
in hartfrequentie en hartminuutvolume. Het slagvolume nam een weinig af 
door de daling van de linker ventrikel vullingsdruk. De gemiddelde arteriele 
bloeddruk veranderde niet. In tegenstelling tot de bevindingen bij de 
genarcotiseerde varkens nam de systemische vaatweerstand slechts weinig af 
in de niet-genarcotiseerde dieren. Na [3-adrenoceptor blokkade waren de door 
de pyridazinone-derivaten geinduceerde stijgingen in hartfrequentie en 
hartminuutvolume geringer en in LVdP/dtmax bijna volledig verdwenen. 
Onveranderd waren de responsies van de linker ventrikel vullingsdruk, de 
arteriele bloeddruk, de systemische vasculaire weerstand en het slagvolume. 
Samenvattend: (i) combinatie therapie van nicorandil of de dihydropyridine-
derivaten met 13-adrenoceptor antagonisten lijkt zinvol aangezien dit de 
reflex -gemedieerde cardiostimulerende resp.onsies verzwakt, (ii) deze 
reflectoire responsies zijn veel sterker in niet-genarcotiseerde dan in 
genarcotiseerde dieren, en (iii) de 13-adrenerge tonus is van belang voor de 
cardiostimulerende werking van pyridazinona-derivaten. 
Vasodilator theraple en myocard lschaemle 
Uit recente studies is gebleken dat vasodilator reserve nog aanwezig kan 
zijn in ischaemisch myocard. Daarom bestudeerden we de effecten van 
nisoldipine op het myocard distaal van een gefixeerde coronair stenose in 
varkens in rust (Hoofdstuk 12) en tijdens inspanning (Hoofdstuk 13). In 
hoofdstuk 12 waren de dieren die bestudeerd werden verdeeld in twee 
groepen gebaseerd op de ernst van de stenose. Deze werd beoordeeld met 
behulp van de procentuele systolische wandverdikking (SW) van het post-
stenotische segment: groep 1 (SW>15%) en groep 2 (SW<10%). De systemisch 
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haemodynamische profielen van groep 1 en 2 waren voor en na orale 
toediening van nisoldipine hetzelfde. Toenamen in hartfrequentie gingen 
vergezeld van stijgingen in hartminuutvolume en LVdP/dtmax , terwijl de 
systemisch vasculaire weerstand en de gemiddelde arteriele bloeddruk daalden. 
Linker ventrikel systolische- en eind-diastolische bloeddruk en slagvolume 
bleven onveranderd. In beide groepen vero_orzaakte nisoldipine een toename 
in doorbloeding van het controle (niet-stenotische) gebied van de linker 
ventrikel waarvan de subepicardiale lagen het meest profiteerden. De 
doorbloeding van het post-stenotische gebied in de varkens behorende tot 
groep 1 was normaal tijdens de controle waarneming maar werd slechts gering 
verhoogd (preferentieel naar het subepicardium) door nisoldipine. In het post-
stenotische gebied van de dieren van groep 2 waren de transmurale en 
subendocardiale doorbloeding tijdens de controle meting verlaagd ten opzichte 
van het niet-stenotische gebied. Nisoldipine had geen effect op de 
subepicardiale bloedstroom maar reduceerde de subendocardiale doorbloeding. 
Concluderend: nisoldipine heeft onder de experimentele condities zoals die 
door zijn ons gebruikt (concentrische stenose, geen coronair collateralen en 
acute toediening van de stof), geen gunstige effecten op post-stenotische 
myocardiale bloedstroom, vooral in dieren met een ernstige stenose. 
In hoofdstuk 13 werden de effecten van oraal toegediend nisoldipine 
geevalueerd voor en tijdens 15-adrenoceptor blokkade met propranolol op 
inspannings-gebonden myocard ischaemie in varkens met een coronair stenose. 
Lopen op een tredmolen tot een snelheid van 4 km.h-1 veroorzaakte een 
toename in hartminuutvolume, hartfrequentie, LVdP/dtmax, linker ventrikel 
systolische en eind-diastolische bloeddruk, terwijl de systolische 
wandverdikking van de post-stenotische linker ventrikel wand werd 
gereduceerd. Nisoldipine beinvloedde noch het haemodynamisch profiel noch 
de inspannings-gebonden afname in wandfunctie tijdens inspanning. 
Propranolol remde zowel de positief chrono- en inotrope effecten als de 
inspannings-gebonden reductie in wandfunctie. Combinatie therapie 
resulteerde tijdens inspanning in een cardiovasculair profiel dat gelijk was 
aan dat verkregen met propranolol. 
echter volledig voorkomen. Dus, 
De afname in wandfunctie werd nu 
nisoldipine had, in tegenstelling tot 
propranolol, geen effect op het verlies aan functie van het post-stenotische 
myocard tijdens inspanning, maar heeft eventueel wel een gunstige werking 
na combinatie met 13-adrenoceptor antagonisten. 
233 
Eindconclusies 
De farmacologische responsies op de vaatverwijders die in dlt proefschrift 
werden bestudeerd geven aan dat deze stoffen een haemodynamisch profiel 
bezitten dat beantwoord aan de eisen voor een therapeutisch gebruik in 
cardiovasculaire aandoeningen zoals coronaire hartziekten, hypertensie en 
hartfalen. Er zijn echter een aantal aspecten die meer aandacht vereisen. 
Ten eerste , wat betreft hypertensie en coronaire hartziekten, kunnen de 
baroreceptor reflex gemedieerde effecten mogelijkerwijs de gunstige effecten 
van nicorandil en de dihydropyridines te niet doen. Om deze negatieve 
effecten te vermijden lijkt een combinatie met een (3-adrenoceptor antagonist 
nuttig. Ten tweede, gebaseerd op de bevindingen in ons model van 
myocardiale ischaemie zou het kunnen zijn dat nisoldipine niet effectief is in 
patienten met een concentrische coronair stenose en een gering ontwikkelde 
collateraal circulatie. Het lijkt daarom belangrijk om patienten te selecteren 
voor behandeling met een stof als nisoldipine op basis van de aard van hun 
stenose en de aanwezigheid van een collateraal circulatie. Daarbij zijn 
studies in experimentele modellen met eccentrische vernauwingen en/of 
collateralen noodzakelijk om hieromtrent meer informatie te verkrijgen. Ten 
derde, wat betreft hartfalen lijken de pyridazinone-derivaten de stoffen met 
het meest geschikte profiel voor deze entiteit. De pyridazinone-derivaten 
verlagen de vullingsdruk en verhogen de contractiliteit van de linker 
ventrikel, wat in dieren met ischaemische harten leidde tot een normalisering 
van de pompfunctie van het hart. Tenslotte, de sterke effecten van 
anaesthesie op de cardiovasculaire reflexen laten zien dat genarcotiseerde 
boven niet-genarcotiseerde dieren te prefereren zijn in het onderzoek van 
vooral myocard ischaemie en hartfalen. 
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DANKWOORD 
Vanaf maart 1985 heeft het Thoraxcentrum (Prof. P.G. Hugenholtz en 
Prof. Dr. J.R.T.C. Roelandt) mij de kans geboden om mezelf "full time" te 
bekwamen in het wetenschappelijk onderzoek, hetgeen uiteindelijk heeft geleid 
tot dit proefschrift. Hierbij wil ik een ieder bedanken die een bijdrage heeft 
geleverd aan het tot stand komen daarvan, in het bijzonder: 
Prof. Dr. P.R. Saxena, u wil ik bedanken voor uw begeleiding als promotor. 
Door de nauwe samenwerking die bestaat tussen de afdelingen Farmacologie 
en Experimentele Cardiologie, d.w.z. tussen u en dr. P.O. Verdouw, heb ik de 
luxe gekend door twee ervaren wetenschappers geestelijk te worden "gekneed". 
Dr. P.O. Verdouw, u wil ik bedanken voor al hetgeen u mij geleerd heeft 
en voor het vertrouwen dat u in mij stelde. Het enthousiasme en de energie 
waarmee u mij stimuleerde ervoer ik soms als "gesel", meestal als stimulans, 
maar wekten altijd mijn bewondering. 
Prof. Dr. Roelandt, Prof. Dr. Struyker Boudier en Prof. Dr. van Zwieten, u 
dank ik voor uw bereidheid het proefschrift te willen beoordelen op zijn 
wetenschappelijke waarde. 
Grote dank gaat uit naar mensen die mij bij het uitvoeren van de acute 
experimenten geholpen hebben: Mw A.M. Rutteman, Dhr R.H. van Bremen, 
Dhr. R.J. Rensen en Dhr. J.P.C. Heiligers. 
Voor de chronische experimenten ·ben ik allereerst de medewerkers van het 
Laboratorium voor Experimentele Chirurgie grote dank verschuldigd, Dhr. 
J. Kasbergen, Mw. J. de Kam, Dhr. E. Ridderhof, Dhr. E.C.C. Collij en "last 
but not least" Dhr. R.C. Spruyt, voor hun hulp bij de operaties en de post-
operatieve zorg voor de varkens. Verder ben ik Dhr. J.M. Hartog, 
Dhr. R.H. van Bremen en Dhr. J.P.C. Heiligers bijzonder erkentelijk voor hun 
bijdrage tijdens operaties en/of uitvoer van het .experimentele protocol. 
Zonder de vliegensvlugge vingertjes van Mw P.H. Vegter, welke zij wist te 
combineren met opgewektheid en geduld was dit proefschrift waarschijnlijk 
niet verschenen. Mijn dank hiervoor is groot. 
De medewerkers van de Centrale Research Werkplaats, ben ik zeer 
erkentelijk voor de fabricage van enkele van de geimplanteerde materialen. 
Bayer Nederland B.V. wordt hartelijk bedankt voor de genereuze donaties 
van farmaca en ondersteunende middelen. 
Het audiovisueel centrum dank ik voor de vervaardiging van de illustraties 
van dit proefschrift. 
Tot slot wil ik mijn ouders bedanken voor hun liefde en zorg zonder welke 
dit alles niet mogelijk zou zijn geweest. 

